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Poly(ADP-ribosyl)ation (PARylation) is an enzymatic reaction whereby ADP-
ribose units from donor NAD+ molecules are covalently attached onto target proteins.  
The regulation of this reaction is overseen by two nuclear enzymes, Poly(ADP-ribose) 
polymerase-1 (PARP-1) and poly(ADP-ribose) glycohydrolase (PARG), that modify 
target proteins in the nucleus by the addition and removal, respectively, of ADP-ribose 
polymers.  While PARP-1 has generally been studied with respect to its role in DNA 
damage repair and cell death pathways, recent studies have revealed a role for PARP-1 
in transcriptional regulation.  The role of PARG in transcriptional regulation, however, 
is less characterized.  In this study, I have investigated the coordinate patterns of gene 
regulation by PARP-1 and PARG in vivo using genomic and gene-specific analyses. 
Specifically, I show that PARP-1 and PARG coordinately regulate global 
patterns of gene expression by affecting genes in the same direction and with similar 
magnitudes.  Further analysis revealed that PARP-1 and PARG localized to the 
promoters of both positively and negatively regulated target genes in parallel binding 
patterns.  I also show that PARP-1 and PARG enzymatic activities are required for 
some, but not all, target genes.  My results indicate that PARP-1 and PARG, two 
nuclear enzymes with opposing enzymatic activities, localize to target promoters and 
act in a similar, rather than antagonistic, manner to regulate gene expression. 
In a follow-up study, I have used a novel method known as Global Run-on 
Sequencing (GRO-seq) to define the role of PARP-1 on the estrogen-regulated 
transcriptome at the level of the nascent transcript, rather than steady-state mRNA 
levels.  I have produced libraries from MCF-7 cells treated with vehicle or 17β-
estradiol (E2) under three conditions: (i) a control knockdown; (ii) a control 
knockdown plus a PARP inhibitor, PJ34; and (iii) a PARP-1 knockdown.  I have 
determined that the estrogen response is highly maintained under PARP-1 knockdown 
or inhibition.  Accordingly, upon estrogen treatment, PARP-1 localization patterns are 
largely unaffected.  However, deeper analyses reveal a small number of genes where 
PARP-1 knockdown or inhibition reduces the estrogen response at the transcription 
level (GRO-seq) and at the steady state mRNA level (RT-qPCR). 
The NAD+ metabolite generated from the PARP-1/PARG reaction, ADP-
ribose (ADPR), is a small molecule ligand that is used by macro domain-containing 
proteins.  The histone variant macroH2A1 is one such protein that has generally been 
studied with respect to its role in transcriptional repression on the inactive X 
chromosome.  However, recent studies have begun to explore a role for macroH2A1 in 
autosomal gene regulation, as a transcriptional repressor and a transcriptional activator.  
Recent results from the Kraus lab have shown that the transcriptional coactivator 
Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) interacts with the macro 
domain of macroH2A1 in a ligand-independent manner and shows a similar genomic 
localization pattern.  I have followed up these observations by investigating the 
mechanisms of gene regulation by macroH2A1 and its interacting proteins using gene-
specific analyses.  Specifically, I have shown that macroH2A1 recruits PELP1 to 
macroH2A1 target gene promoters, but PELP1 is dispensable for the nucleosomal 
deposition of macroH2A1 at these loci.  Together, macroH2A1 and PELP1 
cooperatively regulate the expression of a subset of macroH2A1 target genes. 
Collectively, my studies expand our understanding of the cooperative actions 
of proteins in the NAD+ metabolic pathway in regulating transcription. 
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Minor modifications have been made. 
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1.1.  Summary 
 
Poly(ADP-ribosyl)ation (PARylation) is an enzymatic reaction identified 
nearly 50 years ago whereby ADP-ribose units from donor nicotinamide adenine 
dinucleotide (NAD+) molecules are covalently attached in succession onto target 
proteins (Chambon et al., 1963).  This post-translational modification occurs via 
glycosidic ribose-ribose linkages to form linear or branched structures and is 
collectively known as poly(ADP-ribose) (PAR) (D'Amours et al., 1999).  The 
regulation of PAR is overseen by a multitude of enzymes; in particular, those that 
polymerize and those that hydrolyze PAR chains (D'Amours et al., 1999; Kim et al., 
2005).  Herein, I discuss the molecular functions and interplay of these enzymes in 
various cellular activities.  Of particular focus, I highlight the findings from knockout 
animal models and discuss the contributions to physiological and disease states.  
Finally, I discuss the development of PARP-1 and PARG chemical inhibitors, their 
therapeutic applications, and their future potential for disease treatments. 
 
1.2.  Synthesis of PAR by PARPs 
 
PAR Polymerases (PARPs) have been identified from bacteria to humans, 
although absent from yeast (Hassa et al., 2006; Otto et al., 2005).  In mammalian cells, 
PAR is mainly produced by PARP-1 (Hassa and Hottiger, 2008), the founding 
member of the PARP family (Ame et al., 2004), which is comprised of 17 additional 
members, identified as such through catalytic domain conservation (Ame et al., 2004; 
Hakme et al., 2008; Hassa and Hottiger, 2008; Schreiber et al., 2006).  Some members 
possess only the ability to transfer a single ADP ribose molecule onto target proteins.  
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Recently, a more accurate nomenclature has been proposed in order to distinguish 
mono(ADP-ribosyl) transferases (mARTs) from PARPs (Hottiger et al., 2010). 
PARP family members are located in nearly all cellular compartments, 
including the nucleus, cytoplasm, and mitochondria.  PARPs 1-5 [PARP-1, PARP-2, 
PARP-3, PARP-4 (a.k.a. v-PARP), and PARP-5a and PARP-5b (a.k.a. tankyrase-1 
and -2)] are genuine PARPs, containing a conserved glutamate (Glu 988 in PARP-1) 
that confers PARP catalytic activity (Krishnakumar and Kraus, 2010).  They are all 
exclusively localized in the nucleus, with the exception of PARP-4, which also 
localizes to vault particles (Ame et al., 2004; Hakme et al., 2008; Hassa and Hottiger, 
2008; Schreiber et al., 2006).  PARPs 6-8, 10-12, and 14-16 are identified or putative 
mARTs, some of which can be found in the nucleus, although not exclusively.  Some 
PARPs, such as PARP-9 and -13 (also partially nuclear), lack specific NAD+ binding 
or conserved catalytic residues and are likely inactive (Kleine et al., 2008).  Many of 
the PARP family members function in a wide variety of cellular processes, including 
DNA repair, transcription, genomic maintenance, apoptosis, cell signaling, and cell-
cycle regulation.  However, the functions of some members are less defined or have 
yet to be identified (Ame et al., 2004; Hakme et al., 2008; Hassa and Hottiger, 2008; 
Schreiber et al., 2006).  Both subcellular localization and function are likely to be 
defined by the particular structural and functional domains they each contain.  
Understanding the domain structures for each PARP family member will provide 
useful information toward understanding their individual functions. 
PARP-1 is a highly conserved ~116 kDa nuclear protein (D'Amours et al., 
1999) consisting of three major domains:  (i) an amino-terminal DNA binding domain 
(DBD), (ii) a central auto-modification domain (AMD), and (iii) a carboxy-terminal 
catalytic domain (CATD) (Figure 1.1A; (Krishnakumar and Kraus, 2010)).  The DBD 
contains two zinc finger motifs (Cys-Cys-His-Cys; FI/Zn1 and FII/Zn2), which confer 
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PARP-1 binding to damaged DNA, specific sequences, structures, or nucleosomes 
(Kraus, 2008; Kraus and Lis, 2003).  Recently, a third zinc-binding domain, termed 
Zn3, was identified to bind zinc, but not to DNA and specific residues within this 
domain have been shown to mediate the DNA-dependent activation of PARP-1 
enzymatic function (Langelier et al., 2010; Langelier et al., 2008; Tao et al., 2008).  In 
addition, the DBD contains a nuclear localization signal (NLS) and a caspase-3 
cleavage site (Hakme et al., 2008; Schreiber et al., 2006).  The AMD contains a 
BRCA1 C-terminus-like motif (BRCT), which plays important roles in mediating 
protein-protein interactions that can also allosterically stimulate PARP-1 catalytic 
activity (D'Amours et al., 1999; Kim et al., 2005; Kraus and Lis, 2003).  The CATD 
contains a 50 amino acid active site termed the “PARP signature motif”, which 
confers NAD+ binding and ADP-ribosyl transferase activity (Figure 1.1B; (D'Amours 
et al., 1999; Rolli et al., 2000)).  The CATD, and more specifically the PARP 
signature motif, are highly conserved through evolution, as well as among PARP 
family members.  Not only is the primary amino acid sequence conserved, crystal 
structures of many of the PARP family member catalytic domains have displayed 
highly analogous folds and structures to one another (Krishnakumar and Kraus, 2010). 
 
1.3.  Functional Consequences of PAR Modification 
 
PARP-1 catalytic activity is regulated through a variety of allosteric mechanisms, 
including physical interactions that can stimulate its catalytic function.  Although 
PARP-1 enzymatic activity is targeted to many nuclear proteins including 
transcription factors, histones, and DNA repair factors, the main target is PARP-1 
itself (Kim et al., 2005).  Whether this auto-PARylation reaction occurs in cis or trans 
has been debated, but is primarily thought to be intermolecular (Altmeyer and 
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Hottiger, 2009; Alvarez-Gonzalez and Mendoza-Alvarez, 1995; Langelier et al., 2010; 
Mendoza-Alvarez and Alvarez-Gonzalez, 1993; Mendoza-Alvarez and Alvarez-
Gonzalez, 1999).  The actual residues of modification on target proteins are lysine, 
glutamate, and aspartate residues. Some studies have begun to identify modification 
sites of target proteins, but the list is not extensive (Altmeyer and Hottiger, 2009). 
The PAR modification itself can contain as many as 200 ADP-ribose (ADPR) 
units and can vary in length and complexity.  Based on its chemical similarity to DNA 
and RNA, PAR has been referred to as the "third type of nucleic acid" (D'Amours et 
al., 1999), which is highly negative in charge.  The structure and complexity of PAR 
itself (linear or branched) may also vary depending on the specific PARP enzyme that 
synthesizes it and the cellular condition under which it is synthesized (Figure 1.1B).  
In addition, since many of the PARPs perform the same enzymatic reaction using the 
same NAD+ substrate, determining which PARP is responsible for modifying a protein 
has been more than challenging in vivo.  However, a recent study utilized a clickable 
NAD+ analog to label PARP-1 or tankyrase-1 target proteins in cells and subsequently 
affinity purified and identified the PARylated proteins by mass spectrometry (Jiang et 
al., 2010).  Although this study brings the field one step closer, more work needs to be 
done to truly identify targets of specific PARP proteins. 
What are the functional consequences of such a massive post-translational 
modification?  PAR modification on target proteins can impact their function and 
important molecular interactions.  PAR may alter the activity of PARylated proteins 
by functioning as a site-specific covalent modification or a steric hindrance (Kim et 
al., 2005; Krishnakumar and Kraus, 2010).  For example, inhibition of PARP-1's DNA 
binding activity by autoPARylation may be the result of charge repulsion between 
PAR and DNA, or steric effects of PAR that mask PARP-1's DBD (D'Amours et al., 
1999).  PARylation of some transcription factors (i.e., p53, CREB) affects their DNA- 
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Figure 1.1.  PARP-1 and PARG are regulators of protein PARylation.  A, 
Schematic diagram of the human PARP-1 and PARG structural and functional 
domains.  For PARP-1 (top), the DNA binding domain, zinc fingers (FI and FII), 
nuclear localization signal (NLS), third zinc binding domain (Zn3), automodification 
domain, BRCA1 c-terminal-like motif (BRCT) are shown.  The PARP “signature” 
motif is also shown within the catalytic domain and NAD+-binding region.  The star 
indicates the region of modification of PARP-1 itself.  For PARG (bottom), the 
nuclear localization signal (NLS) and nuclear export signal (NES) are shown within 
the regulatory domain, and the active site is shown within the catalytic domain.    B, 
PARP-1 and PARG chemical reaction.  PARP-1 utilizes NAD+ to PARylate target 
proteins in the nucleus.  The by-produce of this reaction is nicotinamide, a natural 
PARP inhibitor.  PARG hydrolyzes PAR chains through endo- and exo-glycosidic 
activities to release ADPR monomers and short polymers. 
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binding activities, leading to alterations of transcriptional outcomes (Kim et al., 2005).  
PARylation can also inhibit the formation of transcription complexes by preventing or 
promoting certain protein-protein interactions at gene promoters (Ju et al., 2004; Pavri 
et al., 2005).  In addition, PARylation of histones, for example, may alter the 
chromatin conformation by preventing or promoting the association of chromatin 
binding proteins or other chromatin components (Krishnakumar et al., 2008). 
Furthermore, PAR may act as a protein-binding matrix for a variety of nuclear 
proteins.  To date, at least three types of PAR-binding motifs or domains have been 
identified, namely (i) an eight-amino acid PAR-binding motif, (ii) a PAR-binding 
zinc-finger motif, and (iii) macrodomains.  Proteins that contain these motifs or 
domains interact with PAR, which leads to the targeting of those proteins to sites of 
PAR synthesis or to the regulation of the protein activity upon PAR binding.  For 
example, the histone variant macroH2A1.1 is recruited to sites of DNA damage-
induced PARP-1 activation and PAR synthesis in the nucleus, the result of which 
leads to chromatin compaction, altering DNA repair responses (Timinszky et al., 
2009).  In fact, the interaction of macroH2A1.1 with PARP-1 is dependent on the 
ability of macroH2A1.1 to bind PAR (Timinszky et al., 2009).  Interestingly, 
macrodomains can also bind other NAD+ metabolites, such as O-acetyl-ADP-ribose, 
the byproduct of sirtuin-mediated deacetylase reactions, and ADPR, the resulting 
product of PAR hydrolysis reactions (Karras et al., 2005).  These metabolites have the 
ability to compete with PAR-binding, ultimately disrupting macroH2A1.1-protein 
interactions.  DEK, an oncoprotein involved in DNA repair and chromatin 
organization, is PARylated by PARP-1 leading to its release from the chromatin 
(Gamble and Fisher, 2007; Kappes et al., 2008).  Recently, DEK was shown to bind 
PAR via three functional PAR-binding sites in a manner dependent on PAR length 
and can interfere with the multimerization activities of DEK (Fahrer et al., 2010).  
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This demonstrates that the modification of proteins by PARP-1 and the interaction 
with the PAR modification can play separate roles, but may not be mutually exclusive. 
 
1.4.  Catabolism of PAR by PARG 
 
The major enzyme responsible for the degradation of PAR is Poly(ADP-
ribose) Glycohydrolase (PARG) (Amé et al., 2000; Davidovic et al., 2001), which 
catalyzes the hydrolysis of PAR to produce ADP-ribose monomers and short polymers 
(Figure 1.1B; (Davidovic et al., 2001)) via endo- and exoglycosidic enzymatic 
activities.  While PARG is the major contributor to PAR degradation, other enzymatic 
activities exist than can also remove PAR or ADPR monomers from target proteins 
(i.e., poly- and mono(ADP-ribosyl) protein hydrolase and mono(ADP-ribosyl) protein 
lysase (Hassa and Hottiger, 2008; Kim et al., 2005)).  In addition, a recent study has 
identified a “PARG-like” protein, namely ADP-ribose-protein-hydrolase-3 (ARH3), 
shown to possess intrinsic PARG activity, but has yet to be fully characterized (Oka et 
al., 2006).  This finding suggests that the mammalian genome may actually encode 
other proteins with PAR hydrolysis functions.  Perhaps their roles in PAR removal 
may be distinctly defined based on the structure of individual PAR molecules. 
PARG is a highly active enzyme but has been relatively hard to study due to its 
low cellular abundance (Davidovic et al., 2001; Meyer-Ficca et al., 2005a).  Although 
PARP-1 may be present at a 5- to 20-fold molar excess over PARG in some cell types, 
PARG has a higher specific activity than PARP-1 and its enzymatic activity increases 
with increased PAR length (D'Amours et al., 1999).  Specifically, highly branched or 
short polymers are degraded slowly and long linear polymers are degraded quickly 
(Hassa and Hottiger, 2008).  This rapid hydrolysis results in a bulk PAR half-life of as 
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little as one minute (under certain conditions), while the short ADPR polymers can 
have a half-life of up to ten minutes (Bonicalzi et al., 2005). 
There is only one gene encoding PARG in humans, but multiple splice variants 
and cleavage products have been reported, all of which have catalytic activity 
(D'Amours et al., 1999; Lin et al., 1997; Meyer-Ficca et al., 2004).  The longer sets of 
isoforms (~100 – ~110 kDa) are likely shuttled between the nucleus and cytoplasm, 
while the shorter isoform (~65 kDa) resides solely in the cytoplasm (Bonicalzi et al., 
2005; Meyer-Ficca et al., 2004; Meyer-Ficca et al., 2005a; Min and Wang, 2009).  The 
larger PARG isoforms consists of two major domains: (i) an amino-terminal 
regulatory domain, and (ii) a carboxy-terminal catalytic domain (Figure 1.1A; 
(Bonicalzi et al., 2005; Min and Wang, 2009)).  The regulatory domain contains both a 
nuclear localization signal and a nuclear export signal, which mediate shuttling 
between the nuclear and cytoplasmic compartments.  The catalytic domain contains 
the PARG active site, which confers both endoglycosidic and exoglycosidic activity to 
rapidly hydrolyze PAR (Kim et al., 2005; Kraus, 2008; Min and Wang, 2009). While 
PARP-1 and PARG enzymatic actions are intimately linked, the details of their 
functional interplay have not been explored in detail. 
 
1.5.  Regulation of PARP-1 and PARG Enzymatic Activities 
 
PARP-1 and PARG enzymatic activities regulate the dynamics of PAR, as 
described above.  However, the activation or inactivation of the enzymes themselves is 
also subject to regulatory mechanisms.  Although the regulators of PARP-1 enzymatic 
activity have been studied in some depth, recent studies have uncovered new modes of 
PARP-1 enzymatic regulation.  Only a few methods of regulating PARG enzymatic 
activity have been determined, but it is feasible to think that many of the same 
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regulatory mechanisms for PARP-1 can be applicable to PARG and vice versa (Figure 
1.2).  However, much work needs to be done in order to fully understand the 
regulatory mechanisms of both of these enzymes. 
 
1.5.1.  Interactions with DNA and Proteins 
As mentioned above, PARP-1 enzymatic function can be allosterically 
modulated by a variety of mechanisms.  In particular, PARP-1 activity is stimulated 
upon binding to DNA sequences, structures (i.e., double strand or single strand breaks, 
crossovers, or hairpins), and nucleosomes via interactions involving the DBD (Kim et 
al., 2005; Kraus, 2008).  A similar mechanism for PARG activation has yet to be 
identified, likely due to the lack of a DBD.  However, a recent study determined that 
PARG localizes to gene promoters in a pattern similar to that of PARP-1, even without 
possessing a classic DNA binding domain (Frizzell et al., 2009).  In support of this, 
PARP-1 and PARG have been shown to interact under certain conditions and in 
certain cell-types (Keil et al., 2006).  It has been suggested that PARG interaction with 
PARP-1 can regulate PARP-1 activity (Cortes et al., 2004), but whether or not PARP-
1 can modulate PARG activity remains unanswered. 
In addition, PARP-1 binding within various protein complexes may also 
contribute to the regulation of PARP-1 activity.  In this regard, PARP-1 is a known 
component of complexes involved in DNA repair, transcription, insulators, and DNA 
methylation.  The interactions with specific proteins (i.e., XRCC1, Mediator, CTCF, 
and Dnmt-1; (Caiafa et al., 2009; Caiafa and Zlatanova, 2009; El-Khamisy et al., 
2003; Farrar et al., 2010; Guastafierro et al., 2008; Hassa et al., 2005; Heale et al., 
2006; Ju et al., 2004; Malanga and Althaus, 2005; Pavri et al., 2005; Pleschke et al., 
2000; Zampieri et al., 2009)) can stimulate PARP-1 activity, and in some cases, are 
targets of PARylation by PARP-1 (Kim et al., 2005; Kraus, 2008; Kraus and Lis, 
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2003).  It is logical to suppose that PARG interactions with similar proteins may also 
regulate PARG activity, even if the interaction is less stable than that of PARP-1. 
 
1.5.2.  Post-translational Modifications 
 Like many other nuclear proteins, PARP-1 (and other PARPs) and PARG are 
subject to a host of covalent post-translational modifications that can alter their 
enzymatic functions.  Studies focused on PARP-1 have begun to shed light on the 
functional consequences of some modifications while others are less well understood.  
These include PARylation, phosphorylation, acetylation, SUMOylation, and 
ubiquitylation (Krishnakumar and Kraus, 2010).  For example, PARylation of PARP-1 
can inhibit its DNA binding and catalytic activities (D'Amours et al., 1999), as well as 
cause the release of PARP-1 from chromatin (Kim et al., 2004; Tulin and Spradling, 
2003; Wacker et al., 2007), while phosphorylation and acetylation of PARP-1 can 
stimulate its enzymatic activity under certain conditions (Hassa et al., 2005; 
Kauppinen et al., 2006; Rajamohan et al., 2009; Zhang et al., 2007).  SUMOylation 
and ubiquitylation of PARP-1 are fairly recent discoveries that seem to modulate the 
role of PARP-1 as a regulator of chromatin structure and transcription (Krishnakumar 
and Kraus, 2010; Martin et al., 2009; Messner et al., 2009).  How these modifications 
specifically regulate PARP-1 DNA binding or enzymatic activities have not been 
defined.  But, the role of PARP-1 in regulating chromatin structure and transcription 
can depend on its enzymatic activity in some cases (Petesch and Lis, 2008). 
On the other hand, a recent proteomic analysis has identified phosphorylation sites for 
PARG (as well as PARP-1 and PARP-2) caused by various kinases (Gagne et al., 
2008), the consequence of which has yet to be elucidated.  It is likely that these other 
modifications exist for PARG but have not been identified to date.  It will be 
interesting to determine which modifications occur for both PARP-1 and PARG and if 
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Figure 1.2.  Regulating the enzymatic state of PARP-1 and PARG in vivo.  As 
described in the text, there are multiple factors that determine whether or not PARP-1 
and PARG are enzymatically inactive or active.  These factors include physical 
interactions, modifications, and substrate availability.  They can have both positive 
and negative contributions toward either state and are likely not mutually exclusive.  
Together, they contribute to the regulation of PARP-1 and PARG enzymatic activities. 
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similar enzymes are responsible for those modifications.  This information may be 
helpful in understanding the interplay of PARP-1 and PARG molecular actions. 
 
1.5.3.  Substrate Availability 
 One of the most important factors in the regulation of PARP-1 and PARG 
enzymatic activities is the availability of their respective substrates.  Therefore, local 
concentrations of NAD+ and PAR are important, and can be modulated.  NAD+ is 
synthesized in the nucleus (and other cellular compartments) through a de novo 
pathway and a salvage pathway [(Berger et al., 2004; Rongvaux et al., 2003), 
reviewed in (Kim et al., 2005)].  The salvage pathway leads from nicotinamide and is 
catalyzed by the enzymes nicotinamide phosphoribosyltransferase (NAMPT) and 
nicotinamide mononucleotide adenylyltransferase (NMNAT-1, the nuclear form).  
Nicotinamide, the byproduct of the PARP-1 (and SIRT1) reaction, is a natural 
inhibitor of PARP-1 (and SIRT1).  The production of NAD+ and subsequent depletion 
of nicotinamide can positively contribute to PARP-1 action by supplying a local pool 
of NAD+ (Pillai et al., 2005).  Accordingly, NMNAT-1 has been shown to physically 
interact with PARP-1, stimulating its activity (Berger et al., 2004).  A recent study has 
demonstrated that SIRT1 can recruit NMNAT-1 to target gene promoters, most likely 
to supply NAD+ for SIRT1-dependent deacetylase reactions (Zhang et al., 2009).  
Although not yet shown, a similar mechanism likely exists for PARP-1-dependent 
PARylation reactions.  In addition, PARP-1, SIRT1, and other NAD+-utilizing 
enzymes (i.e., other PARPs, etc.) may compete for the nuclear or local NAD+ supply, 
which may also contribute to the regulation of PARP-1 activity. 
 All of these modes of PARP-1 regulation can ultimately lead to changes in 
how much PAR is synthesized and how complex its overall structure is.  As noted 
above, the length and branching complexity of PAR, can determine how active PARG 
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is in degrading the PAR modification.  Specifically, short polymers in low abundance 
or highly branched polymers are not catabolized as fast as long linear polymers 
(Bonicalzi et al., 2005).  This in turn, can modulate the half-life of PAR as well as the 
production of ADPR, the end result of the PARG hydrolysis reaction. 
 
1.5.4.  Subcellular and Genomic Localization 
 The localization of PARP-1 and PARG among subcellular compartments is 
likely to contribute to their overall function, including their enzymatic activities.  This 
is more clearly demonstrated in the case of PARG, where more than one isoform 
exists and their subcellular localizations are different.  For example, the longer 
isoforms of PARG can shuttle between the nucleus and cytoplasm, while the shorter 
isoform is found in the mitochondria (Bonicalzi et al., 2005; Meyer-Ficca et al., 2004; 
Meyer-Ficca et al., 2005a; Min and Wang, 2009).  While the full-length isoform is 
highly active, the cytoplasmic isoforms are in higher abundance and also exhibit high 
activity (Bonicalzi et al., 2005).  It is feasible that the actual localization of the 
individual molecules determines their function, and subsequently, the importance of 
their activities.  Interestingly, the PARG-like protein ARH3 also localizes to the 
mitochondria (Oka et al., 2006), and may contribute to PAR regulation in that context.  
Although PARP-1 is mainly nuclear, a recent study has determined that there exists a 
small pool of PARP-1 that localizes to the mitochondria in a manner dependent on 
mitofilin interaction (Rossi et al., 2009).  It is becoming increasingly clear why 
various PARPs and PARG (or PARG-like proteins) localize to the same subcellular 
compartments, namely for localized PAR regulation.  However, more work is 
necessary to determine what the concerted actions of these enzymes are and how their 
enzymatic (and potentially other) functions are regulated within those compartments. 
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Recently, it was determined that PARP-1 localizes to the promoters of 
expressed genes (Krishnakumar et al., 2008).  Likewise, a gene-specific analysis of 
PARG localization patterns on chromatin in the same cell line revealed that PARG 
also binds gene promoters in a similar pattern as PARP-1 (Frizzell et al., 2009).  In 
fact, PARP-1 and PARG promoter localization is, in some cases, dependent on one 
another (Frizzell et al., 2009).  It has also been reported that PARP-1 can bind to 
intergenic regions, although the consequence of this binding pattern was not 
investigated (Krishnakumar et al., 2008).  The promoter and intergenic binding of 
these factor(s) suggests that they may play different roles depending on where the 
factor(s) are localized, which may also depend on the chromatin structure, 
composition, and histone modifications (Krishnakumar et al., 2008).  It will be 
interesting to understand the role of PARP-1 binding to intergenic regions and in what 
cellular functions does it participate from these locations. 
 
1.6.  Molecular Actions of PAR-regulating Enzymes 
 
 PARP-1, and likely PARG, molecular actions contribute to a variety of cellular 
processes, including DNA damage detection and repair, cell death pathways, insulator 
function, regulation of DNA methylation patterns, and regulation of chromatin 
structure and transcription.  For the latter, PARP-1 has also been linked to a variety of 
signal-mediated transcriptional pathways.  The regulation of many of these processes 
contributes to the broad roles of PARP-1 and PARG in maintaining genomic integrity.  
Since these molecular actions have been reviewed extensively elsewhere, we provide a 
brief description for each and highlight the major findings to date.  In addition, we 
speculate as to the contributions of PARG in each process (Table 1.1). 
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1.6.1.  DNA Damage Detection and Repair 
 PARylation of proteins upon DNA damage induced by oxidation, alkylation, 
and ionizing radiation is a rapid and dramatic response.  PARP-1 binding to sites of 
DNA damage, including single- and double-strand breaks, potently activates its 
enzymatic activity (Kim et al., 2005).  PARP-1 has been shown to play a role in at 
least three DNA repair pathways:  single-strand break (SSB) repair, double-strand 
break (DSB) repair, and, base excision repair (BER) (Bouchard et al., 2003; 
Woodhouse and Dianov, 2008).  In addition, PARP-1 may also play a role in the 
repair of oxidative base damage or UV-induced pyrimidine dimers in a pathway 
dependent on Cockayne syndrome B protein (Flohr et al., 2003).  Notably, PARP-2 
has also been implicated in BER (Schreiber et al., 2002; Yelamos et al., 2006), which 
confirms the notion that PARP-1 and PARP-2 have redundant functions.  In support of 
this, PARP-1 and PARP-2 double knockout mice show considerable genomic 
instability prior to embryonic lethality (Menissier de Murcia et al., 2003).  Under low 
levels of DNA damage, PARP-1 acts as a survival factor by detecting and binding 
DNA damage sites.  However, when DNA damage levels are extremely high, PARP-1 
promotes cell death through at least two modes, (i) energy failure-induced necrosis by 
massively depleting NAD+ levels (and ultimately ATP), and (ii) apoptosis-inducing 
factor-dependent apoptosis (Kim et al., 2005; Krishnakumar and Kraus, 2010). 
The role of PARP-1 in DNA repair and the outcomes listed above are likely to 
be determined by which repair proteins are physically associating or recruited to sites 
of DNA damage and PARylation.  For example, PARP-1 can interact with, and in 
some cases PARylate, DNA damage detection and response proteins (i.e., ATM, p53; 
(Bouchard et al., 2003)), DNA repair proteins (i.e., XRCC1, DNA ligase III; (El-
Khamisy et al., 2003; Pleschke et al., 2000)), and chromatin components (i.e., H1, 
H2B) that regulate the opening of chromatin structure.  Interestingly, PARG has been
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Table 1.1.  Potential roles for PARG in cellular processes involving PARP-1.  
While PARP-1 is known to function in various cellular processes, a role of PARG in 
these processes is just beginning to emerge.  This table summarizes known or 
speculated connections for PARG to many of the cellular processes of which PARP-1 
is known to be involved.  This suggests a potential role for PARG in these cellular 
functions, and warrants further investigation. 
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Speculated Roles for PARG in Various Cellular Processes  
 
(a) DNA Repair (SSBR, DSBR, BER) 
 -  PARG interacts with DNA repair proteins (i.e., XRCC1; (Keil et al., 2006)) 
 -  PARG contributes to local ATP production via PAR hydrolysis? 
 -  PARG regulates PARP-1 PARylation activity? 
 
(b) Cell Death Pathways (Apoptosis, necrosis)  
 -  PARG contributes to local ATP production via PAR hydrolysis? 
 -  Mitochondrial PARG involved in AIF release? 
 -  PARG regulates PAR after caspase-dependent cleavage? 
 
(c) Insulator Function 
 -  PARG dynamically regulates PAR at insulators? 
 
(d) Regulation of DNA Methylation 
 -  PARG regulates Dnmt1 expression? (Zampieri et al., 2009) 
 -  PARG regulates DNMT1 activity via DNMT1-PAR binding? 
 
(e) Modulation of Chromatin Structure 
 -  PARG promoter binding is similar to PARP-1 (Frizzell et al., 2009) 
 -  PARG dynamically regulates PARylation of histones/chromatin-binding factors? 
 
(f) Transcriptional Regulation (Basal, signal-mediated) 
 -  PARG functions as a transcriptional coregulator (Hanai et al., 2004) 
 -  PARG dictates the localization of transcriptional coregulators (Tulin et al., 2005) 
 -  PARG directly regulates PARP-1 function? 
 -  PARG dynamically regulates PAR and/or ADPR at promoters? 
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shown to interact with some of the same proteins (i.e., XRCC1; (Keil et al., 2006)), 
which may be dependent on a physical interaction with PARP-1 itself.  Although the 
role of PARG in DNA damage repair is not completely understood, some studies 
suggest that PARG contributes in at least two ways.  First, by creating free ADPR via 
PAR hydrolysis, PARG (and ADP-ribose pyrophosphorylase) participates in the local 
production of ATP molecules.  In this regard, ATP is absolutely required for the DNA 
replication and ligase activities that occur in order to sufficiently repair damaged DNA 
sites (Oei and Ziegler, 2000).  Second, PARG may regulate the activity of PARP-1 in 
the PARylation of target proteins.  This action of PARG has yet to be shown, but the 
idea makes sense considering the deletion of the full-length PARG isoform in mice 
down-regulates PARP-1 auto-modification.  Overall, the actions of PARP-1 and 
PARG in DNA damage repair and detection are considerable, but more studies are 
needed to discern the exact mechanisms of action within each repair pathway. 
 
1.6.2.  Cell Death Pathways 
 Under conditions of extensive DNA damage, PARP-1 acts to promote cell 
death, as noted above.  To do so, PARP-1 acts in at least two ways, (i) energy failure-
induced necrosis, and (ii) apoptosis-inducing factor (AIF)-dependent apoptosis (Kim 
et al., 2005).  With respect to the former, PARP-1 over-activation leads to massive 
depletion of NAD+ and ATP pools, and subsequently, complete cellular energy failure.  
In this regard, actively dividing cells that are dependent on ATP are more sensitive to 
this catastrophic energy depletion, resulting in necrotic cell death (Zong et al., 2004).  
With respect to the latter, in a more ordered response, PARP-1 activation induces the 
translocation of AIF from the mitochondria to the nucleus (Yu et al., 2002).  There, 
AIF induces chromatin condensation and subsequent DNA fragmentation (Susin et al., 
1999).  The mechanism of how PARP-1 triggers the release of AIF from mitochondria 
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is not clear, but may involve the small fraction of PARP-1 that localizes to the 
mitochondria.  PARG may be involved in this process by preventing massive cell 
death through replenishing ATP pools, therefore guiding the cell toward apoptosis as 
opposed to necrosis (Table 1.1; (Desnoyers et al., 1995)).  It is also possible that the 
mitochondrial PARG is involved in AIF release.  The decision to enter a necrotic 
versus apoptotic pathway is likely to be regulated by a number of factors (i.e., type, 
strength, and duration of the DNA damage stimulus) and much work is needed to 
understand the triggering mechanisms of one pathway versus the other. 
 Once a cell is committed to the apoptotic pathway, caspase-dependent cleavage 
of both PARP-1 and PARG occurs (Affar et al., 2001; Boulares et al., 1999).  For 
PARP-1, this cleavage results in a short N-terminal fragment and a longer C-terminal 
fragment that retains basal activity, but lacks the ability to be induced by DNA 
damage (Kaufmann et al., 1993).  This can protect the cell from ATP depletion and 
from entering the necrotic pathway.  Likewise, PARG cleavage results in the 
generation of a C-terminal fragment that retains full PAR hydrolysis activity (Affar et 
al., 2001).  Although not completely understood, the caspase-dependent cleavage of 
PARP-1 and PARG suggest a higher level of regulation for these two enzymes as they 
modulate PAR metabolism during apoptosis. 
 
1.6.3.  Insulator Function 
 Some time ago, PARP-1 was implicated in regulating the DNA-binding factor 
CTCF, at transcriptional insulators (Yu et al., 2004).  Specifically, the ability of CTCF 
to limit the extent of expression of a specific locus (i.e., Igf2-H19), through changes in 
chromatin structure, was dependent on PARylation.  More generally, this group 
showed that many sites of PARylation were also sites of CTCF occupancy on the 
genome, although the functional significance of this observation was not clear.  Also, 
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CTCF was immunoprecipitated from cells and it was determined that it was, indeed, 
PARylated.  More recently, the PARylation sites of the CTCF protein were 
determined (Farrar et al., 2010).  And, upon mutating these sites, CTCF function in 
transcriptional activation, insulator function, and the inhibition of cell proliferation 
were disrupted, demonstrating a functional significance of PARylation of CTCF.  
Interestingly, PARP-1 and CTCF were recruited to the same genomic loci, and 
presumably interact, in a manner independent of CTCF PARylation.  Although PARG 
has not been studied for a role in insulator function, it is feasible to imagine that 
PARG contributes to the dynamic regulation of PAR at insulators. 
 
1.6.4.  Regulation of DNA Methylation Patterns 
 One of the newest roles for PARP-1 in the cell is regulating DNA methylation 
patterns, which is generally associated with gene repression.  PARP-1 can regulate the 
expression and activity of the DNA methyltransferase Dnmt1 (Caiafa et al., 2009; 
Caiafa and Zlatanova, 2009; Guastafierro et al., 2008), the enzyme that creates this 
stable, epigenetic mark on DNA.  Specifically, PARP-1 binds to the promoter of the 
Dnmt1 gene and protects it from silencing by DNA methylation in a PAR-dependent 
manner.  Interestingly, over-expression of PARG leads to atypical DNA methylation 
at the Dnmt1 promoter, leading to Dnmt1 silencing (Zampieri et al., 2009).  Although 
a role for PARP-1 in regulating DNA methylation has been emerging, this study is the 
first to demonstrate a role and a mechanism for PARG in this process.  Interestingly, 
Dnmt1 can bind PAR, which inhibits its methyltransferase activity (Reale et al., 2005).  
Furthermore, PARyation of CTCF may contribute to this process by providing a PAR 
source for the inactivation of Dnmt1 (Guastafierro et al., 2008).  Further studies are 
needed to fully elucidate the mechanisms of PARP-1 and PARG function in this area. 
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1.6.5.  Regulation of Chromatin Structure  
 Several studies demonstrating the regulation of chromatin structure by PARP-1 
and PARG have emerged over the last decade.  Modulation of chromatin structure can 
affect the transcriptional outcomes of underlying genes as well as the ability of DNA 
repair and replication enzymes to access the DNA during DNA repair and cell death 
pathways.  As shown in the earlier studies, PARP-1 could disrupt chromatin structure 
by PARylating histones, which resulted in the destabilization of nucleosomes 
(Huletsky et al., 1989; Mathis and Althaus, 1987; Poirier et al., 1982).  Other studies 
have shown that PARP-1 can PARylate chromatin-associated (non-histone) proteins or 
complexes, also resulting in changes in chromatin structure.  For example, the 
nucleosome remodeling ATPase, ISWI, is inactivated upon PARylation in Drosophila 
(Sala et al., 2008).  In addition, proteins containing PAR-binding motifs or domains 
can be recruited to sites of PARylation in the genome (Timinszky et al., 2009).  If such 
proteins are chromatin-associated components, such as the histone variant 
macroH2A1, chromatin structure could also be affected.  Furthermore, biochemical 
assays show that PARP-1 can bind to nucleosomes and compact the chromatin by 
bringing neighboring nucleosomes together (Kim et al., 2005; Wacker et al., 2007).  In 
the presence of NAD+, PARP-1 undergoes auto-PARylation and releases from the 
nucleosomes, resulting in the decondensation of chromatin (Kim et al., 2005; Wacker 
et al., 2007).  This action can be reversed with the addition of PARG, resulting in the 
reduction of PAR and the allowing of PARP-1 to re-engage interactions with 
nucleosomes, as expected (Kim et al., 2005).  Many studies in Drosophila have shown 
that PARP inhibition or disruption of the dPARP gene blocks PAR accumulation, 
chromatin decondensation, and transcription at inducible genes (i.e., the heat shock 
gene, Hsp70) (Petesch and Lis, 2008; Tulin et al., 2003; Tulin and Spradling, 2003; 
Tulin et al., 2002).  Interestingly, one study suggests that dPARP is required for the 
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wholesale opening of the chromatin at the Hsp70 locus upon heat shock in a 
transcription-independent manner, further emphasizing a role for PARP-1 in the 
regulation of chromatin structure (Petesch and Lis, 2008). 
 Although the biochemical results suggest a simple model of chromatin 
compaction and decondensation in vitro, the mechanisms of chromatin structure 
regulation in mammalian systems are somewhat less clear.  A recent genomic 
localization study demonstrated that PARP-1 localizes to the promoters of almost all 
actively transcribed genes (Krishnakumar et al., 2008), suggesting a role for PARP-1 
in promoting chromatin formation that is permissive to transcription.  Likewise, a 
recent study showed that PARG localizes to promoters of a subset of genes in a pattern 
similar to that of PARP-1 (Frizzell et al., 2009), although the genomic localization 
pattern is still unknown.  PARP-1 has been shown to be able to modulate the 
association of chromatin-binding factors, such as the linker histone H1 and DEK, both 
of which function in transcriptional repression (Gamble and Fisher, 2007; Kappes et 
al., 2008).  Additionally, PARylation of the insulator protein CTCF can lead to the 
compaction of chromatin to higher order structures (Guastafierro et al., 2008).  In 
almost all of these examples, the enzymatic functions of PARP-1 and PARG are 
required to regulate chromatin structure through PARylation of histones or associated 
factors.  However, the functional consequences of specific chromatin structure 
formation at specific genomic regions remain to be determined. 
The regulation of chromatin structure in mammalian systems seems to be more 
complicated than that in Drosophila, for example, where more than one mechanism of 
regulation may apply.  Also, there have been no reports of wholesale opening or 
closing of chromatin structure at specific gene loci in mammalian cells; however, 
localized changes in chromatin structure or composition have been described (Ju et al., 
2006; Kim et al., 2004; Krishnakumar et al., 2008).  This suggests that PARP-1 
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function in the regulation of chromatin structure in higher order eukaryotes may have 
evolved beyond the simpler models described in Drosophila. 
 
1.6.6.  Transcriptional Regulation 
 Many studies have demonstrated a clear role for PARP-1 in transcriptional 
regulation, but only a handful of studies have demonstrated a role for PARG in gene 
expression. Furthermore, while PARP-1, and likely PARG, localizes to a large 
percentage of expressed genes (Krishnakumar et al., 2008), only a small percentage of 
those genes are actually regulated by PARP-1 (Frizzell et al., 2009).  This suggests 
that transcriptional regulation is likely to involve multiple mechanisms.  Although the 
data for PARG is still emerging, many of the same mechanisms of transcriptional 
regulation are likely to apply.  Specifically, PARP-1 has been shown to regulate gene 
expression through (i) regulation of chromatin structure (discussed above), (ii) 
coregulator action, and (iii) insulator function (discussed below). 
In the case of coregulator function, PARP-1 may be recruited to target 
promoters as a functional endpoint of signaling pathways.  PARP-1 interactions with 
transcription factors (i.e., NFκB, E2F-1; (Hassa et al., 2001; Hassa et al., 2005; 
Simbulan-Rosenthal et al., 2003)) or transcription complexes (i.e., Mediator; (Ju et al., 
2004; Pavri et al., 2005)) at promoters can mediate gene expression outcomes.  For 
example, PARP-1 has been shown to mediate the exchange of (i) an inactive cdk8-
positive Mediator subunit for an active cdk8-negative Mediator subunit during retinoic 
acid signaling (Pavri et al., 2005), and (ii) a TLE1 corepressor complex for a HAT-
containing coactivator complex during signal-dependent gene regulation in neuronal 
cells (Ju et al., 2004).  Interestingly, in addition to factor exchange, PARP-1 has been 
shown to recruit topoisomerase IIβ (TopoIIβ), which can cleave the promoter during 
hormone-induced transcriptional activation (Ju et al., 2006; Ju et al., 2004).  This 
27 
result suggests a new potential mechanism of general transcriptional activation (i.e., 
promoter cleavage), and it demonstrates a multi-pronged approach for gene regulation 
by PARP-1.  Also, PARP-1 enzymatic activity is required for some of these functions 
and is likely to be cell type-, gene-, and signal-specific.  For example, HES1-mediated 
transcription requires PARP-1 enzymatic activity, but not for NFκB- or RAR-
mediated transcription (Hassa and Hottiger, 2002; Kraus and Lis, 2003). 
 Very few studies have focused on regulation of gene expression by PARG.  
Use of a PARG inhibitor activated pro-inflammatory genes in macrophages in a PAR-
dependent manner (Rapizzi et al., 2004), suggesting a role for PARG in gene 
expression, although the mechanism of action is unknown.  One can speculate that 
perhaps PARG acts to regulate PARP-1 activity at target genes.  Or, perhaps PARG 
can regulate gene expression as a coactivator-like protein.  It was demonstrated in 
Drosophila that the absence of PARG activity could disrupt chromatin remodeling and 
transcription during development (Hanai et al., 2004).  One additional study suggests 
that PARG may take on an even more prominent role in regulating transcription by 
dictating the location of transcriptional coregulators (Tulin et al., 2005). 
Interestingly, a recently published global analysis of transcriptional regulation 
showed that both PARP-1 and PARG regulate a similar set of target genes, and that 
they do so in a similar manner (Frizzell et al., 2009).  That is, they regulate the same 
genes in similar directions (both positive and negative) and with similar magnitudes.  
This result coupled with the promoter localization patterns of PARP-1 and PARG, 
suggests a concerted action of PARP-1 and PARG.  Furthermore, this study 
demonstrated a gene-specific requirement for both PARP-1 and PARG enzymatic 
activities with respect to gene regulatory outcomes (Frizzell et al., 2009). 
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1.6.7.  Signal-mediated Transcriptional Regulation 
 A growing body of evidence suggests that PARP-1 functions in signal-
mediated transcriptional responses in the absence of DNA damage.  A few signaling 
pathways have received considerable attention over the past few years and have 
yielded interesting mechanisms of regulation by PARP-1.  They include, NFκB-
dependent proinflammatory responses, heat shock, hormone signaling, and kinase-
dependent signaling.  For example, in response to inflammatory stimuli, PARP-1 is 
acetylated by p300/CBP and subsequently interacts with NFκB subunits and 
components of the Mediator complex to stimulate pro-inflammatory target genes as a 
classic coactivator (Hassa et al., 2003; Hassa et al., 2005).  Recent studies also link 
PARP-1 to the activation of players of the pro-inflammatory pathway upstream of 
NFκB (i.e., IκB kinase) through PARylation activity (Stilmann et al., 2009).  In this 
regard, PARG may be able to add an additional level of regulation of NFκB-
dependent transcription by modulating the activation of IκB.  However, since the 
coactivator function of PARP-1 in this system seemingly does not require PARylation 
activity, it will be interesting to determine if and how PARG functions at those gene 
targets.  Notably, PARG inhibition alters the expression of proinflammatory response 
genes (Erdelyi et al., 2005; Rapizzi et al., 2004), although the mechanism is unclear. 
The studies focused on the heat shock response have elucidated many facets of 
transcriptional regulation by PARP-1 through its role in modulating chromatin 
structure. The results may be specific to Drosophila, as they have yet to be 
demonstrated parallel in mammalian systems, however the concepts may still apply.  
As noted above, upon heat shock, dPARP is activated and participates in the 
chromatin decondensation (a.k.a. “puffing”) at heat shock loci (Petesch and Lis, 2008; 
Tulin et al., 2003; Tulin and Spradling, 2003).  It was recently shown that this 
involves nucleosome loss across the heat shock loci in a transcription-independent 
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manner (Petesch and Lis, 2008).  What controls this mechanism of action is not 
currently known, but may involve interactions with other factors involved in the heat 
shock response at heat shock loci.  PARG-dependent hydrolysis of PAR may 
contribute to this process, but has yet to be shown. 
 Through regulation of chromatin structure and coregulator complex 
components, PARP-1 has been shown to play a role in classic signaling pathways 
involving hormone signaling (i.e., estrogen, retinoic acid; (Ju et al., 2004; Pavri et al., 
2005)) and kinase cascades (i.e., Erk1/2, JNK1, CaMKIIδ; (Cohen-Armon et al., 2007; 
Ju et al., 2004; Kauppinen et al., 2006; Mathieu et al., 2008)).  In some cases, these 
types of signaling pathways may overlap.  In addition, some signaling pathways have 
been shown to result in phosphorylation of PARP-1, which can alter its activity 
(Kauppinen et al., 2006).  Similarly, PARG has been shown to be a target of 
phosphorylation, however, it is not known what the functional significance of this is.  
Since PARP-1, and likely PARG, is modified by various post-translational 
modifications, it is feasible to think that the signaling cascades that govern those other 
types of enzymes may also regulate PARP-1 (and PARG) actions. 
 In all of these examples, the factors involved in determining the overall 
function in one signaling pathway over another, coactivator action versus chromatin 
modulator action, and resulting direction of gene regulation has yet to be identified.  It 
is likely that a host of determinants function to distinguish the various roles of PARP-
1, including the signal- and cell-type, the duration of the signal, and specific genes, as 
well as some factors previously mentioned above (i.e., post-translational modifications 
of PARP-1, subcellular or genomic localization, and substrate availability). 
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1.7.  Global Gene Expression Studies 
Genomic expression studies have been used to identify PARP-1-regulated 
genes in various cell types, some of which are derived from knockout animal models.  
This type of analysis has yielded various ontological categories of genes whose 
expression depends on PARP-1 or PARG actions, which provide insights into the 
molecular and biological functions of PAR-regulating enzymes.   
Comparisons of wild type- and PARP-1-/--derived cell lines (i.e., MEFs, heart 
endothelial cells, liver-derived, and embryonic stem cells) using mouse expression 
microarrays (Carrillo et al., 2004; Ogino et al., 2007; Saenz et al., 2008; Simbulan-
Rosenthal et al., 2000; Zingarelli et al., 2003) resulted in genes enchriched in 
apoptosis, metabolism, cell cycle control, DNA synthesis/repair, stress or immune 
response, signal transduction, transcription, chromosomal integrity, and protein 
processing.  In MCF-7 cells, similar ontological categories were enriched by PARP-1- 
and PARG-regulated genes; namely, metabolism, stress response, cell structure, and 
GTPase regulation (Frizzell et al., 2009).  These data sets corroborate many studies 
showing PARP-1 and PARG function in molecular actions such as DNA repair, stress 
response, cell cycle control, signal transduction, and transcription.  In addition, these 
data suggest more broad functions for PARP-1 and PARG in cancer, inflammation, 
differentiation, and development.  The cellular actions of these PAR-regulating 
enzymes contribute directly to physiological and pathophysiological conditions. 
 
1.8.  Physiological and Pathophysiological Actions of PAR-regulating Enzymes 
 
 Parp-1 and Parg knockout animal models have been generated and fairly well 
characterized in M. musculus and D. melanogaster.  However, only a handful of 
studies have described PARP-1 or PARG homologs in C. elegans and A. thaliana.  
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This section focuses on the contributions of PARP-1 and PARG in various 
physiological and pathophysiological conditions, including aging, inflammation, 
differentiation, and carcinogenesis, as determined by knockout animal models (Table 
1.2).  The data described herein is primarily from mouse and fly models, however, 
findings from other animal and plant models are mentioned where appropriate. 
 
1.8.1.  Viability and Genomic Integrity 
 Due to their roles in maintaining genomic integrity and DNA damage repair, it 
was quite surprising that the first developed Parp-1-/-, Parp-2-/-, and PargΔ2-3/Δ2-3 mice 
are viable and exhibit minimal phenotypes (Cortes et al., 2004; Masutani et al., 1999a; 
Masutani et al., 1999b; Menissier de Murcia et al., 2003; Wang et al., 1995; Wang et 
al., 1997).  For Parp-1-/- mice and Parp-1-/--derived embryonic fibroblasts, initial 
observations reported an increased genomic instability associated with a higher 
frequency of sister chromatid exchange, homologous recombination, and micronuclei 
formation (de Murcia et al., 1997; Kim et al., 2005; Wang et al., 1997).  Under certain 
conditions, genetic backgrounds, or in response to chemical agents, additional 
phenotypes were revealed.  Upon exposure to ionizing radiation or alkylating agents, 
an the frequencies of DNA deletions/insertions, chromosome rearrangements, and 
chromatid breaks increased, and the ability to repair the DNA was disrupted 
(Halappanavar et al., 1999; Masutani et al., 1999a; Masutani et al., 1999b; Menissier 
de Murcia et al., 2003; Shibata et al., 2005; Simbulan-Rosenthal et al., 1999; Trucco et 
al., 1998; Wang et al., 1995; Wang et al., 1997; Yu et al., 2002).  This type of 
hypersensitivity to DNA damaging agents was also evident in Parp-2-/- mice 
(Menissier de Murcia et al., 2003).  These results further corroborate the notion that 
PARP-1 and PARP-2 have overlapping and redundant functions.  In fact, Parp-1-/-
/Parp-2-/- double knockout mice display embryonic lethality prior to E8.0 (Menissier 
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de Murcia et al., 2003).  Interestingly, Parp-1+/-/Parp-2-/- mice show female-specific 
embryonic lethality by E9.5, which was linked to X chromosome instability in those 
females (Menissier de Murcia et al., 2003).  PargΔ2-3/Δ2-3 mice (deletion of exons 2 and 
3, resulting in targeted depletion of the 110-kDa isoform) were shown to also be 
highly sensitive to genotoxic stresses, exhibiting increased lethality (Cortes et al., 
2004).  Interestingly, a PargΔ4/Δ4 embyos (deletion of exon 4, resulting in complete 
depletion of all isoforms) displayed embryonic lethality at E3.5, which was attributed 
to increased apoptosis in embryonic tissues (Koh et al., 2004). 
 The mild or context-dependent phenotypes of the Parp-1-/- and Parg-/- mice are 
likely due to functional redundancy with other PARP family members or PARG 
isoforms, respectively.  However, in Drosophila, the story is quite different, as flies 
only have a single PARP-1-like gene, and a single PARG gene that seemingly encodes 
a single protein isoform.  The phenotype for Parp-/- (null) or ParpCH1/CH1 (reduction in 
expression) in Drosophila is quite dramatic, resulting in larval lethality, likely due to 
increased bacterial infection, changes in chromatin structure, and defective gene 
expression (Miwa et al., 1999; Tulin and Spradling, 2003; Tulin et al., 2002).  
Interestingly, the phenotype for Parg27.1/Y and Parg27.1/27.1 (deletion of the catalytic 
domain) mutants display PAR accumulation and temperature-dependent lethality 
(Hanai et al., 2004).  For example, the mutant exhibited larval lethality at the normal 
development temperature (25°C), but at 29°C, ! of the larvae developed to the adult 
stage and exhibited neurodegenerative phenotypes and a reduced lifespan. 
The phenotype of increased sensitivity to genotoxic stresses is corroborated by 
studies in worm and plant models.  Just a few years ago, the PARP-1- and PARG-like 
genes in C. elegans were identified.  Although genetic manipulations (i.e., knockouts) 
have yet to be made, one study characterized the knockdown of the Parg homologues, 
pme-3 and pme-4, also exhibit sensitivity to ionizing radiation (St-Laurent et al., 
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2007).  Likewise, in A. thaliana, the PARP-1-like genes have been identified, but no 
genetic manipulations exist.  However, mutant Parg1 seedlings exhibit growth 
inhibition and are hypersensitive to DNA damaging agents (Adams-Phillips et al., 
2010).  Taken together, these results demonstrate the importance of regulating PAR in 
animals and plants for the maintenance of genomic integrity, gene expression, and 
development, among other biological processes.  Still, more work is needed to fully 
characterize these models in order to gain a complete understanding of the 
physiological contributions of PARP-1 and PARG. 
 
1.8.2.  Inflammation and Stress Responses 
PARP-1 has been implicated in inflammation and stress responses in a wide range of 
studies from animals to plants.  From simplistic models (i.e., bacterial infection) to 
more complex models (i.e., streptozotocin-induced diabetes or ischemia/reperfusion), 
PARP-1 is a key component of immunity and inflammatory responses in various 
tissues, including the brain and heart.  In many cases, PARP-1 activity is highly 
increased upon cellular stress (Nossa et al., 2009; Tulin and Spradling, 2003) and 
Parp-/- confers a protective effect against infections, toxins, and injury (Ha, 2004; 
Mabley et al., 2001; Oliver et al., 1999).  Conversely, PargΔ2-3/Δ2-3 (110 kDa targeted 
deletion) increases the sensitivity in response to various stresses (Cortes et al., 2004), a 
result suggesting that PARG plays a protective role against such system shocks.  From 
what is known about PARP-1 and PARG molecular functions, it is safe to say that 
their roles in modulating inflammatory responses involve multiple actions.  For 
example, PARP-1 could increase cell death and mediate pro-inflammatory gene 
transcription (through NF-κB pathway) in response to a single agent (Kim et al., 
2005).  In this regard, Parp-/- mice display a down-regulation of pro-inflammatory 
genes (Hassa and Hottiger, 2002; Shall and de Murcia, 2000; Zingarelli et al., 1998), 
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while PargΔ2-3/Δ2-3 mice show an increase of cytokines in the blood serum (Cortes et 
al., 2004),  This result is likely due to an increase in pro-inflammatory gene 
expression, a result also seen with PARG inhibitor treatment (Rapizzi et al., 2004).  
In a model of neuronal injury, the generation of reactive oxygen species and 
nitric oxide cause an increase in DNA damage and PARP-1 activation, leading to 
necrotic cell death (Cole and Perez-Polo, 2004).  In Parp-/- mice, this neurotoxic effect 
is blocked (Cole and Perez-Polo, 2004; Ha and Snyder, 2000; Mandir et al., 2000; 
Zhang et al., 1994).  Interestingly, Parg27.1/27.1 (deletion of the catalytic domain) in 
Drosophila exhibit progressive neurodegeneration in adult flies that survive the 
embryonic lethal phenotype (Hanai et al., 2004).  Together these results suggest that 
the regulation of PAR is important in mediating normal neuronal functions in response 
to injury.  Likewise, in a model of cerebral ischemia/reperfusion, PARP-1 activity is 
also increased and Parp-/- or chemical inhibition exerts a beneficial effect (Eliasson et 
al., 1997; Virag and Szabo, 2002).  However, in this model, treatment with a PARG 
inhibitor can also have a protective effect (Lu et al., 2003).  This protective effects was 
also shown in a kidney ischemia/reperfusion model where PargΔ2-3/Δ2-3 attenuated the 
injury and inflammation phenotype (Patel et al., 2005).  The differences noted here 
might be due to the type or severity of injury, tissue-type, or genetic manipulation.  In 
any case, the result stands that PARP-1 and PARG regulation of PAR is strikingly 
important in modulating responses to stress, inflammation, and injury. 
PARP-1 and PARG homologues in the Arabidopsis model have recently been 
studied in regard to abiotic and biotic stress responses, respectively, in knockdown, 
mutant, or knockout studies (Adams-Phillips et al., 2010; De Block et al., 2005; 
Vanderauwera et al., 2007).  Interestingly, it was shown that the tej mutation in the 
PARG gene disrupted circadian clock-regulated transcription (Panda et al., 2002), 
which may have also an effect on stress responses.  Collectively, PARP-1 disruption 
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Table 1.2.  Summary of combination knockout animals and their phenotypes.  
Parp-1-/- mice have been combined with several knockout mice to determine the 
consequences of a double knockout animal in overall viability, genomic integrity, 
developmental processes, and carcinogenesis.  Although studied under specific 
contexts with regard to specific questions, their reported phenotypes are interesting, 
nonetheless, and justify further investigation in each field. 
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Combination Knockout Phenotypes (ref)  
 
(a) Parp-1-/-/Parp-2-/-  - Embryonic lethality at E8.0 
  (Menissier de Murcia et al., 2003) 
 
(b)  Parp-1-/-/Parg(110)-/-  - Spermiogenesis defects (reduced nuclear elongation 
and chromatin condensation) 
  (Meyer-Ficca et al., 2009) 
 
(c)  Parp-1-/-/p53-/- - Enhanced tumorigenesis in mammary, lung, prostate, 
 (exon 2) skin, and brain tissue 
- Severe chromosome abberations 
  - Disruption of transcriptional responses 
  (Tong et al., 2001; Tong et al., 2003) 
  
 Parp-1-/-/p53-/- - High genomic instability 
 (exon 4) - Decreased tumor formation in T-cell lymphomas 
  - Disruption of transcriptional responses 
  (Conde et al., 2001) 
 
(d)  Parp-1-/-/SCID - Severely high frequency of T-cell lymphoma 
 (DNA-PK mut) (Morrison et al., 1997) 
 
(e)  Parp-1-/-/Atm-/-  - Embryonic lethality at E8.0 
  - Increased apoptosis 
  (Menisser-de Murcia et al., 2001) 
 
(f)  Parp-1-/-/H2AX-/-  - Embryonic lethality 
  (Orsburn et al., 2010) 
 
(g)  Parp-1-/-/53BP1-/-  - Modestly enhances growth retardation, genomic 
instability, and radiosensitivity phenotypes of Parp-1-/- 
  (Orsburn et al., 2010) 
 
(h)  Parp-1-/-/Polβ -/-  - Reverses the MMS-dependent sensitivity of Polβ-/- 
  (Jelezcova et al., 2010) 
 
(i)  Parp-1-/-/Ku80-/-  - Embryonic lethality 
  - Increased apoptosis 
  (Henrie et al., 2003) 
 
(j)  Parp-1-/-/Sirt1-/-  - Increased telomere abnormalities 
  - Decreased cell growth 
  - Increased pot-natal lethality 
  - Reverses genomic abnormalities, nucleolar 
disorganization, and mitotic defects of Sirt1-/- 
  (El Ramy et al., 2009) 
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results in resistance, while PARG disruption results in sensitivity to various stresses in 
plants, much like the results from mouse and fly models. 
 
1.8.3.  Juvenile-onset Diabetes 
 Type-1 diabetes results in the destruction of insulin-producing β-cells of the 
pancreas.  During this process, cytokines, reactive oxygen species, and nitric oxide are 
released, contributing to β-cell death (Bluestone et al., 2010).  Many groups have 
shown that PARP-1 null mice display resistance to the induction of type-1 diabetes by 
streptozotocin treatment (Gonzalez et al., 2002; Mabley et al., 2001; Oliver et al., 
1999; Pieper et al., 1999).  In this regard, Parp-1-/- mice show reduced hyperglycemia, 
normal blood glucose, normal pancreatic islet structure, and a lower incidence of 
diabetes as compared to wild type counterparts upon streptozotocin treatment (Mabley 
et al., 2001; Pieper et al., 1999).  A similar finding was shown upon treatment with a 
PARP inhibitor (Mabley et al., 2001).  Parp-1+/- mice also provide protection, though 
not as dramatic as the null animal (Pieper et al., 1999).  Interestingly, Parg(110)-/- 
mice (targeted depletion of the 110 kDa isoform) displayed an increased susceptibility 
to streptozotocin-induced diabetes (Cortes et al., 2004).  PARP-1 has also been shown 
to bind and regulate the Reg gene, which is known to mediate islet-cell regeneration, 
in a PAR-dependent manner (Akiyama et al., 2001).  Given the role of PARP-1 in 
gene regulation through chromatin modulation and coregulator action, it is feasible to 
think that gene regulatory aspects may also contribute to this process.  This is 
supported by the idea that PARP-1 is linked to endothelial dysfunction, an underlying 
condition to many diabetes-related symptoms, through NF-κB activation (Garcia 
Soriano et al., 2001).  These data suggest that PAR-regulation is important in 
pancreatic β-cell pathology and the onset of type-1 diabetes. 
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1.8.4.  Differentiation and Development 
 PARP-1, PARP-2, and PARG knockout mice develop normally (Cortes et al., 
2004; Koh et al., 2004; Masutani et al., 1999a; Masutani et al., 1999b; Menissier de 
Murcia et al., 2003; Wang et al., 1995; Wang et al., 1997), however, the combination 
of PARP-1/PARP-2 double knockout is embryonic lethal (Menissier de Murcia et al., 
2003).  Interestingly, the complete knockout of PARG in mice, rather than just the 110 
kDa isoform, results in embryonic lethality (Koh et al., 2004).  In Drosophila, the 
knockout animals have a more dramatic phenotype, that is, dPARP and dPARG 
knockouts are lethal at the larval stage (Cortes et al., 2004; Koh et al., 2004).  
Collectively, these results suggest that PARPs and PARG are critical for embryonic 
development (Menissier de Murcia et al., 2003).  This requirement is likely due to a 
variety of factors, including maintenance of genomic integrity and transcriptional 
responses.  New studies are beginning to shed light on the actions of PARPs and 
PARG in differentiation and development, however, there is still much to be learned. 
Germline – Recent studies have suggested a role for PARP-1 and PARP-2 in 
germline development.  Parp-1-/- and Parp-2-/- mice are fertile (de Murcia et al., 1997; 
Masutani et al., 1999a; Menissier de Murcia et al., 2003; Wang et al., 1995), but 
display some defects in oogenesis and spermiogenesis.  For example, Parp-1-/- female 
mice show meiotic defects, including persistent H2AX phosphorylation, increased 
double strand DNA breaks, deficient sister chromatid cohesion, suggesting a role for 
PARP-1 in maintaining chromatin states during oogenesis (Yang et al., 2009).  On the 
other hand, Parp-2-/- male mice have lower fertility attributed to defects in meiotic sex 
chromosome inactivation (Dantzer et al., 2006).  During spermiogenesis, massive 
reorganization of the nucleus occurs; cells elongate, chromatin condenses, 
transcription stops, and histones are replaced by basic proteins (Quenet et al., 2009a).  
Interestingly, PAR levels are at their highest in spermatids where the higher rates of 
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chromatin nucleoprotein exchanges take place (Meyer-Ficca et al., 2005b).  In absence 
of PARP-2, nuclear elongation is delayed and X- and Y-linked expression persists 
(Dantzer et al., 2006; Quenet et al., 2009b).  In addition, Parp-1-/-, Parg(110)-/-, and 
Parp-1-/-Parg(110)-/- double knockout mice exhibit reduced nuclear elongation and 
chromatin condensation (Meyer-Ficca et al., 2009).  Notably, macroH2A1 and PARP-
1 physically and functionally interact to regulate X chromosome inactivation 
(Nusinow et al., 2007), so a functional connection between the PAR-regulating 
enzymes and macroH2A1 may be causal for such germline phenotypes. 
Stem Cells – Recently, studies have revealed a role for PARP-1 in stem cell 
differentiation and reprogramming.  As noted above, gene expression experiments 
using embryonic stem cells (ESCs) derived from PARP-1 null mice show altered 
expression patterns compared to their wild type counterparts (Ogino et al., 2007).  A 
recent study has identified PARP-1 as a cofactor of Oct4 and Sox2 inhibitory 
transcription factors that function in maintaining the pluripotent state of ESCs (Gao et 
al., 2009).  Upon induction of differentiation, PARP-1 physically interacts with and 
PARylates Sox2, leading to the dissociation of Sox2 from the FGF4 enhancer and its 
subsequent degradation.  This action causes an increase in FGF4 expression and 
promotes differentiation.  Interestingly, another study suggests that PARP-1 can 
inhibit ESC differentiation (Hemberger et al., 2003).  Specifically, the study shows 
that ESCs derived from Parp-1-/- mice promotes the development of teratocarcinoma-
like tumors when injected subcutaneously into nude mice.  These results suggest that 
PARP-1 may primarily regulate the pluripotency of ESCs, rather than differentiation. 
Other Cell Differentiation Models – PARP-1 and PARP-2 have also been 
shown to be involved in the differentiation of other cell types, including neuronal, 
immune, endodermal, and fat cells (Ambrose et al., 2009; Bai et al., 2007; Ju et al., 
2004; Morrison et al., 1997; Quenet et al., 2008).  Although not explicitly shown with 
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regard to neuronal differentiation morphology, PARP-1 was shown to regulate 
neuronal gene expression by regulating factor exchange at the promoters of genes 
required for differentiation (Ju et al., 2004).  In immune-related cells, PARP-1 is 
required for T cell-dependent antibody responses (Ambrose et al., 2009) and PARP-2 
is required for T cell survival during thymopoiesis (Yelamos et al., 2006).  
Interestingly, another study shows that PARP-1 knockout in mice actually promotes 
the formation of a specific type of functional T cell (CD4+/CD25+/Foxp3+) (Nasta et 
al., 2010).  The endodermal differentiation models yielded slightly different results in 
that PARP-1 and PARP-2 function in sequence to promote the full differentiation of 
embryonic carcinoma F9 cells into primitive endoderm-like cells and finally into 
parietal endoderm-like cells (Quenet et al., 2008).  Interestingly, even though PARP-1 
and PARP-2 act independently of one another, they both act through physical and 
functional interactions with the heterochromatin-associated proteins HP1 and TIF1β.  
PARP-2 has been implicated in adipogenesis, whereby it functions as a coregulator of 
the PPARγ adipogenic transcription factor (Bai et al., 2007).  And, recently, PARP-1 
was shown to antagonize adipogenesis progression (Devalaraja-Narashimha and 
Padanilam, 2010), although the molecular mechanisms of this action have not been 
determined.  Importantly, this model of adipogenesis can be linked to the onset and 
development of type-2 diabetes and obesity. 
 Collectively, the studies of stem cell and other models of cellular 
differentiation have revealed somewhat controversial roles for PARP-1 in the 
differentiation process.  While some studies have determined that PARP-1 promotes 
differentiation, others have suggested PARP-1 inhibits differentiation.  There does not 
seem to be a unified function for PARP-1 in these processes.  This indicates that there 
are other determinants that may regulate PARP-1 action, such as cell type and 
microenvironment.  In addition, there seems to be a controversy as to whether PARP-1 
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and PARP-2 cooperate or antagonize one another in these systems, suggesting they 
may have multiple independent functions.  There is still much to learn about the 
molecular mechanisms as to how these PAR-regulating enzymes act to regulate the 
differentiation process.  As the field progresses, it will be interesting to see how 
PARPs and PARG regulate these differentiation systems. 
 
1.8.5.  Carcinogenesis 
 Carcinogenesis is the process by which normal cells transform into cancer 
cells.  This progression is likely mediated by a host of cellular processes, including 
genome and cell cycle maintenance, proliferation, differentiation, and cell death 
pathways.  PARPs and PARG have been implicated in all of these aspects in the cell, 
as discussed above.  Therefore, it is certainly likely that disruptions in their functions 
can contribute to cancer development.  Parp-1-/-, Parp-2-/-, and Parg-/- mice have not 
been reported to develop spontaneous tumors, most likely due to functional 
redundancy by other PARPs or PARG-like proteins, leading to a viable mouse.  
However, in the context of chemically induced or transgenic mouse models of cancer, 
Parp-1-/- can cause increased tumor formation (Kim et al., 2005; Masutani et al., 
2005).  For example, in Parp-1-/- mice, models of cancer induced by the chemical 
agents N-nitrosobis(2-hydroxypropyl)amine and azoxymethane displayed a higher 
incidence of liver and colon tumors compared to their Parp-1+/+ counterparts (Nozaki 
et al., 2003; Tsutsumi et al., 2001).  Notably, combinations of these types of cancer 
models and Parp-2-/- or Parg-/- deletions have yet to be investigated. 
 The combination of Parp-1-/- mice with other knockout animals known to play 
roles in DNA damage repair or cancer development have suggested important 
functional interactions between PARP-1 and other factors.  Many of these factors have 
already been identified as PARP-1-interacting proteins or PARP-1 targets of 
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PARylation.  For example, the simultaneous depletion of PARP-1 and p53, a tumor 
suppressor gene required for cell cycle checkpoints and apoptosis following DNA 
damage (Hofseth et al., 2004), displays enhanced tumorigenesis in mammary, lung, 
prostate, skin, and brain tissues (Tong et al., 2001; Tong et al., 2003).  The increase in 
tumor formation is attributed to severe chromosome aberrations (i.e., aneuploidy, 
fragmentations, long and heterogeneous telomeres) and disrupted transcriptional 
responses (i.e., Math1-dependent transcription in the brain).  Interestingly, another 
group investigated the same double-knockout mouse, however the targeted exon for 
genetic manipulation was different (Conde et al., 2001).  This mouse also displayed a 
higher genomic instability, but tumor formation was somewhat reduced.  These 
contradictory results suggest that perhaps the genetic backgrounds of the mice or the 
differing targeted exons contribute to the diparities in these studies. 
 The increase in tumorigenesis in the p53 model was not the only study to 
report this type of phenotype.  Interestingly, the corroborating reports also involve 
proteins of the DNA damage response and cell death pathways.  Severe combined 
immunodeficiency (SCID) mice contain a mutation in the gene encoding the DNA-PK 
catalytic subunit (Prkdc), leading to lyphocyte developmental arrest (Schuler et al., 
1986).   Parp-1-/- in the background of the SCID model displays a severely high 
frequency of T-cell lymphoma (Morrison et al., 1997), indicating that PARP-1 and 
DNA-PK cooperate to minimize genomic damage.  Similarly, in Parp-1-/- in 
combination with Atm-/-, the gene encoding a double-strand break repair and cell cycle 
checkpoint protein, show embryonic lethality by E8.0 caused by increased apoptosis 
(Menisser-de Murcia et al., 2001).  In a further analysis of ATM-regulated factors, it 
was shown that H2AX is essential for viability in a PARP-1-deficient background, 
while 53BP1 enhances PARP-1-deficient phenotypes to be slightly more dramatic 
(i.e., growth retardation, genomic instability) (Orsburn et al., 2010).  Together, these 
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results suggest a functional interplay between PARP-1 and p53, DNA-PK, ATM and 
ATM-regulating factors, all components of DNA damage response and cell cycle 
control pathways, in the control of aberrant cell growth and carcinogenesis. 
 Although not investigated with respect to tumor formation, the combination of 
Parp-1-/- with the knockout of other DNA repair factors, like those involved in base-
excision repair (BER), exhibit similar phenotypes as those described above.  For 
example, the double knockout mouse for PARP-1 and DNA Polβ, shown to interact 
and function in BER, synergistically enhanced the defects in both short and long patch 
BER of 8-oxoG lesions (Dantzer et al., 2000; Le Page et al., 2003).  Interestingly, a 
recent study describes the relationship of PARP-1 and DNA Polβ in double knockout-
derived MEFs.  In this case, Polβ-/- alone is sensitive to the DNA damaging agent, 
MMS, while the Parp-1-/- and Polβ-/- together reverses this effect (Jelezcova et al., 
2010).  PARP-1 may therefore function as a tumor suppressor by initiating cell death.  
Finally, PARP-1 interacts with Ku80, a protein in the non-homologous end joining 
(NHEJ) pathway.  The double knockout Parp-1-/- and Ku80-/- mouse resulted in 
embryonic lethality and increased level of apoptosis (Henrie et al., 2003), much like 
that seen in the Parp-1-/-/Atm-/- mouse.  Therefore, it is likely that these phenotypes are 
a pre-cursor to an increase in genetic aberrations and subsequent tumor development. 
 
1.8.6.  Aging 
 The accumulation of DNA damage over time underlies the aging process.  
Since PARP-1 (and other PARPs) play prominent roles in maintaining genomic 
integrity, they have been implicated in aging and longevity (Beneke et al., 2004; 
Burkle et al., 2005a; Burkle et al., 2005b; Burkle et al., 1992).  Initially, this 
connection became apparent with the conclusion that PARP activity correlated with 
species life span (Grube and Burkle, 1992).  In this regard, the regulation of PAR by 
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PARG may be important in the aging process that has yet to be addressed.   Although 
this field has not been studied extensively, studies are beginning to unveil the potential 
role of PARP-1 in the aging process.  For example, PARP-1 interacts with WRN, a 
helicase involved in DNA replication and repair processes (Lebel et al., 2003).  
Interestingly, WRN mutations are prevelant in a genetic disorder leading to premature 
aging in humans (Lee et al., 2005).  In addition, PARP-1 and other PARPs function in 
maintaining telomere length (Chiang et al., 2006; Dantzer et al., 2004; Smith et al., 
1998), which is important in replicating cells to prevent senescence. 
 Importantly, PARP-1 has been shown to have a functional interplay with 
SIRT1, a NAD+-dependent deacetylase and major contributor of the aging process and 
aging-related diseases (Donmez and Guarente, 2010; Zhang and Kraus, 2010).  PARP-
1 and SIRT1 can compete with one another for nuclear NAD+, as well as the by-
product of their enzymatic reactions, nicotinamide, a natural inhibitor of both enzymes 
(Donmez and Guarente, 2010; Kim et al., 2005; Zhang and Kraus, 2010).  This 
supports the previously suggested notion that PARP-1 and SIRT1 function 
antagonistically (Kolthur-Seetharam et al., 2006).  In fact, PARP-1 activation by 
PCAF-dependent acetylation leads to cell-death, while deacetylation of PARP-1 by 
SIRT1 promotes cell survival (Rajamohan et al., 2009).  Interestingly, Parp-1-/-Sirt1-/- 
double knockout mice display increased telomeric abnormalities, decreased cell 
growth, and increased post-natal lethality (El Ramy et al., 2009).  However, Parp-1-/- 
deletion in the Sirt1-/- background can reverse Sirt1-/--specific phenotypes, such as 
abnormal pericentric heterochromatin, nucleolar disorganization, and mitotic defects 
(El Ramy et al., 2009).  In Drosophila, dPARP and dPARG may contribute to the 
regulation of dSir2 (the Drosophila homolog of the mammalian SIRT1) by 
modulating its chromatin localization (Tulin et al., 2005).  Collectively, these results 
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provide evidence for PARP-1 and PARG in the aging process through genomic 
maintenance and functional interactions with various proteins. 
 
1.9.  Therapeutic Applications of PARP-1 and PARG Inhibitors 
  
Chemical inhibition of PARP-1 activity has potential therapeutic applications 
in both acute and chronic diseases.  For example, PARP-1 inhibitors can potentially 
enhance the cytotoxicity of DNA-damaging anticancer drugs, reduce parenchymal cell 
necrosis in conditions such as stroke or myocardial infarction, and inhibit 
inflammation and tissue injury pathways in conditions such as circulatory shock 
diabetes mellitus (Jagtap and Szabo, 2005).  As noted above, PARP-1 deficiency or 
inhibition in mouse and cell models exerts protective effects against pathological cell 
death and inflammatory responses.  Thus, PARP-1 has been an attractive therapeutic 
target for chemical inhibition.  One concern, however, is that chronic use of PARP-1 
inhibitors could pose a long-term risk for genomic instability and secondary cancers 
(Jagtap and Szabo, 2005).  Clinical trials currently underway will help to resolve if 
this concern is justified.  Studies examining the interplay between PARP-1 and SIRT1 
(see above) suggest that chemical modulators of SIRT1 activity may also be useful as 
therapeutic agents for treating PARP-1-dependent diseases. 
 
1.9.1.  Chemistry and Development of PARP-1 Inhibitors 
Nicotinamide (NAm), a product of PARP-1 enzymatic action on NAD+ and a 
weak inhibitor of PARP-1 activity (Curtin, 2006), was used as a model for the first 
PARP-1 inhibitors, including benzamide and 3-aminobenzamide (3AB, Figure 1.3A; 
(Shall, 1975)).  Benzamide and 3AB inhibit PARP-1 activity in the mM range and 
may also inhibit other PARP family members (e.g., PARP-2 and tankyrase; (Ame et 
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al., 1999; Smith et al., 1998), thus lacking the potency and specificity required for 
therapeutic purposes.  Banasik et al. developed 1,5-dihydroisoquinoline and a variety 
of other inhibitors (Banasik et al., 1992), which were used in turn to develop even 
more inhibitors with greater specificity, potency, and solubility, including PD128763 
(Arundel-Suto et al., 1991; Suto et al., 1991), NU1025 (Griffin et al., 1995), and 
NU1085 (Bryant and Helleday, 2004; Curtin, 2006).  These inhibitors are 50- to 100-
fold more potent than benzamides, inhibiting PARP-1 activity in the µM to nM 
concentration range.  Although the improvements are striking, PD128763, NU1025, 
and NU1085 may still not be potent enough for clinical use. 
The “benzamide” style of PARP-1 inhibitor has recently been improved based 
on X-ray crystal structure data.  The incorporation of bi-, tri-, and tetra-cyclic 
frameworks, and cyclic lactam rings, which interact more strongly with the catalytic 
residue Glu988 (e.g., AG14361), has generated even more potent and specific PARP-1 
inhibitors (Curtin, 2006; Jagtap and Szabo, 2005; Tao et al., 2006; Wells et al., 2006).  
X-ray crystal structures have revealed that most PARP-1 inhibitors bind to the active 
site and mimic the nicotinamide moiety of NAD+ (Jagtap and Szabo, 2005; Oliver et 
al., 2004; Ruf et al., 1998; Ruf et al., 1996).  The key structural features for high 
potency inhibition include an electron-rich aromatic ring system, a non-cleavable bond 
at the 3-position of the benzamide moiety, and a carboxamide group placed in a 
favorable position so as to restrict free rotation of the molecule (Curtin, 2006). 
Although these new generation inhibitors have been improved considerably 
since the development of the benzamide and 3AB prototypes, the development of 
inhibitors that are specific for a single PARP have proved considerably more difficult.  
This is mainly due to the extremely high level of PARP catalytic domain conservation 
(Hakme et al., 2008; Schreiber et al., 2006), which can lead to off-target effects, as 
was shown to occur in a mouse model of diabetes (Mabley et al., 2001).  However, 
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two classes of inhibitors, namely quinazolinone and quinoxaline have displayed higher 
selectivity toward PARP-1 and PARP-2, respectively (Hassa and Hottiger, 2008; 
Ishida et al., 2005; Ishida et al., 2006; Iwashita et al., 2004).  In addition, one 
compound has been reported to inhibit tankyrases 1 and 2 (PARP-5a and -5b), but has 
not been tested against other PARPs (Huang et al., 2009).  Overall, the progression 
and development of PARP inhibitors has improved specificity, potency, solubility, and 
pharmokinetics, which are beginning to prove favorable for therapeutic applications. 
 
1.9.2.  Chemistry and Development of PARG Inhibitors 
 The development of PARG inhibitors is considerably less well developed than 
PARP inhibitors.  The early inhibitor classes, tannins (water-soluble polyphenols), 
were extracted from green tea leaves and include gallotannins, ellagitannins, and 
condensed tannins (Figure 1.3B; (Tanuma et al., 1989a; Tanuma et al., 1989b; Tsai et 
al., 1991)).  Condensed tannins are polymers of flavan-3-ols (Barbehenn et al., 2006) 
and did not appreciably inhibit PARG activity in vitro (Tsai et al., 1991).  However, 
both gallotannins (partial noncompetitive) and ellagitannins (competitive) showed 
inhibitory activity in vitro (Tsai et al., 1991).  Penta-galloyl glucose is the precursor 
for both gallotannins and ellagitannins.  While extra galloyl groups are added to penta-
galloyl glucose to make gallotannins, ellagitannins contain two or more neighboring 
galloyl groups that are oxidatively coupled to form rigid groups, such as 
hexahydroxydiphenoyl (HHDP) units (Barbehenn et al., 2006; Okuda et al., 2000).  
Gallotannins are the most widely used inhibitor and inhibits PARG in the mid-µM 
concentration range (Bonicalzi et al., 2005).  Ellagitannins, including nobotannin B 
(dimer), E (trimer), and K (tetramer), while identified some years ago (Tsai et al., 
1992), are just now being investigated in more detail.  These compounds inhibit 
PARG in the low-µM concentration range (Tsai et al., 1992).  Although their actual 
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IC50 decreases with increasingly complex structure (i.e., tetramer), only nobotannin B 
was found to be a competitive inhibitor (Tsai et al., 1992).  
More recently developed PARG inhibitors include adenosine diphosphate-
(hydroxymethyl)-pyrrolidinediol (ADP-HPD) (Slama et al., 1995a) and mono-galloyl 
glucose derivatives (Formentini et al., 2008).  ADP-HPD is also a partial 
noncompetitive inhibitor, but has an IC50 in the mid-nM range, which significantly 
improved the potency of PARG inhibitors (Slama et al., 1995a).  This is likely due to 
the direct interactions between the adenine ring and a conserved residue in the PARG 
active site (tyrosine 795, Y795) (Koh et al., 2003).  This inhibitor, while potent in 
vitro, is not cell permeable and is suspect to phosphodiesterase cleavage, rendering the 
inhibitor useless (Slama et al., 1995b).  A cell permeable derivative has been 
developed, 8-octylamino ADP-HPD, but has yet to be full characterized in vivo (Coyle 
et al., 2003).  Also, mono-galloyl glucose compounds were found to be just as potent 
as ADP-HPD (Formentini et al., 2008).  In this class, perhaps the less complex the 
structure, the more potent and specific the inhibitor will be.  The use of the current 
inhibitors for molecular and animal studies has yielded useful information toward 
understanding PARG functions and potential therapeutic applications.  However, the 
conclusions from these studies could be vastly improved with the use of more specific 
and potent PARG inhibitors.  For example, a recent study developed a PAR derivative, 
poly(epsilonADP-ribose), which cannot be cleaved by PARG, but can inhibit its PAR 
hydrolase activity, presumably by competing with ADP-ribose (Shirato et al., 2007). 
 Recent studies have revealed some controversy with regard to the efficacy and 
overall experimental use of the current PARG inhibitors.  One group suggests that 
neither gallotannins nor the currently available synthetic inhibitors (i.e., GPI 16552) 
had a detectable effect on PARG function in intact cells due to lack of cell 
permeability and potential anti-oxidant properties (Falsig et al., 2004).  Another study
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Figure 1.3.  PARP-1 and PARG chemical inhibitors.  A, Chemical structures of 
PARP-1 inhibitors discussed in the text.  Nicotinamide, a byproduct of the PARP-1 
enzymatic reaction (shown in Figure 1.1) and a natural inhibitor of PARP-1 activity, 
served as a model for the first synthetic PARP-1 inhibitors, including 3-
aminobenzamide.  Inhibitor development progressed with greater specificity, potency, 
and solubility, evolving into such inhibitors as PJ-34, ABT-888, and Olaparib.  These 
enhanced features allowed for their use in cell and animal models, as well as in human 
clinical trials for cancer treatments.  B, Chemical structures of PARG inhibitors 
discussed in the text.  Early classes of PARG inhibitors include tannins, which were 
extracted from green tea leaves.  While gallotannins (i.e., tannic acid) are the most 
commonly used inhibitors, ellagitannins (i.e., nobotannin B) are being more recently 
investigated as they have a higher potency than gallotannins.  A synthetic PARG 
inhibitor, ADP-HPD, greatly improved potency of inhibition, but is limited in use due 
to its lack of cell permeability. 
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compared expression effects in A549 cells upon treatment with PJ34 (a PARP 
inhibitor) and gallotannin.  The authors concluded that the effects of gallotannin on 
gene expression could not be attributed to PARG inhibition, based on the idea that 
PARP inhibition did not affect the same genes.  This interpretation should be taken 
with caution, since it is possible that these enzymes can take on roles independent of 
one another and their enzymatic activities, leading to transcriptional regulation 
(Frizzell et al., 2009; Krishnakumar and Kraus, 2010).  In fact, re-expressing wild type 
and catalytically inactive mutants in the context of a PARG knockdown corroborated 
the transcriptional effects of gallotannin at target genes, demonstrating that the effects 
of gallotannin are through PARG inhibition (Frizzell et al., 2009). 
 
1.9.3.  Potential Therapeutic Applications (Experimental Models) 
PARP-1 and PARG inhibitors may ultimately have utility as therapeutic agents 
for the treatment of cancers, cardiovascular diseases, diabetes mellitus and other 
diseases.  The examples presented here are only a few of the potential therapeutic 
applications of PARP-1 and PARG inhibitors for the treatment of diseases.  Current 
clinical trials will provide an indication of whether PARP-1 inhibitors will ultimately 
become widely used therapeutic agents.  And, although the current data for PARG 
inhibitors is in the beginning stages, the future applications are promising. 
Cancer – PARP-1 inhibitors promote cell death in chemically-treated or 
radiation therapy-treated cancers by impairing DNA damage response and repair 
pathways, and ultimately promoting apoptosis (Bryant and Helleday, 2004; Curtin et 
al., 2004; Delaney et al., 2000; Inbar-Rozensal et al., 2009; Tentori et al., 2002b).  The 
efficacy of some anti-cancer chemotherapies or radiotherapies is improved when they 
are administered with PARP-1 inhibitors.  For example, in mouse models and human 
cancer cell lines, the efficacy of temozolomide, an anti-cancer alkylating agent that 
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damages DNA and inhibits DNA replication, is improved when co-administered with 
the PARP-1 inhibitor NU1025, which blocks PARP-1's DNA repair activities 
(Delaney et al., 2000; Tentori et al., 2002a; Tentori et al., 2002b).  Some PARP-1 
inhibitors, such as AG14361, are being tested in clinical trials as therapeutic agents for 
cancers ((Curtin et al., 2004); described below).  In many cases, the cancers in 
question already have a genetic aberration causing a defect in a DNA repair process.  
The goal for PARP-1 inhibitors is to target these particular cells and impair the “back-
up” repair pathway, ultimately leading to cell death, an effect that has been shown by 
many groups to occur in cell models (Inbar-Rozensal et al., 2009).  In a model of acute 
promyelocytic leukemia, NB4 cells undergo granulocytic differentiation in response to 
all-trans retinoic acid.  Interestingly, co-treamtment with a PARP inhibitor triggered 
apoptosis, rather than differentiation (Berry et al., 2000), demonstrating another 
method in which PARP-1 inhibitors could be useful for treating cancer. 
Although their non-specific proteins interaction and high molecular weights 
have been limiting their use for therapeutic applications (Lipinski et al., 2001), similar 
types of results have been demonstrated using PARG inhibitors.  For example, 
treatment with gallotannin and nobotannin reduced astrocyte cell death upon hydrogen 
peroxide treatment (Ying et al., 2001; Ying and Swanson, 2000).  In a model of 
melanoma, GPI 16552 showed a synergistic inhibition of melanoma growth and 
metastasis in combination with temozolomide (Tentori et al., 2005).  In addition, 
gallotannin was found to suppress tumor growth factors in a CT26 colon carcinoma 
cell lines (Lin et al., 2009).  The results from these studies suggest the potential for 
PARG inhibitors in the treatment of cancer, although much work is needed in 
experimental trials before moving on to clinical trials. 
 Inflammation and Stress Response – PARP-1 inhibitors can provide protection 
from cardiovascular diseases.  Acute and chronic cardiovascular disease can lead to 
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the release of oxidants and free radicals that promote DNA damage within cells, as 
well as the release of toxic mediators to nearby tissues.  Inhibition of PARP-1 can 
attenuate these effects, promoting cell survival and improved cellular function within 
the affected area.  Some PARP-1 inhibitors, such as PJ34, may also have utility as 
therapeutic agents in diabetes mellitus, acting to protect against islet necrosis by 
reducing the levels of nitric oxide and reactive oxygen species through reduced 
cytokine production (Beneke et al., 2004; Tentori et al., 2002a).  Additionally, PJ34 
can reduce hyperactivation of PARP-1 in response to massive DNA damage, thereby 
blocking the PARP-1-dependent necrotic cell death pathway.  The ability of PARP-1 
inhibitors to block pathological inflammatory responses may have therapeutic utility.  
However, treating patients chronically with PARP-1 inhibitors increases the potential 
for long-term consequences of accumulating DNA breaks in normal tissues, which is a 
major concern for this type of application (Ferraris, 2010).  This concern is 
corroborated by a severe diabetes model, where the continued use of PARP-1 
inhibitors lead to the development of β-cell tumors due to the survival of damaged 
cells and the increase in genomic instability (Yamagami et al., 1985). 
The use of PARG inhibitors in such models of inflammation are far more 
limited, but are beginning to display potential and warrant further investigation.  For 
example, treatment with the PARG inhibitors GPI 18214 and GPI 16552 reduced 
zymosan-induced peritonitis and mortality in mice (Genovese et al., 2004).  These 
particular inhibitors have also been shown to protect mice from dinitrobezene sulfonic 
acid-induced colitis by blocking pro-inflammatory cytokine production and cell death 
(Cuzzocrea et al., 2007).  A similar protective effect of GPI 16552 was also found in a 
model of spinal cord inflammation (Cuzzocrea et al., 2006), a mouse model of stroke 
(Lu et al., 2003), and a neuronal cell model of hydrogen peroxide-induced cell death 
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(Ying et al., 2001).  Collectively, these results display the potential of using both 
PARP-1 and PARG inhibitors in the treatment of diseases. 
 
1.9.4.  Clinical Trials 
 Currently, over 50 clinical trials involving PARP inhibitors are active, actively 
recruiting participants or just completed, according to the registry of federally and 
privately supported clinical trials conducted in the United States and around the world 
(Table 1.3; www.clinicaltrials.gov).  Collectively, there are eight PARP inhibitors 
represented spanning all phases of the clinical trial process; notably, there are no trials 
involving PARG inhibitors.  Although pharmaceutical companies are supporting the 
majority of trials, there are a few being conducted by various research and academic 
institutions in collaboration with the company responsible for the development of the 
inhibitor.    And, while the overwhelming majority of trials are focused on cancer, two 
trials are investigating INO-1001 (Phase II) with respect to heart disease. 
 The ongoing clinical trials demonstrate the wide-range of applications and 
great potential for PARP inhibitors in cancer treatment.  There are at least 15 different 
types of cancer being investigated, ranging from those of the reproductive tissues (i.e., 
breast, uterus, ovary, fallopian tube, prostate), immune system (i.e., lymphoma, 
leukemia), and central nervous system (i.e., glioma, glioblastoma), among others.  
There is also a broad range of tumor stages and aggressive behaviors represented (i.e., 
solid tumors, metastatic, advanced, recurrent/relapsed).  The inhibitors are being 
investigated for anti-tumor activity in both genetically “normal” and “altered” cancer 
types (i.e., mutations in p53 or BRCA1/2).  In addition, they are being tested as single 
agents and in combinations with standard radiotherapies and chemotherapies.  All of 
these conditions are detailed in recent reviews (Fauzee et al., 2010; Ferraris, 2010; 
Rouleau et al., 2010; Underhill et al., 2010)). 
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Of particular interest are those focusing cancers of the breast and ovary, where 
PARP inhibitors have shown the most promise.  There has been increasing evidence 
linking PARP-1 to breast cancer.  For example, PARP-1-deficient mice exhibit 
increased spontaneous mammary carcinoma formation, the latency of which is 
increased by mutations in p53 (Tong et al., 2007).  In addition, PARP activity in 
human peripheral blood lymphocytes has been linked with breast cancer (Pero et al., 
1990) and low levels of PARP-1 gene expression are associated with increased genetic 
instability in breast cancers (Bieche et al., 1996).  Furthermore, certain polymorphisms 
in PARP-1 may contribute to the development of breast cancers and influence the 
effectiveness of hormone therapies (Cao et al., 2007).  Interestingly, PARP inhibition 
(1) sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis 
(Munoz-Gamez et al., 2005) and (2) selectively kills breast cancer cells with 
hereditary inactivating mutations in BRCA1 and BRCA2, which encode proteins 
critical for DNA repair by homologous recombination (Drew and Calvert, 2008).  
Finally, the PARP inhibitor, olaparib, has anti-tumor activity in breast or ovarian 
cancers containing BRCA1 and BRCA2 mutations at safely administrable doses with 
minimal side effects (Audeh et al., 2010; Fong et al., 2009; Tutt et al., 2010). 
Interestingly, a recent study provides evidence that certain PARP inhibitors 
might also inhibit the growth and promote the death of non-hereditary breast cancer 
cells lacking mutations in BRCA1 or BRCA2 (Inbar-Rozensal et al., 2009).  In 
addition, breast cancers harboring the “triple-negative” characteristic (i.e., those that 
do not express estrogen receptor (ER), progesterone receptor (PR), and the human 
epidermal growth factor receptor HER2) also exhibit an increase in PARP-1 
expression (Tuma, 2009).  HER2 is a cell membrane receptor tyrosine kinase involved 
in signaling pathways leading to cell proliferation (Lohrisch and Piccart, 2001).  
Functional connections between HER2, ERKs, and PARP-1 might play a role in
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Table 1.3.  Summary of clinical trials for PARP inhibitors.  Based on the 
government website (www.clinicaltrials.gov), there exist over 50 clinical trials 
involving PARP inhibitors.  This table summarizes the ongoing or recently completed 
clinical trials for eight independent PARP inhibitors.  Overall, these trials cover 
multiple cancer types stemming from a variety of tissues, as well as stages of growth, 
metastasis, and aggressive behaviors.  In addition, many trials are focused on cancers 
with genetic abnormalities.  And, finally, about 70% of these trials are conducting 
combination therapies with commonly used radio- or chemo-therapy agents.  Notably, 
there are no trials involving PARG inhibitors. 
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Compound Sponsor Phase Condition  
 
MK4827 Merck I Advanced solid tumors, ovarian 
neoplasms, prostate cancer 
 
E7016 Eisai I Advanced solid tumors; in 
combination with temozolomide 
 
CEP-9722 Cephalon I Advanced solid tumors; in 
combination with temozolomide 
 
INO-1001 Inotek II Heart disease; patients having heart 
surgery involving heart-lung bypass 
 
 Inotek II Acute myocardial infarction; acute 
heart attack patients undergoing 
primary percutaneous coronary 
intervention 
 
AG-014699 Pfizer I Advanced solid tumors; in 
combination with carboplatin, 
paclitaxel, cisplatin, epirubicin, 
pemetrexed, or cyclophosphamide 
 
 Cancer Research UK II Advanced, metastatic or BRCA1/2 
mutatant breast or ovarian cancer 
 
 Hoosier Oncology II Triple negative and BRCA1/2 
 Group  mutant breast cancer; in 
combination with cisplatin 
 
BSI-201 BiPar I & II Malignant gliomas; in combination 
(iniparib)   with temozolomide 
 
 BiPar II Platinum-sensitive recurrent 
ovarian cancer 
 
 BiPar II Triple-negative breast cancer; in 
combination with gemcitabine or 
carboplatin 
 
 BiPar II Triple-negative breast cancer brain 
metastasis; in compination with 
irinotecan 
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Table 1.3 (continued) 
 
 Sanofi-Aventis II Non-small cell lung carcinoma; in 
combination with gemcitabine or 
cisplatin 
 
 Sanofi-Aventis II Metastatic triple-negative breast 
cancer; in combination with 
gemcitabine or carboplatin 
 
 Sanofi-Aventis II Triple-negative breast cancer; in 
combination with paclitaxel 
 
 BiPar II BRCA1/2 mutant-associated 
advanced epithelial ovarian, 
fallopian tube, or primary peritoneal 
cancer 
 
 BiPar II Breast cancer; in combination with 
gemcitabine or carboplatin 
 
 BiPar III Advanced squamous cell lung 
cancer; in combination with 
gemcitabine or carboplatin 
 
ABT-888 Abbott I Metstatic prostate cancer; in 
(veliparib)   combination with temozolomide 
 
 Abbott I Colorectal cancer; solid tumors 
 
 Pediatric Brain I Recurrent or refractory central 
 Tumor Consortium  nervous system tumors in young 
patients; in combination with 
temozolomide 
 
 Univ. of Maryland I Acute Leukemia; in combination 
 Greenbaum Cancer Center  with temozolomide 
 
 Gynecologic I Newly diagnosed stage II, III, or IV 
 Oncology Group  ovarian epithelial, fallopian tube, 
primary peritoneal cancer; in 
combination with carboplatin, 
paclitaxel, or bevacizumab 
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Table 1.3 (continued) 
 
 Abbott I Brain or nervous system neoplasms, 
neoplasm metastasis, brain or 
nervous system diseases; in 
combination with whole brain 
radiation therapy 
 
 Abbott I Advanced solid tumors; in 
combination with carboplatin or 
gemcitabine 
 
 National Cancer I Solid tumors, lymphomas, or 
 Institute  leukemia; in combination with 
cyclophosphamide 
 
 National Cancer I Advanced or refractory solid 
 Institute  tumors, lymphomas, or leukemia; in 
combination with topotecan 
 
 Fred Hutchinson I Recurrent or metastatic, triple 
 Cancer Research Center  negative, BRCA1/2 mutant, male, 
or late stage breast cancer; in 
combination with cisplatin, or 
vinorelbine ditartrate 
 
 Abbott I Non-hematologic malignancies, 
metastatic melanoma, breast, 
ovarianc, primary peritoneal, 
fallopian tube, or liver cancer; in 
combination with temozolomide 
 
 National Cancer I Leukemia, lymphoma, or regratory 
 Institute  solid tumors 
 
 Georgetown Univ. II Colorectal cancer; in combination 
with temozolomide 
 
 Massachusetts II Metastatis or BRCA1/2 mutant 
 General Hospital  breast caner; in combination with 
temozolomide 
 
 Georgetown Univ. II Liver cancer; in combination with 
temozolomide 
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Table 1.3(continued) 
 
AZD-2281 AstraZeneca I Triple-negative breast or advanced 
(olaparib)   ovarian cancer; in combination with 
carboplatin or paclitaxel 
 
 National Cancer I BRCA1/2 mutant, hereditary, triple 
 Institute  negative, unresectable breast or 
ovarian cancer; in combinatin with 
carboplatin 
 
 AstraZeneca I Pancreatic cancer; in combination 
with gemcitabine 
 
 AstraZeneca I Ovarian neoplasms or BRCA1/2 
mutant cancer 
 
 National Cancer I Unresectable or metastatic solid 
 Institute  tumors; in combination with 
cisplatin or gemcitabine 
 
 AstraZeneca I Malignant solid tumors; in 
combination with tepotecan 
 
 AstraZeneca I Melanoma neoplasms; in 
combination with dacarbazine 
 
 AstraZeneca I Neoplasm metasasis or solid 
metastatic tumors 
 
 AstraZeneca I Advanced solid tumors; in 
combination with bevacizumab 
 
 AstraZeneca II Gastric cancer; in combination with 
paclitaxel 
 
 AstraZeneca II colorectal cancer with microsatellite 
instability phenotype 
 
 AstraZeneca II BRCA1/2 mutant ovarian or breast, 
prostate, pancreatic, or advanced 
solid tumors 
 
 AstraZeneca II Ovarian neoplasms; in combination 
with liposomal doxorubicin 
61 
Table 1.3 (continued) 
 
 AstraZeneca II Advanced ovarian cancer; in 
combination with paclitaxel or 
carboplatin 
 
 AstraZeneca II Ovarian carcinoma, BRCA1/2 
mutant or triple-negative breast 
cancer 
 
 AstraZeneca II Platinum-sensitive serous ovarian 
cancer 
 
 AstraZeneca II BRCA-positive breast neoplasms 
 
 AstraZeneca II BRCA-positive ovarian neoplasms 
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determining the sensitivity of breast cancers to PARP inhibitors.  This sub-type of 
breast cancer is now a major target for PARP inhibitor anti-tumor activity, and the 
results thus far are promising (Hashimoto and Tamura, 2010).  These intriguing results 
might lead the way to new approaches for treating a broad spectrum of breast cancers.  
 It will be important to understand the mechanism of action for any of the 
inhibitors that have an effect on tumor growth and progression.  For example, based 
on the previous results with the BRCA1/2-deficent cells, the assumption is that the 
ultimate target of the PARP inhibition is a DNA repair pathway.  Although some 
tumors are apparently wild type for BRCA1/2, they may harbor mutations in genes 
encoding other DNA repair and checkpoint proteins (e.g., Rad51, Chk1/2) that could 
render them sensitive to PARP inhibitors.  Importantly, nuclear PARPs, such as 
PARP-1 and PARP-2, also play key roles in gene regulation (Kim et al., 2005; Kraus, 
2008); so transcriptional effects cannot be ruled out as the cause of PARP inhibitor 
sensitivity.  Experiments with depletion of specific PARPs will help to determine the 
relevant targets.  In addition, there may be cell cycle effects caused by the PARP 
inhibitors through signal transduction pathways involving cell cycle proteins (e.g., 
p21, cyclins, cdc2,) and ERK-dependent kinase cascades.  This is a reasonable 
hypothesis given the involvement of these pathways in cell cycle progression and 
proliferation in a variety of cancers as well as the connection between ERK2 and 
PARP-1 activation (Cohen-Armon et al., 2007).  Information of this kind will be 
extremely useful for the design of next-generation inhibitors for specific cancers. 
 
1.10.  Perspectives 
 
 Two enzymes in the nucleus, PARP-1 and PARG, oversee the majority of 
PARylation activity in the cell.  Based on the summary presented here, it is clear that 
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these enzymes are involved in numerous molecular activities, from DNA damage 
repair and cell death to transcriptional regulation.  It is also clear that their molecular 
functions dictate their physiological functions.  However, in order to achieve a 
complete understanding of both aspects, further investigation is required.  For 
example, we are just beginning to understand the functional consequences of the PAR 
modification and ADPR as a signaling molecule and/or protein-binding platform.  
Understanding how these contribute to overall PARP-1/PARG molecular functions is 
necessary.  In addition, we are lacking considerable information about how these 
enzymes cooperate or oppose one another.  Just because they have enzymatic activities 
that polymerize or hydrolyze the PAR modification, does not mean they always 
counter each other’s actions.  In this regard, having side-by-side comparisons of cell or 
animal models would be informative.  In addition, having tissue-specific knockout 
animal models will also aid in our understanding of PARP-1/PARG function and 
increase the knowledge base for improving inhibitor development.   
It is absolutely imperative that the development of next generation PARP-1 
and PARG inhibitors is significantly enhanced.  Even though PARP inhibitors have 
advanced over the last few years, we are still lacking inhibitors specific to single 
PARP family members.  Disrupting PARP-1 functions outside of NAD+ binding might 
be useful in this regard, for example interrupting complex formation.  In addition, 
understanding the size and branching properties of PAR itself can also yield 
information useful for generating inhibitors that mimic PAR.  For PARG, the overall 
chemical structure needs to be revamped, allowing for higher specificity, potency, and 
cell permeability.  It is expected that the use of PARP-1 and PARG inhibitors in 
clinical trials will be far more extensive in the coming years, as they are proving 
useful for a multitude of diseases.  It will be exciting to see the potential for more 
therapeutic applications as the field progresses. 
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CHAPTER 2 
 
 
 
 
 
 
Global Analysis of Transcriptional Regulation by  
Poly(ADP-ribose) Polymerase-1 and Poly(ADP-ribose) Glycohydrolase  
in MCF-7 Human Breast Cancer Cells* 
 
 
 
 
 
* This research was published as Frizzell KM, Gamble MJ, Berrocal JG, Zhang T, 
Krishnakumar R, Cen Y, Sauve AA, and Kraus WL.  Global Analysis of 
Transcriptional Regulation by Poly(ADP-ribose) Polymerase-1 and Poly(ADP-ribose) 
Glycohydrolase in MCF-7 Human Breast Cancer Cells.  Journal of Biological 
Chemistry.  2009; 284(49):33926-33938. © the American Society of Biochemistry and 
Molecular Biology.  Minor modifications have been made.  Contributions by other 
authors to this work were as follows:  M.J.G., expression microarray and analyses, and 
RT-qPCR (Figures 2.3, 2.4, and 2.5); J.G.B., RT-qPCR (Figure 2.5); T.Z., expression 
microarray analyses (Figures 2.3, 2.4, and 2.5); R.K., assisted with PAR westerns and 
inhibitor experiments (Figures 2.1 and 2.14); Y.C. and A.A.S., NAD+ measurements 
(Figure 2.1). 
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2.1.  Summary 
 
Poly(ADP-ribose) polymerase-1 (PARP-1) and poly(ADP-ribose) 
glycohydrolase (PARG) are enzymes that modify target proteins in the nucleus by the 
addition and removal, respectively, of ADP-ribose polymers.  Although a role for 
PARP-1 in gene regulation has been well established, the role of PARG is less clear.  
To investigate how PARP-1 and PARG coordinately regulate global patterns of gene 
expression, we used short hairpin RNAs (shRNAs) to stably knockdown PARP-1 or 
PARG in MCF-7 cells, followed by expression microarray analyses.  Correlation 
analyses showed that the majority of genes affected by the knockdown of one factor 
were similarly affected by the knockdown of the other factor.  That is, the changes 
generally occurred in the same direction and with similar magnitudes.  The most 
robustly regulated common genes were enriched for stress response and metabolic 
functions.  In chromatin immunoprecipitation assays, PARP-1 and PARG localized to 
the promoters of both positively and negatively regulated target genes.  The levels of 
chromatin-bound PARG at a given promoter generally correlated with the levels of 
PARP-1 across the subset of promoters tested.  For about half of the genes tested, the 
binding of PARP-1 at the promoter was dependent on the binding of PARG.  
Experiments using stable re-expression of shRNA-resistant catalytic mutants showed 
that PARP-1 and PARG enzymatic activities are required for some, but not all, target 
genes.  Collectively, our results indicate that PARP-1 and PARG, two nuclear 
enzymes with opposing enzymatic activities, localize to target promoters and act in a 
similar, rather than antagonistic, manner to regulate gene expression. 
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2.2.  Introduction 
 
Poly(ADP-ribosyl)ation (PAR-ylation) is a post-translational modification 
involving the polymerization of ADP-ribose (ADPR) units from donor NAD+ 
molecules on target proteins (D'Amours et al., 1999; Kim et al., 2005).  PARylation 
occurs on a variety of target proteins in all cellular compartments and plays roles in a 
wide array of processes, such as stress responses, DNA repair, and transcriptional 
regulation (D'Amours et al., 1999; Kim et al., 2005).  Nuclear targets include core 
histones, the linker histone H1, and an variety of transcription factors (Kraus and Lis, 
2003).  The synthesis and degradation of poly(ADP-ribose) (PAR) is catalyzed by two 
types of enzymes: PAR polymerases (PARPs) and PAR glycohydrolases (PARGs), 
respectively (Amé et al., 2004; Davidovic et al., 2001).  Although recent studies have 
begun to explore the functional interplay between these two types of enzymes, a clear 
picture of how they cooperate to regulate cellular processes remains unclear. 
PARP-1, a ubiquitous 116 kDa nuclear enzyme, is the founding member of the 
PARP superfamily (Amé et al., 2004; Kim et al., 2005).  It is a highly abundant 
protein (1 to 2 million molecules per cell) that is likely responsible for the majority of 
PAR synthesis in cells (D'Amours et al., 1999).  PARP-1 has three major structural 
and functions domains: (i) an amino-terminal DNA binding domain (DBD), (ii) a 
central automodification domain (AMD), and (iii) a carboxyl-terminal catalytic 
domain with low basal activity (D'Amours et al., 1999; Rolli et al., 2000).  The 
catalytic activity of PARP-1 is potently allosterically activated by the binding of 
PARP-1 to certain forms of DNA (Kun et al., 2004; Kun et al., 2002; Lonskaya et al., 
2005; Potaman et al., 2005), nucleosomes (Kim et al., 2004; Wacker et al., 2007a; 
Wacker et al., 2007b), and protein binding partners (Ju et al., 2006; Ju et al., 2004; Oei 
and Shi, 2001).  In vivo, PARP-1 is the major target for PARP-1-mediated PARylation 
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through an automodification reaction involving the AMD (D'Amours et al., 1999; 
Ogata et al., 1981), although an array of other nuclear targets has been described 
(D'Amours et al., 1999; Kim et al., 2005; Kraus and Lis, 2003).  Its DNA binding, 
catalytic, and automodification functions allow PARP-1 to modulate a wide variety of 
cellular processes involving genomic DNA. 
Cellular PARG activities in mammals are mediated by multiple PARG 
isoforms encoded by a single gene (Davidovic et al., 2001; Meyer-Ficca et al., 2004; 
Meyer-Ficca et al., 2005).  The predominant isoforms, all of which have catalytic 
activity, include: (i) a set of long (~100 to ~110 kDa) isoforms that may shuttle 
between the nucleus and cytoplasm and (ii) a short (~65 kDa) isoform that resides in 
the cytoplasm (Meyer-Ficca et al., 2004; Meyer-Ficca et al., 2005).  These PARG 
isoforms catalyze the hydrolysis of PAR to produce ADPR monomers and short 
ADPR polymers (Davidovic et al., 2001).  The longest PARG isoforms contain two 
major functional domains: (i) a regulatory domain and (ii) a catalytic domain 
(Davidovic et al., 2001; Kim et al., 2005; Kraus and Lis, 2003).  The regulatory 
domain contains both nuclear localization and nuclear export signals, which mediate 
shuttling between the nuclear and cytoplasmic compartments (Bonicalzi et al., 2003; 
Ohashi et al., 2003).  The catalytic domain contains the enzyme active site, which 
confers both endoglycosidic and exoglycosidic activities, allowing for the rapid 
hydrolysis of PAR (Davidovic et al., 2001). 
PARP-1 and PARG play important roles in an overlapping set of biological 
processes.  For example, gene-specific and genomic studies have revealed a clear role 
for PARP-1 in transcriptional regulation (Hassa and Hottiger, 2002; Kim et al., 2005; 
Kraus, 2008; Kraus and Lis, 2003; Tulin et al., 2003), and PARP-1 localizes to the 
promoters of more than 90% of expressed genes in MCF-7 human breast cancer cells 
(Krishnakumar et al., 2008).  Likewise, although more limited, recent gene-specific 
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studies have also implicated PARG in transcriptional regulation (Kim et al., 2004; 
Rapizzi et al., 2004; Tulin et al., 2005).  Few studies have directly examined the 
interplay between PARP-1 and PARG in the regulation of their biological endpoints in 
side-by-side experiments in the same cell type.  As such, the means by which PARP-1 
and PARG coordinate their enzymatic activities to regulate gene expression across the 
genome are unknown.  Based on the opposing enzymatic activities of PARP-1 and 
PARG, one might expect PARG to counter the gene regulatory actions of PARP-1 by 
degrading the PAR chains synthesized by PARP-1.  Yet, PARP-1 and PARG have 
similar effects on many biological endpoints (Cortes et al., 2004; Fisher et al., 2007; 
Kim et al., 2005; Koh et al., 2004; St-Laurent et al., 2007; Tulin et al., 2003; Tulin et 
al., 2005; Tulin and Spradling, 2003; Tulin et al., 2002; Wang et al., 1995; Wang et 
al., 1997), suggesting that this simple model is unlikely to be correct.   
In the current studies, we used a series of genomic and gene-specific assays to 
explore the coordinated regulation of gene expression by PARP-1 and PARG, 
including the role of their respective enzymatic activities.  Our results indicate that 
PARP-1 and PARG localize to target promoters and act in a similar, rather than 
antagonistic, manner to regulate global patterns of gene expression. 
 
2.3.  Results 
 
Generation of PARP-1 and PARG knockdown cell lines.  To explore the role of 
PARP-1 and PARG in the regulation of gene expression, we used short hairpin RNA 
(shRNA)-mediated knockdown to deplete each of the proteins individually in MCF-7 
human breast cancer cells.  Two distinct shRNA sequences targeting either luciferase 
(Luc, used as a control), PARP-1, or PARG were stably introduced into MCF-7 cells 
using sequential retrovirus-mediated gene transfer, creating cells doubly targeted for a 
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given factor.  Stably transduced cell populations, rather than clonal lines, for each 
double knockdown were isolated by appropriate drug selection (see Experimental 
Procedures) and tested for knockdown by Western blot analysis.  The PARP-1 and 
PARG proteins were depleted by approximately 90 percent and 70 percent, 
respectively, compared to the Luc control  (Figure 2.1A).  A Western blot for SIRT1 
was included as a loading control.  Similar effects were also observed on the levels of 
PARP-1 and PARG mRNA (Figure 2.1B).  Notably, knockdown of either PARP-1 or 
PARG had no discernable effect on proliferation or cell cycle progression relative to 
the Luc control for cells in subconfluent growth conditions (Figure 2.2A and 2.2B).  
To further characterize these knockdown cell lines, we analyzed PAR (Figure 
2.1A and 2.1C) and NAD+ (Figure 2.1C) levels.  Knockdown of PARP-1 in MCF-7 
cells reduced, while knockdown of PARG enhanced cellular PAR levels, as 
determined by Western blot with a PAR-specific antibody.  Using a quantitative 
HPLC/mass spectrometry method with 18O-labeled standards (Yang et al., 2007; Yang 
and Sauve, 2006; Zhang et al., 2009), we observed an increase in total cellular NAD+ 
levels upon PARP-1 knockdown, and a slight decrease upon PARG knockdown.  
Together, these results demonstrate that depletion of PARP-1 and PARG alters NAD+ 
and PAR levels in MCF-7 cells in a predictable manner.  Thus, we have generated cell 
lines with stable shRNA-mediated knockdown of PARP-1 or PARG that can serve as 
useful models for studying gene regulation by PARP-1 or PARG. 
 
PARP-1 and PARG regulate global patterns of gene expression in MCF-7 cells.  To 
determine the effects of PARP-1 and PARG knockdown on global patterns of gene 
expression in MCF-7 cells, we isolated total RNA from three control-matched sets of 
independently generated Luc, PARP-1, and PARG knockdown cell populations.  The 
use of three independently generated populations of cells represents a stringent Figure 
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2.1.  shRNA-mediated knockdown of PARP-1 and PARG in MCF-7 cells.  A, 
Whole cell lysates collected from Luc, PARP-1, and PARG stable shRNA-mediated 
knockdown cell lines were subjected to Western blotting analyses for PARP-1 and 
PARG.  SIRT1 was analyzed as a loading control.  PAR levels were analyzed by 
Western blotting using nuclear extracts from the same cell lines.  B, RT-qPCR analysis 
confirms the knockdown PARP-1 and PARG mRNA in MCF-7 cells.  Total RNA was 
isolated from Luc, PARP-1, and PARG knockdown cells, reverse transcribed, and 
subjected to qPCR using gene-specific primers to PARP-1 and PARG.  Each bar is the 
mean + SEM (error bars) for three independent RNA isolations.  Bars marked with an 
asterisk are statistically different from the Luc control, as determined by a Student's t-
test with a p-value threshold of < 0.05.  C, Total cellular NAD+ levels (black bars) in 
Luc, PARP-1, and PARG knockdown cells were measured using a quantitative 
HPLC/mass spectrometry method with 18O standards.  PAR levels (grey bars) were 
quantified from Western blots (from A, above) by densitometry.  The data are shown 
as the mean + range or SEM (error bars) from two or more independent biological 
replicates.  Bars marked with an asterisk are statistically different from the Luc 
control, as determined by a Student's t-test with a p-value threshold of < 0.05. 
98 
 
 
99 
Figure 2.2.  PARP-1 or PARG knockdown does not significantly alter MCF-7 cell 
proliferation or cell cycle progression.  A, PARP-1 or PARG knockdown does not 
significantly affect the proliferation of MCF-7 cells.  The specified knockdown cell 
lines were seeded and counted every two days over an 8-day period.  Data is shown as 
the mean ± SEM (error bars) for four independent experiments.  The significant 
differences between the samples as determined by ANOVA with a p-value threshold 
of < 0.05, are indicated by an asterisk (i.e. day 8).  All expression and ChIP 
experiments were conducted 3 to 4 days post plating, as indicated, where growth 
differences were determined to be insignificant.  Stock cells were maintained as 
subconfluent cultures and passaged at the point indicated.  B, PARP-1 or PARG 
knockdown does not significantly affect cell cycle progression.  The specified 
knockdown cell lines were subjected to FACS analysis to determine percent of cells in 
each cell cycle phase.  Data is shown as the mean ± SEM (error bars) for four 
independent experiments.  The differences between the samples are not significantly 
different as determined by ANOVA with a p-value threshold of < 0.05. 
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approach to control for experimental variability and limits the complications that may 
be observed when using clonally selected lines.  Total RNA was isolated, labeled, and 
hybridized to Affymetrix U133A 2.0 human expression microarrays, which contain 
more than 22,000 probe sets, including 14,500 well-characterized human genes.  The 
raw data were normalized using Affymetrix GCOS software and adjusted for batch 
effects using an empirical Bayes method (Johnson et al., 2007).  Next, the data were 
log2 transformed, median centered, and filtered as described in the Materials and 
Methods.  In our initial analyses, we performed filtering based on (i) a detection call of 
“present” or “marginal” in two of the three replicates for both Luc and PARP-1/PARG 
and (ii) a Student’s t-test p-value cutoff of < 0.05 (Figure 2.3 and Figure 2.4).  In 
subsequent analyses, we also applied a log2 fold change cutoff of > 0.5 or < -0.5 (see 
Figure 2.5).  The fully processed and analyzed data yielded lists of genes regulated by 
PARP-1 or PARG (i.e., genes whose expression changed upon PARP-1 or PARG 
knockdown; see Tables 2.1, 2.2, and 2.3 for the regulated gene lists).  These data sets 
contain genes both directly regulated (i.e., primary effects) and indirectly regulated 
(i.e., secondary effects) by PARP-1 or PARG.  For the mechanistic studies described 
herein, we chose a set of target genes based on the criteria discussed below. 
The application of a p-value cutoff without a fold change cutoff is one useful 
approach to define sets of significantly regulated genes in expression microarray 
experiments (Dow, 2003; Hess and Iyer, 2007; Murphy, 2002).  Analysis of our 
expression microarray data in this manner defined ~1200 genes (~8.7% of all genes 
tested) regulated by PARP-1 knockdown and ~1100 genes (~8.1% of all genes tested) 
regulated by PARG knockdown at 95% confidence, with a commonly regulated gene 
set (i.e., intersection) of ~500 genes (~3.5% of all genes tested) (Figure 2.3A).  A heat 
map representation (Figure 2.3B) and a Spearman correlation analysis (Figure 2.3C) of 
the PARP-1 and PARG commonly regulated gene set (i.e., intersection) shows that the 
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majority of genes affected by the knockdown of one factor were similarly affected by 
the knockdown of the other factor.  That is, the changes (i.e., either up- or down-
regulated) generally occurred in the same direction and with the same magnitude for 
both PARP-1 and PARG knockdown (Figures 2.3B and 2.3C).  This pattern was also 
evident in the union of regulated gene sets (Figure 2.4), indicating that even for genes 
not passing the p-value cutoff in one condition (i.e., PARP-1 or PARG knockdown), 
the pattern of regulation was similar.  Together, these data indicate that PARP-1 and 
PARG regulate the expression of a common set of genes in a largely similar manner. 
Next, to define the sets of genes most robustly regulated by PARP-1 and 
PARG knockdown (i.e., the top 15% to 20% of the regulated genes), we applied a fold 
change cutoff (log2 fold change of > 0.5 or < -0.5) to the data pre-filtered for both 
detection call and p-value (Figure 2.3A).  By these criteria, we identified 204 PARP-1-
regulated genes and 217 PARG-regulated genes (Figure 2.5A).  About half of each 
group of the most robustly regulated genes was up-regulated, while the other half was 
down-regulated (Figure 2.5B).  Fifty of the most robustly regulated genes were in both 
the PARP-1- and PARG-regulated lists (i.e., the intersection).  As expected based on 
Figure 2.3C and Figure 2.4C, the most robustly regulated genes were regulated in the 
same direction and with the same magnitude, as illustrated by a Spearman correlation 
analysis (Figure 2.5C).  The most robustly regulated genes are listed in Tables 2.1-2.3. 
Gene-specific mRNA determinations by RT-qPCR were used to confirm the 
microarray expression data for a subset of genes falling into four classes: (i) up-
regulated by both PARP-1 and PARG knockdown, (ii) down-regulated by both PARP-
1 and PARG knockdown, (iii) differentially regulated by both PARP-1 and PARG 
knockdown, and (iv) not regulated by PARP-1 or PARG knockdown (Figure 2.5D).  
This analysis confirmed a group of more than 20 genes with consistent and well-
characterized patterns of regulation in response to PARP-1 and PARG knockdown. 
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Figure 2.3.  PARP-1 and PARG coordinately regulate global patterns of gene 
expression in MCF-7 cells (Intersection).  A, Venn diagram of PARP-1- and PARG-
regulated genes in MCF-7 cells as defined by shRNA-mediated knockdown and 
expression microarrays.  Genes passing both present call and p-value < 0.05 criteria 
for at least one factor represent the union (see also Figure 2.4.), whereas genes 
regulated by both factors represent the commonly regulated genes or intersection).  B, 
Heatmap showing the expression profiles of the commonly regulated genes (i.e., 
intersection; 485 genes) from panel A.  The genes are ranked in the heatmap by log2 
fold change in the PARP-1 knockdown cell line (see color scale).  C, Correlation 
analysis of the commonly regulated genes (i.e., intersection; 485 genes) from panel A.  
The Spearman correlation coefficient (c.c.) and p-value are indicated. 
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Figure 2.4.  PARP-1 and PARG coordinately regulate global patterns of gene 
expression in MCF-7 cells (Union).  A, Venn diagram of PARP-1- and PARG-
regulated genes in MCF-7 cells as defined by shRNA-mediated knockdown and 
expression microarrays.  Genes passing both present call and p-value < 0.05 criteria 
for at least one factor represent the union, whereas genes regulated by both factors 
represent the commonly regulated genes or intersection (see also Figure 2.3.).  B, 
Heatmap showing the expression profiles of the union of regulated genes.  The genes 
are ranked in the heatmap by log2 fold change in the PARP-1 knockdown cell line (see 
color scale).  C, Correlation analysis of the union of regulated genes from panel A.  
The Spearman correlation coefficient (c.c.) and p-value are indicated. 
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Figure 2.5.  Defining the genes most robustly regulated by PARP-1 and PARG.  
A, Venn diagram of PARP-1- and PARG-regulated genes after applying a fold change 
cutoff of log2 < -0.5 or > 0.5.  Of the union of 371 genes most robustly regulated by 
either PARP-1 or PARG, 50 are commonly regulated.  B, The distribution of the most 
robustly up-regulated or down-regulated genes upon knockdown of PARP-1 or PARG 
is indicated.  C, Correlation analysis comparing the magnitude and direction of 
regulation of the 371 most robustly regulated genes shown in panels A and B.  The 
Spearman correlation coefficient (c.c.), p-value, and fold change cutoff are indicated.  
D, Gene specific confirmation of the expression microarray results by RT-qPCR.  Luc, 
PARP-1, and PARG knockdown MCF-7 cells were seeded and grown under the same 
conditions used for the expression microarrays.  Total RNA was isolated, reverse 
transcribed, and subjected to qPCR using gene-specific primers.  Genes were 
considered to be regulated if the log2 fold change was < -0.5 or > 0.5 (values falling 
outside of the shaded box).  Each bar represents the mean + SEM (error bars) from 
three or more independent determinations.  All bars with a mean value falling outside 
of the shaded box are statistically different than the Luc control, as determined by a 
Student’s t-test with a p-value threshold of < 0.05. 
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Table 2.1.  List of 154 of the most robustly regulated genes affected by PARP-1 
knockdown only.  List of genes regulated by PARP-1 only (from Figure 2.5A), which 
include genes passing the present call, p-value, and fold change criteria noted in the 
text.  The degree of change upon PARP-1 knockdown is listed as log2 fold change 
relative to the Luc control. 
 
 Gene Log2 FC Gene Log2 FC 
 
ADAMTSL3 -0.711 
ADCK2 0.519 
ALDH5A1 0.519 
AMY1A -0.695 
ANKRD17 -0.536 
AQP3 0.919 
ARL4D -0.693 
ATP2A3 0.651 
AVEN 0.522 
BCAT1 0.564 
BCORL1 0.511 
C10orf110 -0.940 
C10orf56 0.837 
C10orf84 0.732 
C11orf32 0.561 
C11orf9 -0.514 
C18orf25 0.800 
C2orf34 0.628 
C8orf1 -0.575 
CALML5 0.921 
CAMK2N1 -0.515 
CAV1 -0.744 
CCDC14 -1.631 
CDC42BPB 0.504 
CDC6 0.554 
CEACAM6 1.069 
CENPI -0.610 
CHKB -0.580 
CPM 0.656 
CREB3L1 0.672 
CRISPLD2 -0.650 
DBR1 0.576 
DDX19A 0.633 
DEGS1 -0.595 
DKFZp667G2110 -0.570 
DKFZP686A01247 -0.516 
DNAJC12 -0.656 
DST 0.503 
DUSP2 -0.755 
DUSP5 0.654 
DYNC2LI1 0.641 
DZIP3 -0.667 
EIF2C4 -1.404 
ELF5 0.584 
ENAH -0.588 
ETS2 0.540 
EXTL2 -0.568 
F2RL1 0.602 
FADS1 0.572 
FAM117A -0.587 
FARP1 0.517 
FHL1 0.604 
FHL2 0.872 
FLJ23172 0.804 
FZD3 0.501 
FZD7 -0.880 
GDF15 1.036 
GNAS -0.780 
GP1BA 0.695 
GPR30 -0.519 
GPR64 -0.554 
GUSBP1 -0.568 
HADHA -0.561 
HHEX 0.501 
HIST1H2AM 0.618 
HMGA2 -0.787 
HTR2C -0.656 
HYAL2 0.594 
ID1 -0.606 
ID2 -0.536 
ID3 -0.660 
INHBB 0.617 
 
 
110 
Table 2.1. (continued) 
 
Gene Log2 FC 
 
IQSEC1 0.584 
KIAA0040 0.601 
KIAA0367 0.868 
KIAA0683 0.532 
KIAA0776 -0.583 
KLF4 0.574 
KPNA5 -0.822 
LAMC1 -0.531 
LOC92249 -0.617 
LRRFIP2 0.533 
LTBP1 0.508 
MANEA 0.671 
MAP3K5 -0.718 
MAP3K9 0.515 
MARS -0.617 
MCAM -0.618 
MED6 0.622 
MORC4 0.507 
MUC5AC 0.661 
MZF1 -0.663 
NAV3 -0.555 
NCKAP1 -0.598 
NEK4 0.552 
NETO2 -0.642 
NFAT5 -0.808 
NIPSNAP3B -0.827 
NMB -0.550 
NR2F2 0.528 
NRF1 0.588 
NVL -0.736 
ODF2 0.597 
OSBPL1A -0.549 
PADI2 0.698 
PAH -0.758 
PALMD -0.662 
PARP1 -2.711 
PARP12 0.775 
PCGF1 -0.753 
PDLIM7 0.740 
PER3 -0.574 
PFDN1 -1.027 
 
 
Gene Log2 FC 
 
PFTK1 -0.501 
PGK1 -0.700 
PIK3R1 -0.654 
PLA2G2A -0.803 
PLEKHB1 0.595 
PSEN2 -0.675 
PTGER3 -0.536 
PTPN3 0.504 
RAI16 0.594 
RAP2C 0.652 
RBM21 0.541 
RHBDD3 0.539 
RHOBTB3 -0.511 
RRAGD 0.662 
SCAMP1 -0.536 
SCN1A -1.036 
SEMA4D -0.517 
SEPP1 -0.524 
SLC16A2 -0.985 
SLC29A1 0.536 
SLC2A10 0.554 
SMOX 0.571 
SORD 0.542 
SSBP2 -0.520 
SSH1 -0.567 
SYCP2 -1.048 
TBCA -0.812 
TBCE 0.511 
TBX10 0.627 
TNRC9 0.901 
TPK1 0.602 
TRPC1 -0.733 
UBN1 -0.645 
UTP18 -0.661 
UTRN -0.577 
VGLL1 0.903 
WASL 0.521 
YIPF4 0.541 
ZNF133 -0.519 
ZNF35 -0.524 
ZNF571 -0.55
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Table 2.2.  List of 167 of the most robustly regulated genes affected by PARG 
knockdown only.  List of genes regulated by PARG only (from Figure 2.5A), which 
include genes passing the present call, p-value, and fold change criteria noted in the 
text.  The degree of change upon PARG knockdown is listed as log2 fold change 
relative to the Luc control. 
 
 Gene Log2 FC Gene Log2 FC 
 
ABCA5 -0.517 
ABCC4 0.504 
ABCD1 0.684 
ACOT2 0.703 
ACOX1 -0.812 
AGPAT3 0.524 
AMDHD2 -0.660 
AMPH -0.779 
AOX1 0.703 
AP4E1 0.772 
APH1B -0.755 
ARL4C -0.615 
ARMC6 0.525 
ARPC4 0.722 
ATP11A -0.528 
ATP11B 0.660 
AZIN1 -0.618 
BBS1 -0.557 
BCAR3 0.502 
BFSP1 -0.519 
BHLHB2 -0.903 
BRAF -0.818 
C14orf45 -0.617 
C20orf117 -0.773 
C5orf13 0.831 
C9orf156 0.594 
CARD14 -0.528 
CASP2 0.624 
CDC14B -0.844 
CDKN2C -0.509 
CES2 -0.707 
CLIC4 -0.580 
CLTA -0.702 
CNN2 0.664 
COL11A2 0.668 
COQ7 -0.553 
CRISP3 0.551 
CRLF1 -0.584 
CROT 0.519 
DEPDC5 0.611 
DICER1 -0.627 
dJ222E13.2 0.521 
DLEU2 -0.762 
DTNA -0.511 
EEF1D -0.720 
EFEMP1 0.834 
EHF -0.547 
EMCN -0.625 
ENPEP -0.515 
EZH1 -0.681 
FAM116B -0.884 
FBXO22 -0.973 
FBXW7 0.603 
FGFR1 0.719 
FLJ12151 -0.583 
FLJ21820 -0.561 
FLJ22662 0.602 
GALNT12 0.609 
GDAP1 -0.559 
GEM -0.722 
GLE1L 0.586 
GNE 0.871 
GPC5 0.553 
GSPT1 0.712 
GTF2F1 0.614 
GULP1 0.654 
HLA-A -0.510 
HNRPD -0.552 
H-plk 0.680 
HSF1 0.583 
IFT122 -0.872 
INSIG1 0.571 
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Table 2.2. (continued) 
 
Gene Log2 FC 
 
IREB2 0.528 
ITFG2 0.653 
KCNJ5 0.796 
KIAA0562 0.593 
KIAA2010 -0.810 
KIF14 -0.552 
KLF3 0.663 
KRT86 0.540 
KYNU 0.566 
LIG3 0.530 
LOC441296 -0.559 
LOC93349 0.567 
LRRC40 -0.954 
LTBP3 0.695 
MAP4 -0.521 
MARCKS -0.655 
MAX -0.815 
MBNL2 0.608 
MCFD2 0.577 
MED6 -1.098 
MIER2 -0.523 
MLF1 -0.578 
MNS1 -0.682 
MTSS1 -0.684 
MUM1 1.199 
MYO9B 0.551 
NAT1 -0.857 
NCAM2 -0.957 
NEK1 -0.793 
NEK7 -0.920 
NFATC1 0.542 
NFYB 0.509 
NUP62CL -0.865 
OLR1 0.573 
OPN3 0.651 
OR7E37P -0.738 
P18SRP 0.591 
PARD3 0.545 
PARG -1.514 
PCP4 0.502 
PDCD4 0.523 
PHF3 -0.744 
PHLPPL -0.658 
PLD3 -0.652 
PPAP2B 0.598 
PPFIBP2 -0.754 
PPP1R15A -0.778 
 
 
Gene Log2 FC 
 
PPP1R9A -0.630 
PRO0149 0.750 
PRO1843 -0.537 
RAB28 0.529 
RASL11B -0.584 
RBM7 0.503 
RET -0.599 
RPL23 -0.957 
RRM2 -0.545 
RXRB 0.657 
SAV1 0.647 
SF3B3 0.604 
SIPA1L1 -0.612 
SKIP -0.562 
SLC6A14 1.362 
SNRPN 0.935 
SOCS2 -0.974 
SPATA2 0.702 
SRGAP3 -0.768 
STK3 0.507 
STX6 -0.646 
TAF1 -0.793 
TBC1D5 -0.729 
TFF1 -0.576 
TFF3 -0.869 
TGFB2 0.694 
TMC5 0.640 
TMCO3 0.824 
TMSL8 -1.295 
TNFSF13 -0.627 
TPM4 0.799 
TPR 0.554 
TTC12 -0.615 
TTC30A -0.803 
TWIST1 -0.586 
URG4 -1.281 
USP24 0.583 
VAPA -0.528 
VAV3 -0.738 
VCX -0.950 
VCX2 -0.555 
WSB2 -0.661 
WTAP -0.512 
YWHAZ -0.926 
ZIC1 0.708 
ZNF165 0.506 
ZNF202 0.614 
ZNF606 -0.73
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Table 2.3.  List of 50 of the most robustly regulated genes affected by both PARP-
1 and PARG knockdown.  List of genes regulated by both PARP-1 and PARG (from 
Figure 2.5A), which include genes passing the present call, p-value, and fold change 
criteria noted in the text.  The degree of change upon PARP-1 or PARG knockdown is 
listed as log2 fold change relative to the Luc control. 
 
Gene PARP-1 PARG Gene PARP-1 PARG 
 
ALDH1A3 1.41 0.99 
ALOX15 0.70 0.69 
ANKRD12 -0.51 -0.54 
ATXN10 1.14 1.26 
C10orf97 0.59 0.66 
C14orf78 0.65 0.60 
CALM1 0.78 0.92 
CCNA2 0.50 0.56 
CENTD1 -0.87 -0.58 
CTDSPL 0.70 0.91 
CYB561 0.68 0.78 
EPS15 0.66 0.79 
FGFR2 0.65 0.53 
FLJ11151 1.24 1.25 
GRSF1 0.52 0.72 
HGD 0.66 0.80 
ITPR1 -0.73 -0.98 
KCNK5 0.60 0.94 
KIAA0999 0.65 0.73 
LGALS3BP 0.79 0.62 
LYRM1 0.65 0.55 
MBOAT2 0.60 0.62 
MSMB 0.76 0.62 
MTR 0.60 0.82 
MYB -0.63 -0.86 
NELL2 -0.54 -1.14 
NR4A2 0.53 0.53 
OGFR 0.87 0.79 
PAQR6 -0.78 -0.74 
PCCA 0.52 0.61 
PDLIM5 0.73 0.65 
PGM3 0.66 0.75 
PPP2R1B 0.56 0.61 
PRODH 0.89 0.82 
PRUNE 0.50 0.53 
PVALB -0.64 -0.57 
QPRT 0.85 0.86 
RIPK2 0.69 0.94 
RPL23AP7 0.75 1.02 
SERINC3 0.63 0.60 
SGK3 0.89 0.66 
SLC35A3 0.65 0.94 
ST3GAL5 -0.67 -0.57 
TARP -1.03 -1.44 
TBC1D4 0.83 0.69 
TGOLN2 0.58 0.57 
TMOD3 0.91 1.12 
TROVE2 -0.85 -0.89 
UBE2B 0.51 0.52 
ZMYM6 0.70 0.60 
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Figure 2.6. Comparison of two independent shRNA target sequences for the 
knockdown of PARP-1 or the knockdown of PARG.  A, Knockdown of PARP-1 
or PARG by two independent shRNA target sequences.  Whole cell lysates were 
collected from Luc, PARP-1, and PARG stable shRNA-mediated single knockdown 
cell lines.  Two independent shRNA sequences (#1 and #2) targeting PARP-1 (top) 
or PARG (bottom) were analyzed by Western blotting for their ability to knockdown 
their cognate proteins relative to the Luc control.  B, RT-qPCR analysis confirms the 
knockdown PARP-1 and PARG mRNA in the single knockdown cell lines described 
in panel A.  Total RNA was isolated from Luc, PARP-1, and PARG single 
knockdown cells, reverse transcribed, and subjected to qPCR using gene-specific 
primers to PARP-1 and PARG.  Each bar is the mean + SEM (error bars) for three 
independent RNA isolations.  C, Comparable effects on gene expression for single 
and double PARP-1 knockdown.  Luc and PARP-1 single and double knockdown 
MCF-7 cells were seeded and grown under the conditions described in the text.  Total 
RNA was isolated, reverse transcribed, and subjected to qPCR using gene-specific 
primers.  The effect of single knockdown (PARP-1 shRNA #1 or PARP-1 shRNA#2) 
and double knockdown were compared for the PARP-1 target genes identified in 
Figure 2.5 (left).  Each bar represents the mean + SEM (error bars) from three or 
more independent determinations.  A correlation analysis comparing the effects of 
PARP-1 shRNA #1 and PARP-1 shRNA #2 at 40 target genes indicates that both 
shRNAs produce similar effects on target gene expression.  The Spearman correlation 
coefficient (c.c.) and p-value are indicated (right).  D, Comparable effects on gene 
expression for single and double PARG knockdown.  Experiments similar to those 
described for PARP-1 in panel C were performed for PARG. 
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We focused on these confirmed genes for further analysis in the experiments described 
below.  Additional gene-specific RT-qPCR assays comparing gene expression profiles 
from single knockdown cell populations indicate that the gene regulatory effects of the 
shRNAs used in our assays are unlikely to be due to off target effects (Figure 2.6). 
 
Genes commonly regulated by PARP-1 and PARG are enriched in metabolism and 
stress response functions.  To explore the function of the genes most robustly 
regulated by PARP-1 and PARG knockdown, we performed gene ontology (GO) 
analyses using the DAVID Bioinformatics Database Resource (Table 2.4).  Both the 
PARP-1- and PARG-regulated genes from Figure 2.5A (i.e., genes passing the present 
call, p-value, and fold change criteria noted above) are enriched in cell structure and 
metabolism functions (e.g., ITPR1 for PARP-1, SOCS2 and MTR for PARG).  The 50 
commonly regulated genes are enriched in stress response and metabolism functions 
(e.g., LGALS3BP), consistent with the stress- and metabolic-related phenotypes of 
PARP-1 and PARG knockout mice or cells from the knockout animals grown in 
culture (Cortes et al., 2004; Koh et al., 2004; Wang et al., 1995; Wang et al., 1997). 
 
Exploring the mechanisms of PARP-1- and PARG-mediated gene expression at 
target gene promoters.  After examining the control of global patterns of gene 
expression in MCF-7 cells by PARP-1 and PARG, we sought to determine the 
underlying mechanisms of regulation at specific target gene promoters.  We 
considered a variety of criteria that might help us identify target genes for mechanistic 
studies.  Ultimately, we focused on a set of genes (i) showing the most robust 
alterations in gene expression upon knockdown of PARP-1 and PARG (i.e., from the 
list of the 50 most robustly regulated genes; see Figure 2.5A and Table 2.3), (ii) 
exhibiting binding of PARP-1 and PARG at their promoters by ChIP assays (see the 
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next section), and (iii) whose expression can be complemented by re-expression of 
PARP-1 or PARG in the corresponding knockdown cell lines (see below).  We also 
considered other existing evidence of regulation at the promoters of possible target 
genes, including changes in chromatin composition (e.g., linker histone binding) and 
structure (promoter chromatin architecture; see Discussion section).  Together, these 
criteria were used as a set of parameters to identify targets for further analysis. 
 
PARP-1 and PARG localize to the promoters of target genes and can affect each 
other's binding.  Previous studies have shown that PARP-1 localizes (and in some 
cases, is recruited in a signal-dependent manner) to the promoters of target genes (Ju 
et al., 2006; Ju et al., 2004; Krishnakumar et al., 2008; Pavri et al., 2005).  In fact, a 
recent genomic analysis from our lab has shown that PARP-1 localizes to the 
promoters of most expressed genes in the genome of MCF-7 cells (Krishnakumar et 
al., 2008).  Whether PARG also localizes to target genes has not been determined.   
To address this question, we first needed to validate the use of a new custom 
PARG antibody for chromatin immunoprecipitation (ChIP) assays.  ChIP coupled 
with Western blotting of the immunoprecipitated material (i.e., "ChIP-Western"), 
demonstrated that our previously validated PARP-1 antibody (Krishnakumar et al., 
2008), as well as a new custom PARG antibody, specifically immunoprecipitate 
PARP-1 and PARG, respectively, under ChIP conditions (Figure 2.7A).  Notably, 
while our custom antibody recognizes many of the known PARG isoforms in a whole 
cell lysate (i.e., ChIP Input), it specifically enriches for two isoforms in a ChIP assay 
(Figure 2.7A).  The longest of the PARG isoforms is 110 kDa and is nuclear, while 
other slightly shorter isoforms are both nuclear and cytoplasmic (Meyer-Ficca et al., 
2004; Meyer-Ficca et al., 2005).  Our ChIP-Western results demonstrate that the 
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longest PARG isoforms are chromatin-bound.  Thus, these antibodies are useful for 
exploring the localization of PARP-1 and PARG at native promoters in ChIP assays. 
 We then used the gene expression data from Figures 2.2 through 2.5, as well as 
our existing PARP-1 genomic localization data set from MCF-7 cells (Krishnakumar 
et al., 2008), to identify genes for further examination in ChIP-qPCR assays for 
PARP-1 and PARG.  Our analyses showed that both PARP-1 and PARG localize to 
the promoters of genes from Figure 2.5D with signals of ~5- to ~20-fold over the "no 
antibody" (NA) control, but not to the promoter of an unregulated gene (i.e., 
SEMA4G) (Figure 2.8).  Specificity was demonstrated by a reduction of the ChIP 
signals upon PARP-1 or PARG knockdown (Figures 2.7B and 2.7C).  PARP-1 and 
PARG occupy the promoters of both up-regulated and down-regulated target genes, 
indicating gene-specific effects for transcriptional regulation by these factors.  
Interestingly, the levels of PARG were proportional to the levels of PARP-1 across the 
genes we examined (Figure 2.8).  That is, a higher PARG signal corresponded to a 
higher PARP-1 signal (Spearman correlation coefficient of 0.645, p-value < 0.05), 
even for genes that were regulated by knockdown of one factor, but not the other (e.g., 
ITPR1 and NVL).  This latter result fits well with the striking correlation between the 
patterns of gene regulation by PARP-1 and PARG in the microarray expression 
experiments (Figures 2.3C, 2.4C and 2.5C). 
Our previous genomic study showed that PARP-1 is enriched at promoters, 
with regions containing high levels of binding and regions containing low levels of 
binding (Krishnakumar et al., 2008).  ChIP-qPCR analyses in "off-peak" regions 
confirmed this pattern of binding for both PARP-1 and PARG at selected target gene 
promoters (e.g., the TSS for PVALB) (Figure 2.9A).  ChIP "tiling" through the 
LGALS3BP and PVALB promoter regions further confirmed this pattern of binding for 
both PARP-1 and PARG (Figure 2.9B).   Together, these results indicate that PARG, 
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Table 2.4.  Gene ontology of PARP-1-, PARG-, and commonly-regulated genes in 
MCF-7 cells.  The PARP-1- and PARG-regulated gene lists from Fig. 2.5A and 
Tables 2.1, 2.2, and 2.3, which include genes passing the present call, p-value, and 
fold change criteria noted in the text, were subjected to GO analyses using the DAVID 
Bioinformatics Database Resource.  Resulting terms were grouped together under each 
category and duplicate probe sets were removed for accurate percentage representation 
of individual genes.  Only those GO terms yielding a p-value < 0.05 by a Fisher exact 
test were considered significantly enriched in each gene list. 
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Category Count Percent of Total p-value Example8 
 
A. PARP-1-Regulated Genes 
Cell Structure1 33 16% < 0.045 ITPR1* 
Metabolism2 24 12% < 0.049 ALDH5A1 
 
B. PARG-Regulated Genes 
Cell Structure3 49 23% < 0.049 SOCS2*, TMOD3*  
Metabolism4 24 11% < 0.028 MTR*, NAT1* 
GTPase Regulation5 9 4% < 0.046 VAV3 
 
C. Commonly-Regulated Genes 
Stress Response6 8 16% < 0.033 LGALS3BP* 
Metabolism7 8 16% < 0.049 PRODH 
 
 
1 GO Terms:  plasma membrane 
2 GO Terms:  organic acid metabolism, carboxylic acid metabolism, amine 
metabolism, nitrogen compound metabolism, aromatic compound metabolism, and 
regulation of transferase activity 
3 GO Terms:  actin binding, cytoplasmic membrane-bound vesicle, cytoplasmic 
vesicle, membrane-bound vesicle, vesicle, cytoskeletal protein binding, 
cytoskeleton, endomembrane system, cell organization and biogenesis, and nuclear 
envelope 
4 GO Terms:  amino sugar metabolism, amine metabolism, cofactor biosynthesis, 
coenzyme metabolism, nitrogen compound metabolism, cofactor metabolism, 
carboxylic acid metabolism, and organic acid metabolism 
5 GO Terms:  GTPase regulator activity, GTPase activator activity 
6 GO Terms:  Response to stress 
7 GO Terms:  amine metabolism, nitrogen compound metabolism, carboxylic acid 
metabolism, organic acid metabolism, amino acid metabolism, and amino acid and 
derivative metabolism 
8 Examples of representative gene(s) for each ontological category.  Those marked 
with an asterisk are genes whose expression patterns in the PARP-1 and PARG 
knockdown cell lines were confirmed by RT-qPCR, as shown in Fig. 2.5D.
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Figure 2.7.  PARP-1 and PARG antibodies immunoprecipitate their cognate 
proteins from crosslinked chromatin.  A, (Top) Crosslinked and sheared chromatin 
from MCF-7 cells was subjected to ChIP-Western analyses for PARP-1 and PARG, 
demonstrating the ability of PARP-1 and PARG antibodies to immunoprecipitate their 
cognate proteins.  In, Input; NA, no antibody control; IP, immunoprecipitate.  
(Bottom) A higher resolution Western blot demonstrates the ability of the PARG 
antibody to specifically enrich for two PARG isoforms, denoted by asterisks, relative 
to the input material during ChIP.  Isoforms not enriched during ChIP are denoted by 
pluses.  B and C, ChIP-qPCR analyses demonstrate a reduction in PARP-1 ChIP 
signal upon knockdown of PARP-1 (panel B) and, likewise, a reduction in PARG 
ChIP signal upon knockdown of PARG (panel C), indicating that the antibodies 
specifically recognize their cognate proteins. 
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Figure 2.8.  PARP-1 and PARG localize to the promoters of regulated target 
genes.  A, PARP-1 and PARG show similar patterns of localization at the promoters of 
commonly regulated target genes.  The occupancy of PARP-1 (black bars) and PARG 
(grey bars) at the promoters of co-regulated genes was examined by ChIP analyses.  
Each bar represents the mean + SEM (error bars) from three or more independent 
determinations.  Bars that are not marked with an asterisk are statistically different 
from the NA control, as determined by a Student's t-test with a p-value threshold of < 
0.05.  SEMA4G is a gene not regulated by knockdown of PARP-1 or PARG (see 
Figure 2.5.).  The effects of PARP-1 and PARG knockdown (from Figure 2.5.) are 
indicated for comparison: (1) –, no effect; (2) ⇑, up-regulated by both PARP-1 and 
PARG knockdown; (3) ⇓, down-regulated by both PARP-1 and PARG knockdown; 
and (4) ⇑⇓, differentially regulated by PARP-1 and PARG knockdown. 
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Figure 2.9.  PARP-1 and PARG binding patterns are similar across individual 
target gene promoters.  PARP-1 and PARG binding patterns are similar across 
individual promoters with both high and low occupancy.  A, The occupancy of PARP-
1 (black bars) and PARG (grey bars) at two regions (~1 kb apart) of the GDF15, 
PVALB, LGALS3BP, and NELL2 promoters was determined by ChIP analyses.  Each 
bar represents the mean + SEM (error bars) from three or more independent 
determinations.  B, PARP-1 (solid line) and PARG (dotted line) occupancy was 
examined by ChIP-tiling analyses over a 2.5 kb region of the PVALB and LGALS3BP 
promoters.  Each point represents the mean + SEM from three or more independent 
determinations; all values are statistically different from the "no antibody" control, as 
determined by a Student’s t-test with a p-value threshold of < 0.05. 
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like PARP-1, can localize to the promoters of target genes.  Furthermore, they show 
that the localization of PARG correlates with the localization of PARP-1.The similar 
localization patterns of PARP-1 and PARG at promoters raised the question of 
whether they might affect each other's binding (e.g., one recruits the other or they bind 
cooperatively).  To address this issue, we examined the effect of knockdown of one 
protein on the promoter binding of the other in ChIP assays.  Our results indicate that 
PARP-1 and PARG can indeed affect each other's binding, but that they do so in a 
gene-specific manner (Figure 2.10).  For example, we found genes, such as NAT1, 
where the binding of PARP-1 and PARG appear to occur independently; genes, such 
as NVL, where the binding of PARP-1 requires the binding of PARG; and genes, such 
as GDF15, where PARP-1 and PARG require each other for binding.  These results 
support the hypothesis that there is a functional interplay between PARP-1 and PARG 
at target gene promoters, although, the details of the mechanisms may differ between 
promoters (see Discussion).  Collectively, our ChIP analyses indicate that PARP-1 and 
PARG localize to promoters of target genes to regulate their expression. 
 
Catalytically inactive mutants of PARP-1 and PARG support the wild-type 
expression patterns of some, but not all, target genes.  Previous studies have 
provided mixed results about the requirement for PARP-1's enzymatic activity during 
gene regulation.  Some studies have indicated that PARP-1's enzymatic activity is 
required (Butler and Ordahl, 1999; Ju et al., 2006; Ju et al., 2004; Kim et al., 2004; 
Miyamoto et al., 1999; Nirodi et al., 2001; Tulin and Spradling, 2003), while others 
have indicated that it is not (Anderson et al., 2000; Cervellera and Sala, 2000; Hassa et 
al., 2001; Meisterernst et al., 1997; Pavri et al., 2005).  The role of PARG enzymatic 
activity in the regulation of gene expression has not been examined extensively.  To 
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Figure 2.10.  PARP-1 and PARG can affect each other's binding at target gene 
promoters.  To determine if PARP-1 and PARG can affect each other’s binding, the 
occupancy of PARP-1 and PARG was examined by ChIP analyses in the control and 
knockdown cell line of the opposing factor.  A, The occupancy of PARP-1 was 
examined by ChIP analyses in the Luc (black bars) and PARG (grey bars) knockdown 
cell lines.  Each bar represents the mean + SEM (error bars) from three or more 
independent determinations.  B, The occupancy of PARG was examined by ChIP 
analyses in the Luc (black bars) and PARP-1 (white bars) knockdown cell lines.  Each 
bar represents the mean + SEM (error bars) from three or more independent 
determinations.  The data revealed three groups of PARP-1 and PARG binding 
patterns, as indicated.  All changes in occupancy for PARP-1 (Group I and II) and 
PARG (Group I) are statistically different between the control and knockdown cell 
line, as determined by a Student’s t-test with a p-value threshold of < 0.05. 
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determine the specific requirement of PARP-1 and PARG enzymatic activities in the 
regulation of target gene expression, we devised a system to stably re-express FLAG-
tagged versions of wild-type or catalytically inactive mutants of PARP-1 and PARG in 
their respective knockdown cell lines using retrovirus-mediated gene transfer.  To 
prevent knockdown of the re-expressed proteins in the PARP-1 and PARG MCF-7 
knockdown cell lines, we used shRNA-resistant versions of the PARP-1 and PARG 
cDNAs (Figures 2.11A and 2.11C; see Experimental Procedures).  Using this 
approach, we were able to restore PARP-1 expression levels to about 20 percent of the 
levels in parental cells and PARG expression levels to about 10 to 20 times the levels 
in parental cells (Figures 2.11B and 2.11D).  These levels of re-expression were 
consistent across multiple independent gene transfer experiments.  Re-expression of 
wild-type PARP-1 modestly, but reproducibly, increased total PAR levels above the 
levels seen in the PARP-1 knockdown cells, while re-expression of the catalytically 
inactive PARP-1 mutant did not (Figure 2.12A). Similarly, re-expression of wild-type 
PARG reduced total PAR levels below the levels seen in the PARG knockdown cells, 
while re-expression of the catalytically inactive PARG mutant did not (Figure 2.12B).  
These results illustrate that wild-type PARP-1 and PARG and their catalytically 
inactive mutants alter cellular PAR levels as expected in vivo. 
We used these "knockdown/add-back" cell lines to analyze the roles of PARP-
1 and PARG catalytic activity in target gene expression.  The expression of selected 
target genes from the gene-specific expression (Figure 2.5D) and ChIP (Figure 2.8) 
experiments was tested in the knockdown/add-back cell lines.  For example, the levels 
of LGALS3BP mRNA, which increased in response to both PARP-1 and PARG 
knockdown, was largely restored to control levels upon re-expression of either wild-
type or catalytically inactive PARP-1 or PARG (Figures 2.13A and 2.13B, left 
panels).  These results suggest that neither PARP-1 nor PARG enzymatic activity is 
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required for the proper expression of LGALS3BP.  In contrast, the levels of NELL2 
mRNA, which decreased in response to both PARP-1 and PARG knockdown, was 
largely restored to control levels upon re-expression of either wild-type or catalytically 
inactive PARP-1, as well as wild-type PARG, but not catalytically inactive PARG 
(Figures 2.13A and 2.13B, middle panels).  These results suggest that the catalytic 
activity of PARG, but not PARP-1, is required for the proper expression of NELL2.  
For this gene, PARG may be required to degrade an alternate source of PAR, perhaps 
from PARP-2, another nuclear PARP enzyme (Amé et al., 2004).  Other genes (e.g., 
NVL and PVALB) also showed a requirement for PARP-1 or PARG catalytic activity 
for proper expression (Figures 2.13A and 2.13B, right panels).  For the genes not 
dependent on PARP-1 or PARG catalytic activity, dominant negative effects of the 
catalytically inactive mutants may contribute to the gene expression outcomes. 
The results for LGALS3BP and NELL2 were explored further using chemical 
inhibitors of PARP-1 (i.e., PJ34) and PARG (i.e., gallotannin, GT; a.k.a. common 
tannic acid).  After verifying the efficacy of the inhibitors using autoPARylation of 
PARP-1 as an endpoint (Figure 2.14A), we examined their effects on gene expression 
(Figures 2.14B and 2.14C).  As expected based on the knockdown/add-back 
experiments, PJ34 had no effect on the expression of LGALS3BP and NELL2, 
verifying that PARP-1 enzymatic activity is not required for the proper expression of 
these genes.  Likewise, gallotannin inhibited proper expression of NELL2, but not 
LGALS3BP, verifying the requirement (or lack of requirement) for PARG enzymatic 
activity (Figures 2.14B and 2.14C).  Overall, of the nine PARP-1- or PARG-regulated 
genes that we tested in detail, about half required the enzymatic activity of the 
regulating protein (Figure 2.13 and data not shown).  These results suggest alternate 
non-enzymatic functions for PARP-1 and PARG (e.g., protein-protein interactions or 
scaffolding) in some gene contexts may be important, as suggested by other studies 
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(Anderson et al., 2000; Cervellera and Sala, 2000; Hassa et al., 2001; Meisterernst et 
al., 1997; Pavri et al., 2005). 
 
2.4.  Discussion 
 
Both PARP-1 and PARG, two enzymes functionally linked in the nuclear PAR 
metabolic pathway, have been implicated in the regulation of gene expression.  
However, the means by which they coordinate their gene regulatory actions both 
globally and at specific target genes, as well as the role of their enzymatic activities in 
the regulation of gene expression, have not been clearly established.  In the current 
study, we used both genomic and gene-specific assays to address both of these 
questions in MCF-7 cells.  Collectively, our results indicate that PARP-1 and PARG, 
two nuclear enzymes with opposing enzymatic activities, localize to target promoters 
and generally regulate gene expression in a similar, rather than antagonist, manner. 
 
PARP-1 and PARG act in concert to regulate a largely overlapping gene set in a 
similar manner.  Our microarray experiments have revealed a number of interesting 
and unexpected facets of global gene regulation by PARP-1 and PARG that were not 
revealed in previous studies focusing on one factor or the other.  First, PARP-1 and 
PARG regulate the expression of a common gene set generally in the same direction 
and with the same magnitude (Figures 2.3, 2.4, and 2.5).  Based on the seemingly 
opposing enzymatic activities of PARP-1 and PARG, this result was unexpected.  
Second, the most robustly regulated common genes are enriched for stress response 
and metabolic functions (Table 2.4), which fits well with the known biological roles of 
PARP-1 and PARG from animal studies.  Third, PARG localizes to the promoters of 
its target genes (Figures 2.8 and 2.9), as has been demonstrated previously for PARP-1 
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Figure 2.11.  Stable re-expression of shRNA-resistant PARP-1 and PARG in their 
cognate knockdown cell lines.  A, Schematic diagram of the human PARP-1 
structural and functional domains.  The DNA binding domain (DBD), zinc fingers (Zn 
Fingers), nuclear localization signal (NLS), third zinc binding domain (Zn3), 
automodification domain (AMD), and PARP "signature" motif are shown.  Open 
triangles indicate the location of the 21-nucleotide shRNA recognition sequences used 
for knockdown.  Filled circles indicate the location of the silent point mutations 
engineered into the cDNAs to make them resistant to the shRNAs.  The open circle 
indicates the location of the inactivating point mutation (Glu 988 to Lys) that inhibits 
PARP-1 enzymatic activity in the catalytically inactive mutant (CatMut).  B, FLAG-
tagged RNAi-resistant wild-type (Wt) or catalytically inactive (CatMut) PARP-1 was 
stably expressed in MCF-7 PARP-1 knockdown (KD) cell lines.  Re-expression was 
confirmed by Western blotting for PARP-1 and FLAG.  An empty vector was used as 
a control (Empty) in both Luc and PARP-1 knockdown cell lines.  C, Schematic 
diagram of the rat PARG structural and functional domains.  The regulatory domain, 
catalytic domain, active site, nuclear localization signal (NLS), and nuclear export 
signal (NES) are shown.  Open triangles indicate the location of the 21-nucleotide 
shRNA recognition sequences used for knockdown.  Filled circles indicate the 
location of the silent point mutation engineered into the cDNAs to make them resistant 
to the shRNA.  The open circles indicate the location of the inactivating point 
mutations (Tyr 788 to Phe and Tyr 791 to Ala) that inhibit PARG enzymatic activity 
in the catalytically inactive mutant (CatMut).  D, FLAG-tagged RNAi-resistant wild-
type (Wt) or catalytically inactive (CatMut) PARG was stably expressed in MCF-7 
PARG knockdown (KD) cell lines.  Re-expression was confirmed by Western blotting 
for PARG and FLAG.  An empty vector was used as a control (Empty) in both Luc 
and PARP-1 knockdown cell lines. 
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Figure 2.12.  Stable re-expression of wild-type PARP-1 or PARG re-establishes 
cellular PAR levels, while catalytically inactive mutants do not.  A and B, RNAi-
resistant wild-type (Wt) or catalytically inactive (CatMut) PARP-1 (panel A) or PARG 
(panel B) were stably expressed in their respective MCF-7 knockdown cells, as shown 
in Figure 2.11.   Whole cell lysates from each cell line were isolated and assayed for 
total cellular PAR levels by Western blot. 
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Figure 2.13.  Catalytically inactive mutants of PARP-1 and PARG support the 
wild-type expression patterns of some, but not all, target genes.  RNAi-resistant 
wild-type (Wt) or catalytically inactive (CatMut) PARP-1 and PARG were stably 
expressed in their respective MCF-7 knockdown cells using retrovirus-mediated gene 
transfer, as shown in Figure 2.11.  Total RNA was isolated from the cells, reverse 
transcribed, and subjected to qPCR using gene-specific primers.  Each bar represents 
the mean + SEM (error bars) from three or more independent determinations.  Bars 
that do not share at least one lower case letter marking (a, b, or c) within each graph 
are statistically different, as determined by analysis of variance (ANOVA) with a p-
value threshold of < 0.05.  A, Re-expression of PARP-1 after PARP-1 knockdown 
restores the wild-type expression pattern of some PARP-1 target genes.  B, Re-
expression of PARG after PARG knockdown restores the wild-type expression pattern 
of some PARG target genes. 
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Figure 2.14.  Treatment with PARP-1 or PARG chemical inhibitors, PJ34 or 
Gallotannin (GT), independently confirms that some genes do not require PARP-
1 or PARG enzymatic activity for proper gene expression.  A, PJ34 and GT inhibit 
and enhance the autoPARylation of PARP-1, respectively, without altering total 
PARP-1 or PARG levels.  Parental MCF-7 cells were seeded and grown to ~80% 
confluence and subsequently treated with PJ34 (1 µM) or GT (100 µM) for 6 hrs 
immediately prior to collection of the cells.  (Left) Whole cell extracts were monitored 
for PARP-1 and PARG by Western blotting under the treatment conditions noted.  U, 
Untreated; PJ, PJ34-treated; GT, gallotannin-treated. (Right) PARP-1 was 
immunoprecipitated from whole cell extracts (bottom) and analyzed for 
autoPARylation by Western blotting under the treatment conditions noted using a 
PAR-specific antibody (top-bracket).  Oligo(ADP-ribosyl)ated PARP-1 and 
poly(ADP-ribosyl)ated are indicated.  B and C, Total RNA was isolated from PJ34- or 
GT-treated cells, reverse transcribed, and subjected to qPCR using gene-specific 
primers.  Each bar represents the mean + SEM (error bars) from three or more 
independent determinations.  Bars that do not share at least one lower case letter 
marking (a, b, c, or d) with each graph are statistically different, as determined by 
analysis of variance (ANOVA) with a p-value threshold of < 0.05.  B, PJ34 has no 
effect on LGALS3BP or NELL2 gene expression, independently confirming that 
PARP-1 enzymatic activity is not required to regulate these genes.  The 
knockdown/add-back data is shown for comparison. C, GT has no effect on 
LGALS3BP gene expression, independently confirming that PARG enzymatic activity 
is not required to regulate this gene.  The effect of GT on NELL2 is shown as a 
control.  The knockdown/add-back data is shown for comparison. 
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 (Ju et al., 2006; Ju et al., 2004; Krishnakumar et al., 2008; Pavri et al., 2005).  
Furthermore, the levels of chromatin-bound PARG at a given promoter generally 
correlate with the levels of PARP-1, at least across the subset of promoters tested 
herein.  Finally, PARP-1 and PARG enzymatic activities are required for the 
regulation of some, but not all, target genes (Figure 2.13).  
In a simple model of gene regulation, PARG opposes the actions of PARP-1 
by degrading the PAR chains synthesized by PARP-1.  With respect to the expression 
analyses presented herein, this model fails in at least two ways.  First, PARP-1 and 
PARG enzymatic activities are required for the regulation of a subset of target genes 
(Figure 2.13).  Second, as noted above, gene regulation by PARP-1 and PARG 
generally occurs in the same direction and with the same magnitude.  Thus, our results 
point to concerted, rather than opposing, actions of PARP-1 and PARG in gene 
regulation.  Interestingly, PARP-1 and PARG animal models demonstrate similarities 
in the biological endpoints analyzed (Cortes et al., 2004; Fisher et al., 2007; Kim et al., 
2005; Koh et al., 2004; St-Laurent et al., 2007; Tulin et al., 2003; Tulin et al., 2005; 
Tulin and Spradling, 2003; Tulin et al., 2002; Wang et al., 1995; Wang et al., 1997).  
Although they have not yet been explored with respect to gene expression, perhaps the 
concerted actions of PARP-1 and PARG revealed by our gene expression analyses can 
provide an explanation to these biological phenomena. 
 
Gene ontology analyses reveal common functions for PARP-1- and PARG-
regulated genes.  Both PARP-1- and PARG-regulated genes are enriched in cell 
structure and metabolism functions  (e.g., ITPR1 for PARP-1, SOCS2 and MTR for 
PARG), with the common genes enriched in stress response and metabolism functions 
(e.g. LGALS3BP) (Table 2.4).  These results are consistent with (i) the stress- and 
metabolic-related phenotypes of PARP-1 and PARG knockout animals (mice, flies, 
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and worms) or cells from knockout mice grown in culture (Conde et al., 2001; Cortes 
et al., 2004; Gao et al., 2007; Hanai et al., 2004; Koh et al., 2004; Mabley et al., 2001; 
Morrison et al., 1997; Oliver et al., 1999; St-Laurent et al., 2007; Tong et al., 2001; 
Tulin and Spradling, 2003; Tulin et al., 2002; Wang et al., 1995; Wang et al., 1997; 
Yu et al., 2002; Zong et al., 2004) and (ii) previous gene ontology analyses from 
microarray expression experiments examining PARP-1-dependent gene regulation.  
With respect to the latter, PARP-1-regulated genes in mouse embryonic fibroblasts 
were found to be enriched in functions related to apoptosis, cell cycle control, DNA 
synthesis/repair, stress and immune responses, chromosomal integrity, and protein 
processing (Simbulan-Rosenthal et al., 2000; Simbulan-Rosenthal et al., 1999; 
Zingarelli et al., 2003).  Likewise, PARP-1-regulated genes from mouse embryonic 
stem cells and livers were found to be enriched in functions related to metabolism, 
signal transduction, cell cycle control, and transcription. (Ogino et al., 2007). 
The known functions of the ITPR1, SOCS2, MTR, and LGALS3BP gene 
products fit with the roles of PARP-1 and PARG in cellular physiology.  ITPR1 
encodes the type 1 inositol 1,4,5-trisphosphate receptor (Yamada et al., 1994), which 
plays a critical role in Ca2+ signaling in neuronal, immune, and other cell types 
(deSouza et al., 2007; Inoue et al., 1998).  SOCS2 encodes a cytokine-inducible SH2 
protein that functions as a suppressor of cytokine signaling 2 and plays a role in 
insulin signaling pathways (Dey et al., 1998; Minamoto et al., 1997).  MTR encodes 5-
methyltetrahydrofolate-homocysteine methyltransferase (a.k.a. methionine synthase), 
an enzyme that catalyzes the remethylation of homocysteine to methionine (Leclerc et 
al., 1996; Li et al., 1996).  Impaired methionine synthase activity leads to elevated 
levels of plasma homocysteine, which is a risk factor in both birth defects and vascular 
disease (Watkins and Rosenblatt, 1989).  LGALS3BP encodes lectin galactoside-
binding soluble 3-binding protein (a.k.a. Mac-2-binding protein and tumor-associated 
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antigen 90K) (Koths et al., 1993), a protein that promotes integrin-mediated cell 
adhesion and is found in increased levels under pathophysological conditions (e.g., 
cancer and viral infections) (Tinari et al., 2001).  Collectively, our studies indicate a 
clear role for PARP-1- and PARG-regulated genes in metabolism, stress, DNA repair, 
and signaling functions, findings corroborated by other studies. 
 
How might PARP-1 and PARG act in concert to regulate gene expression?  The 
specific mechanisms of PARP-1- and PARG-dependent gene regulation are likely to 
differ depending on the requirement for PARP-1 and PARG catalytic activity at a 
particular gene.  Previous studies have used chemical inhibitors and mutants to explore 
the roles of PARP-1 and PARG catalytic activities in the regulation of gene expression 
(Kim et al., 2005; Kraus and Lis, 2003).  In some gene-specific studies, PARP-1 
enzymatic activity was required for its gene regulatory functions (Butler and Ordahl, 
1999; Ju et al., 2006; Ju et al., 2004; Kim et al., 2004; Miyamoto et al., 1999; Nirodi et 
al., 2001; Tulin and Spradling, 2003), while in others it was not (Anderson et al., 
2000; Cervellera and Sala, 2000; Hassa et al., 2001; Meisterernst et al., 1997; Pavri et 
al., 2005).  The results for PARG have also been variable (Kim et al., 2004; Rapizzi et 
al., 2004; Tulin et al., 2005).  These results suggest gene-specific (and perhaps cell 
type-specific) requirements for the PARP-1 and PARG catalytic activities, a result 
supported by our observations described herein. 
For genes requiring PAR metabolism, the goal of the combined PARP-1 and 
PARG enzymatic activities may be the production of ADPR, rather than the addition 
and removal of PAR per se.  ADPR may function as a signaling molecule in the 
nucleus by binding as a small molecule ligand to the macro domain of the histone 
variant macroH2A1.1 (Karras et al., 2005; Kustatscher et al., 2005), which may act to 
regulate gene expression in a chromatin-dependent manner.  For genes that do not 
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require PAR metabolism, PARP-1 and PARG may function as classical coregulators, 
as has been described previously for PARP-1 (Hassa and Hottiger, 1999; Hassa and 
Hottiger, 2002; Ju et al., 2006; Ju et al., 2004; Pavri et al., 2005). Whether they act 
within common coregulatory complexes is unknown, although a physical interaction 
between PARP-1 and PARG has been reported in vitro and in vivo, under certain 
cellular conditions (Keil et al., 2006).  Interestingly, PARP-1 and PARG localize to a 
similar set of target gene promoters at proportional levels (i.e., higher levels of PARG 
correspond to higher levels of PARP-1; Figures 2.8 and 2.9).  In addition, PARP-1 and 
PARG facilitate each other's binding to certain promoters (Figure 2.10), which is 
consistent with the presence of both factors in the same complex.  However, we also 
observe independent binding of PARP-1 and PARG to some promoters, suggesting 
that these factors are also able to function distinctly in some cases.  Unlike PARP-1, 
PARG does not have a DNA binding domain.  Thus, when it binds to chromatin 
independently of PARP-1, it must do so by binding to histones or through interactions 
with other DNA- or chromatin-binding proteins.  
Our results demonstrating non-enzymatic functions for PARP-1 and PARG 
suggest that they may also function as scaffolding proteins.  Indeed, PARP-1 has been 
shown to participate as a component of promoter-bound coregulatory complexes, 
perhaps serving as a protein scaffold or "exchange factor" within those complexes 
(Hassa and Hottiger, 2002; Kraus, 2008; Pavri et al., 2005).  Such a scaffolding role 
has not yet been described for PARG.  Furthermore, PARP-1 and PARG may be 
subject to post-translational modifications that modulate their gene regulatory actions.  
For example, PARP-1 is known to be phosphorylated by various cellular kinases that 
can, in some cases, enhance its DNA-binding or catalytic activity (Gagne et al., 2008; 
Kauppinen et al., 2006; Mathieu et al., 2008). 
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The regulation of chromatin structure may also be a common component of 
PARP-1- and PARG-dependent gene expression outcomes (Kraus, 2008).  We have 
shown previously that PARP-1 can bind specifically to nucleosomes and modulate 
chromatin structure in the absence of NAD+ (Kim et al., 2004; Wacker et al., 2007b), 
although the release of PARP-1 from the nucleosomes, requires its enzymatic activity 
(Kim et al., 2004; Wacker et al., 2007b).  The binding of PARP-1 and PARG at 
promoters can also affect the binding of other factors.  For example, PARP-1 can 
regulate the binding of the linker histone H1 at target gene promoters.  Specifically, 
we showed that RNAi-mediated knockdown of PARP-1 increases the levels of H1 at 
the ITPR1, NAT1, NELL2, PVALB, and SOCS2 promoters concomitant with reduced 
expression of the genes ((Krishnakumar et al., 2008); R.K. and W.L.K., unpublished).  
Given the inhibitory effect of H1 on transcription, the increase in H1 upon the 
knockdown of PARP-1 is likely to be accompanied by the formation of less accessible 
and more repressive chromatin structures.  These actions of PARP-1 are consistent 
with previous biochemical assays, suggesting a role for both PARP-1 and PARG in 
the regulation of chromatin structure and transcription (Kim et al., 2004). 
 
2.5.  Experimental Procedures 
 
Antibodies - The custom rabbit polyclonal antibodies against PARP-1 and PARG used 
for Western blotting and ChIP assays were generated by using a purified fragment of 
human PARP-1 (amino-terminal, PARP-N (Kim et al., 2004)) and full-length rat 
PARG as antigens (Pocono Rabbit Farm and Laboratory, Inc.).  The antibodies were 
screened for: (i) specificity by Western blotting MCF-7 cell extracts, (ii) the ability to 
immunoprecipitate their cognate antigens from formaldehyde crosslinked chromatin 
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samples by a ChIP-Western protocol (Kim et al., 2004) (Figure 2.7), and (iii) a 
reduction in Western blot signal upon knockdown of PARP-1 or PARG (see Figure 
2.1).  The custom rabbit polyclonal antibody against SIRT1 used for Western blotting 
was generated by using full-length mouse SIRT1 as an antigen (Zhang et al., 2009).  
The mouse monoclonal PAR antibody was purchased from Trevigen (4335-AMC-
050).  The mouse monoclonal FLAG antibody was purchased from Sigma (F3165). 
 
Chemical inhibitors - PJ34 was purchased from Alexis Biochemicals.  Gallotannin 
("GT"; a.k.a. common tannic acid) was purchased from Sigma Chemical Co.  Both 
inhibitors were dissolved in distilled water, pH-adjusted to approximately 7.5, and 
added to the cell culture medium for six hours at 1 µM.  
 
Oligonucleotides - The oligonucleotide sequences listed below were used for the 
shRNA constructs and site-directed mutagenesis.  Those sequences denoted with an 
asterisk (*) were chosen based on priority score described at the website. 
 
shRNA constructs -  
Target Sequence Source 
Luc 5’ - gatatgggctgaatacaaa - 3’ (Reynolds et al., 2004) 
hPARP-1 #1 5’ - gggcaagcacagtgtcaaa - 3’  (Ju et al., 2004; Shah et al., 2005) 
hPARP-1 #2* 5’ - acacctctctactatataa - 3’ Dharmacon siDESIGN® Center 
hPARG #1* 5’ - caataccactcctgaaaca - 3’  Dharmacon siDESIGN® Center 
hPARG #2* 5’ - agagaccgctgaccattca - 3’ Dharmacon siDESIGN® Center 
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Site-directed mutagenesis - 
• Primers for site-directed mutagenesis to generate an RNAi-resistant hPARP-1 
cDNA: 
1. Recognition site #1 (Wt and CatMut) 
5’ - caggttacccaagggcaaacatagcgttaaaggtttgggcaaaac - 3’ and  
5’ - gttttgcccaaacctttaacgctatgtttgcccttgggtaacctg - 3’ 
Specific changes relative to the first nucleotide of the first codon: 
g2835a, c2838t, t2841c, c2844t 
 
2. Recognition site #2 (Wt) 
5’ - ctggtgtgaatgacacgtcgctgctgtataacgagtacattgtc - 3’ and  
5’ - gacaatgtactcgttatacagcagcgacgtgtcattcacaccag - 3’ 
      Specific changes relative to the first nucleotide of the first codon: 
c2946g, t2949g, a2952g, a2955g 
 
 3. Recognition site #2 (CatMut) 
5’ - ctggtgtgaatgacacgtcgctgctgtataacaagtacattgtc - 3’ and  
5’ - gacaatgtacttgttatacagcagcgacgtgtcattcacaccag - 3’ 
      Specific changes relative to the first nucleotide of the first codon: 
  c2946g, t2949g, a2952g, a2955g 
 
• Primers for site-directed mutagenesis to generate an RNAi-resistant rPARG cDNA: 
 1. Recognition site #1 (Wt and CatMut) 
5’ - tttgcacccagccaataccgcttctcaagcagaagatgaacc - 3’ and  
5’ - ggttcatcttctgcttgagaagcggtattggctgggtgcaaa - 3’ 
      Specific changes relative to the first nucleotide of the first codon: 
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  a1827g, g1833c, a1836g 
 
 2. Recognition site #2 (Wt and CatMut) - Not altered 
Differences between the human-based PARG shRNA#2 sequence and 
the rat PARG cDNA abrogated the need to alter the #2 recognition site 
 
PARP-1 and PARG knockdown and expression constructs - Short hairpin RNA 
(shRNA) expression constructs for retroviral-mediated knockdown of PARP-1 and 
PARG were made using the pSUPER.retro vector (OligoEngine).  Double stranded 
oligonucleotides containing shRNA sequences targeting either luciferase (Luc 
control), PARP-1, or PARG were cloned into the vector (puromycin or neomycin 
resistant) using BglII and XhoI restriction sites as described by the manufacturer.  The 
shRNA sequences (one for Luc, two for PARP-1, and two for PARG; listed above) 
were based on sequences reported in the literature (Ju et al., 2004; Shah et al., 2005) or 
designed using the Dharmacon siDESIGN® Center software (www.dharmacon.com).  
All constructs were confirmed by sequencing. 
Wild-type and catalytically inactive point mutants of human PARP-1 and rat 
PARG were used in the studies described herein.  The catalytically inactive human 
PARP-1 contained a change at Glu 988 to Lys (E988K) (Marsischky et al., 1995; Rolli 
et al., 1997), whereas the catalytically inactive rat PARG contained changes at Tyr 
788 and 791 to Phe and Ala, respectively (Y788F/Y791A) (Shimokawa et al., 1999).  
CMV-based mammalian expression constructs for full-length wild-type or 
catalytically inactive human PARP-1 (with a carboxyl-terminal 6xHis/FLAG tag) or 
rat PARG (with a carboxyl-terminal FLAG tag) were generated by PCR-based cloning 
of the tagged cDNAs into pCMV5.  The pCMV5-hPARP-1-His/FLAG and pCMV5-
rPARG-FLAG vectors were then used as templates to generate cDNAs resistant to the 
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shRNAs noted above by site-directed mutagenesis (QuikChange® Site-Directed 
Mutagenesis Kit from Stratagene).  The following nucleotides relative to the first 
nucleotide of the first codon were changed in the hPARP-1 cDNA: g2835a, c2838t, 
t2841c, c2844t (for shRNA#1) and c2946g, t2949g, a2952g, a2955g (for shRNA#2).  
The following nucleotides were changed in the rPARG cDNA: a1827g, g1833c, 
a1836g (for shRNA#1); note that differences between the human-based PARG 
shRNA#2 sequence and the rat PARG cDNA eliminated the need to alter the #2 
recognition site).  Positive clones were identified by sequencing and then cloned into 
the pQCXIH retroviral expression vector (BD Biosciences; hygromycin resistant) 
using NotI and BamHI restriction sites.  
 
Generation and culture of MCF-7-derived cell lines - Parental MCF-7 human breast 
cancer cells, kindly provided by Dr. Benita Katzenellenbogen, were maintained in 
MEM Eagle medium containing Hanks' salts, L-glutamine, and non-essential amino 
acids (Sigma) supplemented with 5% bovine calf serum (CS; Sigma), 20 mM HEPES 
(pH 7.6), 100 units/mL penicillin, 100 µg/mL streptomycin, 25 µg/mL gentamycin, 
and 0.22 % sodium bicarbonate.  The shRNA knockdown ("knockdown") and shRNA 
knockdown + shRNA-resistant re-expression ("knockdown/add-back") cell lines used 
in these studies were generated by sequential retroviral infections of parental MCF-7 
cells with the appropriate shRNA and cDNA expression vectors (see below).  In each 
case, the final cell line constructions were populations of individual transformants, not 
clonal lines.  A minimum of two independently generated populations were made and 
tested for each cell line.  The Luc, PARP-1, and PARG knockdown cells express two 
distinct shRNA sequences targeting the intended factor.  These same shRNA 
sequences were tested individually in gene-specific expression studies (Figure 2.6). 
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Retroviruses were generated by transfection of the pSUPER.retro or pQCXIH 
vectors described above with an expression vector for the VSV-G envelope protein 
into Phoenix Ampho cells using GeneJuice transfection reagent (Novagen) according 
to the manufacturer’s protocol.  The resulting viruses were collected, filtered through a 
0.45 µm syringe filter to remove any remaining cells, and used to infect the parental 
MCF-7 cells.  Stably transduced cells were isolated under appropriate selection with 
puromycin (Sigma; 0.5 µg/mL), G418 sulfate (Gibco/BRL; 800 µg/mL), or 
hygromycin (Cellgro; 200 µg/mL), expanded, and frozen in aliquots for future use.  
The cells were grown under subconfluent conditions for experimental procedures.  
For experiments, cells from the various lines were plated in MEM modified 
Eagle medium with Earle's salts and non-essential amino acids, without phenol red 
(Sigma), supplemented 5% charcoal/dextran-treated bovine calf serum (CDCS; 
Sigma) and the other additives noted above.  Subconfluent populations of cells were 
collected for analysis between 3 and 4 days post-plating. 
 
Cell proliferation analyses - For analysis of cell proliferation, stable Luc, PARP-1, 
and PARG knockdown cells were seeded at ~2 x 104 cells per well in 6-well plates in 
MEM containing 5% CDCS and the additives noted above.  Every two days during an 
8-day time course, the cells were collected by trypsinization and counted using a 
hemacytometer.  All experiments were conducted a minimum of three times to ensure 
reproducibility.  Analysis of variance (ANOVA) with a p-value threshold of < 0.05 
was used to determine the significance of differences between samples. 
 
Cell cycle analyses - For FACS analysis, stable Luc, PARP-1, and PARG knockdown 
cells were seeded at ~5 x 105 cells per 6 cm diameter dish in MEM containing 5% 
CDCS and the additives noted above.  After three days (at ~50 to 60% confluence), 
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the cells were collected by trypsinization, washed twice with ice-cold PBS, and fixed 
with 70% ethanol for at least 1 hour at 4°C.  The cells were then washed again with 
ice-cold PBS and stained with a propidium iodide solution (40 µg/mL propidium 
iodide, 0.1% Triton X-100, 200 µg/mL RNase A).  The samples were incubated at 
37°C for 30 minutes and analyzed by flow cytometry at Cornell University’s 
Biomedical Sciences Flow Cytometry Laboratory.  Briefly, DNA content was 
measured with a BD Biosciences LSRII (San Jose, CA).  Propidium iodide was 
excited with a 488nm laser and emission collected through a 576/26BP filter.  Gating 
and analysis were done using the BD Biosciences FACSDiVa software.  All 
experiments were conducted a minimum of three times to ensure reproducibility. 
Analysis of variance (ANOVA) with a p-value threshold of < 0.05 was used to 
determine the significance of differences between samples. 
 
PAR and NAD+ Measurements - Stable Luc, PARP-1, and PARG knockdown cells 
were seeded at ~6 x 105 cells per 15 cm plate and grown for at least 3 days in MEM 
containing 5% CDCS and the additives noted above.  After three days (at ~60 to 80% 
confluence), the cells were collected by trypsinization, washed with ice-cold PBS, and 
frozen in liquid nitrogen.  The levels of PAR were determined by Western blotting of 
whole cell or nuclear extracts prepared in the presence of gallotannin to prevent 
degradation of the PAR polymers by PARG.  The signals were quantified by 
densitometry using ImageQuant software (Molecular Dynamics).  The concentration 
of NAD+ in whole cell extracts for each cell line was determined by using a 
quantitative HPLC/mass spectrometry method (HPLC/MALDI/MS) with 18O 
Standards (Yang et al., 2007; Yang and Sauve, 2006).  
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Expression microarrays - Stable Luc, PARP-1, and PARG knockdown cells were 
seeded at ~8 x 105 cells per 10 cm diameter dish and grown for at least 3 days in MEM 
containing 5% CDCS and the additives noted above.  Three independently-generated 
populations of cells were used for these experiments.  The cells were collected and 
total RNA was isolated using Trizol Reagent (Invitrogen) followed by an RNeasy 
column (Qiagen) according to the manufacturers' protocols.  The RNA quality was 
assessed using an Agilent Bioanalyzer 2100, and suitable RNA was analyzed for 
global patterns of gene expression at Cornell University's Microarray Core Facility.  
Briefly, 7 mg of total RNA was labeled using Affymetrix's standard one-cycle 
amplification and labeling protocol.  The labeled cRNA was then hybridized to 
Affymetrix Human U133A 2.0 GeneChips, which were scanned using a GeneChip 
Scanner 3000.  The raw array data was processed by Affymetrix GeneChip Operating 
Software (GCOS) to obtain detection calls and signal values.  The signals were 
normalized by scaling to a target value of 500 using GCOS.  To adjust for batch 
effects due to day-to-day differences in RNA isolations, the empirical Bayes method 
was applied to the data set (Johnson et al., 2007).  After adjusting any values less than 
0.01 to 0.01, the data was log2 transformed, median centered for each array, and 
median centered for each individual probe set.  The criteria for a gene to be considered 
regulated by PARP-1 or PARG was: (i) detection call flagged as present or marginal 
in 2 out of 3 array replicates for both control and factor knockdown cell lines and (ii) 
significance of values between control and knockdown cell lines for any given gene 
had a two-tailed Student’s t-test with a p-value < 0.05 (see Figure 2.3A, Union).  To 
determine the genes most robustly regulated by PARP-1 or PARG, we added a fold 
change criterion between 0.5 and -0.5 compared to the Luc control knockdown cells 
(the final gene lists can be found in Tables 2.1, 2.2, and 2.3.  The heatmaps used to 
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visualize the microarray expression data (Figures 2.3B and 2.4B) were generated using 
Java Treeview (http://www. jtreeview.sourceforge.net/) (Saldanha, 2004). 
 
Gene ontology analyses - Gene ontology (GO) analyses of the microarray expression 
data were performed using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) Bioinformatics Database Resource website for gene ontology 
analysis (http://david. abcc.ncifcrf.gov/) (Dennis et al., 2003).  PARP-1- and PARG-
regulated gene lists (consisting of 204 and 217 genes, respectively; see Figure 2.5A 
and 2.5B) were generated according to the present call, p-value, and fold change 
criteria as noted above.  The commonly regulated gene list (50 genes) represents the 
overlap between the PARP-1- and PARG-regulated gene lists.  Affymetrix gene ID 
numbers for each list were entered into DAVID website for gene ontology analysis.  
Resulting terms were grouped together under each category and duplicate probe sets 
were removed.  Only those GO terms yielding a p-value < 0.05 using a Fisher exact 
test were considered significantly enriched in each gene list. 
 
mRNA expression analyses by RT-qPCR - For gene-specific mRNA expression 
analyses, "knockdown" or "knockdown/ add-back" MCF-7 cells were grown under 
standard conditions (see above).  For experiments, the cells were seeded at ~1.5 x 105 
cells per well in 6-well plates and grown for 3 days in MEM containing 5% CDCS and 
the additives noted above.  Total RNA was isolated using Trizol Reagent (Invitrogen), 
reverse transcribed, and subjected to real-time quantitative PCR using gene specific 
primers.  All target gene transcripts were normalized to the β-actin transcript, which 
was unaffected by PARP-1 or PARG knockdown (data not shown).  All experiments 
were conducted a minimum of three times with independent RNA isolations. 
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Chromatin immunoprecipitation assays - Parental or knockdown MCF-7 cells were 
seeded at ~6 x 105 cells per 15 cm plate and grown for at least 3 days in MEM 
containing 5% CDCS and the additives noted above.  The cells were crosslinked with 
1% formaldehyde in PBS at 37°C for 10 min immediately prior to harvesting.  ChIP 
assays were performed as described previously (Kininis et al., 2007; Krishnakumar et 
al., 2008) using polyclonal antibodies against PARP-1 and PARG (see above), as well 
as "no antibody" controls.  The "no antibody" signals from the ChIP assays are 
comparable to pre-immune sera in both ChIP-Western and ChIP-qPCR assays (data 
not shown).  The resulting ChIP DNA material was used in gene-specific qPCR 
analyses (see below for description and primer sequences).  For ChIP-Western 
analysis (FIgure 2.7), a small aliquot was removed from the input and ChIP samples 
prior to reversing the crosslinks for conventional Western blotting. 
 
Quantitative PCR analyses (RT-qPCR and ChIP-qPCR) - Gene-specific mRNA 
expression and ChIP analyses were analyzed by quantitative PCR in a similar manner.  
Briefly, reactions containing DNA from either source, 1x SYBR Green PCR master 
mix, and forward and reverse primers (500 nM) were used in 40-45 cycles of 
amplification (95°C for 15 sec, 60°C for 1 min) using an MJ Research DNA Engine 
Opticon 2  (96-well) or an Applied Biosystems 7900 HT Sequence Detection System 
(384-well) following an initial 10 min incubation at 95°C.  Melting curve analysis was 
performed to ensure that only the targeted amplicon was amplified. 
 
Verification of PARP-1 and PARG inhibitor activity - To verify the inhibitory 
activities of PJ34 and GT, we monitored autoPARylation of PARP-1 by using an 
immunoprecipitation-Western blotting protocol.  Briefly, parental MCF-7 cells were 
seeded at ~4 x 105 cells per 10 cm diameter plate and grown for at least 3 days in 
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MEM containing 5% CDCS and the additives noted above.  At ~80% confluence, the 
cells were treated with PJ34 (1 µM) or GT (100 µM) for 6 hrs immediately prior to 
collection of the cells for analysis.  The cells were then rinsed with ice-cold PBS, 
collected into ice-cold PBS (containing PJ34 or GT where appropriate), and pelleted 
by centrifugation.  The cell pellets were resuspended in 300 mL of lysis buffer [25 
mM Tris•HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 0.1 mM EDTA, 0.1% NP-40, 1 
mM DTT, and a protease inhibitor cocktail (Roche Molecular Biochemicals)].  The 
samples were mixed at 4°C for 30 minutes and centrifuged at 12,000 rpm for 20 min 
at 4°C in a microcentrifuge.  The resulting supernatants were used for 
immunoprecipitation of PARP-1, which was performed for 2 hrs at 4°C using the 
PARP-1 polyclonal antibody described in the main text.  Immune complexes were 
collected by the addition of 40 µL of a 50% protein A-agarose slurry with an 
additional 2 hr incubation at 4°C.  The agarose beads were washed three times for 5 
min each in wash buffer [25 mM Tris•HCl (pH 7.5), 300 mM NaCl, 10% glycerol, 0.1 
mM EDTA, 0.1% NP-40, and 1 mM DTT].  Bound proteins were eluted by boiling in 
SDS loading solution and analyzed by Western blotting for PARP-1 and PAR. 
 
Effect of PARP-1 and PARG inhibition on gene expression - Parental MCF-7 cells 
were treated with PJ34 (1 µM) or GT (100 µM) for 6 hrs immediately prior to 
collection of the cells for analysis.  The cells were seeded at ~1.5 x 105 cells per well 
in 6-well plates and grown for 3 days in MEM containing 5% CDCS and the additives 
noted in the main text.  Total RNA was isolated using Trizol Reagent (Invitrogen), 
reverse transcribed, and subjected to real-time quantitative PCR using gene specific 
primers.  All target gene transcripts were normalized to the β-actin transcript.  All 
experiments were conducted a minimum of three times with independent RNA 
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isolations to ensure reproducibility.  Analysis of variance (ANOVA) with a p-value 
threshold of < 0.05 was used to determine significant differences between samples. 
 
Statistical analyses - For the NAD+ measurements in Figure 2.1, the ChIP-qPCR 
assays in Figures 2.8, 2.9, and 2.10, and the RT-qPCR assays in Figures 2.1B and 
2.5C, a paired Students’ t-test with a p-value threshold of < 0.05 was used to 
determine the significance of differences between the control and experimental 
samples.  For the gene-specific expression analyses in Figures 2.13 and 2.14, analysis 
of variance (ANOVA) with a p-value threshold of < 0.05 was used to determine the 
significance of differences between samples. 
 
Primer Sequences – The primer sequences listed below were used for the RT-qPCR 
and ChIP-qPCR amplification reactions. 
 
RT-qPCR - 
Gene Name Primer Sequence  
β-ACTIN Fwd 5’-AGCTACGAGCTGCCTGAC-3’ 
β-ACTIN Rvs 5’-AAGGTAGTTTCGTGGATGC-3’ 
DNAJC12 Fwd 5’-GAATGTCACCCAGACAAGC-3’ 
DNAJC12 Rvs 5’-GAATGGCATCGACATCTG-3’ 
GAPDH Fwd 5’-CCCAACCACCTGCTGCTTTAACCTG-3’ 
GAPDH Rvs 5’-TGGCTTTGGAGTTGGAGATTTTTGG-3’ 
GDF15 Fwd 5’-CTACAATCCCATGGTGCTCA-3’ 
GDF15 Rvs 5’-TATGCAGTGGCAGTCTTTGG-3’ 
ITPR1 Fwd 5’- TGCCTCCACAATTCTACG-3’ 
ITPR1 Rvs 5’- TGAATGTCCCACAGTTGC-3’ 
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LGALS3BP Fwd 5’-AATGTCACCATGAGTGTGG-3’ 
LGALS3BP Rvs 5’-ACTGACGACAGGGTGATG-3’ 
MTR Fwd 5’-ACAACAGCCTATGTCCTCTG-3’ 
MTR Rvs 5’-CCATCATAGAAGGCGTTTC-3’ 
NAT1 Fwd 5’-CTTCACCCTCACCCATAGGA-3’ 
NAT1 Rvs 5’-TTTGGGCACAAGCTTTCTCT-3’ 
NELL2 Fwd 5’-TGAAGGGAACCACCTACC-3’ 
NELL2 Rvs 5’-ATTTGCCATCCACATACG-3’ 
NFAT5 Fwd 5’-ACCTCTTCCAGCCCTACCAT-3’ 
NFAT5 Rvs 5’-CCTCTTCGGTGTTGATGGAT-3’ 
NVL Fwd 5’-ACGAAGAATTGTAGCCCAAC-3’ 
NVL Rvs 5’-CGAGTCTGGTCGATTAGTAGC-3’ 
PARP-1 Fwd 5’-GTGTGGGAAGACCAAAGGAA-3’  
PARP-1 Rvs 5’-TTCAAGAGCTCCCATGTTCA-3’ 
PARG Fwd 5’-GACGCAATCTCTTCCACACA-3’ 
PARG Rvs 5’-TGAGTCAGGATGGAGGGAGT-3’ 
PFDN1 Fwd 5’-TGCCTTCTCCCATACATTCC-3’ 
PFDN1 Rvs 5’-CAGGATTATGGCGTCCATCT-3’ 
PHF3 Fwd 5’- AATTCCACACCCTCTTGTG-3’ 
PHF3 Rvs 5’- TGCTGTCGCTTCAGTTTC-3’ 
PLA2G2A Fwd 5’- GATCCAGGGAGCATTCAC-3’ 
PLA2G2A Rvs 5’- TGTTTGTTCTGCACTCCTG-3’ 
PVALB Fwd 5’-CTGAACGCTGAGGACATC-3’ 
PVALB Rvs 5’-TTCACATCATCCGCACTC-3’ 
RAPGEF4 Fwd 5’-ATGGAAACGGGCTCTAAC-3’ 
RAPGEF4 Rvs 5’-AGCAGGACGAAGAGGAAC-3’ 
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SEMA4G Fwd 5’-TGGGGGTCTTGTTAGTCTGG-3’ 
SEMA4G Rvs 5’-GTGAGGATGCTGAGGAGGAG-3’ 
SOCS2 Fwd 5’-ACACGTCAGCACCATCTCTG-3’ 
SOCS2 Rvs 5’-TGGCACCGGTACATTTGTTA-3’ 
TMOD3 Fwd 5’-GGAAGTAGTAATGGTGTTGACC-3’ 
TMOD3 Rvs 5’-GCTCATCAAATACCGGAAG-3’ 
 
ChIP-qPCR - 
Gene Name Primer Sequence 
DNAJC12 promoter Fwd 5’-GCTATGTGGAACATGCTGCT-3’ 
DNAJC12 promoter Rvs 5’-GTCCTTCTTCCCTCGGAAAC-3’ 
GDF15 -500 Fwd 5’-ACACATCAAGGTTGCCCTTC-3’ 
GDF15 -500 Rvs 5’-TGGTGAAAAACAAAGGAAGCA-3’ 
GDF15 0 Fwd (promoter) 5’-CTCAGATGCTCCTGGTGTTG-3’ 
GDF15 0 Rvs (promoter) 5’-CTCGGAATCTGGAGTCTTCG-3’ 
GDF15 1500 Fwd 5’-TTTGACTGCCAGAAGAAAAGC-3’ 
GDF15 1500 Rvs 5’-AGGCAGCCTGAGATTCCAAC-3’ 
ITPR1 promoter Fwd 5’-ACTGAGGTCGCGGTTTGTAT-3’ 
ITPR1 promoter Rvs 5’-AAGGAGCCGTGTTGTGACTT-3’ 
LGALS3BP -500 Fwd (promoter) 5’-GGGCACCCCTCTCTCTACAC-3’ 
LGALS3BP -500 Rvs (promoter) 5’-TGATTGTTGCTGGACTCAGG-3’ 
LGALS3BP 0 Fwd 5’-GGGGCATTTCAGAGATGAGA-3’ 
LGALS3BP 0 Rvs 5’-GTTTGGGGTAGAGGCACAAA-3’ 
LGALS3BP 500 Fwd 5’-ACAGAAACCCCAGCATCATC-3’ 
LGALS3BP 500 Rvs 5’-CTCTGCACTCCTGTCCTTCC-3’ 
LGALS3BP 1000 Fwd 5’- CTCAGTGAGGCAATCAGCAG-3’ 
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LGALS3BP 1000 Rvs 5’-CAAGGCTCATCCAGAACCAT-3’ 
LGALS3BP 1500 Fwd 5’-TCCACCCTCTCTGTGCTCTT-3’ 
LGALS3BP 1500 Rvs 5’-GACAGTGCCATGCAACCTT-3’ 
LGALS3BP 2000 Fwd 5’-GACTGGTCCTTTGACCCAGA-3’ 
LGALS3BP 2000 Rvs 5’-CCAATCCCGGAAGACATCTA-3’ 
NAT1 promoter Fwd 5’-CCGGCTGAAATAACCTGGTA-3’ 
NAT1 promoter Rvs 5’-TATGTGCCAGCCACACTTTC-3’ 
NELL2 promoter Fwd 5’-TCCCCGGAGGAGCAGTCT-3’ 
NELL2 promoter Rvs 5’-CGCCCGAACCTGTTGTAAAG-3’ 
NVL promoter Fwd 5’-TGCAACCAAACGGATCAATA-3’ 
NVL promoter Rvs 5’-TGAATTAAGTATTAGATTTCCCACTCA-3’ 
PVALB -1000 Fwd (promoter) 5’-GCTCCCCTATCTGCACACTC-3’ 
PVALB -1000 Rvs (promoter) 5’-CAAAGGCTGTTTGGAAGCTC-3’ 
PVALB 0 Fwd 5’-CTGCTGCATCCCTCTATCCT-3’ 
PVALB 0 Rvs 5’-CTCACTTCCCGACAGGACTT-3’ 
RAPGEF4 promoter Fwd 5’-GTAACTCCCGACGACAGCTC-3’ 
RAPGEF4 promoter Rvs 5’-CTGTCACAGCCTGGAAACAA-3’ 
SEMA4G promoter Fwd 5’-AAACGGACCTCAGAAAACCA-3’ 
SEMA4G promoter Rvs 5’-CCATGGTGAGAGGGAGTTGT-3’ 
SOCS2 promoter Fwd 5’-TTCAAGCTTTCGAGCAGTGA-3’ 
SOCS2 promoter Rvs 5’-CCCTTAACAATCACGGGAAA-3’ 
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CHAPTER 3 
 
 
 
 
 
 
Role of Poly(ADP-ribose) Polymerase-1 in Mediating the Effects of Estrogen on 
the Transcriptome of MCF-7 Human Breast Cancer Cells* 
 
 
 
 
 
 
 
 
 
* This research was conducted with contributions from Hah, N., Luo, X., Sun, M., 
Krishnakumar, R., and Danko, C. as follows:  N.H. and X.L. assisted with GRO-seq 
library generation (Figure 3.6); M.S. conducted computational analyses for GRO-seq 
and ChIP-chip (Figures 3.6-3.10, 3.12, and 3.14-3.16); and R.K. performed and 
analyzed the ChIP-chip experiments using the custom promoter array (Figure 3.11).  
C.D. developed all of the computational tools for the GRO-seq data analysis.  N.H. 
also provided GRO-seq data (MCF-7 parental) for comparison analyses (Figures 3.9 
and 3.16). 
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3.1.  Summary 
 
Poly(ADP-ribose) Polymerase-1 is a nuclear enzyme that modifies target 
proteins by the covalent attachment of ADP-ribose polymers.  Over the last ten years, 
a role for PARP-1 in regulating transcription has become apparent in both basal and 
signal-mediated conditions, including stress response and hormone-mediated 
transcription.  Although considerable attention has been paid investigating the 
mechanisms of regulation at the gene-specific level, global effects on signal-mediated 
gene regulation by PARP-1 still remain unclear.  I have used a novel method known as 
Global Run-on Sequencing (GRO-seq) to define the role of PARP-1 on the estrogen-
regulated transcriptome.  GRO-seq libraries from MCF-7 cells treated with vehicle or 
17β-estradiol (E2) under three conditions: (i) a control knockdown; (ii) a control 
knockdown plus a PARP inhibitor, PJ34; and (iii) a PARP-1 knockdown were 
produced, sequenced, and compared.  I have determined that the estrogen response is 
highly maintained under PARP-1 knockdown or inhibition.  Accordingly, upon 
estrogen treatment, PARP-1 localization patterns are largely unaffected.  However, 
deeper analyses reveal a small number of genes where PARP-1 knockdown or 
inhibition reduces the estrogen response at the transcription level (GRO-seq) and at 
the steady state mRNA level (RT-qPCR). 
 
3.2.  Introduction 
 
Poly(ADP-ribose) Polymerase-1 (PARP-1) is a nuclear enzyme that modifies 
target proteins by the covalent attachment of ADP-ribose polymers, generated from 
donor nicotinamide adenine dinucleotide (NAD+) molecules (D'Amours et al., 1999; 
Kim et al., 2005).  This process is known as poly(ADP-ribosyl)ation (PARylation).  
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PARP-1 is the founding member and most characterized of the PARP superfamily 
(Ame et al., 2004; Kim et al., 2005) and is responsible for the majority of poly(ADP-
ribose) (PAR) synthesis in the cell (D'Amours et al., 1999).  PARylation occurs on a 
variety of target proteins, including transcription factors, histones, DNA repair factors, 
and PARP-1 itself, all of which play roles in a wide range of cellular processes, such 
as stress response, DNA damage repair, and transcriptional regulation (D'Amours et 
al., 1999; Kim et al., 2005; Krishnakumar and Kraus, 2010). 
PARP-1 consists of three major domains:  (i) an amino-terminal DNA binding 
domain (DBD), (ii) a central auto-modification domain (AMD), and (iii) a carboxy-
terminal catalytic domain (CATD) (Krishnakumar and Kraus, 2010).  PARP-1 binding 
to various forms of DNA (Kun et al., 2004; Kun et al., 2002; Lonskaya et al., 2005; 
Potaman et al., 2005), nucleosomes (Kim et al., 2004; Wacker et al., 2007a; Wacker et 
al., 2007b), and interactoring with various proteins (Ju et al., 2006; Ju et al., 2004; Oei 
and Shi, 2001) can potently stimulate its enzymatic activity (Krishnakumar and Kraus, 
2010).  The CATD confers NAD+ binding and ADP-ribosyl transferase activity 
(D'Amours et al., 1999; Rolli et al., 2000).  The combinatorial actions of each of these 
domains allow PARP-1 to be involved in many cellular processes involving genomic 
DNA, including transcriptional regulation. 
PARP-1 localizes to promoters of the majority of expressed genes in MCF-7 
human breast cancer cells (Krishnakumar et al., 2008).  This promoter localization is 
likely to allow for PARP-1 to function in transcriptional regulation.  PARP-1 can 
modulate transcriptional responses in numerous ways, including (i) functioning as a 
direct DNA binding factor, (ii) regulating the actions of insulators and insulator-
binding factors, (iii) functioning as a classical coregulator, and (iv) regulating 
chromatin structure and composition (reviewed in (Kim et al., 2005; Kraus, 2008; 
Kraus and Lis, 2003; Tulin et al., 2003)).  Importantly, these functions are not 
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mutually exclusive and may depend on cell-type, specific genes, and the type and 
strength of the various environmental signals.  In this regard, PARP-1 has been show 
to modulate various types of signal-mediated transcription, involving signals such as 
heat shock (Tulin et al., 2003), cytokines (Hassa and Hottiger, 1999), and steroid 
hormones (Ju et al., 2004; Pavri et al., 2005).  Although many of these areas have 
received considerable attention at the gene-specific level, global effects on signal-
mediated gene regulation by PARP-1 still remain unclear. 
In this study, I have investigated the role of PARP-1 in mediating estrogen-dependent 
transcription.  Estrogen (17β-estradiol, E2; Figure 3.1A) is a naturally produced 
steroid hormone whose actions are involved in the normal physiology of both males 
and females, such as reproduction, sexual development, and cardiovascular and 
neuronal function among various tissues in the body (Couse and Korach, 1999a; 
Couse and Korach, 1999b; Gruber et al., 2002; Nef and Parada, 2000).  In addition, 
estrogens function to promote various diseases (i.e. osteoporosis and breast, uterine, 
and ovarian cancers), but are also used for medicinal purposes (i.e. postmenopausal 
hormone replacement therapy, contraceptives) (Deroo and Korach, 2006; Foster et al., 
2001; Prall et al., 1998; Sommer and Fuqua, 2001).  Interestingly, PARP-1 has also 
been shown to play a role in the progression of various types of cancer, including 
those of the breast, uterus, and ovary.  In fact, treatment of these types of cancers with 
PARP inhibitors can be detrimental, both in cell models, as well as in clinical settings 
(Bryant et al., 2005; Farmer et al., 2005; Fong et al., 2009; Inbar-Rozensal et al., 2009; 
Munoz-Gamez et al., 2005).  However, the molecular mechanism of PARP-1 action in 
the progression of cancer is not clear.  For example, we do not understand the 
contributions of DNA damage repair versus transcriptional regulation by PARP-1.  
This information would further our understanding of PARP-1 actions, which would 
enhance the development of more effective inhibitors for therapeutic applications. 
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Figure 3.1.  Estrogen-mediated transcription in the context of chromatin.  A, 
Chemical structure of the steroid hormone, 17β-estradiol (estrogen; E2), an estrogen 
receptor-specific ligand.  B, Upon binding E2, estrogen receptor (α or β isoform, ER) 
dimerizes and binds to specific DNA elements, or known as estrogen receptor binding 
sites (ERBS).  This results in the recruitment of multiple coregulators, including 
bridging factors (i.e., Mediator), histone modifying enzymes (i.e., p300/CBP), and 
chromatin remodeling complexes (i.e., SWI/SNF), all of which cooperate to regulate 
the recruitment and activity of RNA polymerase II (RNA Pol II). 
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Estrogen actions at the molecular level are mediated by estrogen receptors 
alpha and beta (ERα and β), through both genomic and non-genomic actions (Marino 
et al., 2006; Ordonez-Moran and Munoz, 2009).  In the “classic” view, estrogen-bound 
ERs bind to specific DNA elements (directly or indirect association through tethering 
mechanisms) and function to recruit various classes of coregulators to the gene 
promoters (Kininis and Kraus, 2008).  These include bridging factors (i.e. Mediator), 
histone modifying enzymes (i.e. p300/CBP), and chromatin remodeling complexes 
(i.e. SWI/SNF), as shown in Figure 3.1B, all of which function to modulate RNA Pol 
II recruitment and activity.  PARP-1 has previously been implicated in regulating 
estrogen-dependent transcription at the TFF1 promoter (Ju et al., 2006; Lis and Kraus, 
2006) by promoting the recruitment of topoisomerase IIβ (TopoIIβ), leading to 
promoter DNA cleavage, coregulator exchange, and activation of transcription (Ju et 
al., 2006).  However, the mechanisms of PARP-1 action at a single gene are not 
indicative of global actions on transcription. 
In the study described herein, I have used a novel method known as Global 
Run-on Sequencing (GRO-seq) to define the role of PARP-1 on the estrogen-regulated 
transcriptome at the level of the nascent transcript.  GRO-seq libraries from MCF-7 
cells treated with vehicle or 17β-estradiol (E2) under three conditions: (i) a control 
knockdown; (ii) a control knockdown plus a PARP inhibitor, PJ34; and (iii) a PARP-1 
knockdown were produced, sequenced, and compared.  I have determined that the 
estrogen response is highly maintained under PARP-1 knockdown or inhibition.  
Accordingly, upon estrogen treatment, PARP-1 localization patterns are largely 
unaffected.  However, upon deeper analyses, my data reveal a few genes where 
PARP-1 knockdown or inhibition reduces the estrogen response at the transcription 
level (GRO-seq) and at the steady state mRNA level (RT-qPCR). 
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3.3.  Results 
 
GRO-seq experimental design.  To explore the role of PARP-1 and PARP activity in 
the regulation of estrogen-dependent transcription, I designed a Global Run-On 
sequencing (GRO-seq) experiment under various conditions, including estrogen 
treatment, PARP-1 knockdown, and PARP inhibition.  GRO-seq is a highly sensitive 
and quantitative methodology that maps the position, orientation, and amount of 
transcriptionally engaged polymerases in the cell (Core et al., 2008).  In addition, this 
method is exceptional in detecting transcriptional changes upon a signal over time 
(N.H. and W.L.K., unpublished).  Importantly, GRO-seq detects transcription, or 
changes in transcription, at the level of the nascent transcript, rather than at the steady-
state mRNA level, giving a direct measure of transcription occurring on the DNA. 
I used luciferase (Luc, used as a control) and PARP-1 stably transduced short 
hairpin RNA (shRNA)-mediated knockdown cell lines, previously described and 
characterized (Chapter 2; (Frizzell et al., 2009)).   The reduction in PARP-1 protein 
and mRNA levels were previously determined to be approximately 90 percent, 
compared to the Luc control (Frizzell et al., 2009).  To compare the role of PARP-1 
protein to PARP activity, I also treated the control cells with a PARP inhibitor, PJ34 
(Figure. 3.2A; (Abdelkarim et al., 2001)), previously shown to largely inhibit PARP-1 
automodification (Frizzell et al., 2009).  Interestingly, this inhibitor was shown to 
block cell cycle progression and trigger apoptosis in MCF-7 cells at high doses (Inbar-
Rozensal et al., 2009).  This result was recapitulated in Luc knockdown cells treated 
with increasing doses of PJ34 over a 48 hour period (Figure 3.2B).  MCF-7 cell 
survival dramatically decreased with increasing doses of PJ34.  Interestingly, this 
effect of PJ34 was not altered upon PARP-1 knockdown, a perplexing result given the 
fact that the majority of PAR is generated by PARP-1 in the cell (Kim et al., 2005; 
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Krishnakumar and Kraus, 2010).  This indicates that total PARP activity is absolutely 
required for MCF-7 cell survival.  In addition, the lack of reversal of the PJ34 effect 
by PARP-1 knockdown suggests that more than one PARP is involved in regulating 
cell cycle progression and cell death pathways, since PJ34 inhibits more than one 
PARP.  To determine the effect of PARP inhibition at the transcription level, which is 
likely to precede cell cycle arrest and cell death, I determined that short treatment 
times (1 hr) and low doses (1 µM) of PJ34 would be suitable for my experiment. 
I treated Luc and PARP-1 knockdown cells with or without PJ34 for 1 hr, directly 
followed by treatment with or without 17β-estradiol (estrogen, E2) for 40 minutes 
(Figure 3.3A).  The time of estrogen treatment was determined using previously 
generated GRO-seq data in the Kraus lab (N.H. and W.L.K., unpublished), as well as 
previously published genomic and gene-specific analyses (Kininis et al., 2007; Kininis 
et al., 2009; Kininis and Kraus, 2008).  Immediately following estrogen treatment, the 
cells were collected and used for further experimentation.  Examination of whole cell 
lysates and nuclear extracts by Western blot analysis (Figure 3.3B) showed a reduction 
in PARP-1 protein levels and PAR modification in the PARP-1 knockdown cell line, 
as described previously (Frizzell et al., 2009).  In addition, treatment with PJ34 
completely blocked the production of PAR, without affecting PARP-1 levels, as 
determined previously (Frizzell et al., 2009).  Importantly, PARP-1 and PAR levels 
were not altered upon estrogen treatment, nor were the levels of estrogen receptor 
alpha (ERα), the nuclear receptor that mediates estrogen-dependent transcription.  A 
Western blot for Actin was included as a loading control. 
 
Generation of GRO-seq libraries.  Nuclei from Luc and PARP-1 knockdown cell 
lines, treated under the conditions noted above, were isolated and used for GRO-seq 
library generation, using the methods described in the Experimental Procedures and in 
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Figure 3.2.  PJ34, a PARP inhibitor, causes MCF-7 cell death at high doses.  A, 
Chemical structure of the competitive PARP inhibitor, PJ34 (PJ), and the enzymatic 
reaction that it inhibits.  B, MCF-7 cell survival decreases with increasing doses of 
PJ34, irrespective of PARP-1 levels.  Stable Luc and PARP-1 shRNA-mediated 
knockdown cell lines were subjected to treatment with PJ34 at various doses for 48 
hours.  Cells were trypsinized, collected, and counted to determine percent survival 
rate.  The data are shown as the mean ± SEM (error bars) for at least two three 
independent experiments.  All experiments were conducted using the lowest dose of 
PJ34 (1 µM; denoted by asterisk) at short treatment times to avoid cell growth arrest. 
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Figure. 3.3.  Experimental design and conditions for GRO-seq experiment.  A, 
Schematic of cell lines and treatments conditions for GRO-seq.  Stable Luc and 
PARP-1 shRNA-mediated knockdown cell lines were grown in estrogen-free medium 
for at least three days prior to conditional treatments.  Cells were then treated with 
vehicle or PJ34 (1 µM) for 1 hour, directly followed by treatment with vehicle or E2 
(100 nM) for 40 minutes, as indicated.  The cells were immediately collected and 
nuclei were isolated, frozen, and stored as described in the Experimental Procedures.  
The GRO-seq experiment was conducted using two independently isolated replicates 
for each condition.  B, Western blot analysis confirms PARP-1 knockdown and 
inhibition by PJ34.  Whole cell lysates collected from Luc and PARP-1 knockdown 
cells under the conditions described in (A) were subjected to Western blotting 
analyses for PARP-1 and ERα.  Actin was also analyzed as a loading control.  PAR 
levels were analyzed by Western blotting using nuclear extracts from the same cell 
lines and treatment conditions. 
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Core et al (Figure 3.4; (Core et al., 2008)).  The experiment was conducted using two 
biological replicates for each condition.  Briefly, an in vitro run-on reaction was 
performed in the presence of sarkosyl (to inhibit non-engaged polymerases from re-
engaging) and the NTP-analog, Bromo-UTP (Br-UTP; to allow for 
isolation/purification of nascent RNA).  The NTP-analog, α32P-CTP, was also 
included for the purpose of tracking the RNAs by autoradiography.  RNA polymerases 
were allowed to run-on ~100 bases, using conditions previously determined (Core et 
al., 2008).  The nuclear run-on RNA (NRO RNA) was then isolated, hydrolyzed to 
~100 bases, and enriched using α-BrdUTP-conjugated agarose beads.  The bound 
RNAs were washed several times and eluted, the 5’ RNA caps were removed, and the 
ends repaired for subsequent adapter ligation steps.  Small RNA adapters (Illumina) 
were ligated to the 5’ end, followed by a second bead-binding enrichment.  These two 
steps were repeated for the 3’ adapter.  An example of bead binding and elution of 
base-hydrolyzed Br-UTP-incorporated RNA to α-BrdUTP beads is shown in Figure 
3.5A.  To assess the efficiency of bead binding, equivalent amounts of the Input (I), 
flow through (Unbound, U), and eluted (Bound, B) fractions for each bead binding 
step were run on a denaturing PAGE and visualized by autoradiography.  With each 
bead-binding step, the enrichment of NRO RNAs over the unbound fraction is 
dramatically enhanced (~5-15X).  The resulting RNAs were reverse transcribed and 
PCR amplified using adapter-specific primers at an overall size of ~170 bases in 
length (Figure 3.5B).  The cDNA libraries were then PAGE purified (Figure 3.5C) and 
sequenced from the 5’ end on the Illumina 1G genome analyzer. 
An average of 42 million reads were generated for each experimental condition 
(summed reads of biological replicates for each condition), approximately 70% of 
which were uniquely mapped to the human genome (Figure 3.6A).  Notably, estrogen 
treatment, PJ34 treatment, and PARP-1 knockdown had no discernable effect on the 
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Figure 3.4.  GRO-seq method.  Nuclei isolated from Luc and PARP-1 knockdown 
cell lines, under the treatment conditions described in Figure 3.3, were subjected to 
GRO-seq methodology.  Briefly, RNA polymerases were allowed to run-on ~100 
bases in the presence of sarkosyl and the NTP-analog, Bromo-UTP (Br-UTP).  The 
RNA was then isolated, hydrolyzed to ~100 bases, and bound to α-BrdUTP-
conjugated agarose beads.  The 5’ RNA caps were removed and the ends repaired for 
subsequent adapter ligation steps.  Small RNA adapters (Illumina) were ligated to the 
5’ and 3’ ends, each step followed by a second bbead-binding enrichment.   These two 
steps were repeated for the 3’ adapter.  The resulting RNAs were reverse transcribed 
and PCR amplified.  The cDNA libraries were then PAGE purified and sequenced 
from the 5’ end on the Illumina 1G genome analyzer.  This figure was taken from 
Core et al (Core et al., 2008). 
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Core et al, Science, 2008 
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Figure 3.5.  Bead-binding, PCR amplification, and PAGE purification of GRO-
seq libraries.  A, Example of binding and elution of base-hydrolyzed Br-UTP-RNA to 
α-BrdUTP beads.  Isolated RNA from a nuclear run-on containing Br-UTP and α32P-
CTP was base hydrolyzed to ~100-120 bases (compare to marker, M), bound to α-
BrdUTP-conjugated agarose beads, washed several times, and eluted from the resin.  
Equivalent amounts of the Input (I), flow through (Unbound, U), and eluted (Bound, 
B) fractions from each of the three bead-binding enrichment steps (1, 2, and 3) were 
run on a 6% denaturing PAGE and visualized by autoradiography to assess the 
efficiency of bead binding.  B, Example of PCR amplification of NRO RNA.  After 
the third bead-binding, the isolated NRO RNA was subjected to reverse transcription 
and subsequently amplified by 15-17 cycles of PCR.  The resulting cDNA was 
visualized on an agarose gel to assess the size and quantity.  C, Example of PAGE-
purified cDNA libraries.  After PCR amplification, the cDNA was run on a 6% non-
denaturing acrylamide gel, the library was cut from the gel, and the cDNA was eluted 
and purified.  A small fraction was the run on a 6% non-denaturing gel to assess the 
size, quantity, and quality of the gel-excised material. 
187 
A 
B 
100 ! 
M I U B I U B I U B 
150 ! 
200 ! 
330 ! 
bp 
50 ! 
Bead Binding 
1 2 3 
1 M 1 
PCR 
Amplify 
(agarose) 
Gel 
Extract 
(native) 
M 2 
100 - 
200 - 
500 - 
bp 
100 - 
200 - 
500 - 
bp 
2 
188 
resulting library read counts.  To determine the variability among libraries, a Pearson 
correlation analysis was performed between individual biological replicates for 
uniquely mapped reads from +1 to +13 kb relative to the TSS for annotated RefSeq 
genes (Figure 3.6B).  Biological replicates for any given condition (grey boxes, 
diagonal) were among the highest correlations values.  Upon estrogen treatment, the 
correlations between samples were reduced (i.e. Luc KD –E2 compared to Luc KD + 
E2), indicative of changes in gene expression.  This effect was also seen in previously 
generated data sets from the Kraus lab (N.H. and W.L.K., unpublished).  Notably, 
PJ34 treatment and PARP-1 knockdown did not have a discernable effect on the 
correlations between samples (unlike E2 treatment). 
As a control, I compared the GRO-seq data to RT-qPCR data for previously 
identified PARP-1-regulated genes (Figure 3.7; (Frizzell et al., 2009)).  For each gene, 
the GRO-seq reads were summed throughout the entire transcription unit (Figure 
3.7A) and RT-qPCR analysis was performed (Figure 3.7B) for each of the three 
conditions (i) Luc KD, (ii) Luc KD + PJ34, and (iii) PARP-1 KD.  Overall, the raw 
GRO-seq data matches well with the RT-qPCR measurements, an example of which is 
shown in Figure 3.7C.  This suggests that, at the most basic level, the GRO-seq data 
set is reflective of changes seen at the mRNA level for gene-specific analyses. 
 
Defining the estrogen-regulated transcriptome.  After all the GRO-seq reads were 
mapped to the genome, I focused my analyses on annotated RefSeq genes.  I plotted 
the sum of reads at each position (weighted by expression level and normalized to 
both number of genes and total reads) and centered the data at the TSS for each 
condition examined for all RefSeq genes (Figure 3.8).  The resulting metagene profiles 
display reads on the sense strand moving toward the right (red), and antisense strand 
(blue) moving toward the left.  This analysis revealed interesting aspects of my data. 
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Figure 3.6.  Total read counts and correlations among GRO-seq libraries.  A, The 
reads from biological replicates were summed to yield the total reads from Illumina 
sequencing for each condition.  Also listed are the read counts that mapped uniquely to 
the human genome (hg19 assembly) and the overall percentage of mapped reads, 
relative to the total.  B, Correlation analysis between individual biological replicates 
for each condition.  Uniquely mapped reads from +1 to +13 kb relative to the TSS 
were used for Pearson correlation analyses for all condition combinations.  Values in 
grey boxes represent the correlation between biological replicates in each condition. 
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Figure 3.7.  GRO-seq data confirms PARP-1-regulated genes defined by 
expression microarray and RT-qPCR.  A, The relative number of GRO-seq reads 
per transcription unit was summed and plotted for eight previously characterized 
PARP-1-regulated genes (Frizzell et al., 2009) for the basal conditions of the GRO-seq 
experiment (i.e., Luc KD, Luc KD + PJ34, and PARP-1 KD; non-estrogen treated).  B,  
RT-qPCR analysis reflects similar trends to the GRO-seq data for the same gene set.  
Total RNA was isolated from Luc and PARP-1 knockdown cell lines in the absence or 
presence of PJ34, reverse transcribed, and subjected to qPCR using gene-specific 
primers.  Each bar is the mean + SEM (error bars) for three or more independent 
RNA isolations.  The data for Luc KD and PARP-1 KD is exactly as published 
previously (Chapter 2; (Frizzell et al., 2009)).  C, An example of GRO-seq data at a 
PARP-1 down-regulated gene, ITPR1, whose expression is not affected by PJ34 
treatment, is shown via the University of California Santa Cruz (UCSC) Genome 
Browser.  Each graph has identical x- and y-axes and only the plus strand is depicted. 
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Primarily, PJ34 treatment and PARP-1 knockdown does not seem to have a dramatic 
effect in overall gene transcription.  In addition, changes in the height of the paused 
polymerase peak at the TSS are altered upon estrogen treatment, as well as with PJ34 
treatment and PARP-1 knockdown.  For example, upon estrogen treatment, the height 
of the paused peak increases in the Luc knockdown condition (Figure 3.8A and B), a 
result also seen in the previously generated GRO-seq data set in the Kraus lab (N.H. 
and W.L.K., unpublished).  Notably, further analyses suggest that while the estrogen-
dependent increase in RNA Pol II pausing is a consistent effect, the PJ34- and PARP-1 
knockdown-dependent increase in RNA Pol II pausing is not statistically significant.  
Finally, the average peak position of the paused polymerase is altered upon PJ34 
treatment, PARP-1 knockdown, and even estrogen treatment, which may coincide 
with the increase in the paused polymerase.  Further analysis is required to determine 
if this positional element is a genuine effect. 
In order to compare the estrogen-regulated transcriptome in each of the three 
conditions (i) Luc KD, (ii) Luc KD + PJ34, and (iii) PARP-1 KD, the total reads from 
+1 to +13 kb relative to the TSS for all 12 samples (all pairs of biological replicates) 
were used as input into the EdgeR software package (Robinson et al., 2010).  The 
EdgeR software quantile normalizes all the reads within the given window, forcing the 
distribution of all samples to be equal, and calculates the parameters for a negative 
binomial distribution based on all pairs of biological replicates.  For each gene, the 
read counts are compared between pair-wise conditions using an exact test, the p-value 
of which is corrected for multiple hypothesis testing using a false discovery rate 
(FDR) cut-off (i.e. 0.1%), defining the change as significantly different (or not) from 
the control.  This analysis can be used for any pair-wise condition comparison (i.e. 
vehicle and estrogen treatment, or control and knockdown).  The resulting data is 
plotted as the Log10 (gene body reads/total reads) for one condition versus another 
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Figure 3.8.  Metagene profiles for all Ref-seq genes for each GRO-seq condition.  
A through F, The metagene profiles for vehicle and E2-treated samples are shown for 
Luc KD (A and B), Luc KD + PJ34 (C and D), and PARP-1 KD (E and F) conditions.  
The data are aligned at the TSS of all Ref-seq genes, and normalized as described in 
the text.  The reads on the + strand (red) and – strand (blue) are shown. 
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(Figures 3.9, 3.13, and 3.15).  Black circles represent genes whose change between the 
two conditions is not statistically different, while red circles represent genes whose 
change between the two conditions is statistically different. 
Using this analysis (0.1% FDR), I identified 1055 genes significantly regulated 
by estrogen in the Luc KD control condition (Figures 3.9A).  Importantly, ~75% of 
these genes were previously identified to be regulated by estrogen in GRO-seq 
experiments in the Kraus lab (Figure 3.9B), conducted under nearly identical 
conditions (N.H. and W.L.K., unpublished).  In that study, MCF-7 parental cells were 
grown and treated with estrogen for 40 minutes, much like the conditions in this study.  
However, there are a few important differences between them.  First, although the 
experimental conditions are similar, the Luc knockdown cells in my study have 
undergone two independent shRNA integrations and are maintained under puromycin 
and G418 drug selection.  This may interfere with basal as well as estrogen-mediated 
transcription.  In addition, separate individuals performed the two studies at separate 
times.  Due to these major differences, it is not uncommon to identify genes regulated 
in one study and not in another.  However, of the nearly 800 genes that were defined 
as regulated in both studies, the estrogen response is highly reproducible, as 
determined using a Spearman’s correlation analysis (Figure 3.9C; correlation 
coefficient = 0.88, p-value < 2.2 x 10-16). 
 
PARP-1 promoter localization is maintained upon estrogen treatment.  In order to 
determine how PARP-1 might be altering the estrogen response, I asked whether or 
not PARP-1 protein localization was altered upon estrogen treatment.  Using an 
antibody specific for PARP-1, I performed ChIP-chip experiments in MCF-7 cells 
using the high density tiling Niblegen platform (HD2) previously described (Gamble 
et al., 2010; Krishnakumar and Kraus, 2010), representing nearly 23,000 promoters 
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Figure 3.9.  Comparison of E2-regulated genes in Luc knockdown and parental 
MCF-7 cells.  A, Defining E2-regulated genes in Luc KD cells.  Gene body reads 
(from +1 to +13 kb relative to the TSS) normalized to total reads in vehicle (U) and 
E2-treated (E) samples were compared in the Luc KD condition using the method and 
parameters described in the text.  Each circle represents the degree of change upon E2 
treatment for a single gene; black indicates no significant change, red indicates a 
significant change (0.1% FDR).  Red circles below the diagonal represent a down-
regulation upon E2-treatment, while those that are above the diagonal represent an up-
regulation upon E2-treatment.  B, Venn diagram of the unique E2-regulated genes in 
Luc KD and parental MCF-7 cells (unpublished data, N.H. and W.L.K).  C, 
Correlation analysis of the commonly regulated genes (intersection) from panel B.  
The Spearman correlation coefficient and p-value are indicated. 
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tiled from -7 to +3 kb surrounding the TSSs.  Using previously defined criteria 
(Gamble et al., 2010; Krishnakumar et al., 2008; Krishnakumar and Kraus, 2010), I 
determined the promoter localization of PARP-1 in the absence and presence of 
estrogen.  To determine if PARP-1 localization patterns changed upon estrogen 
treatment, I depicted the ChIP-chip data sets for each condition as a heat map in which 
each row corresponds to the ChIP-chip signal from -3 to +3 kb relative to the TSS for 
each gene represented on the array (Figure 3.10A).  When the data are ordered for 
increasing average intensity of PARP-1 in the vehicle-treated condition (U), an 
obvious correspondence for PARP-1 in the E2-treated condition (E) is evident.  An 
averaging analysis for all genes represented on the ChIP-chip array clearly displays 
the same result (Figure 3.10B).  Furthermore, for estrogen-regulated genes defined by 
the GRO-seq analysis for which ChIP-chip data exists, the PARP-1 localization 
patterns do not change upon estrogen treatment (Figure 3.10C), regardless of direction 
of gene regulation (Figure 3.10D-F).  These results are also seen for the same gene 
categories using a custom-designed Nimblegen platform previously described 
(Gamble et al., 2010; Krishnakumar et al., 2008), representing 4.14 Mb of genomic 
DNA including 1829 gene promoters typically tiled from -25 to +5 kb surrounding the 
TSSs (Figure 3.11B-E).  Importantly, the PARP-1 profiles are nearly identical 
between the two platforms, albeit with differences in overall signal, and the overall 
histone levels are not altered upon E2-treatment (Figure 3.11A).  Taken together, the 
results of my PARP-1 ChIP-chip experiments using two independent array platforms 
show that PARP-1 localization patterns are unaltered upon estrogen treatment. 
 
PJ34 treatment and PARP-1 knockdown reduces the magnitude of the estrogen 
response.  To determine the effect of PJ34 treatment and PARP-1 knockdown on 
estrogen-regulated genes, I first aligned my GRO-seq data to categories of estrogen-
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Figure 3.10.  PARP-1 localization is unaltered upon E2-treatment.  A, Heat maps 
showing PARP-1 ChIP-chip data across ~23,000 promoters, tiled from -3 to +3 kb 
surrounding the transcription start sites (TSS).  Parental MCF-7 cells were grown in 
estrogen-free medium for a minimum of three days, treated with vehicle (U) or 
estrogen (100 nM, E) for 40 minutes, crosslinked with formaldehyde, and subjected to 
a ChIP assay using the PARP-1 antibody, as described in the Experimental 
Procedures.  The data in both panels are ordered for the average PARP-1 intensity in 
the U condition.  B, Averaging analysis of the Log2 enrichment ratios for PARP-1 
under vehicle (blue) and E2 (red) treated MCF-7 cells in shown for all genes 
represented on the array.  C, D, E, and F, For genes defined as E2-regulated by GRO-
seq in the Luc KD condition, described in Figure 3.9, the average Log2 enrichment 
ratios for the corresponding PARP-1 ChIP-chip data is plotted.   The PARP-1 profile 
in vehicle (blue) and E2 (red) treated MCF-7 cells in shown for all E2-regulated genes 
(C) for which ChIP-chip data exists, only up-regulated genes (D), non-regulated genes 
(E), and only down-regulated genes (F). 
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Figure 3.11.  Comparison of PARP-1 ChIP-chip data across platforms.  A, 
Averaging analysis of the Log2 enrichment ratios for PARP-1 under vehicle (blue, 
light blue) and E2 (red, orange) treated MCF-7 cells for the 1401 genes represented on 
both the Nimblegen HD2 and custom-designed array platforms.  H3 ChIP-chip data 
(custom platform only) is shown for comparison. B, D, D, and E, For genes defined as 
E2-regulated by GRO-seq in the Luc KD condition, described in Figure 3.9, the 
average Log2 enrichment ratios for the corresponding PARP-1 ChIP-chip data (custom 
platform only) is plotted.   The PARP-1 profile in vehicle (light blue) and E2 (orange) 
treated MCF-7 cells in shown for all E2-regulated genes (B) for which ChIP-chip data 
exists, only up-regulated genes (C), non-regulated genes (D), and only down-regulated 
genes (E). Although the number of genes in each category is smaller, the overall 
trends of PARP-1 localization remain consistent between platforms. 
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regulated genes previously identified from GRO-seq experiments in parental MCF-7 
cells (Figure 3.12; N.H. and W.L.K., unpublished).  For genes that are up-regulated 
(peak at 40 min E2; Figure 3.12A) or down-regulated (at 10, 40, or 160 min E2; 
Figure 3.12B) by estrogen, I plotted the sum of reads at each position (weighted by 
expression level and normalized to both number of genes and total reads) and centered 
the data at the TSS.  Regardless of the cell line or treatment condition, the overall 
trends for estrogen up-regulated and down-regulated genes are largely similar. 
Using the analysis and parameters described above, I identified the estrogen-
regulated genes in all three of my experimental conditions:  (i) Luc KD, (ii) Luc KD + 
PJ34, and (iii) PARP-1 KD (Figure 3.13A).  PJ34 treatment slightly increased the total 
number of estrogen-responsive genes, while PARP-1 knockdown slightly reduced the 
total number of estrogen-responsive genes.  However, most of the genes (nearly 90%) 
in any of the three conditions were also regulated in at least one other condition 
(Figure 3.13B).  This result indicates that the general estrogen response is highly 
maintained upon PARP inhibition and specific depletion of PARP-1, an effect noted 
using estrogen-regulated genes in MCF-7 parental cells (Figure 3.12).  And, although I 
have identified approximately 12% of genes in each condition that are regulated by 
estrogen in only that condition, many of these genes contain low read counts, which 
may be indicative of noise, rather than effective regulation.  Thus, these classes need 
to be interpreted with caution.  In support of this result, only the largest class of genes 
is significantly enriched in gene ontological categories that are indicative of estrogen 
signaling pathways (Table 3.1), while the outlying classes are not.  In addition, PARP-
1 localization patterns are similar across all classes in the Venn diagram (Figure 3.14). 
Importantly, there are very few genes regulated by PJ34 treatment and PARP-1 
knockdown as compared to the Luc knockdown control (Figure 3.15), indicating that 
basal transcription is not significantly altered.  Therefore, any alterations in the 
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Figure 3.12. Metagene profiles of previously defined estrogen-regulated genes for 
each GRO-seq condition.   A and B, The metagene profiles for vehicle (blue, light 
blue) and E2-treated (red, pink) samples are shown for Luc KD, Luc KD + PJ34, and 
PARP-1 KD conditions.  The genes shown in each panel are estrogen up-regulated 
(A), which peak at 40 min of estrogen treatment, and estrogen down-regulated (B), as 
defined by GRO-seq time-course experiments (unpublished data, N.H. and W.L.K.).  
The data are aligned at the TSS and normalized as described in the text.  The reads on 
the + strand (red, blue) and – strand (pink, light blue) are shown.  
206 
L
u
c
 K
D
 
D
is
ta
n
c
e
 R
e
l.
 t
o
 T
S
S
 (
k
b
) 
-4
 
-2
 
0
 
2
 
4
 
L
u
c
 K
D
 +
 P
J
3
4
 
D
is
ta
n
c
e
 R
e
l.
 t
o
 T
S
S
 (
k
b
) 
-4
 
-2
 
0
 
2
 
4
 
P
A
R
P
-1
 K
D
 
D
is
ta
n
c
e
 R
e
l.
 t
o
 T
S
S
 (
k
b
) 
-4
 
-2
 
0
 
2
 
4
 
L
u
c
 K
D
 
D
is
ta
n
c
e
 R
e
l.
 t
o
 T
S
S
 (
k
b
) 
-4
 
-2
 
0
 
2
 
4
 
L
u
c
 K
D
 +
 P
J
3
4
 
D
is
ta
n
c
e
 R
e
l.
 t
o
 T
S
S
 (
k
b
) 
-4
 
-2
 
0
 
2
 
4
 
P
A
R
P
-1
 K
D
 
D
is
ta
n
c
e
 R
e
l.
 t
o
 T
S
S
 (
k
b
) 
-4
 
-2
 
0
 
2
 
4
 
A
 
B
 80
 
4
0
 
2
0
 
0
 
-2
0
 
Reads Per Gene 
6
0
 
-4
0
 
U
 
E
 
U
 
E
 
U
 
E
 
U
 
E
 
U
 
E
 
U
 
E
 
-4
0
0
0
-2
0
0
0
0
2
0
0
0
4
0
0
0
-40-20020406080
c(
-1
0
0
0
0
:1
0
0
0
0
)
Luc_Meta[3, ]
8
0
 
4
0
 
2
0
 
0
 
-2
0
 
Reads Per Gene 
6
0
 
-4
0
 
8
0
 
4
0
 
2
0
 
0
 
-2
0
 
Reads Per Gene 
6
0
 
-4
0
 
8
0
 
4
0
 
2
0
 
0
 
-2
0
 
Reads Per Gene 
6
0
 
-4
0
 
8
0
 
4
0
 
2
0
 
0
 
-2
0
 
Reads Per Gene 
6
0
 
-4
0
 
8
0
 
4
0
 
2
0
 
0
 
-2
0
 
Reads Per Gene 
6
0
 
-4
0
 
-4
0
0
0
-2
0
0
0
0
2
0
0
0
4
0
0
0
-40-20020406080
c(
-1
0
0
0
0
:1
0
0
0
0
)
PJ_Meta[3, ]
-4
0
0
0
-2
0
0
0
0
2
0
0
0
4
0
0
0
-40-20020406080
c(
-1
0
0
0
0
:1
0
0
0
0
)
PK_Meta[3, ]
-4
0
0
0
-2
0
0
0
0
2
0
0
0
4
0
0
0
-40-20020406080
c(
-1
0
0
0
0
:1
0
0
0
0
)
PK_Meta[5, ]
-4
0
0
0
-2
0
0
0
0
2
0
0
0
4
0
0
0
-40-20020406080
c(
-1
0
0
0
0
:1
0
0
0
0
)
PJ_Meta[5, ]
-4
0
0
0
-2
0
0
0
0
2
0
0
0
4
0
0
0
-40-20020406080
c(
-1
0
0
0
0
:1
0
0
0
0
)
Luc_Meta[5, ]
207 
Figure 3.13.  The estrogen response is highly maintained upon PJ34 treatment 
and PARP-1 knockdown.  A, Defining E2-regulated genes in Luc KD, PJ34-treated, 
and PARP-1 KD cells.  Gene body reads (from +1 to +13 kb relative to the TSS) 
normalized to total reads in all biological replicates were compared the methods and 
parameters described in the text.  The vehicle (U) treated and E2-treated (E) samples 
were compared in Luc KD, Luc KD + PJ34, and PARP-1 KD conditions.  Each circle 
represents the degree of change upon E2 treatment for a single gene; black indicates 
no significant change, red indicates a significant change (0.1% FDR).  Red circles 
below the diagonal represent a down-regulation upon E2-treatment, while those that 
are above the diagonal represent an up-regulation upon E2-treatment.  The total 
number of unique genes regulated upon E2 treatment is listed.  B, Venn diagram 
comparing E2-regulated genes in the three experimental conditions. 
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Table 3.1.  Summary of the most significant gene ontology terms enriched in each 
Venn diagram class shown in Figure 3.12.  The enrichment of gene ontology terms 
in estrogen regulated genes in one, two, or three GRO-seq conditions (i.e. each 
category in the Venn diagram shown in Figure 3.12) was compared to all RefSeq 
genes in the human genome for all three ontology aspects.  Only those categories with 
significant GO terms (p-value < 0.0001) are represented. 
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Gene Ontology Terma Aspectb P-value 
 
Luc KD (142 genes) 
Membrane CC 7.65 x 10-5 
 
Luc KD and Luc KD + PJ34 (169 genes) 
Membrane CC 5.45 x 10-5 
 
Luc KD and Luc KD + PJ34 and PARP-1 KD (687 genes) 
Membrane CC 5.01 x 10-13 
Cell part CC 5.75 x 10-13 
Cell CC 5.86 x 10-13 
Cytoplasm CC 5.75 x 10-9 
Plasma membrane CC 7.38 x 10-8 
Intracellular CC 1.48 x 10-7 
Membrane part CC 1.87 x 10-7 
Plasma membrane part CC 2.83 x 10-6 
Intracellular part CC 4.18 x 10-6 
Cell surface CC 1.14 x 10-5 
Insoluble fraction CC 6.49 x 10-5 
Cell fraction CC 8.54 x 10-5 
Protein binding MF 1.68 x 10-14 
Binding MF 2.16 x 10-12 
PDZ domain binding MF 1.75 x 10-7 
Protein domain specific binding MF 2.85 x 10-6 
Enzyme regulator activity MF 2.02 x 10-5 
Multicellular organismal development BP 5.20 x 10-20 
Developmental process BP 6.89 x 10-20 
System development BP 8.76 x 10-20 
Anatomical structure development BP 4.51 x 10-18 
Biological regulation BP 5.13 x 10-17 
Multicellular organismal process BP 7.34 x 10-17 
Organ development BP 8.50 x 10-17 
Regulation of cellular process BP 2.96 x 10-16 
Regulation of biological process BP 1.65 x 10-15 
Signaling BP 9.43 x 10-15 
Signaling pathway BP 4.69 x 10-14 
Cellular process BP 1.20 x 10-12 
Cell differentiation BP 1.26 x 10-12 
Negative regulation of biological process BP 2.27 x 10-12 
Cellular developmental process BP 3.11 x 10-12 
Negative regulation of cellular process BP 9.69 x 10-12 
Signaling process BP 6.92 x 10-11 
Signal transmission BP 1.34 x 10-10 
Regulation of multicellular organismal process BP 1.79 x 10-10 
Signal transduction BP 2.35 x 10-10 
Anatomical structure morphogenesis BP 3.70 x 10-10 
Organ morphogenesis BP 2.57 x 10-9 
Cell communication BP 3.98 x 10-9 
Tissue development BP 7.63 x 10-9 
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Table 3.1 (cont’d) 
 
Intracellular signaling pathway BP 1.14 x 10-8 
Regulation of signaling pathway BP 3.23 x 10-8 
Response to chemical stimulus BP 4.32 x 10-8 
Cell surface receptor linked signaling pathway BP 4.98 x 10-8 
Regulation of developmental process BP 9.30 x 10-8 
Regulation of cell communication BP 1.66 x 10-7 
Cell migration BP 2.34 x 10-7 
Regulation of cell differentiation BP 2.48 x 10-7 
Intracellular signal transduction BP 2.85 x 10-7 
Positive regulation of biological process BP 3.65 x 10-7 
Nervous system development BP 3.93 x 10-7 
Regulation of cellular component movement BP 4.19 x 10-7 
Cell development BP 5.26 x 10-7 
Regulation of localization BP 5.50 x 10-7 
Cell proliferation BP 6.30 x 10-7 
Regulation of cell migration BP 8.74 x 10-7 
Regulation of phosphorylation BP 1.48 x 10-6 
Positive regulation of cellular process BP 1.81 x 10-6 
Regulation of phosphate metabolic process BP 1.87 x 10-6 
Regulation of phosphorus metabolic process BP 1.87 x 10-6 
Cell motility BP 1.91 x 10-6 
Localization of cell BP 1.91 x 10-6 
Regulation of biological quality BP 5.48 x 10-6 
Regulation of multicellular organismal development BP 7.55 x 10-6 
Regulation of locomotion BP 8.54 x 10-6 
Response to steroid hormone stimulus BP 8.87 x 10-6 
Regulation of metabolic process BP 9.75 x 10-6 
Regulation of cell proliferation BP 1.25 x 10-5 
Response to estrogen stimulus BP 1.78 x 10-5 
Response to hormone stimulus BP 2.14 x 10-5 
Lipid metabolic process BP 2.54 x 10-5 
Cellular response to chemical stimulus BP 3.58 x 10-5 
Localization BP 3.65 x 10-5 
Cellular component movement BP 3.77 x 10-5 
Enzyme linked receptor protein signaling pathway BP 3.81 x 10-5 
Response to endogenous stimulus BP 4.39 x 10-5 
Positive regulation of macromolecule metabolic process BP 4.46 x 10-5 
Negative regulation of signaling pathway BP 5.35 x 10-5 
Regulation of signaling process BP 5.77 x 10-5 
Cell morphogenesis involved in differentiation BP 6.39 x 10-5 
Regulation of primary metabolic process BP 7.05 x 10-5 
Regulation of cellular metabolic process BP 8.29 x 10-5 
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Figure 3.14.  PARP-1 localization is unaltered upon E2-treatment among each 
Venn diagram category.  A-G, Averaging analysis of the Log2 enrichment ratios for 
PARP-1 under vehicle (blue) and E2 (red) treated MCF-7 cells is shown for genes 
within each Venn diagram category, described in Figure 3.12, for which ChIP-chip 
data exists.  PARP-1 profiles are plotted for genes regulated by estrogen in only one 
condition (A, B, and C), two conditions (D, E, and F), and three conditions (G). 
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estrogen response can be attributed to changes in the treated condition, rather than the 
untreated condition.  While this basal comparison is seemingly different than the 
expression microarray and qPCR analyses previously reported (Figure 3.7 and Chapter 
2; (Frizzell et al., 2009)), one should use caution in this interpretation.  This GRO-seq 
analysis is performed using stringent statistical criteria, incorporating the data and 
variation of at least 6 samples.  Thus, global analyses are not as useful for detecting 
subtle changes that can be detected at the gene-specific level.  Finally, the GRO-seq 
data reflects events occurring on the genomic DNA level, while RT-qPCR analyses 
reflect stead-state levels of mRNA, two independent measurements. 
 My results indicate that PJ34 treatment and PARP-1 knockdown does not 
dramatically change the genes that are responsive to estrogen.  To answer this question 
with regard to the fold estrogen response at each gene, I compared the PJ34 treated or 
PARP-1 knockdown condition to the Luc knockdown control, plotting the fold 
estrogen response (Figure 3.16A and B, respectively).  Only those genes that are 
considered regulated by estrogen in at least one of the two conditions is plotted.  
Overall, the correlations are tight, with some variation.  By applying a fold change cut-
off (Log2 FC >2 or <-2 in one condition and Log2 FC >-1 or <1 in the other condition), 
I identified only a few genes regulated by estrogen in one condition, but not in the 
other (shown in red).  Two of the nine genes were tested in gene-specific RT-qPCR 
assays (Figure 3.16C), and confirm this result. 
However, this analysis does not indicate whether the overall magnitude of the 
estrogen response is enhanced or reduced by PARP inhibition or PARP-1 knockdown, 
although there was some variation in the graphical representation (Figure 3.16B, for 
example).  In order to determine if the magnitudes of estrogen-responsive genes are 
changed under these conditions, I compared the 697 genes defined to be estrogen-
regulated in all three conditions examined (Figure 3.13B).  Of these, ~1/3 of the genes
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Figure 3.15.  PJ34 treatment and PARP-1 knockdown does not alter basal 
transcription in MCF-7 cells.   A and B, Gene body reads (from +1 to +13 kb relative 
to the TSS) normalized to total reads in Luc KD and Luc KD + PJ34 (A) or PARP-1 
KD (B) samples were compared using the method and parameters described in the 
text.  Each circle represents the degree of change upon PJ34-treatment or PARP-1 KD 
for a single gene; black indicates no significant change, red indicates a significant 
change (0.1% FDR).  Red circles below the diagonal represent a down-regulation 
upon PJ34-treatment or PARP-1 KD, while those that are above the diagonal represent 
an up-regulation upon PJ34-treatment or PARP-1 KD.  The two genes that are 
considered statistically different than Luc KD are indicated in each panel. 
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Figure 3.16.  Few genes are estrogen responsive in only one GRO-seq condition.   
A and B, The Log2 estrogen response relative to the vehicle treated (E/U) in Luc KD 
and Luc KD + PJ34 (A) or PARP-1 KD (B) samples were compared using the method 
and parameters described in the text.  Only those genes displaying a significant 
estrogen response in at least one of the two conditions is shown.  Each circle 
represents the degree of change upon E2-treatment for a single gene.  Black indicates 
significant changes in both conditions; red indicates a significant change in one 
condition but not the other (Log2 fold change > 2 or < -2 in one condition and Log2 
fold change > -1 and < 1 for the other condition; 0.1% FDR).  Only a few genes are 
considered regulated by estrogen in only Luc KD, Luc KD + PJ34, or PARP-1 KD.  C, 
RT-qPCR analysis for two genes identified from the analysis in panels A and B.  Total 
RNA was isolated from Luc and PARP-1 knockdown cell lines in the absence or 
presence of PJ34 and E2 for the time points indicated, reverse transcribed, and 
subjected to qPCR using gene-specific primers for ABCA4 and CALCR.  Each point is 
the mean + SEM (error bars) for four independent RNA isolations. 
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are down-regulated in response to estrogen, while ~2/3 are up-regulated in response to 
estrogen (defined by the E2-response in the Luc KD condition).  For the E2 down-
regulated genes (Figure 3.17A), PJ34 treatment and PARP-1 knockdown have little 
effect on the median and overall dynamic range of the estrogen response.  However, 
for the E2 up-regulated genes (Figure 3.17B), PJ34 treatment and PARP-1 knockdown 
seemingly quenches the overall dynamic range of the estrogen response.  An example 
of this result is depicted in Figure 3.17C at the HSPB8 gene. 
Interestingly, further analysis revealed that the most up-regulated and most 
down-regulated genes have the largest degree of change in the estrogen response upon 
PJ34 treatment and PARP-1 knockdown (Figure 3.18A and B).  In both cases, the 
effective estrogen response is reduced and PARP-1 knockdown has a greater effect 
than PJ34 treatment.  Notably, regardless of the degree of estrogen response, PARP-1 
levels remain unchanged upon estrogen treatment (Figure 3.19A and B).  For up-
regulated genes, PARP-1 knockdown also affects genes with the lowest basal 
expression level, many of which also have the highest estrogen responses.  Again, 
regardless of expression level in the basal state, PARP-1 remains unchanged upon 
estrogen treatment (Figure 3.19C and D).  However, the overall levels are different 
between low expressed and high expressed gene classes, a result previously reported 
(Krishnakumar et al., 2008).  I tested ~50 of the most E2 up- and down-regulated 
genes that are affected by PJ34 treatment and/or PARP-1 knockdown from this 
analysis in gene-specific RT-qPCR assays (Figures 3.20 and 3.21).  For the most part, 
at the mRNA level, the effect of PJ34 or PARP-1 knockdown on these genes is 
minimal, if not negligible.  Together, my results indicate that both PARP-1 protein and 
activity are important for a complete estrogen response at a subset of genes. 
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Figure 3.17.  The magnitude of the estrogen response is slightly reduced upon 
PJ34 treatment or PARP-1 knockdown.  A and B, Box plots of the estrogen 
response for the overlapping E2 down-regulated (A) and up-regulated (B) genes in 
Luc KD, Luc KD + PJ34, and PARP-1 KD conditions.  C, An example of GRO-seq 
data at an estrogen up-regulated gene, HSPB8, whose expression is slightly reduced by 
PJ34 treatment and PARP-1 knockdown.  The data was visualized using the 
University of California Santa Cruz (UCSC) Genome Browser.  Each graph has 
identical x- and y-axes and both the plus (red) and minus (blue) strands are depicted. 
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Figure 3.18.  The magnitude of the estrogen response is reduced upon PJ34 
treatment or PARP-1 knockdown at the most up- and down-regulated genes.  A 
and B, The average degree of change in the E2 response is plotted for PJ34 treatment 
(green) and PARP-1 KD (blue) among pentiles of down-regulated genes (A) and up-
regulated genes (B), defined in Figure 3.17.  Pentiles are defined by the degree of 
estrogen response.  C and D, Same as in A and B.  Pentiles are defined by the level of 
expression (GRO-seq read count) in the basal (vehicle-treated) condition. 
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Figure 3.19. PARP-1 localization is unaltered upon E2-treatment regardless of 
degree of estrogen response or basal expression level.  A-D, Averaging analysis of 
the Log2 enrichment ratios for PARP-1 under vehicle (blue, light blue) and E2 (red, 
orange) treated MCF-7 cells is shown for genes within pentiles 1 and 5 from each 
panel in Figure 3.18, for which ChIP-chip data exists.  PARP-1 profiles are plotted for 
genes down-regulated by estrogen in (A and C) and up-regulated by estrogen (B and 
D).  For genes with either a high or low estrogen response (A and B), PARP-1 
localization patterns are unaltered upon estrogen treatment.  For genes with either a 
high or low basal expression level, PARP-1 localization patterns are unaltered upon 
estrogen treatment.  Notably, genes with a low expression level have a lower amount 
of PARP-1, compared to genes with a higher expression level. 
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Figure 3.20.  PJ34 treatment and PARP-1 knockdown only mildly alter estrogen-
dependent changes in steady-state mRNA levels.  A and B, Total RNA was isolated 
from Luc and PARP-1 knockdown cell lines in the absence or presence of PJ34 and 
E2 for the time points indicated, reverse transcribed, and subjected to qPCR using 
gene-specific primers.  Each point is the mean + SEM (error bars) for four 
independent RNA isolations.  Of the 51 genes up-regulated or down-regulated by 
estrogen that were tested from the categories most affected by PJ34 treatment or 
PARP-1 knockdown, only a few confirmed this result (A), while others did not (B).  
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Figure 3.21.  Graphs showing all estrogen-regulated genes that were tested for 
PJ34- or PARP-1-dependent changes at the steady-state mRNA level.  Total RNA 
was isolated from Luc and PARP-1 knockdown cell lines in the absence or presence of 
PJ34 and E2 for the time points indicated, reverse transcribed, and subjected to qPCR 
using gene-specific primers.  Each point is the mean + SEM (error bars) for four 
independent RNA isolations.  51 genes up-regulated or down-regulated by estrogen 
were tested (including Figure 3.20) from the categories most affected by PJ34 
treatment or PARP-1 knockdown.  Of those that confirmed a change in mRNA level 
upon estrogen treatment, most were not affected by PARP-1 perturbation. 
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3.4.  Discussion 
 
Poly(ADP-ribose) Polymerase-1 is a nuclear enzyme that has been implicated in 
signal-mediated transcriptional regulation, including that modulated by estrogen.  
However, global effects on estrogen-dependent gene regulation by PARP-1 have not 
been established.  In the current study, I have used GRO-seq to define the role of 
PARP-1 and PARP activity on the estrogen-regulated transcriptome.  Collectively, my 
results suggest that the estrogen response is highly maintained under PARP-1 
knockdown or inhibition at both the transcription and steady-state mRNA levels. 
 
PARP-1 is required for a complete estrogen response.  The data described herein 
have revealed unexpected facets of PARP-1 action in estrogen-dependent gene 
regulation.  First, PJ34 treatment and PARP-1 knockdown largely do not affect the 
estrogen response in MCF-7 cells (Figures 3.12, 3.13, and 3.16).  Based on previously 
published data (Ju et al., 2006), this result was somewhat unexpected.  In fact, my data 
did not recapitulate that previously reported for the TFF1 gene. 
Second, even though the majority of genes are still regulated by E2 under PJ34 
treatment and PARP-1 knockdown, these conditions seemingly quench the spectrum 
of the estrogen response.  That is, PARP inhibition and PARP-1 knockdown reduce 
the degree of estrogen regulation for the top 10-20% of up-regulated and down-
regulated genes (Figure 3.18).  At the gene-specific level, most GRO-seq-defined 
effects of PARP-1 inhibition or knockdown were not confirmed.  However, this could 
be a result of (i) the difference in GRO-seq transcription versus steady-state mRNA 
levels, (ii) the subtlety of the effects, resulting in low confirmation rate, or (iii) a high 
false positive/negative rate in the GRO-seq data itself. 
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Third, PARP-1 promoter localization is largely unaltered upon estrogen 
treatment at estrogen-regulated genes, regardless of direction of regulation or 
magnitude of the response.  In fact, PARP-1 localization patterns are not changed at 
the top 10-20% of up-regulated and down-regulated genes.  At these genes, it is 
possible that PARP-1 might be regulating the chromatin structure or the recruitment of 
a protein at these estrogen-regulated promoters, such as histone modifying enzymes. 
 
Basal transcription is unaffected by PJ34 treatment and PARP-1 knockdown.  
Another result gained from my GRO-seq experiment is that PJ34 treatment and 
PARP-1 knockdown to do alter basal transcription in MCF-7 cells (Figure 3.15).  
Given that PARP-1 knockdown changes the expression levels of over 1000 genes in 
the same cell line as shown by expression microarray experiments (Frizzell et al., 
2009), this result was unexpected.  How is it possible that a GRO-seq detects minimal 
changes in the basal state, but mRNA levels change upon PARP-1 knockdown?  One 
possible explanation is that the statistical criteria used to make “changes in transcript” 
calls, is too stringent to detect subtle changes, as noted above.  However, the raw read 
counts at specific genes seemingly matches that of RT-qPCR analyses (Figure 3.7), 
indicating that those changes are reflected in the raw data. 
Another explanation is that PARP-1 may be functioning as an RNA processing 
factor at promoters, or participating in mRNA stability.  This is not an unreasonable 
hypothesis given that PARP-1 interacts with factors involved in RNA processing and 
export from the nucleus (i.e. nucleolin, nucleophosmin; (Fu and Fenselau, 2005; 
Isabelle et al., 2010; Meder et al., 2005)) and localizes with those factors in the 
nucleolus (Meder et al., 2005).  In addition, many other PARP-1-interacting factors 
localize to the nucleolus, such as XRCC1 and CTCF (Kotoglou et al., 2009; Torrano et 
al., 2006).  Interestingly, it was recently shown that PARP-1 can regulate 
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inflammatory gene expression by increasing the mRNA stability of target genes via 
modulating proper p38/MAPK signaling cascades (Galbis-Martinez et al., 2010).  
Further experiments are required to prove such hypotheses. 
 In conclusion, my studies reveal that while PARP-1 and its activity may be 
important at a subset of estrogen responsive genes, they are largely dispensable for 
estrogen-mediated transcriptional outcomes in MCF-7 human breast cancer cells. 
 
2.5.  Experimental Procedures 
 
Antibodies - The custom rabbit polyclonal antibody against PARP-1 used for Western 
blotting, ChIP-chip, and ChIP-qPCR assays was generated by using a purified 
fragment of human PARP-1 (amino-terminal, PARP-N (Kim et al., 2004)) (Pocono 
Rabbit Farm and Laboratory, Inc.).  The antibody was previously screened for: (i) 
specificity by Western blotting MCF-7 cell extracts, (ii) the ability to 
immunoprecipitate its cognate antigen from formaldehyde-crosslinked chromatin 
samples by a ChIP-Western protocol (Kim et al., 2004), and (iii) a reduction in 
Western blot signal upon PARP-1 knockdown (Chapter 2; (Frizzell et al., 2009)).  The 
custom rabbit polyclonal antibody against ERα used for Western blotting was 
generated by using a purified fragment of human ERα (Pocono Rabbit Farm and 
Laboratory, Inc.) (Kim et al., 2006).  The rabbit polyclonal H3 antibody used for 
ChIP-chip was purchased from Abcam.  The mouse monoclonal PAR antibody used 
for Western blotting was purchased from Trevigen.  The mouse monocolonal β-Actin 
antibody used for Western blotting was purchased from Sigma-Aldrich. 
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Culture and treatment of MCF-7-derived cell lines – Luciferase (Luc) and PARP-1 
knockdown MCF-7 cell lines (generated and previously characterized, Chapter 2; 
(Frizzell et al., 2009)) were maintained in MEM Eagle medium containing Hanks' 
salts, L-glutamine, and non-essential amino acids (Sigma) supplemented with 5% 
bovine calf serum (CS; Sigma), 20 mM HEPES (pH 7.6), 100 units/mL penicillin, 100 
µg/mL streptomycin, 25 µg/mL gentamycin, and 0.22 % sodium bicarbonate.  The 
medium was supplemented with puromycin (Sigma; 0.5 µg/mL) and G418 sulfate 
(Gibco/BRL; 800 µg/mL) for stock cultures. 
 For experiments, cells were plated in MEM modified Eagle medium with 
Earle's salts and non-essential amino acids, without phenol red (Sigma), supplemented 
5% charcoal/dextran-treated bovine calf serum (CDCS; Sigma) and the other additives 
noted above.  Subconfluent populations of cells were treated as indicated in the figure 
legends and collected for analysis between 3 and 4 days post-plating.   
The PARP-1 chemical inhibitor, PJ34, was purchased from Alexis 
Biochemicals, dissolved in distilled water, pH-adjusted to approximately 7.5.  PJ34 (1 
µM, unless otherwise noted) or dH2O (vehicle) was added to the cell culture medium 
for 1 hr at 37°C prior to treatment with estrogen (was not removed during estrogen 
treatment).  17β-estradiol (E2) was purchased from Sigma and dissolved in ethanol.  
E2 (100 nM) or ethanol (vehicle) was added to the cell culture medium for 40 min at 
37°C prior to collecting the cells, unless otherwise indicated. 
 
Cell survival assay - For analysis of cell survival, stable Luc and PARP-1 knockdown 
cells were seeded at ~5 x 105 cells per well in 6-well plates in MEM containing 5% CS 
and the additives noted above.  After 24 hours, the cells were treated with increasing 
doses of PJ34 for a period of 48 hours.  The cells were collected by trypsinization, 
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stained with trypan-blue, and surviving cells were counted using a hemacytometer.  
Experiments were conducted a minimum of three times to ensure reproducibility. 
 
Global Run-on Sequencing (GRO-seq) - The GRO-seq methodology was performed 
essentially as described previously (Core et al., 2008), with minor modifications. 
 
Isolation of MCF-7 Nuclei - Luc or PARP-1 knockdown MCF-7 cells were seeded at 
~6 x 105 cells per 15 cm plate and grown for at least 3 days in MEM containing 5% 
CDCS and the additives noted above.  After at least three days of estrogen deprivation 
and at nearly 100% confluence, cells were treated with or without PJ34 and E2 at the 
indicated concentrations and times noted above.  Cells were washed directly on the 
plate three times with ice-cold PBS.  10 mL of ice-cold lysis buffer [10 mM Tris•HCl 
(pH 7.4), 2 mM MgCl2, 3 mM CaCl2, 10% Glycerol, 0.5% NP-40, 1 mM DTT, a 
protease inhibitor cocktail (Roche Molecular Biochemicals), and 2 U/mL SUPERase-
Inhibitor (Ambion)] was added directly on the plate and allowed to incubate on ice for 
5 min.  Cells were scraped using a plastic scraper, collected into a 15-mL conical tube, 
and pelleted for 10 min at 4°C using setting 4 in a clinical centrifuge.  The cell pellets 
were resuspended in 1.5 mL of lysis buffer and gently pipetted up and down ~30 times 
using a cut p1000 pipette tip to reduce shearing.  The volume was then brought to 10 
mL with lysis buffer, inverted gently to mix, and pelleted again.  The nuclei pellet was 
again resuspended in 1 mL of lysis buffer and gently pipetted to resuspend fully.  The 
samples were transferred to a 1.7 mL tube and centrifuged at 3,000 rpm for 5 min at 
4°C in a microcentrifuge.  The nuclei were then resuspended in freezing buffer [50 
mM Tris•HCl (pH 8.3), 5 mM MgCl2, 40% Glycerol, 0.1 mM EDTA (pH 8.0), and 4 
U/mL SUPERase-Inhibitor] and centrifuged at 13,000 rpm for 1 min at 4°C in a 
microcentrifuge.  Nuclei were resuspended in freezing buffer and stored in aliquots of 
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~5 x 106 nuclei per 100 µL at -80°C.  All stock buffers and solutions were made with 
DEPC-treated water (for RNA work, Fisher) and filtered to avoid RNA degradation. 
 
Library Generation – Construction of the nuclear run on (NRO) library consists of 
multiple steps:  (i) Run-on reaction; (ii) Base Hydrolysis; (iii) Immuno-purification; 
(iv) End Repair; (v) 5’- and 3’-adapter ligation; (vi) Reverse transcription and PCR 
amplification; and (vii) PAGE purification.  All stock buffers and solutions were made 
with DEPC-treated water (for RNA work, Fisher) to avoid RNA degradation.  At each 
major step, 1.25-2.5% of each reaction was removed for analysis on a 6% PAGE-urea 
gel, followed by autoradiographic analysis using a PhosphorImager (Molecular 
Dynamics) and visualized using ImageQuant software. 
 
 (i) Run-on reactions were conducted exactly as described in Core et al (Core et 
al., 2008), except for the amount of RQ1 RNase free DNase I used (5 µL, rather than 
10 µL).  Each reaction used ~5 x 106 MCF-7 Luc or PARP-1 knockdown nuclei (100 
µL) either treated with PJ34 and/or E2, as described above. 
 
(ii) Base hydrolysis of NRO RNA was conducted exactly as described in Core 
et al (Core et al., 2008), except for (a) the time of hydrolysis (20 min, rather than 30 
min), and (b) the amount of EDTA stopping the reaction (2 mM, rather than 10 mM). 
 
 (iii) Immuno-purification of NRO RNA was conducted using Anti-deoxyBrU 
beads (Santa Cruz Biotechnology), which were blocked for at least 1 hour rotating 
(10-15 rotations per minute) at room temperature using blocking buffer [1X SSPE, 1 
mM EDTA, 0.1% Tween, 0.1 % PVP, and 1 mg/ml Ultrapure BSA (Ambion)].  100 
µL of NRO RNA was heated to 70°C for 5 min, followed by 2 min on ice, and 
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subsequently added to 60 µL beads (washed twice with binding buffer), in a total 
reaction volume of 500 µL supplemented with binding buffer [0.25X SSPE, 1 mM 
EDTA, 0.05 % Tween, and 37.5 mM NaCl].  The NRO RNAs were allowed to bind 
for 1 hour while rotating at room temperature.   The beads were then washed (5 min 
each, rotating at room temperature) once in binding buffer, once in low salt buffer 
[0.25X SSPE, 1 mM EDTA, and 0.1% Tween], once in high salt buffer [0.25X SSPE, 
1 mM EDTA, 0.1% Tween, and 150 mM NaCl], and twice in TET buffer [1x TE and 
0.1% Tween].  The BrU RNA was then eluted two times using 125 µL and once using 
250 µL of elution buffer [20 mM DTT, 300 mM NaCl, 50 mM Tris•HCl (pH 7.5), 1 
mM EDTA, and 0.1% SDS].  The elutions were then combined, extracted and 
precipitated exactly as described in Core et al (Core et al., 2008).  All buffers were 
supplemented with 1 µL SUPERase-Inhibitor per 5 mL of buffer. 
 
 (iv) End repair of the enriched RNAs was conducted exactly as described in 
Core et al (Core et al., 2008), except for (a) the amount of Tobacco acid 
pyrophosphatase (TAP, 1.5 µL, rather than 2.5 µL), (b) the time of incubation with 
TAP enzyme (1.5 hrs, rather than 1 hr), (c) the amount of MgCl2 added to the kinase 
reaction (0.3 µL of 1 M MgCl2, rather than 0.5 µL of 5 mM MgCl2), (d) the amount of 
polynucleotide kinase (PNK, 2 µL, rather than 1 µL), and (e) the amount of EDTA 
used to stop the reaction (5 µL, rather than 10 µL). 
 
 (v) Adapter ligation reactions were conducted directly after end repair (5’) and 
after the 2nd Br-U enrichment step (3’).  The RNA was resuspended in 8.5 µL prior to 
the adapter ligation step, directly mixed with 1.5 µL of 10 µM adapter oligo (Illumina 
Small RNA Isolation Kit) and 6 µL 50% PEG, and subsequently heated to 70°C for 5 
min followed by 2 min on ice.  1 µL of SUPERase-Inhibitor, 2 µL 10X RNA ligation 
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buffer, and 1.5 µL of T4 RNA ligase (NEB) were added and the reactions were 
incubated on the bench top for 4 hours (5’) or 6 hours (3’).  The reactions were 
stopped with a mixture of 2 µL 500 mM EDTA and 28 µL DEPC water.  The 
reactions were then enriched over anti-deoxyBrU beads, as described above. 
 
 (vi) Reverse transcription of enriched RNAs were conducted in a single 20 µL 
reaction.  RNAs were combined with 1 µL of 100 µM RT Primer (Illumina Small 
RNA Isolation Kit) and subsequently heated to 70°C for 5 min followed by 2 min on 
ice.  4 µL of 5X First Strand buffer, 2 µL 10 mM dNTPs, 2 µL 100 mM DTT, and 1 
µL SUPERase-Inhibitor were added and incubated at 48°C for 3 minutes.  2 µL of 
SSIII RT enzyme (Invitrogen) was added and RNA was reverse transcribed by 
incubating at 44°C for 20 minutes followed by 52°C for 45 minutes.  RNAs were then 
degraded by addition of RNAse cocktail (Ambion) and RNase H (Ambion) for 15 min 
at 37°C, followed by extraction and precipitation as described above.  DNA was then 
amplified in duplicate 50 µL reactions for 15 cycles using Phusion high fidelity DNA 
polymerase (Finnzymes) and the PCR primers specified by Illumina.  After 
confirming the amplification by agarose gel electrophoresis, cDNAs were extracted 
and precipitated as described previously above. 
 
 (vii) NRO cDNA libraries were purified using a non-denaturing acrylamide gel 
exactly as described in Core et al (Core et al., 2008), except for using a 6% acrylamide 
gel, rather than 8%.  Libraries were quantified and sequenced at the Cornell 
University’s Fee-for-service Core Sequencing Facility using the Illumina 1G Genome 
Analyzer.  A single lane was sequenced for each biological replicate. 
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GRO-seq Analyses - The GRO-seq analyses were performed using the statistical 
programming language R (R Development Core Team).  The general protocols for 
each of the following sections were followed from Core et al (Core et al., 2008). 
 
Alignment of GRO-seq Reads to the Human Genome - Alignments of each 43-bp read 
to the hg19 assembly of the human genome were performed with the Short 
Oligonucleotide Alignment Package (SOAP) alignment tool (Li et al., 2008).  
Alignments allowed up to three mismatches per sequence to account for sequencing 
errors and SNPs between the cell line and the sequenced genome.  Since sequencing 
was performed from the 5’ end of the library, the 5’ coordinate of each read was used 
as the position of engaged polymerase for all future analyses. 
 
Correlation Analyses - A Pearson correlation analysis was performed between 
individual biological replicates for uniquely mapped reads from +1 to +13 kb relative 
to the TSS.  All pair-wise comparisons were made for all conditions. 
 
Defining Changes in Expression - To define changes in gene expression among any 
pair-wise comparisons, the total reads from +1 to +13 kb relative to the TSS for all 12 
samples (all pairs of biological replicates) were used as input into the EdgeR software 
package (Robinson et al., 2010).  The EdgeR software quantile normalizes all the 
reads within the given window, forcing the distribution of all samples to be equal, and 
calculates the parameters for a negative binomial distribution based on all pairs of 
biological replicates.  For each gene, the read counts are compared between pair-wise 
conditions using an exact test, the p-value of which is corrected for multiple 
hypothesis testing using a false discovery rate (FDR) cut-off of 0.1%, defining the 
change as significantly different (or not) between two conditions.  The resulting data is 
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plotted as the Log10 (gene body reads/total reads) for one condition versus another (as 
in Figures 3.9, 3.13, and 3.15).  Black circles represent genes whose change between 
the two conditions is not statistically different, while red circles represent genes whose 
change between the two conditions is statistically different. 
 
Metagene Profiles - The sum of reads at each position (weighted by expression level 
and normalized to both number of genes and total reads) and centered the data at the 
TSS for each condition examined for all Ref-seq (Figures 3.8) or estrogen-regulated 
(Figure 3.12) genes.  The resulting metagene profiles display reads on the sense strand 
moving toward the right (red), and antisense strand (blue) moving toward the left. 
 
mRNA expression analyses by RT-qPCR - For gene-specific mRNA expression 
analyses, total RNA was isolated from Luc and PARP-1 knockdown cells treated with 
vehicle, PJ34 (1 µM, 1 hr) or E2 (100 nM, 3 hrs) using Trizol Reagent (Invitrogen), 
reverse transcribed, and subjected to real-time quantitative PCR using a set of gene 
specific primers.  All target gene transcripts were normalized to the β-actin transcript, 
which was unaffected by estrogen treatment, PJ34 treatment, or PARP-1 knockdown 
(data not shown).  All experiments were conducted a minimum of three times with 
independent RNA isolations to ensure reproducibility. 
 
Quantitative PCR analyses (RT-qPCR) - Gene-specific mRNA expression analyses 
were analyzed by quantitative PCR in a similar manner.  Briefly, reactions containing 
DNA from either source, 1x SYBR Green PCR master mix, and forward and reverse 
primers (250 nM for ChIP, 500 nM for expression) were used in 40-45 cycles of 
amplification (95°C for 15 sec, 60°C for 1 min) using a Roche LightCycler® 480 
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System (384-well) following an initial 10 min incubation at 95°C.  Melting curve 
analysis was performed to ensure that only the targeted amplicon was amplified. 
 
Chromatin immunoprecipitation assays - ChIP assays were performed essentially as 
described previously (Gamble et al., 2010; Krishnakumar et al., 2008).  The 
immunoprecipitations were performed from crosslinked knockdown MCF-7 cells with 
antibodies against PARP-1 or histone H3, using “no antibody” as a control.  The 
resulting Input and ChIP DNA material was used for ChIP-chip analyses. 
 
ChIP-chip - The ChIP-chip sample processing and analysis were done essentially as 
described previously (Gamble et al., 2010; Krishnakumar et al., 2008).  Briefly, 
PARP-1-specific immunoprecipitated genomic DNA and reference DNA was blunted, 
amplified by ligation-mediated PCR (LM-PCR), labeled with Cy5 and Cy3, 
respectively, and used to probe a custom human oligonucleotide genomic array (HD2 
Platform or custom-designed, Nimblegen) (Gamble et al., 2010; Krishnakumar et al., 
2008).  The PARP-1 ChIP-chip was run in duplicate to ensure reproducibility and H3 
ChIP-chip was run only on the custom-designed platform. 
 
ChIP-chip Analyses - The Genomic data analyses for the PARP-1 ChIP-chip were 
performed as described previously (Gamble et al., 2010; Krishnakumar et al., 2008), 
using the statistical programming language R (R Development Core Team). 
 
Primer Sequences – The primer sequences listed below were used for RT-qPCR. 
 
Gene Name Primer Sequence  
β-ACTIN forward 5’-AGCTACGAGCTGCCTGAC-3’ 
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β-ACTIN reverse 5’-AAGGTAGTTTCGTGGATGC-3’ 
ABCA4 forward 5’-CAGCCAGAAAGGAACTCTGG-3’ 
ABCA4 reverse 5’-CATGCTCCTCGTGTGTTTGT-3’ 
AMOT forward 5’-TAAACGGCCAAATCAAGAGC-3’ 
AMOT reverse 5’-CCTTGTCCTCACCCTCAAAA-3’ 
AMTN forward 5’-CAGTGGCACAGATGACGACT-3’ 
AMTN reverse 5’-CCAAATTCGAGGCAGCTTAG-3’ 
ATP13A4 forward 5’-GGACTTGGCAAATGACCCTA-3’ 
ATP13A4 reverse 5’-GCATGTCAGAGTGGGAGGTT-3’ 
B3GNT6 forward 5’-TACATCCTGGCTCCATCTCC-3’ 
B3GNT6 reverse 5’-ATTCGCATCACTGGAGGAAC-3’ 
C14ORF49 forward 5’-CGCTACCAGTGGATGCTGTA-3’ 
C14ORF49 reverse 5’-CTCCCCTGGAGAACTTTGTG-3’ 
C9ORF44 forward 5’-GGACTCCTCTTGGCTGTGAC-3’ 
C9ORF44 reverse 5’-TGCACCTGATTAGGGCTCTT-3’ 
CACNA2D2 forward 5’-GCAGAGACTGACCAACACCA-3’ 
CACNA2D2 reverse 5’-GTATCGCGGTCTCTGCACTA-3’ 
CALCR forward 5’-CTGGCGACATCCCAATTTAC-3’ 
CALCR reverse 5’-GCTGGTTCATTCCTCAGCTC-3’ 
CD22 forward 5’-AGTGGGCGACTATGAGAACG-3’ 
CD22 reverse 5’-TGAATCCCCTCATCTTCTGG-3’ 
CDH7 forward 5’-GACATGGCTGCACTGAGAAA-3’ 
CDH7 reverse 5’-AAAGCTGGTCGACTCAGGAA-3’ 
COL27A1 forward 5’-TGGACAGACGTGTCTCAAGC-3’ 
COL27A1 reverse 5’-AGCTTAGCAGGTGCAGGAAA-3’ 
COLEC12 forward 5’-TGGAACGATTTCCAATGTGA-3’ 
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COLEC12 reverse 5’-GGAGTGTCCTTTGCCTTTGA-3’ 
ERBB4 forward 5’-AGGCCGAGGATGAGTATGTG-3’ 
ERBB4 reverse 5’-GTTGGCAAAGGTGTTGAGGT-3’ 
FILIP1 forward 5’-ACCCGCATTCCTATGTCAAA-3’ 
FILIP1 reverse 5’-GGTCAGATTTCCTGCTCCTG-3’ 
FOXN1 forward 5’-ATGCCATCAATCCCTCACTC-3’ 
FOXN1 reverse 5’-AGGGCCAAGCTATCATCCTT-3’ 
GATA4 forward 5’-AAATGCAGCTGGCAACTTCT-3’ 
GATA4 reverse 5’-AGCGGGAAGAGGGATTTTTA-3’ 
GDF15 forward 5’-CTACAATCCCATGGTGCTCA-3’ 
GDF15 reverse 5’-TATGCAGTGGCAGTCTTTGG-3’ 
GRAMD3 forward 5’-TGAGGCGTTTTGTTTGAGTG-3’ 
GRAMD3 reverse 5’-TCCACATGCAATGTCTGGAT-3’ 
HEY2 forward 5’-GTACCTGAGCTCCGTGGAAG-3’ 
HEY2 reverse 5’-CGCAAGTGCTGAGATGAGAC-3’ 
HIVEP2 forward 5’-CCTTTTCCCTGAGGGTCCTA-3’ 
HIVEP2 reverse 5’-TGTTGCTGAGAGTGGAGTGG-3’ 
ITPR1 forward 5’- TGCCTCCACAATTCTACG-3’ 
ITPR1 reverse 5’- TGAATGTCCCACAGTTGC-3’ 
KCNG3 forward 5’-CCCGTCACTTCATTGGTCTT-3’ 
KCNG3 reverse 5’-ACCATCTCTCGGTAGCAACG-3’ 
KCNK17 forward 5’-TGCTCTTCTCCCACATGGA-3’ 
KCNK17 reverse 5’-AGGGTGATGAAGGCGAAGTA-3’ 
KRT24 forward 5’-GGAAGCTGTTCTGGTCAAGG-3’ 
KRT24 reverse 5’-GCCATCCACCAACTCCTCTA-3’ 
KRT73 forward 5’-AGCTCTAAGCTCACCCACCA-3’ 
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KRT73 reverse 5’-TGGGCTGTGTTGCACTTTTA-3’ 
LPAR1 forward 5’-ACTCCTACCGCGACAAAGAA-3’ 
LPAR1 reverse 5’-TGTGAACTCCAGCCAAGATG-3’ 
LRG1 forward 5’-GAACCAGTTGGAGACCTTGC-3’ 
LRG1 reverse 5’-TGCCGTTCAGGAAGAGGTAG-3’ 
MAP2K6 forward 5’-CGGTTGACCCTACTGTGGAT-3’ 
MAP2K6 reverse 5’-TGGGAGAGAAAACCCTCTGA-3’ 
MN1 forward 5’-GGTCTGAGTCTGCGGTTCTC-3’ 
MN1 reverse 5’-GCTTTGTCTGCCCTCTGAAG-3’ 
MS4A15 forward 5’-CTCTGGCATTCCACAGAGGT-3’ 
MS4A15 reverse 5’-ATGGATGTGGCAACAGATGA-3’ 
MTR forward 5’-ACAACAGCCTATGTCCTCTG-3’ 
MTR reverse 5’-CCATCATAGAAGGCGTTTC-3’ 
NAT1 forward 5’-CTTCACCCTCACCCATAGGA-3’ 
NAT1 reverse 5’-TTTGGGCACAAGCTTTCTCT-3’ 
NFAT5 forward 5’-ACCTCTTCCAGCCCTACCAT-3’ 
NFAT5 reverse 5’-CCTCTTCGGTGTTGATGGAT-3’ 
NKAIN1 forward 5’- GCGGCTTTGACTCCTACG -3’ 
NKAIN1 reverse 5’-ACAGAGGCTGCAGCTGTAAA-3’ 
NLRP6 forward 5’-GTCTGCCGAGACCTTTCTGA-3’ 
NLRP6 reverse 5’-TCACTCAGCATACGCAGTCC-3’ 
NXPH1 forward 5’-CACAGACTTTTCGTGGCAAA-3’ 
NXPH1 reverse 5’-CAGTCCCAGAGGTCTTGCTC-3’ 
PDLIM3 forward 5’-GATAAGTACCGGCACCCTGA-3’ 
PDLIM3 reverse 5’-CCCTTTTGCTTGAGGTTGAG-3’ 
PKD2L2 forward 5’- GGCAGAAGGCTAGATTTTGAA -3’ 
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PKD2L2 reverse 5’- GCTTGTTCAGCCAAATCTCC -3’ 
PLIN4 forward 5’-TACAGTGGCCTGGTCTCCA-3’ 
PLIN4 reverse 5’-CGATGCCATAGAGCTCACAG-3’ 
PLIN5 forward 5’-CCAGGCAGAGCTGGAGAC-3’ 
PLIN5 reverse 5’-TGGACTCCAGAGCCTCTACC-3’ 
PLXNC1 forward 5’-TGAAGAAGTGGCCTTGACAG-3’ 
PLXNC1 reverse 5’-CCAGCCCTCGTTCTCTTTCT-3’ 
PRDM16 forward 5’-GCGGTCTGTTAGCTTTGGAG-3’ 
PRDM16 reverse 5’-CCTGCCTGCACAGTGTATGT-3’ 
PRKAG2 forward 5’-TGGTGGTGGTAAATGAAGCA-3’ 
PRKAG2 reverse 5’-GTTCTCCTCCTAGGGCGTCT-3’ 
PTPRH forward 5’-CGTTGATGGTGCAGACTGAG-3’ 
PTPRH reverse 5’-CGACATCCTCATACGGGACT-3’ 
RAPGEF4 forward 5’-ATGGAAACGGGCTCTAAC-3’ 
RAPGEF4 reverse 5’-AGCAGGACGAAGAGGAAC-3’ 
SEC14L5 forward 5’-CATAGCAGCTCCCTGGTCTC-3’ 
SEC14L5 reverse 5’-GCTGGCTTCTCATTCTGGAC-3’ 
SERPINA1 forward 5’-TGGAGGAGGAATGAAGAAAGCA-3’ 
SERPINA1 reverse 5’-AGCAGGACCCCAAATTCTGA-3’ 
SGK1 forward 5’-GCAGAAGGACAGGACAAAGC-3’ 
SGK1 reverse 5’-TTTGGGTTAAAAGGGGGAGT-3’ 
SLC47A1 forward 5’-CGAACGATGTTGGAAAGACA-3’ 
SLC47A1 reverse 5’-CCAGCTGTTTCCTGGACAAT-3’ 
SLC6A14 forward 5’-GCAGTGGGATTAGGAAATG-3’ 
SLC6A14 reverse 5’-GCAAATTGTCCCAGTGAAC-3’ 
SLIT1 forward 5’-GGACTTTCACCAGGTCCAGA-3’ 
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SLIT1 reverse 5’-GTGAACTTCCTCCGCTTCAG-3’ 
SMTNL2 forward 5’-GAATCTGGCCAACTGTGAGC-3’ 
SMTNL2 reverse 5’-CATCACCATCATGTCCTCCA-3’ 
SOCS2 forward 5’-ACACGTCAGCACCATCTCTG-3’ 
SOCS2 reverse 5’-TGGCACCGGTACATTTGTTA-3’ 
STOM forward 5’-CACCATTGCTGCTGAGAAAA-3’ 
STOM reverse 5’-TTTGCCCCTATGATTCCTTG-3’ 
TGM2 forward 5’-ACCCTTCAGACCCCAGTTCT-3’ 
TGM2 reverse 5’-CAGCTAAGGCTGTTGGGAAG-3’ 
TMOD3 forward 5’-GGAAGTAGTAATGGTGTTGACC-3’ 
TMOD3 reverse 5’-GCTCATCAAATACCGGAAG-3’ 
TRIB2 forward 5’-GATGATTCCCTCTCCGACAA-3’ 
TRIB2 reverse 5’-GTAGCTGCCACTGGTGTTCA-3’ 
VEGFC forward 5’-AAAGAACCTGCCCCAGAAAT-3’ 
VEGFC reverse 5’-TGGTGGTGGAACTTCTTTCC-3’ 
WISP2 forward 5’-TGCATGGGACATTCACCAAA-3’ 
WISP2 reverse 5’-TTCCTTATGGGATTGTTGTGCAT-3’ 
ZNF804A forward 5’-CAAAGGGAATTTGCTCGAAA-3’ 
ZNF804A reverse 5’-TTGGAGTGCCTTTTCCTGTT-3’ 
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CHAPTER 4 
 
 
 
 
 
 
The Histone Variant macroH2A1 Regulates Target Gene Expression in Part by 
Recruiting the Transcriptional Coregulator PELP1* 
 
 
 
 
 
 
 
 
 
 
 
* Contributions by other authors to this work were as follows:  M.J.G., GST-pull 
downs, PELP1 ChIP-chip, and computational analyses, ChIP-qPCR, and RT-qPCR 
(Figures 4.1-4.6 and 4.10-4.12); E.P., GST-pull downs (Figures 4.1 and 4.2); C.Y., 
PELP1 knockdown cell line generation and RT-qPCR (Figures 4.8-4.10); N.H., MCF-
7 TetR cell line generation (Figure 4.9 and data not shown); H.E-B. and P.T., MS/MS 
analyses (Figure 4.1). 
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4.1.  Summary 
 
 MacroH2A1 is a distinct histone variant harboring a ~30 kDa carboxyl-
terminal macro domain.  Due to its enrichment on the inactive X chromosome, 
macroH2A1 has long been thought to play a role in transcriptional repression.  
However, recent studies have begun to shed light on a more complex role for 
macroH2A1.  That is, macroH2A1 occupies autosomal chromatin and regulates genes 
in a context-specific manner.  The globular macro domain protruding from the 
nucleosome core may be a major player in the modulation of gene expression 
outcomes via physical interactions with effector proteins, which may depend on the 
ability of the macro domain to bind NAD+ metabolite ligands.  Here, we identify 
Proline, glutamate, and leucine rich protein 1 (PELP1), a chromatin-associated factor 
and classic transcriptional coregulator, as a novel ligand-independent macro domain-
interacting factor.  We used chromatin immunoprecipitation coupled with tiling 
microarrays (ChIP-chip) to determine the genomic localization of PELP1 in MCF-7 
human breast cancer cells.  Our data reveal that PELP1 genomic localization is highly 
correlated with that of macroH2A1.  Additionally, PELP1 positively correlates with 
heterochromatic chromatin marks and negatively correlates with active transcription 
marks, much like macroH2A1.  We show that macroH2A1 specifically recruits PELP1 
to the promoters of macroH2A1 target genes, but macroH2A1 deposition occurs 
independent of PELP1.  Furthermore, we demonstrate that this recruitment allows for 
macroH2A1 and PELP1 to cooperatively regulate gene expression outcomes. 
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4.2.  Introduction 
 
The canonical nucleosome architecture, two copies each of histones H2A, 
H2B, H3, and H4, organizes the genomes of Eukaryotes and is locally modified in a 
multitude of ways for various regulatory purposes.  These modifications include the 
post-translational modification of histones, changes in nucleosome positioning, and 
the replacement of canonical histones with their histone variant counterparts.  
MacroH2A1 is one such histone variant that can substitute for at least one copy 
of H2A in a subset of nucleosomes in vertebrates.  At three times the size of histone 
H2A, macroH2A1 is made up of an amino-terminal histone like regions with 64% 
identity to H2A and a carboxyl-terminal ~30 kDa macro domain.  Based largely on the 
observation that macroH2A1 is enriched on the transcriptionally silent inactive X 
chromosome (Xi) (Costanzi and Pehrson, 1998; Mietton et al., 2009), macroH2A1 was 
originally hypothesized to play a role in transcriptional repression (reviewed in 
(Ladurner, 2003)).  However, later studies demonstrated that macroH2A1 is not 
required for the initiation or maintenance of X-inactivation (Changolkar et al., 2007; 
Csankovszki et al., 1999; Rasmussen et al., 2001; Wutz et al., 2002), casting doubt on 
a general role for macroH2A in transcriptional repression. 
Recent work from our lab and others has determined that macroH2A1 is not 
only a component of chromatin on the Xi, it occupies approximately a quarter of the 
autosomal genome (Buschbeck et al., 2009; Gamble et al., 2010).  Additionally, 
macroH2A1 is generally associated with transcriptionally repressive heterochromatin 
across autosomes where it co-localizes with other heterochromatin marks such as 
histone H3 lysine 27 trimethylation (H3K27me3) (Buschbeck et al., 2009; Gamble et 
al., 2010).  However, while macroH2A1 is a component of autosomal 
heterochromatin, it is not generally required for the repression of genes found in 
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macroH2A1-containing domains (Gamble et al., 2010), similar to the lack of a general 
requirement for macroH2A1 in the transcriptional repression of genes on the Xi.  A 
growing body of evidence suggests that macroH2A1 can play either a positive or 
negative role in regulating the transcription of genes found in its domains in a context-
specific manner (Agelopoulos and Thanos, 2006; Buschbeck et al., 2009; Changolkar 
et al., 2007; Changolkar et al., 2008; Gamble et al., 2010; Gamble and Kraus, 2010). 
MacroH2A1-containing nucleosomes and canonical nucleosomes are 
structurally similar.  They both organize the same amount of DNA and their crystal 
structures are also highly comparable (Abbott et al., 2004; Chang et al., 2005; 
Changolkar and Pehrson, 2002).  However, the macro domain protruding from the 
nucleosome core has important biochemical consequences for macroH2A1-containing 
nucleosomes.  For example, macroH2A1-containing nucleosomes display increased 
nuclease protection near the dyad of symmetry (Changolkar and Pehrson, 2002).  
Some transcription factors cannot bind to their DNA sites specifically when they are 
incorporated into a macroH2A1-containing nucleosome (Agelopoulos and Thanos, 
2006; Angelov et al., 2003).  Additionally, macroH2A1-containing nucleosomes are 
poor substrates for ATP-dependent chromatin remodeling enzymes, in the absence of 
histone chaperones (Angelov et al., 2006; Angelov et al., 2003; Chang et al., 2008).  
Macro domains are ancient domains that have been identified in proteins from 
bacteria to humans (Pehrson and Fuji, 1998).  In macroH2A1-containing nucleosomes, 
this extra 30-kDa globular domain may be responsible for recruiting additional 
effector proteins to macroH2A1-containing chromatin in order to facilitate the 
regulation of gene expression (Chakravarthy et al., 2005; Hernandez-Munoz et al., 
2005; Nusinow et al., 2007; Ouararhni et al., 2006).  Recent work from Ladurner’s 
group and others suggest that most macro domains are ligand binding domains for 
NAD+ metabolites such as poly(ADP-ribose) (PAR), a post-translational modification 
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catalyzed by a family of PAR polymerases (PARPs), monomeric ADP-ribose, and O-
acetyl-ADP-ribose, produced as a by-product of sirtuin family deacetylase reactions 
(Ahel et al., 2009; Gottschalk et al., 2009; Karras et al., 2005; Kraus, 2009; 
Kustatscher et al., 2005; Timinszky et al., 2009).  Ligand binding by macro domains 
appears to have two functions that have been identified thus far.  First, ligand binding 
can alter the affinity of some proteins to interact with macro domains.  For example, 
the macro domain of macroH2A1.1 interacts specifically with automodified PARP-1, 
in a manner that requires the ability of the macro domain to bind PAR (Nusinow et al., 
2007; Timinszky et al., 2009).  Second, macro domains can mediate the recruitment of 
factors that contain these domains to genomic sites of PAR accumulation (Ahel et al., 
2009; Gottschalk et al., 2009; Timinszky et al., 2009). 
 Here, we report the identification of the transcriptional coactivator Proline-, 
glutamic acid-, and leucine-rich protein 1 (PELP1) as a novel factor that interacts with 
the macro domain of macroH2A1.  PELP1, otherwise known as modulator of the non-
genomic activities of estrogen receptor (MNAR), has been shown to promote estrogen 
receptor-dependent transcription as both a classical coactivator and through a 
controversial plasma membrane signaling mechanism (Cheskis et al., 2008; 
Vadlamudi et al., 2001).  PELP1 is also a chromatin-associated factor that has been 
shown to interact with a variety of transcription factors (i.e. AR, GR), covalently 
modified histone H3, and the linker histone H1 (Choi et al., 2004; Khan et al., 2006; 
Nair et al., 2007; Nair et al., 2004; Nair et al., 2010).  Recently, PELP1 has been 
shown to stimulate transcription by displacing the linker histone H1 and/or by 
recruiting the lysine demethylase KDM1 to demethylate H3K9me2 (Nair et al., 2010).  
Taken together, these studies suggest that PELP1 is multifunctional protein that can 
regulate chromatin-dependent transcriptional processes through many mechanisms. 
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In the studies described herein, we document the physical and functional 
interactions of macroH2A1 with PELP1, using a series of biochemical, genomic, and 
gene-specific analyses.  We demonstrate that PELP1 and macroH2A1 interact in a 
manner that is independent of macroH2A1’s ability to bind NAD+ metabolites.  Using 
ChIP-chip, we show that macroH2A1 and PELP1 are highly correlated in their 
genomic localization patterns.  Furthermore, we demonstrate that macroH2A1 
specifically recruits PELP1 to a subset of macroH2A1 target gene promoters to 
cooperatively modulate gene expression outcomes. 
 
4.3.  Results 
 
A GST pull-down using the macro domain of the histone variant macroH2A1.1 
reveals interactions with a multitude of nuclear proteins.  Our previous work 
demonstrated that macroH2A1-containing chromatin can both positively and 
negatively regulate the expression of its target genes in a context-specific manner.  
The histone variant macroH2A1.1, depicted in Figure 4.1A, consists of a canonical 
histone H2A region, followed by a basic linker and a globular macro domain.  The 
macro domain of macroH2A is the most striking feature differentiating macroH2A1-
containing nucleosomes from canonical nucleosomes.  At ~30 kDa, the globular 
macro domain extends near the dyad axis of the nucleosome and makes minimal 
contact with DNA (Changolkar and Pehrson, 2002), suggesting that the macro domain 
may make important protein-protein interactions that facilitate the regulation of 
transcription by macroH2A1.  To identify the proteins interacting with this macro 
domain, we performed a GST pull-down assay using the basic linker and macro 
domain regions of macroH2A1.1 (GST-macro1.1) as bait (Figure 4.1B).  GST alone or 
GST-macro1.1 was immobilized using glutathione affinity resin and incubated with or 
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without HeLa nuclear extract.  After washing the resin, the bound fraction was eluted 
from the resin using glutathione.  The eluates were separated by SDS-PAGE and 
visualized by silver staining.  GST-macro1.1-specific protein bands were excised from 
the gel, trypsinized, and protein fragments were identified by mass spectrometry. 
 The GST-macro1.1-interacting proteins we identified are chromatin-associated 
and nucleolar components that participate in cellular activities such as transcription, 
ribosome biogenesis/export, RNA maturation, protein chaperoning, and maintenance 
of chromatin structure (see supplementary Figure 4.2 and Table 4.1).  Notably, both 
Poly(ADP-ribose) Polymerase-1 (PARP-1) and Proline, glutamate, and leucine rich 
protein 1 (PELP1) were identified as factors that interact with the macro domain of 
macroH2A1.1.  PARP-1 has previously been identified as a factor that interacts with 
the macroH2A macro domain (Nusinow et al., 2007; Ouararhni et al., 2006), 
validating our results.  PELP1 is a nuclear protein (~180 kDa) that modulates both 
genomic and non-genomic activities of nuclear receptors through interactions with 
nuclear proteins (i.e., HDAC2, SUMO2, ERα, AR, GR, RXRA, STAT3; (Brann et al., 
2008; Choi et al., 2004; Khan et al., 2006; Manavathi et al., 2005; Nair et al., 2007; 
Rosendorff et al., 2006; Singh et al., 2006)) and chromatin components (i.e., H1 and 
H3; (Nair et al., 2004; Nair et al., 2010)) involved in transcriptional regulation.  
Previous reports indicate that the interaction of macroH2A1 and PARP-1 is modulated 
by the macro domain ligand, ADP-ribose (ADPR) (Timinszky et al., 2009).  We 
hypothesized that macroH2A1 and PELP1 may interact in a similar manner.  To test 
this, the GST pull-down assay was repeated in the presence of the macro domain 
ligand ADPR or NAD+ as a control (Figure 4.1C).  Using Western blot analyses, we 
were able to confirm the specific interactions of both PARP-1 and PELP1 with GST-
macro1.1, compared to GST alone.  As previously shown (Timinszky et al., 2009), 
PARP-1 binding was lost in the presence of ADPR, but not with NAD+.  However, we 
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Figure 4.1.  PELP1 interacts with the macro domain of the histone variant 
macroH2A1.1 in an ADPR-independent manner.  A, Schematic diagram of the 
histone variant macroH2A1.1 and GST-tagged macro domain.  The histone H2A-like 
region (H2A), macro domain, and the basic linker region (Basic), are shown.  The 
GST-macro1.1 fusion consists of GST fused to the non-histone regions only.  GST 
alone, used as a control, is shown for comparison.  B, Silver stain image of GST-
macro1.1 interacting proteins from a GST pull-down assay.  GST alone or GST-
macro1.1 fusion protein were immobilized on glutathione affinity resin and incubated 
with or without HeLa nuclear extract.  Bound fractions were washed, eluted with 
glutathione, and separated by SDS-PAGE.  Resulting eluates were visualized by silver 
stain.  GST-macro1.1-specific protein bands were excised from the gel, trypsinized, 
and identified by mass spectrometry.  Macro domain-interacting proteins, PELP1 and 
PARP-1, are shown.  The full data set of identified proteins can be found in 
supplementary Figure 4.2 and Table 4.1.  C, PELP1 and PARP-1 interactions with the 
macro domain of macroH2A1 are differentially mediated by the macro domain ligand, 
ADP-ribose (ADPR).  The GST pull-down assay described in panel B was repeated in 
the absence and presence of ADPR or NAD+, as a control.  Western blotting confirms 
PELP1 and PARP-1 interaction with GST-macro1.1 (None).  ADPR impedes the 
interaction of PARP-1 with the macro domain, but not that of PELP1 (ADPR). 
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Figure 4.2.  The macro domain of the histone variant MacroH2A1.1 interacts 
with a both chromatin-associated proteins and nucleolar components.  A, Silver 
stain image of GST-macro1.1 interacting proteins from a GST pull-down assay.  GST 
alone or GST-macro1.1 fusion protein were immobilized on glutathione affinity resin 
and incubated with or without HeLa nuclear extract.  Bound fractions were washed, 
eluted with free glutathione, and separated by SDS-PAGE.  Resulting eluates were 
visualized by silver stain.  GST-macro1.1-specific protein bands were excised from 
the gel, trypsinized, and identified by mass spectrometry.  All identified macro 
domain-interacting proteins are described further in Table 4.1.  B, Western blotting 
confirms the interaction of GST-macro1.1 with nucleolin and SET. 
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Table 4.1.  Proteins identified as interactors of the histone variant macroH2A1 
macro domain are categorized as chromatin-associated and nucleolar 
components.  For each identified protein, the gene symbol, protein name, and known 
cellular functions are listed, based on GeneCards descriptions. 
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found that the PELP1 interaction with GST-macro1.1 was not interrupted in the 
presence of either ADPR or NAD+.  These results demonstrate that PELP1 interacts 
with the macro domain of macroH2A1 in an ADPR-independent manner. 
 
PELP1 occupies large chromatin domains in the MCF-7 genome and is enriched in 
macroH2A1-bound regions.  Recently, our lab reported the genomic localization 
patterns of macroH2A1 in MCF-7 cells using chromatin immunoprecipitation (ChIP) 
coupled to genomic tiling microarrays (i.e., ChIP-chip; (Gamble et al., 2010)).  Those 
results indicated that macroH2A1 occupies large chromatin domains and that the 
boundaries of those occupied regions are near transcription start sites.  For a subset of 
genes, macroH2A1 bound regions occupy the transcribed region.  Since our in vitro 
assay suggested that macroH2A1 and PELP1 interact, we sought to determine if 
PELP1 associated to the genome in a similar localization pattern to macroH2A1. 
Using an antibody specific for PELP1, we performed ChIP-chip experiments in 
MCF-7 cells using a custom-designed Nimblegen platform previously described 
(Gamble et al., 2010; Krishnakumar et al., 2008), representing 4.14 Mb of genomic 
DNA including 1829 gene promoters typically tiled from -25 to +5 kb surrounding the 
TSSs.  Using our previously defined criteria (Gamble et al., 2010), we determined that 
PELP1 significantly bound over 1953 regions on the array ranging in size from 1.5 to 
7.5 kb (average ~1.9 kb) covering ~9% of the genome represented on the array.  In 
total, PELP1 is found within 3 kb of the TSS for 257 (14.1%) genes on the array. 
We compared the binding pattern of PELP1 to our previously published 
macroH2A1 ChIP-chip data set (National Institutes of Health GEO accession number 
GSE9607).  Comparisons across several genomic loci, including all forty-four 
ENCODE regions (2004), revealed a striking correspondence between the PELP1 and 
macroH2A1 genomic occupancy (Figure 4.3).  In order to determine if macroH2A1 
 269 
and PELP1 associated with similar genomic regions on a global scale, we depicted 
each ChIP-chip data set as a heat map in which each row corresponds to the 
macroH2A1 or PELP1 ChIP-chip signal from -25 kb to +5 kb relative to the TSS for 
each TSS represented on the array.  When the data from both heat maps are ordered 
for increasing average intensity of PELP1, an obvious correspondence between the 
two data sets can be observed (Figure 4.4A).  This pattern is also clearly evident by an 
averaging analysis of all TSSs represented on our array (Figure 4.4B).  As would be 
expected from these results, there is a significant correlation between the global 
localization pattern of macroH2A1 and PELP1 (Spearman correlation coefficient of 
~0.53, P-value < 10-300).  Further analysis indicated that 67.7% of the PELP1-bound 
regions overlap with macroH2A1-containing domains (Figure 4.4C).  In fact, there is 
over a 27-fold enrichment of PELP1 binding in macroH2A1-containing regions of the 
genome (P-value < 10-300) (Figure 4.4D).  Finally, of the 257 genes marked by PELP1 
occupancy, 200 (78%) are co-occupied by macroH2A1.  Overall, this data indicates 
that there is a tight statistical association between PELP1 and macroH2A1 binding 
across the genome in MCF-7 cells.  Combined with the interaction data shown in 
Figure 4.1, this data supports the hypothesis that macroH2A1 and PELP1 are 
interacting with each other over many regions across the genome. 
Despite the strong statistical enrichment of PELP1 in macroH2A1-containing 
domains, we are not able to detect PELP1 at all sites of macroH2A1 deposition in 
MCF-7 cells.  In fact, PELP1 occupies only 29% of macroH2A1-bound regions 
(Figure 4.4C).  Additionally, 22% of PELP1-bound genes do not contain significant 
levels of macroH2A1 within 3 kb of the TSS.  The lack of complete overlap of PELP1 
and macroH2A1 binding may indicate that PELP1 binding functionally distinguishes a 
subset of macroH2A1-containing regions.  Alternatively, these differences could be 
due to the reduced efficiency of the PELP1 ChIP compared to that of macroH2A1.  To 
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Figure 4.3.  A comparison across several genomic loci reveals a striking 
correspondence between PELP1 and macroH2A1.  A and B, Histograms depicting 
the Log2 ratios of PELP1 and macroH2A1 ChIP-chip signals from MCF-7 cells across 
a representative ENCODE region (A) and a region centered around the SOCS2 
promoter (B) represented on our custom-designed ChIP-chip array.  The genomic 
location is shown and the position and orientation of RefSeq genes are depicted below 
each track.  The genes are color-coded according to expression microarray data:  
green, expressed; blue, unexpressed; grey, ambiguous. 
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Figure 4.4.  PELP1 is significantly enriched in macroH2A1-bound regions and is 
also negatively correlated with gene expression.  A, Heat maps showing 
macroH2A1 and PELP1 ChIP-chip data across 2149 promoters, tiled from -25 to +5 
kb surrounding the transcription start sites.  The data, ordered for average PELP1 
intensity, reveal similar genomic localization patterns for both factors.  B, Averaging 
analysis of the Log2 enrichment ratios (IP/Input) for all windows from macroH2A1 
(red) and PELP1 (blue) ChIP-chip data along the 30 kb regions represented on the 
array.  Histone H3 (green) ChIP-chip data is shown for comparison.  C, Venn diagram 
representing the number of well-tiled windows bound by macroH2A1, PELP1, or both 
(Intersection).  Nearly 23% of macroH2A1 bound windows are also bound by PELP1, 
while 68% of PELP1 bound windows are also bound by macroH2A1.  PELP1 bound 
“regions” are defined as consecutive windows bound by PELP1.  D, Histogram 
depicting the fraction of macroH2A1 bound or unbound regions that are also bound by 
PELP1.  The enrichment value (E) and P-value (p) from a Fisher exact test are shown.  
E, Histogram depicting the average Log2 ratios of PELP1 and macroH2A1 signal 
within 3 kb of the TSS at genes within each pentile of expression, as determined from 
MCF-7 expression microarray data.  The correlation coefficient (c.c.) and P-value (p) 
for PELP1 and macroH2A1 with gene expression is shown.  mH2A1, macroH2A1. 
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examine these possibilities we set out to determine if PELP1 has a similar correlation 
to gene expression and histone marks, as well as gene ontology enrichment as 
previously observed for macroH2A1 (Gamble et al., 2010). 
MacroH2A1 is negatively correlated with gene expression in both IMR90 cells 
and in MCF-7 cells (Gamble et al., 2010).  By calculating the average macroH2A1 and 
PELP1 ChIP-chip signal within 3 kb of all TSSs and comparing to previously 
published Affymetrix expression data from MCF-7 cells (Kininis et al., 2007) we 
determined that similar to macroH2A1 (correlation coefficient of -0.25, P-value = 2 x 
10-23), PELP1 (correlation coefficient of -0.17, P-value = 7.7 x 10-12) is significantly 
negatively correlated with gene expression (Figure 4.4E).  
Previous gene ontology analysis determined that macroH2A1-containing 
domains are enriched for genes that are involved in developmental processes and 
signaling events.  MacroH2A1-containing genes also often encode proteins that are 
secreted from the cell (Gamble et al., 2010).  We performed a similar gene ontology 
analysis for PELP1-bound genes, as well as for those genes that are bound by both 
macroH2A1 and PELP1.  We found that PELP1-bound genes are enriched for a 
similar set of ontological processes (Table 4.2 and Table 4.3). 
Previously, we correlated macroH2A1 occupancy to 362 publically available 
ChIP-chip data sets and determined that macroH2A1 positively correlates with 
heterochromatic histone marks, including histone H3 lysine 27 trimethylation 
(H3K27me3), while negatively correlating with active transcription marks, such as 
RNA Polymerase II (RNA Pol II) (Gamble et al., 2010).  By performing a similar 
analysis for PELP1 (Figure 4.5A), we found that PELP1 correlates with many of the 
same marks as macroH2A1 (Figure 4.5B), both positively and negatively.  In addition, 
PELP1 correlates with factors and histone marks independent of macroH2A1 (Figure
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Table 4.2.  Summary of the most significant gene ontology terms enriched in 
genes with macroH2A1, PELP1, or both within 3kb surrounding the TSS. The 
enrichment of gene ontology terms in genes with macroH2A1-bound or PELP1-bound 
regions found within 3kb of the TSS in MCF-7 cells was compared with all other 
genes represented on the ChIP-chip array for all three ontology aspects. 
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Gene Ontology Terma Aspectb P-value 
 
macroH2A1-bound Genesc 
Multicellular organismal process BP 4.46 x 10-5 
System development BP 7.44 x 10-5 
Multicellular organismal development BP 0.00011 
Anatomical structure development BP 0.00087 
Developmental process BP 0.00103 
Organ development BP 0.00288 
Regulation of localization BP 0.00342 
Signaling BP 0.00663 
Cell surface receptor linked signaling pathway BP 0.00948 
Extracellular region CC 2.60 x 10-7 
Extracellular region part CC 1.82 x 10-5 
Pattern binding MF 0.00072 
Polysaccharide binding MF 0.00072 
Glycosaminoglycan binding MF 0.00200 
 
PELP1-bound Genesd   
Multicellular organismal process BP 0.00020 
Cell surface receptor linked signaling pathway BP 0.00878 
Extracellular region part CC 0.00071 
Proteinaceous extracellular matrix CC 0.00128 
Extracellular matrix CC 0.00175 
 
macroH2A1- and PELP1-bound Genese 
Multicellular organismal development BP 4.74 x 10-5 
Organ development BP 0.00023 
Multicellular organismal process BP 0.00024 
Developmental process BP 0.00026 
System development BP 0.00142 
Anatomical structure development BP 0.00216 
Extracellular region part CC 0.00011 
Proteinaceous extracellular matrix CC 0.00022 
Extracellular matrix CC 0.00023 
Extracellular region CC 0.00645 
 
a Gene ontology terms were generated using the Generic Gene Ontology Term Finder 
(http://go.princeton.edu/cgi-bin/GOTermFinder/GOTermFinder). 
b The aspects covered include:  bp, biological process; cc, cellular component; and mf, 
molecular function. 
c, d, and e The genes that correspond to each category can be found listed in Table 4.3. 
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Table 4.3.  Gene lists used for gene ontology analysis. Gene lists consist of 
significantly bound or unbound macroH2A1 or PELP1, or both and subsequently used 
for gene ontology analysis, as shown in Table 4.2.   (MacroH2A1 ChIP-chip data was 
accessed from the NCBI GEO website using accession number GSE9607.) 
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(i) macroH2A1-bound Genes 
 
AADAT 
ABHD6 
ACADL 
ACCN4 
ACSL6 
ACTA2 
ACTB 
ADAM2 
ADAMTS9 
ADAMTSL1 
ADAMTSL3 
ADIPOQ 
ADRB1 
ADRBK1 
ADSSL1 
ALDH5A1 
AMIGO2 
AMMECR1 
AMOTL2 
ANKRD43 
ANKRD55 
ANXA3 
APOA1 
APOA4 
APOA5 
APOC3 
ARAP2 
AREG 
ARHGAP18 
ARHGAP26 
ARHGDIG 
ARL14 
ARL4A 
ASB13 
ASCL1 
ASPH 
ASZ1 
ATF7IP 
ATL2 
AVPR2 
B3GAT2 
BCAS1 
BCAT1 
BCL6 
BIRC5 
BMP4 
BMPER 
BPIL2 
BRAF 
BTG2 
BUB1 
C11orf21 
C11orf9 
C13orf18 
C14orf23 
C16orf38 
C1orf107 
C20orf118 
C21orf54 
C22orf42 
C3 
C3orf54 
C5orf13 
C5orf35 
C8orf74 
CACNA1G 
CACNG6 
CACNG7 
CADM1 
CALCR 
CALD1 
CALML3 
CALML5 
CAMK2N1 
CAPN9 
CAPZA2 
CAV1 
CAV2 
CBFA2T3 
CCBP2 
CCL2 
CCNI2 
CD209 
CDC2 
CDC42EP4 
CDH16 
CDH2 
CDH29 
CDH5 
CDKN2C 
CEACAM4 
CEACAM6 
CEBPB 
CEP55 
CERK 
CFTR 
CH25H 
CHAC1 
CIDEC 
CKMT1A 
CKMT1B 
CLEC10A 
CLEC11A 
CLEC4M 
CRAT 
CSGALNACT1 
CST5 
CSTA 
CTAG1A 
CTAG2 
CTDSPL 
CTGF 
CTSD 
CTTNBP2 
CTXN2 
CXADR 
CXCL12 
CXCR4 
CXCR7 
CYB561 
CYP1A1 
CYP1A2 
DAPK2 
DBP 
DCLK1 
DDX18 
DEGS1 
DES 
DHRS3 
DIAPH2 
DIRAS1 
DKC1 
DKFZP434K028 
DKK1 
DLL4 
DNAJB3 
DNASE1L3 
DUSP1 
DUSP3 
DUSP4 
DYNC2LI1 
DYRK2 
EDAR 
EFEMP1 
EGFR 
EGR3 
EIF6 
ELL2 
EMD 
ENAH 
ENC1 
ENPP2 
EPHB2 
EPN3 
ERBB4 
ERG 
ESR2 
ETS2 
EVX1 
F10 
F13A1 
F2RL1 
F7 
FAM117A 
FAM13A 
FAS 
FBN2 
FCGR2B 
FER1L4 
FGF1 
FGFR2 
FHL2 
FLJ32063 
FLJ43752 
FLJ44054 
FLNA 
FLRT2 
FOS 
FOXG1 
FOXN3 
FOXP2 
FST 
FZD1 
FZD7 
GAB3 
GADD45A 
GALNT12 
GAS6 
GATM 
GDF15 
GDF5 
GEM 
GLRB 
GPC5 
GPRC5A 
GRAMD3 
GRB10 
GREB1 
GRM1 
GRM8 
GTF2A1 
GULP1 
H19 
H1FNT 
H1FOO 
HAPLN1 
HBA1 
HBA2 
HBE1 
HBM 
HBP1 
HBZ 
HCCA2 
HEY2 
HIGD1A 
HILS1 
HISPPD2A 
HIST1H1C 
HIST1H1D 
HIST1H1E 
HIST1H2AB 
HIST1H2AL 
HIST1H3B 
HIST1H3I 
HIST1H4B 
HIST1H4F 
HIST1H4L 
HMGA2 
HMSD 
HOXA1 
HOXA10 
HOXA11 
HOXA11AS 
HOXA13 
HOXA2 
HOXA3 
HOXA4 
HOXA5 
HOXA6 
HOXA7 
HOXA9 
IGF1 
IGF2 
IGF2AS 
IGFBP4 
IGFBP5 
IL13 
IL1R1 
IL24 
INPP5J 
INS-IGF2 
IQGAP1 
IRF1 
IRX5 
ISL1 
ITGA6 
ITGB3 
ITGB4 
ITK 
ITPR2 
KCNK1 
KCNK5 
KCNN2 
KIAA1026 
KIR2DL1 
KIR2DL3 
KIR2DL4 
KIR3DL1 
KIR3DL3 
KIR3DP1 
KIR3DX1 
KLC3 
KLF4 
KLF6 
KLF9 
KREMEN2 
KRT13 
KRT222P 
KRT81 
KRT86 
KRTAP5-2 
L1CAM 
LACE1 
LAD1 
LAIR1 
LAIR2 
LEFTY1 
LHX2 
LILRA1 
LILRA2 
LILRA3 
LILRA4 
LILRA5 
LILRA6 
LILRB1 
LILRB2 
LILRB3 
LILRB4 
LILRB5 
LILRP2 
LOC100188949 
LOC26010 
LOC284067 
LOC441108 
LOC441864 
LOC91149 
LRIG1 
LRRC15 
LRRK2 
LSP1 
LTF 
LUZP2 
MAP2K6 
MAP3K1 
MAPK11 
MAPK12 
MBNL2 
MBOAT7 
MCAM 
MCF2L 
MCM3 
MCTP2 
MDFI 
MDFIC 
MEGF8 
MET 
METTL9 
MGAT3 
MICB 
MIER3 
MMP1 
MMP2 
MN1 
MPP1 
MPPED2 
MSL3L2 
MSLN 
MT1A 
MT1B 
MT1DP 
MT1F 
MT1M 
MTSS1 
MYB 
MYCN 
MYCNOS 
MYEF2 
MYLK
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MYO1F 
MYOT 
NACC2 
NCKAP1 
NCR2 
NDP 
NEK1 
NELL2 
NFAT5 
NFKBIE 
NISCH 
NKX2-1 
NMU 
NOX3 
NPY5R 
NR2E1 
NR4A1 
NR5A2 
NRAP 
NRXN2 
NTM 
ODAM 
OLIG1 
OLIG2 
OPN1LW 
OR51A4 
OR51Q1 
OR51T1 
OR52N4 
OR56B1 
OSBPL1A 
OVGP1 
PADI2 
PALMD 
PAPSS2 
PAQR4 
PARP1 
PARP12 
PBX1 
PCDH7 
PDE4DIP 
PDE6A 
PDLIM4 
PDLIM5 
PDZD2 
PEG10 
PERP 
PFTK1 
PGC 
PI4KB 
PICALM 
PIK3IP1 
PKIA 
PLAC1 
PLBD1 
PLCL1 
PLCL2 
PNRC1 
PPAP2B 
PPARG 
PPFIBP2 
PPP2R1B 
PPP2R2B 
PPP2R3A 
PPP2R4 
PRDX2 
PRKAG2 
PRKCA 
PRKCG 
PRL 
PROM1 
PRSS23 
PRX 
PTGER3 
PTPN21 
PTPRK 
PVALB 
RAB28 
RAB9A 
RAMP3 
RAPGEF4 
RAPGEF5 
RARG 
RASGRP1 
RASGRP2 
REEP1 
RET 
RFPL2 
RFPL3S 
RGS10 
RHO 
RICH2 
RNASEH2A 
RND3 
RNF43 
RP1L1 
RPL39L 
RPRM 
RPSAP52 
S100A10 
S1PR1 
SAMD3 
SATB1 
SATB2 
SAV1 
SCGB1D2 
SCN1A 
SEC1 
SEC14L2 
SELENBP1 
SEMA3G 
SEMA4G 
SENP7 
SERPINA1 
SERPINB2 
SERPINB9 
SGCA 
SGCE 
SGK1 
SGK3 
SHANK1 
SHROOM1 
SIRT1 
SIVA1 
SIX2 
SLC22A11 
SLC22A12 
SLC26A2 
SLC2A13 
SLC5A4 
SLCO4C1 
SNX24 
SOBP 
SOCS2 
SOX1 
SOX4 
SOX9 
SPEG 
SPP2 
SPSB1 
ST6GALNAC4 
ST7 
ST7OT1 
ST7OT4 
STATH 
STC1 
STEAP1 
STEAP2 
STK3 
STMN4 
STXBP1 
SULT1E1 
SYN2 
SYN3 
SYT8 
TACC1 
TAL1 
TARP 
TBKBP1 
TBX3 
TES 
TFAP2A 
TFB1M 
TFEB 
TFF1 
TFF3 
TFPI 
TGFBR2 
TGFBR3 
TGM2 
TGM3 
TH 
THBS1 
THOC2 
TIMP3 
TMEM145 
TMEM151B 
TMEM71 
TMOD3 
TMPRSS2 
TMPRSS3 
TMSB15A 
TNC 
TNFRSF11B 
TNFSF10 
TNNC1 
TNNI2 
TNNT3 
TP53BP1 
TRAF1 
TRIB2 
TRIM22 
TRIM34 
TRIM5 
TRIM6 
TRIM6-TRIM34 
TRPM8 
TSC22D3 
TSEN34 
TSPAN32 
TSPAN5 
TTLL7 
TTYH1 
UBAC1 
UBASH3A 
UBE2D1 
UGT1A1 
UGT1A3 
UGT1A4 
UGT1A6 
UGT1A7 
UGT1A9 
UGT2B15 
UGT8 
UTRN 
VEGFA 
VTCN1 
WDR44 
WFS1 
WISP2 
WNT2 
WWC1 
YAP1 
ZC3H14 
ZCCHC24 
ZIC1 
ZIC4 
ZMYND10 
ZNF259 
ZNF462 
ZNF711 
ZNF804A 
ZSCAN2 
 
 
(ii) PELP1-bound Genes 
 
ABCC4 
ACADL 
ACSL6 
ACTB 
ADAM2 
ADAMTS9 
ADIPOQ 
AGPAT3 
ANKRD13C 
APH1B 
ARAP2 
AREG 
ARHGAP18 
ARHGAP26 
ARL14 
ASB13 
ASCL1 
ASPH 
ASZ1 
ATL2 
ATP11B 
AXIN1 
BBS1 
BCAS1 
BCL2A1 
BCL6 
BMP4 
BMPER 
BRIP1 
BUB1 
C10orf84 
C21orf49 
C21orf66 
C22orf42 
C6orf221 
CACNG6 
CADM1 
CALCR 
CALML3 
CAV1 
CAV2 
CCL2 
CDC2 
CDC42EP4 
CDH16 
CDK3 
CEBPB 
CFTR 
CG030 
CH25H 
CHD1 
CRAT 
CSTA 
CTDSPL 
CTGF 
CTTNBP2 
CTXN2 
CYP1A1 
CYP1A2 
DAPK2 
DBP 
DBT 
DCLK1 
DDX18 
DIAPH2 
DKK1 
DTNA 
DUSP4 
DYNC2LI1 
DYRK2 
EDAR 
EFEMP1 
EGR3 
ELL2 
ENAH 
ENPP2 
ERBB4 
ERG 
ETS2 
F13A1 
FAM117A 
FAM13A 
FAS 
FHL2
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FLJ32063 
FLJ44054 
FLRT2 
FOS 
FOXP2 
FRAT1 
FST 
GAB3 
GADD45A 
GALK2 
GAS6 
GDF9 
GEM 
GLRB 
GPC5 
GREB1 
GULP1 
H19 
HAPLN1 
HBA1 
HBA2 
HBBP1 
HBM 
HES4 
HEY2 
HHLA3 
HILS1 
HIST1H1D 
HIST1H2AB 
HIST1H2AL 
HMGA2 
HMSD 
HOXA1 
HOXA3 
IGF1 
IGF1R 
IGF2 
IGF2AS 
IGFBP5 
IL1R1 
IL5 
INPP4A 
IRF1 
ITGA6 
ITK 
KIAA0776 
KIR2DL1 
KIR3DX1 
KLF9 
KRT81 
KRT86 
LOC100188949 
LOC26010 
LOC441108 
LSP1 
MANEA 
MARCKS 
MBOAT7 
MCAM 
MCFD2 
MDFI 
MDFIC 
MET 
MMP1 
MMP26 
MPP1 
MT1DP 
MT1F 
MYB 
MYCN 
MYCNOS 
MYEF2 
MYO1F 
NCOA2 
NKX2-1 
NR0B1 
NR5A2 
NRAP 
ODAM 
OR51A7 
OR51B2 
OR51B5 
OR51F1 
OR51Q1 
OR51T1 
OR51V1 
OR52R1 
OR56B1 
OSBPL1A 
PBX1 
PCM1 
PDE6A 
PDZD2 
PEG10 
PERP 
PFTK1 
PGC 
PLA2G16 
PPAP2B 
PPP2R4 
PRKAG2 
PRL 
PROM1 
PTGER3 
PTPN21 
PTPRK 
RABL5 
RAPGEF5 
RET 
RFPL3S 
RHO 
RICH2 
RND3 
RXRA 
SATB1 
SATB2 
SAV1 
SCGB1D2 
SCN1A 
SEC1 
SERPINB2 
SGCE 
SIRT1 
SLC22A5 
SLC2A2 
SLC35A3 
SLC38A6 
SLCO4C1 
SOBP 
SOX4 
ST6GALNAC4 
STEAP2 
STMN4 
SULT1E1 
SYTL2 
TARP 
TFAP2A 
TFDP1 
TFF1 
THBS1 
TIMP3 
TMEM71 
TMPRSS3 
TNC 
TNFRSF11B 
TNFSF10 
TRAF1 
TRIM34 
TRIM6 
TRMT5 
TRPM8 
TSC22D3 
TSEN34 
TTLL7 
UBASH3A 
UBE2B 
UCP2 
UGT1A1 
UGT2B15 
UGT8 
UPF1 
UQCRQ 
UTRN 
VEGFA 
VPS41 
WFS1 
WNT2 
ZC3H14 
ZIC1 
ZIC4 
ZNF238 
ZNF711 
ZNF804A
 
 
(iii) macroH2A1- and PELP1-bound Genes 
 
ACADL 
ACSL6 
ACTB 
ADAM2 
ADAMTS9 
ADIPOQ 
ARAP2 
AREG 
ARHGAP18 
ARHGAP26 
ARL14 
ASB13 
ASCL1 
ASPH 
ASZ1 
ATL2 
BCAS1 
BCL6 
BMP4 
BMPER 
BUB1 
C22orf42 
CACNG6 
CADM1 
CALCR 
CALML3 
CAV1 
CAV2 
CCL2 
CDC2 
CDC42EP4 
CDH16 
CEBPB 
CFTR 
CH25H 
CRAT 
CSTA 
CTDSPL 
CTGF 
CTTNBP2 
CTXN2 
CYP1A1 
CYP1A2 
DAPK2 
DBP 
DCLK1 
DDX18 
DIAPH2 
DKK1 
DUSP4 
DYNC2LI1 
DYRK2 
EDAR 
EFEMP1 
EGR3 
ELL2 
ENAH 
ENPP2 
ERBB4 
ERG 
ETS2 
F13A1 
FAM117A 
FAM13A 
FAS 
FHL2 
FLJ32063 
FLJ44054 
FLRT2 
FOS 
FOXP2 
FST 
GAB3 
GADD45A 
GAS6 
GEM 
GLRB 
GPC5 
GREB1 
GULP1 
H19 
HAPLN1 
HBA1 
HBA2 
HBM 
HEY2 
HILS1 
HIST1H1D 
HIST1H2AB 
HIST1H2AL 
HMGA2 
HMSD 
HOXA1 
HOXA3 
IGF1 
IGF2 
IGF2AS 
IGFBP5 
IL1R1 
IRF1 
ITGA6 
ITK 
KIR2DL1 
KIR3DX1 
KLF9 
KRT81 
KRT86 
LOC100188949 
LOC26010 
LOC441108 
LSP1 
MBOAT7 
MCAM 
MDFI 
MDFIC 
MET 
MMP1 
MPP1 
MT1DP 
MT1F 
MYB 
MYCN 
MYCNOS 
MYEF2 
MYO1F 
NKX2-1 
NR5A2 
NRAP 
ODAM 
OR51Q1 
OR51T1 
OR56B1 
OSBPL1A 
PBX1 
PDE6A 
PDZD2 
PEG10 
PERP 
PFTK1 
PGC 
PPAP2B 
PPP2R4 
PRKAG2 
PRL
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PROM1 
PTGER3 
PTPN21 
PTPRK 
RAPGEF5 
RET 
RFPL3S 
RHO 
RICH2 
RND3 
SATB1 
SATB2 
SAV1 
SCGB1D2 
SCN1A 
SEC1 
SERPINB2 
SGCE 
SIRT1 
SLCO4C1 
SOBP 
SOX4 
ST6GALNAC4 
STEAP2 
STMN4 
SULT1E1 
TARP 
TFAP2A 
TFF1 
THBS1 
TIMP3 
TMEM71 
TMPRSS3 
TNC 
TNFRSF11B 
TNFSF10 
TRAF1 
TRIM34 
TRIM6 
TRPM8 
TSC22D3 
TSEN34 
TTLL7 
UBASH3A 
UGT1A1 
GT2B15 
UGT8 
UTRN 
VEGFA 
WFS1 
WNT2 
ZC3H14 
ZIC1 
ZIC4 
ZNF711 
ZNF804A
 
 
(iv) macroH2A1-bound and PELP1-unbound Genes (no GO terms) 
 
AADAT 
ABHD6 
ACCN4 
ACTA2 
ADAMTSL1 
ADAMTSL3 
ADRB1 
ADRBK1 
ADSSL1 
ALDH5A1 
AMIGO2 
AMMECR1 
AMOTL2 
ANKRD43 
ANKRD55 
ANXA3 
APOA1 
APOA4 
APOA5 
APOC3 
ARHGDIG 
ARL4A 
ATF7IP 
AVPR2 
B3GAT2 
BCAT1 
BIRC5 
BPIL2 
BRAF 
BTG2 
C11orf21 
C11orf9 
C13orf18 
C14orf23 
C16orf38 
C1orf107 
C20orf118 
C21orf54 
C3 
C3orf54 
C5orf13 
C5orf35 
C8orf74 
CACNA1G 
CACNG7 
CALD1 
CALML5 
CAMK2N1 
CAPN9 
CAPZA2 
CBFA2T3 
CCBP2 
CCNI2 
CD209 
CDC2 
CDH2 
CDH29 
CDH5 
CDKN2C 
CEACAM4 
CEACAM6 
CEP55 
CERK 
CHAC1 
CIDEC 
CKMT1A 
CKMT1B 
CLEC10A 
CLEC11A 
CLEC4M 
CSGALNACT1 
CST5 
CTAG1A 
CTAG2 
CTSD 
CXADR 
CXCL12 
CXCR4 
CXCR7 
CYB561 
DEGS1 
DES 
DHRS3 
DIRAS1 
DKC1 
DKFZP434K028 
DLL4 
DNAJB3 
DNASE1L3 
DUSP1 
DUSP3 
EGFR 
EIF6 
EMD 
ENC1 
EPHB2 
EPN3 
ESR2 
EVX1 
F10 
F2RL1 
F7 
FBN2 
FCGR2B 
FER1L4 
FGF1 
FGFR2 
FLJ43752 
FLNA 
FOXG1 
FOXN3 
FZD1 
FZD7 
GALNT12 
GATM 
GDF15 
GDF5 
GPRC5A 
GRAMD3 
GRB10 
GREB1 
GRM1 
GRM8 
GTF2A1 
H1FNT 
H1FOO 
HBE1 
HBP1 
HBZ 
HCCA2 
HIGD1A 
HISPPD2A 
HIST1H1C 
HIST1H1E 
HIST1H3B 
HIST1H3I 
HIST1H4B 
HIST1H4F 
HIST1H4L 
HOXA10 
HOXA11 
HOXA11AS 
HOXA13 
HOXA2 
HOXA3 
HOXA4 
HOXA5 
HOXA6 
HOXA7 
HOXA9 
IGF2 
IGFBP4 
IL13 
IL24 
INPP5J 
INS-IGF2 
IQGAP1 
IRX5 
ISL1 
ITGB3 
ITGB4 
ITPR2 
KCNK1 
KCNK5 
KCNN2 
KIAA1026 
KIR2DL3 
KIR2DL4 
KIR3DL1 
KIR3DL3 
KIR3DP1 
KLC3 
KLF4 
KLF6 
KREMEN2 
KRT13 
KRT222P 
KRTAP5-2 
L1CAM 
LACE1 
LAD1 
LAIR1 
LAIR2 
LEFTY1 
LHX2 
LILRA1 
LILRA2 
LILRA3 
LILRA4 
LILRA5 
LILRA6 
LILRB1 
LILRB2 
LILRB3 
LILRB4 
LILRB5 
LILRP2 
LOC284067 
LOC441864 
LOC91149 
LRIG1 
LRRC15 
LRRK2 
LTF 
LUZP2 
MAP2K6 
MAP3K1 
MAPK11 
MAPK12 
MBNL2 
MCF2L 
MCM3 
MCTP2 
MEGF8 
METTL9 
MGAT3 
MICB 
MIER3 
MMP2 
MN1 
MPPED2 
MSL3L2 
MSLN 
MT1A 
MT1B 
MT1M 
MTSS1 
MYLK 
MYOT 
NACC2 
NCKAP1 
NCR2 
NDP 
NEK1 
NELL2 
NFAT5 
NFKBIE 
NISCH 
NMU 
NOX3 
NPY5R 
NR2E1 
NR4A1 
NRXN2 
NTM 
OLIG1 
OLIG2 
OPN1LW 
OR51A4 
OR52N4 
OVGP1 
PADI2 
PALMD 
PAPSS2 
PAQR4 
PARP1 
PARP12 
PCDH7
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PDE4DIP 
PDLIM4 
PDLIM5 
PI4KB 
PICALM 
PIK3IP1 
PKIA 
PLAC1 
PLBD1 
PLCL1 
PLCL2 
PNRC1 
PPARG 
PPFIBP2 
PPP2R1B 
PPP2R2B 
PPP2R3A 
PRDX2 
PRKCA 
PRKCG 
PROM1 
PRSS23 
PRX 
PVALB 
RAB28 
RAB9A 
RAMP3 
RAPGEF4 
RARG 
RASGRP1 
RASGRP2 
REEP1 
RFPL2 
RGS10 
RNASEH2A 
RNF43 
RP1L1 
RPL39L 
RPRM 
RPSAP52 
S100A10 
S1PR1 
SAMD3 
SEC14L2 
SELENBP1 
SEMA3G 
SEMA4G 
SENP7 
SERPINA1 
SERPINB9 
SGCA 
SGK1 
SGK3 
SHANK1 
SHROOM1 
SIVA1 
SIX2 
SLC22A11 
SLC22A12 
SLC26A2 
SLC2A13 
SLC5A4 
SNX24 
SOCS2 
SOX1 
SOX9 
SPEG 
SPP2 
SPSB1 
ST7 
ST7OT1 
ST7OT4 
STATH 
STC1 
TEAP1 
STEAP2 
STK3 
STXBP1 
SYN2 
SYN3 
SYT8 
TACC1 
TAL1 
TBKBP1 
TBX3 
TES 
TFAP2A 
TFB1M 
TFEB 
TFF3 
TFPI 
TGFBR2 
TGFBR3 
TGM2 
TGM3 
TH 
THOC2 
TMEM145 
TMEM151B 
TMOD3 
TMPRSS2 
TMPRSS3 
TMSB15A 
TNNC1 
TNNI2 
TNNT3 
TP53BP1 
TRIB2 
TRIM22 
TRIM34 
TRIM5 
TRIM6 
TRIM6-TRIM34 
TSPAN32 
TSPAN5 
TTYH1 
UBAC1 
UBE2D1 
UGT1A3 
UGT1A4 
UGT1A6 
UGT1A7 
UGT1A9 
UGT8 
VTCN1 
WDR44 
WISP2 
WWC1 
YAP1 
ZCCHC24 
ZMYND10 
ZNF259 
ZNF462 
ZSCAN2
 
 
(v) PELP1-bound and macroH2A1-unbound Genes (no GO terms) 
 
ABCC4 
AGPAT3 
ANKRD13C 
APH1B 
ATP11B 
AXIN1 
BBS1 
BCL2A1 
BRIP1 
C10orf84 
C21orf49 
C21orf66 
C6orf221 
CDK3 
CG030 
CHD 
DBT 
DTNA 
FRAT1 
GALK2 
GDF9 
HBBP1 
HES4 
HHLA3 
IGF1R 
IL5 
INPP4A 
KIAA0776 
MANEA 
MARCKS 
MCFD2 
MMP26 
NCOA2 
NR0B1 
OR51A7 
OR51B2 
OR51B5 
OR51F1 
OR51V1 
OR52R1 
PCM1 
PLA2G16 
RABL5 
RXRA 
SLC22A5 
SLC2A2 
SLC35A3 
SLC38A6 
SYTL2 
TFDP1 
TRMT5 
UBE2B 
UCP2 
UPF1 
UQCRQ 
VPS41 
ZNF238
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4.5C), e.g. histone 3 lysine 9 trimethylation (H3K9me3), while negatively correlating 
with active transcription marks and factors. 
Overall, these analyses demonstrate that PELP1 and macroH2A1 have a highly 
similar pattern of genomic occupancy.  While bound to a subset of macroH2A1-
containing regions, PELP1 genomic association correlates with gene expression, 
histone marks, and functional classes of genes in a manner that is highly similar to that 
of macroH2A1.  Taken together, the results from our biochemical GST pull-down and 
genomic ChIP-chip analyses indicate that PELP1 and macroH2A1 interact with each 
other and co-localize across the genome of MCF-7 cells.   
 
PELP1 is recruited to the genome by macroH2A1, but macroH2A1 deposition is 
independent of PELP1.  The high degree of coincidence between macroH2A1 and 
PELP1 genomic occupancy led us to explore the hypothesis that macroH2A1 
functions in recruiting PELP1 to the genome.  In order to determine the effect of 
macroH2A1 knockdown on the localization of PELP1, we took advantage of the 
shRNA-mediated stable macroH2A1 knockdown cell line described previously 
(Gamble et al., 2010).  MacroH2A1 knockdown did not alter the overall levels of 
PELP1 in MCF-7 cells (Figure 4.6A) compared to the luciferase (Luc) knockdown 
control.  For our ChIP assays, we focused on gene promoters previously shown to 
contain and be regulated by macroH2A1 (Gamble et al., 2010).  At these promoters, 
knockdown of macroH2A1 significantly decreased macroH2A1 levels, as would be 
expected (Figure 4.6B).  We were able to confirm the occupancy of PELP1 at these 
gene promoters, as predicted from the ChIP-chip data.  Interestingly, at all regions 
tested, we observed that PELP1 genomic occupancy decreased upon macroH2A1 
knockdown (Figure 4.6C), a finding independent of nucleosome loss (Figure 4.7), 
suggesting that macroH2A1 is required to recruit PELP1 to chromatin.  
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Figure 4.5.  PELP1 occupancy correlates with heterochromatic chromatin marks 
and negatively correlates with active chromatin marks.  A, Volcano plot of 
Spearman’s correlation coefficients for the PELP1 ChIP-chip data with each of 362 
ChIP-chip data sets versus the corresponding significance score (-Log2 P-value).  The 
grey box depicts those data sets that positively or negatively correlate with PELP1 
occupancy using a correlation coefficient of ±0.20 and P-value of < 10-100 as cutoffs of 
significance.  B and C, Average Log2 ratios (IP/Input) in PELP1-bound (black bars) or 
unbound (grey bars) regions for the factors correlating positively or negatively with 
both PELP1 and macroH2A1 (B) or with PELP1 only (C).  The corresponding data for 
macroH2A1 is shown for comparison (right).  The correlating factor and cell line 
source are listed.  mH2A1, macroH2A1. 
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Figure 4.6.  PELP1 is recruited to gene promoters by macroH2A1.  A, Western 
blot showing the shRNA-mediated depletion of macroH2A1 in MCF-7 cells compared 
to luciferase (Luc) knockdown cells.  Total cellular levels of PELP1 is unaffected by 
macroH2A1 knockdown.  β-actin and histone H3 were also analyzed as loading 
controls.  B and C, MacroH2A1 and PELP1 occupancy is reduced upon macroH2A1 
depletion at gene promoters.  The occupancy of macroH2A1 (B) and PELP1 (C) was 
examined by ChIP analyses in the Luc (black bars) and macroH2A1 (white bars) 
knockdown cell lines.  Each bar represents the mean + SEM (error bars) from three or 
more independent determinations.  All changes in occupancy for macroH2A1 (B) and 
PELP1 (C) upon macroH2A1 knockdown are statistically different then the control 
cell line, as determined by a Student’s t-test with a P-value threshold of < 0.05.  Luc, 
luciferase; mH2A1, macroH2A1; KD, knockdown. 
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Figure 4.7.  Reductions in both mH2A1 and PELP1 upon mH2A1 depletion is not 
due to loss of nucleosomes.  The occupancy of histone H3 was examined by ChIP 
analyses in the Luc (black solid bars) and mH2A1 (black striped bars) knockdown 
cell lines.  Each bar represents the mean + SEM (error bars) from two independent 
determinations.  All changes in occupancy for H3 are not statistically different then 
the control cell line, as determined by a Student’s t-test with a P-value threshold of < 
0.05.  Luc, luciferase; mH2A1, macroH2A1; KD, knockdown. 
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To determine whether macroH2A1 deposition was reciprocally dependent on 
PELP1, we used an analogous set of experiments.  We developed a PELP1 
knockdown cell line in MCF-7 cells to compare macroH2A1 promoter occupancy in 
control versus PELP1 knockdown.  Our initial attempts to create a stable cell line 
using shRNA-mediated knockdown of PELP1, much like that shown above for 
macroH2A1, were unsuccessful, as PELP1 expression reverted to wild type levels 
after only a couple of passages (data not shown).  In an alternative approach, we 
developed a “Tet-on” inducible knockdown system where treatment of doxycycline 
induced the expression of shRNA in MCF-7 cells via a Tet-responsive promoter.  
Using this system, we created MCF-7 cells stably expressing both the Tet Repressor 
(TetR) and either a doxycycline (dox) responsive Luc or PELP1 shRNA. 
The resulting inducible knockdown cell lines, Luci and PELP1i, were treated 
with or without dox (see Experimental Procedures) and tested for cellular PELP1 
levels by Western blot analysis.  As expected, dox treatment induced shRNA 
expression, leading to a decrease in PELP1 mRNA levels and PELP1 protein by ~80% 
compared to the Luc control (Figure 4.8A and Figure 4.9).  Notably, PELP1 
knockdown did not have an effect on total cellular levels of macroH2A1 (Figure 4.8A 
and Figure 4.9).  We performed ChIP assays at the same promoter regions using our 
inducible knockdown cell lines to determine if macroH2A1 localization was altered in 
response to PELP1 depletion.  Upon PELP1 knockdown, macroH2A1 recruitment 
remained constant, even though PELP1 levels at the promoters were significantly 
reduced (Figure 4.8B and 4.8C).  These results demonstrate that while macroH2A1 
deposition into nucleosomes occurs independent of PELP1 recruitment, it is necessary 
in order to recruit PELP1 to the chromatin.  
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Figure 4.8.  macroH2A1 deposition is independent of PELP1.  A, Western blot 
showing the doxycycline-inducible shRNA-mediated depletion of PELP1 in MCF-7 
cells compared to luciferase (Luc) knockdown cells.  Cellular levels of macroH2A1 is 
unaffected by PELP1 knockdown.  β-actin and histone H3 were also analyzed as 
loading controls.  Only the + dox condition (those marked with an asterisk; *) for Luci 
and PELP1i was analyzed for gene-specific experiments.  B and C, MacroH2A1 
occupancy is unaffected by PELP1 depletion at gene promoters.  The occupancy of 
macroH2A1 (B) and PELP1 (C) was examined by ChIP analyses in the Luci (dark 
grey bars) and PELP1i (light grey bars) inducible knockdown cell lines.  Each bar 
represents the mean + SEM (error bars) from three or more independent 
determinations.  All changes in occupancy for PELP1 (C) upon PELP1 knockdown are 
statistically different then the control cell line, as determined by a Student’s t-test with 
a P-value threshold of < 0.05.  Luc, luciferase; mH2A1, macroH2A1; KD, knockdown; 
dox, doxycycline; i, inducible. 
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Figure 4.9.  Comparison of two independent shRNA target sequences for the 
inducible knockdown of PELP1.  A, Knockdown of PELP1 by two independent 
shRNA target sequences.  Whole cell lysates or acid extracted pellets (for mH2A1, 
e.g.) were collected from doxycycline-treated Luci or PELP1i stable shRNA-mediated 
knockdown cell lines.  Two independent shRNA sequences (#1 and #2) targeting 
PELP1 were analyzed by Western blotting for their ability to knockdown PELP1 
relative to the Luc control.  PARP-1 and β-actin were also analyzed as loading 
controls.  B, RT-qPCR analysis confirms the knockdown of PELP1 mRNA in the 
knockdown cell lines described in (A).  Total RNA was isolated from Luci and PELP1i 
knockdown cells, reverse transcribed, and subjected to RT-qPCR using gene-specific 
primers to PELP1.  Each bar is the mean + SEM (error bars) for three independent 
RNA isolations.  C, Comparable effects on gene expression for each PELP1i shRNA 
sequence.  Total RNA was isolated from Luci and PELP1i knockdown cells, reverse 
transcribed, and subjected to RT-qPCR using gene-specific primers.  The effect of 
each knockdown (PELP1 shRNA #1 or PELP1 shRNA#2) was compared for a subset 
of target genes identified in Fig. 5.  Each bar represents the mean + SEM (error bars) 
from three or more independent determinations.  D, A correlation analysis comparing 
the effects of PELP1 shRNA #1 and PELP1 shRNA #2 at 22 genes indicates that both 
shRNAs produce similar effects on gene expression.  The Spearman correlation 
coefficient (c.c.) and P-value are indicated.  For all other experiments, only shRNA #2 
was used.  Luc, luciferase. 
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Figure 4.10.  PELP1 knockdown alters the mRNA levels of a subset of 
macroH2A1-regulated genes in a similar manner to macroH2A1.  Previously 
identified macroH2A1-regulated genes (Gamble et al., 2010) were analyzed for 
changes in mRNA levels upon PELP1i knockdown (grey bars).  Total RNA from Luci 
or PELP1i knockdown cells (+ dox) was isolated, reverse-transcribed, and subjected to 
qPCR using gene-specific primers.  The effect of macroH2A1 knockdown (from 
Gamble et al (Gamble et al., 2010), black bars) is shown for comparison.  Each bar 
represents the mean + SEM (error bars) from three or more independent 
determinations.  Bars marked with an asterisk are statistically different from the 
luciferase knockdown control, as determined by a Student’s t-test with at P-value 
threshold of < 0.05.  mH2A1, macroH2A1. 
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PELP1 regulates a subset of macroH2A1-regulated genes in a similar manner to 
macroH2A1 in both basal and signal-regulated transcription.  Thus far, our results 
demonstrate that macroH2A1 interacts with PELP1 and is responsible for the 
recruitment of PELP1 to target gene promoters.  We hypothesized that these genes, 
previously shown to be regulated by macroH2A1 (Gamble et al., 2010), would also be 
regulated by PELP1.  We examined the expression levels of macroH2A1-regulated 
genes in Luci and PELP1i knockdown cell lines by RT-qPCR.  Our analyses show that 
PELP1 knockdown alters the expression levels of a subset of macroH2A1-regulated 
genes (Figure 4.10).  Interestingly, the direction of regulation is similar to that of 
macroH2A1 knockdown, which is shown for comparison (data from Gamble et al 
(Gamble et al., 2010)).  This result suggests that both macroH2A1 and PELP1 are 
required for proper expression of a subset of genes. 
 We previously reported that macroH2A1 could also participate in signal-
regulated transcription.  As a model, we investigated both serum starvation and TPA 
signaling systems and showed that macroH2A1 can function both positively and 
negatively in regulated signal-induced transcription (Gamble et al., 2010; Gamble and 
Kraus, 2010).  Specifically, macroH2A1 potentiates the response of serum starvation-
induced genes found in macroH2A1 domains.  Additionally, macroH2A1 abrogates 
the expression of TPA-responsive genes found in these domains.  We asked whether 
PELP1 could modulate transcription in the same signaling pathways.  To test this, we 
considered TPA- or serum starvation-induced genes whose expression pattern was 
altered upon macroH2A1 knockdown (Figure 4.11A and Figure 4.12).  We assayed 
the mRNA levels of these genes upon Luci and PELP1i knockdown.  PELP1 
involvement in signal-regulated transcription was limited to a subset of genes, as 
shown under resting conditions.  For example, knockdown of PELP1 further enhanced 
the expression of the TPA-induced CCL2 gene similarly to macroH2A1 knockdown, 
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Figure 4.11.  PELP1 acts to repress the transcriptional induction of the TPA-
responsive gene, CCL2.  A, macroH2A1 and PELP1 knockdown results in further 
induction of the TPA-responsive gene, CCL2.  Luc and macroH2A1 knockdown cells 
and Luci and PELP1i knockdown cells (+ dox) were treated with vehicle (–) or 100 
nM TPA (+) for 3 hrs.  Total RNA was isolated, reverse-transcribed, and subjected to 
qPCR using gene-specific primers.  AREG is shown as a control, as it is only 
modulated by macroH2A1.  Each bar represents the mean + SEM (error bars) from 
three or more independent determinations.  Bars marked with an asterisk are 
statistically different from the corresponding luciferase knockdown control (Luc, in 
the case of macroH2A1; Luci in the case of PELP1i), as determined by a Student’s t-
test with at P-value threshold of < 0.05.  The Luc and macroH2A1 knockdown data 
for AREG is taken from Gamble and Kraus (Gamble et al., 2010).  B, macroH2A1 and 
PELP1 occupancy are reduced downstream of the CCL2 TSS upon TPA treatment.  
MacroH2A1 and PELP1 ChIP assays were performed from parental MCF-7 cells were 
treated with vehicle (–) or 100 nM TPA (+) for 1.5 hrs.  Primers were designed to 
regions upstream and downstream of the TSS.  Each bar represents the mean + SEM 
(error bars) from three or more independent determinations.  Bars marked with an 
asterisk are statistically different from the vehicle treated control, as determined by a 
Student’s t-test with at P-value threshold of < 0.05.  The macroH2A1 ChIP data for 
AREG is taken from Gamble and Kraus (Gamble and Kraus, 2010).  Luc, luciferase; 
mH2A1, macroH2A1; i, inducible; U, upstream of the TSS; D, downstream of the TSS. 
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Figure 4.12.  PELP1 acts to potentiate the transcriptional induction of the serum 
starvation-responsive gene, SOCS2.  A, macroH2A1 and PELP1 knockdown 
represses the induction of the serum starvation-responsive gene, SOCS2.  Luc and 
macroH2A1 knockdown cells and Luci and PELP1i knockdown cells (+ dox) were 
cultured with serum (+) or serum deprivation (–) for 24 hrs.  Total RNA was isolated, 
reverse-transcribed, and subjected to qPCR using gene-specific primers.  ASCL1 is 
shown as a control, as it is only modulated by macroH2A1.  Each bar represents the 
mean + SEM (error bars) from three or more independent determinations.  Bars 
marked with an asterisk are statistically different from the corresponding luciferase 
knockdown control (Luc, in the case of macroH2A1; Luci in the case of PELP1i), as 
determined by a Student’s t-test with at P-value threshold of < 0.05.  The Luc and 
macroH2A1 knockdown data for SOCS2 and ASCL1 is taken from Gamble et al 
(Gamble et al., 2010).  B, macroH2A1 and PELP1 occupancy are unaltered at the 
promoters of serum starvation-responsive genes.  MacroH2A1 and PELP1 ChIP 
assays were performed from parental MCF-7 cells were cultured with serum (+) or 
serum deprivation (–) for 24 hrs.  Primers were designed to regions upstream and 
downstream of the TSS.  Each bar represents the mean + SEM (error bars) from three 
or more independent determinations.  The macroH2A1 ChIP data for SOCS2 and 
ASCL1 is taken from Gamble et al (Gamble et al., 2010).  Luc, luciferase; mH2A1, 
macroH2A1; i, inducible; U, upstream of the TSS; D, downstream of the TSS. 
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Figure 4.13.  TPA and serum starvation does not cause loss of nucleosomes at 
target gene promoters.  A and B, An H3 ChIP was performed from parental MCF-7 
cells treated with vehicle (–) or 100 nM TPA (+) for 1.5 hrs (A), or with 0% serum (–) 
for 24 hours (B).  Primers were designed to regions upstream and downstream of the 
TSS.  Each bar represents the mean + SEM (error bars) from three or more 
independent determinations.  U, upstream of the TSS; D, downstream of the TSS. 
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but had no effect on AREG expression (Figure 4.11A).  In addition, like macroH2A1, 
PELP1 occupancy upon TPA treatment is reduced downstream of the TSS at the 
CCL2 promoter (Figure 4.11B, (Gamble and Kraus, 2010)), but not at the AREG 
promoter.  This result is not due to nucleosome loss, as H3 levels remain constant 
(Figure 4.13A).  In the case of serum starvation, PELP1 acts similarly to macroH2A1 
at the SOCS2 promoter but not at the ASCL1 promoter, although the effects were less 
striking (Figure 4.12 and 4.13B, (Gamble et al., 2010).  Taken together, these results 
demonstrate that PELP1 modulates a subset of macroH2A1-regulated genes in a 
manner similar to macroH2A1 in both basal and signal-regulated systems. 
 
4.4.  Discussion 
 
The histone variant macroH2A1 can both positively and negatively regulate target 
genes within macroH2A1-containing chromatin in a context-specific manner 
(Agelopoulos and Thanos, 2006; Buschbeck et al., 2009; Changolkar et al., 2007; 
Gamble et al., 2010; Gamble and Kraus, 2010).  However, the mechanism(s) by which 
macroH2A1 regulates the expression of its target genes has yet to be fully elucidated.  
As the distinguishing feature of macroH2A1, the large C-terminal globular macro 
domain plays a key role in determining the specific context in which an underlying 
gene will be modulated through specific recruitment and physical interaction of 
effector proteins.  Here, we identify a chromatin-associated transcriptional 
coregulator, PELP1, as a novel interacting protein of the macro domain of 
macroH2A1. Collectively, our biochemical, genomic, and gene-specific analyses 
suggest that macroH2A1 specifically recruits PELP1 to the genome and together, 
cooperatively regulates of a subset of macroH2A1 target genes. 
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The macro domain of macroH2A1 interacts with chromatin-associated and 
nucleolar components.  Our GST-pull down assay identified a host of novel macro 
domain-interacting factors that can be classified into two categories:  those that are 
chromatin-associated and those that are nucleolar components (Figure 4.1 and Figure 
4.2 and Table 4.1).  The chromatin-associated factors (PELP1, PARP-1, WDR18, and 
SET) are involved in cellular processes such as transcription and chromatin 
maintenance, while the nucleolar components (TCOF1, NCL, NPM1, MDN1, 
DDX46, TEX10, and Nol9) are generally involved in transcription, ribosome 
biogenesis/export, protein chaperoning, and RNA processing.  The identification of 
these proteins fits well with emerging evidence that macroH2A1 is involved in 
regulating autosomal genes, as many of these proteins are known to function in 
various aspects of transcriptional control.  It is interesting to note that PELP1 and 
PARP-1 have also been shown to interact with proteins of the same family as those we 
identified interacting with the macro domain of macroH2A1.  For example, PELP1 
can interact with WDR5 as part of the MLL1 complex (Dou et al., 2005; Kashiwaya et 
al., 2010) or members of the DEAD-box RNA helicase and AAA ATPase family 
members (Andersen et al., 2002), which are involved in RNA processing.  
Additionally, PARP-1 has been shown to interact with nucleolar proteins and 
transcriptional coregulators (nucleolin and nucleophosmin) in a number of contexts 
(Fu and Fenselau, 2005; Isabelle et al., 2010; Meder et al., 2005). 
Macro domains have recently been identified as ligand binding domains for 
NAD+ metabolites such as PAR, ADPR, and O-acetyl-ADPR (Ahel et al., 2009; 
Gottschalk et al., 2009; Karras et al., 2005; Kraus, 2009; Kustatscher et al., 2005; 
Timinszky et al., 2009).  This action may change (i) the affinity of macro domain-
interacting proteins or (ii) the recruitment of factors containing these domains to 
genomic sites of PAR accumulation (Ahel et al., 2009; Gottschalk et al., 2009; 
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Timinszky et al., 2009).  While PARP-1 has previously been shown to associate with 
the macro domain of macroH2A1 in a manner dependent on macroH2A1’s ability to 
bind NAD+ metabolite ligands (i.e., ADPR), we determined that the interaction with 
PELP1 is independent of ADPR binding (Figure 4.1C).  This begs the question:  what 
modulates the interaction of PELP1 with the macro domain of macroH2A1?  In 
addition, this finding brings up an interesting question of whether or not PELP1 
interacts with other macro domain-containing proteins, and whether those interactions 
are ligand-dependent or mediated by the non-macro domain regions of the protein.  
Interestingly, both PELP1 and macroH2A1 are subject to a variety of post-
translational modifications (Abbott et al., 2005; Bernstein et al., 2008; Chu et al., 
2006; Kashiwaya et al., 2010; Nagpal et al., 2008; Rosendorff et al., 2006), which may 
modulate the ability of these factors to interact.  Further studies are required to 
determine the mechanisms that regulate these interactions.  
  
PELP1 is a reader of the “histone code” and the “histone variant code”.  In a 
process termed the “histone code”, specific combinations of covalent modifications of 
the histone tails of nucleosomes specify positive or negative gene expression outcomes 
(Jenuwein and Allis, 2001).  These histone modifications exert their effects by 
recruiting transcriptional coregulators that can “read” these marks.  PELP1 has 
recently been shown to be a reader of the histone code, where it specifically 
recognizes both H3K9me2 and H3K4me2 (Nair et al., 2010).  Furthermore, PELP1 
can also recruit additional chromatin modifying enzymes to the sites where it is found.  
For example, PELP1 has been shown to recruit KDM1 (lysine demethylase 1) and 
HDAC2 to nucleosomes (Choi et al., 2004; Nair et al., 2010).  We show that PELP1-
bound regions correlate with the linker histone H1, the histone modifications 
H3K27me3 and H3K9me3, and repressive transcription factors E2F6 and ZNF217 
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(Figure 4.5), all of which are known to generally mark heterochromatic chromatin 
and/or participate in the repression of gene expression (Banck et al., 2009; Reid et al., 
2009; Trimarchi and Lees, 2002).  Interestingly, E2F6 can act to recruit chromatin-
remodeling and protein complexes that harbor histone 3 methyltransferase activity at 
lysine 4 and lysine 9 (Dou et al., 2005; Ogawa et al., 2002).  These findings expand 
upon the recently identified role of PELP1 as a “reader” of histone marks.  Although 
our correlation analysis does not indicate causality, it is also possible that these 
repressive transcription factors, E2F6 and ZNF217, function in recruiting PELP1 to 
the chromatin, much like the recruitment of histone modifying enzymes. 
 In a corollary to the “histone code”, histone variants can also mark chromatin 
to specify positive or negative gene expression outcomes.  As for the histone code, it 
follows that specific effector proteins capable of reading the “histone variant code” are 
necessary to facilitate gene expression outcomes.  We demonstrate that PELP1 is 
broadly recruited to macroH2A1-containing chromatin across the genome.  This data 
suggests that PELP1 is not only a reader of the “histone code” but is also a reader of 
the “histone variant code”, where it specifically recognizes macroH2A1-containing 
nucleosomes.  Furthermore, given the inclination of PELP1 to interact with histone 
modifying enzymes (e.g KDM1, HDAC2, p300/CBP (Choi et al., 2004; Nair et al., 
2010; Vadlamudi et al., 2001)), it is possible that recruitment of PELP1 to 
macroH2A1-containing regions of the genome leads to further chromatin 
modifications.  Further experiments are required to determine the role of PELP1 in 
further modifying macroH2A1-containing chromatin structure. 
  
PELP1 and macroH2A1 are context-specific transcriptional coregulators.  For quite 
a while, macroH2A1 was considered a transcriptionally repressive histone mark, 
exclusively.  Recent work from our lab and others has determined that macroH2A1 
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can function as a positive or negative regulator of transcription depending on the 
specific context (Choi et al., 2004; Kayahara et al., 2008; Mishra et al., 2004; Nair et 
al., 2004; Nair et al., 2010; Singh et al., 2006; Vadlamudi et al., 2001).  While 
originally identified as a coactivator for the estrogen receptor alpha (ERα) (Vadlamudi 
et al., 2001), PELP1 is now known to function as a coactivator for several 
transcription factors including ERα, ERβ, and RXR (Mishra et al., 2004; Singh et al., 
2006; Vadlamudi et al., 2001), demonstrating that, like macroH2A1, PELP1 also 
modulates transcription in context-specific ways.  Conversely, recent studies suggest 
that PELP1 can also function as a transcriptional corepressor in concert with several 
transcription factors, including GR, AP1, NFκB, and SRF (Choi et al., 2004; Kayahara 
et al., 2008).  Therefore, PELP1 can either positively or negatively regulate gene 
expression in a context-specific fashion.  The coordinated regulation of PELP1 and 
macroH2A1 target gene expression described above demonstrates a connection 
between the determinants that specify these factors as transcriptionally permissive or 
repressive.  Specifically, at genes coregulated by macroH2A1 and PELP1, if one 
factor supports target gene expression so does the other and vice versa.  
 There is much that remains to be elucidated about the concerted roles of 
macroH2A1 and PELP1 in transcriptional regulation of target genes.  One major 
question centers on identifying the determinants that allow macroH2A1 and PELP1 to 
function as transcriptional activators and those specific for transcriptional repression.  
One possibility is that further histone modifications are required to specify direction of 
macroH2A1/PELP1-mediated transcriptional outcomes.  In addition, macroH2A1 and 
PELP1 are themselves targets of various covalent modifications (reviewed in (Nagpal 
et al., 2008; Thambirajah et al., 2009)), which may also play a role in determining the 
direction of regulation.  Alternatively, the specific transcription factors that bind near 
(or are specifically recruited to) macroH2A1/PELP1 positively and negatively 
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regulated genes may be different.  Understanding the context-specific transcriptional 
outcomes mediated by PELP1 and macroH2A1, will lead to a greater understanding of 
how particular chromatin states regulate gene expression. 
 
4.5.  Experimental Procedures 
 
Antibodies - The rabbit polyclonal PELP1 and macroH2A1 antibodies used for 
Western blotting, ChIP-chip, and ChIP-qPCR were purchased from Bethyl 
Laboratories, Inc (A300-180A) and Millipore (07-219), respectively.  The antibodies 
were screened for: (i) specificity by Western blotting MCF-7 cell extracts, (ii) the 
ability to immunoprecipitate their cognate antigens from formaldehyde crosslinked 
chromatin by a ChIP-Western protocol, and (iii) a reduction in Western blot signal 
upon knockdown of PELP1 or macroH2A1.  The rabbit polyclonal H3 antibody used 
for Western blotting, ChIP-chip, and ChIP-qPCR was purchased from Abcam 
(ab1791-100).  The custom rabbit polyclonal antibody against PARP-1 used for 
Western blotting was generated by using a purified fragment of human PARP-1 
(amino-terminal, PARP-N; Pocono Rabbit Farm and Laboratory, Inc.) and previously 
characterized (Frizzell et al., 2009; Kim et al., 2004).  The rabbit polyclonal Nucleolin 
(C-23) and SET antibodies used for Western blotting were purchased from Santa Cruz 
Biotechnology, Inc. (sc-13057 and sc-25564, respectively) and the mouse monoclonal 
β-Actin antibody was purchased from Sigma-Aldrich (A5316). 
 
Oligonucleotides - The oligonucleotide sequences listed below were used for the 
shRNA constructs.  Those sequences denoted with an asterisk (*) were chosen based 
on priority score according to criteria described at the website 
(https://rnaidesigner.invitrogen.com/rnaiexpress). 
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shRNA constructs -  
Target Sequence Source 
Luc 5’-gatatgggctgaatacaaa-3’ (Reynolds et al., 2004) 
PELP1 #1* 5’-ggagcattcagcaggtgttac-3’ Invitrogen BLOCK-iT RNAi Designer 
PELP1 #2 5’-ggaccaaggtgtatgcgatat-3’  (Dimple et al., 2008) 
mH2A1 #1 5’-gcaatgcagcgagagacaaca-3’  (Gamble et al., 2010) 
mH2A1 #2 5’-gcgtgtgttgtggtgctttat-3’ (Gamble et al., 2010) 
 
GST-macro1.1 pull-down and Protein Identification - The GST-macro1.1 vector was 
made by cloning the non-histone region of macroH2A1.1 (e.g. amino acids 123 to 
368) into pGEX-2TK.  The vector was induced in BL21(DE3) and the protein was 
purified using glutathione-agarose.  GST alone or GST-macro1.1 (2 !g) was pre-
bound to 15 ul of glutathione-agarose in a 150 !l final volume of buffer containing 20 
mM Tris pH 7.5, 0.1 M NaCl, 0.1 mM EDTA, 5% glycerol, 0.1% Tween-20.  After 30 
min of pre-binding, the beads were washed three times with the same buffer.  The 
GST- or GST-macro1.1-bound beads were then incubated in a final volume of 150 !l 
with 250 !g of HeLa nuclear extract.  Where indicated, 20 !M of ADPR or NAD+ was 
added to the reaction.  The binding reactions were nutated for 2 hrs at 4oC.  The beads 
were then washed 3 times using the buffer conditions noted above.  For immunoblots 
the proteins were eluted directly with SDS and subjected to SDS-PAGE.  
For mass spectrometric identification the bound proteins were eluted with 
reduced glutathione (Sigma) and separated by SDS-PAGE.  Proteins excised from gels 
were digested with trypsin, and resulting peptide pools analyzed by matrix-assisted 
laser-desorption / ionization reflectron time-of-flight (MALDI-reTOF) MS using a 
BRUKER UltraFlex TOF/TOF instrument (Bruker Daltonics; Bremen, Germany) 
 311 
(Erdjument-Bromage et al., 1998; Sebastiaan Winkler et al., 2002).  Selected 
experimental masses (m/z) were taken to search the human segment of a non-
redundant protein database (‘NR’ on April 8th 2010; ~233,131 entries; National Center 
for Biotechnology Information; Bethesda, MD), utilizing the Mascot Peptide Mass 
Fingerprint (PMF) program, version 2.3.01 for Windows (www.matrixscience.com), 
with a mass accuracy restriction better than 40 ppm, and maximum one missed 
cleavage site allowed per peptide.  To confirm PMF results with scores <40, mass 
spectrometric sequencing of selected peptides was done by MALDI-TOF/TOF 
(MS/MS) analysis on the same prepared samples, using the UltraFlex instrument in 
‘LIFT’ mode.  Fragment ion spectra were taken to search NR using the Mascot 
MS/MS Ion Search program (Matrix Science, www.matrixscience.com). 
 
Luci and PELP1i inducible knockdown constructs - For the “Tet-on” inducible 
knockdown constructs (Luci and PELP1i), the pSUPER.retro vector (puromycin 
resistant) was first modified by replacing the H1 promoter with one harboring a Tet 
operator sequence (from the pTER+ modified vector, kindly provided by H. Th. Marc 
Timmers (van de Wetering et al., 2003)) using BglII and EcoRI restriction sites.  The 
resulting vector is termed pSUPER.retro.TO (Tet operon).  Double stranded 
oligonucleotides containing shRNA sequences targeting either luciferase (Luc control) 
or PELP1 were cloned into the pSUPER.retro.TO (puromycin resistant) vector using 
BglII and XhoI restriction sites, as described by the manufacturer.   
The shRNA sequences were based on sequences reported in the literature 
(Dimple et al., 2008; Reynolds et al., 2004) or designed using the Invitrogen BLOCK-
iT RNAi Designer (https://rnaidesigner.invitrogen.com/rnaiexpress), as noted above.  
All constructs were confirmed by sequencing. 
 
 312 
Generation, culture, and treatments of MCF-7-derived cell lines - Parental MCF-7 
human breast cancer cells, kindly provided by Dr. Benita Katzenellenbogen, were 
maintained in MEM Eagle medium containing Hanks' salts, L-glutamine, and non-
essential amino acids (Sigma) supplemented with 5% bovine calf serum (CS; Sigma), 
20 mM HEPES (pH 7.6), 100 units/mL penicillin, 100 µg/mL streptomycin, 25 µg/mL 
gentamycin, and 0.22 % sodium bicarbonate.  The Luc and macroH2A1 knockdown 
cell lines were generated and cultured as described previously (Gamble et al., 2010). 
 For the “Tet-on” inducible knockdown system, parental MCF-7 cells were 
stably transfected with a Tet Repressor (TetR) cDNA (pcDNA6/TR; kindly provided 
by H. Th. Marc Timmers).  Stable transfectants were clonally selected using 
hygromycin (200 µg/mL), expanded, and tested for TetR expression and activity by 
Western blotting and transient transfection/luciferase reporter gene assay, respectively 
(see Appendix).  The resulting cell line, termed MCF-7 TetR, was maintained under 
similar conditions as described above, with the exception of the serum (5% Tet-
approved FBS (Tet FBS); Clonetech) to reduce background shRNA expression in the 
absence of doxycycline.  MCF-7 TetR cells were used to make the Luci and PELP1i 
knockdown cell lines by retroviral infection with the appropriate shRNA vectors. 
Retroviruses were generated by transfection of the pSUPER.retro or 
pSUPER.retro.TO vectors described above with an expression vector for the VSV-G 
envelope protein into Phoenix Ampho cells using GeneJuice transfection reagent 
(Novagen) according to the manufacturer’s protocol.  The resulting viruses were 
collected, filtered through a 0.45 µm syringe filter to remove any remaining cells, and 
used to infect the MCF-7 or MCF-7 TetR cells where appropriate.  Stably transduced 
cells were isolated under appropriate selection with puromycin (Sigma; 0.5 µg/mL) 
and/or G418 sulfate (Gibco/BRL; 800 µg/mL), expanded, and frozen in aliquots for 
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future use.  The cells were grown under subconfluent conditions for routine 
maintenance and most experimental procedures.  
 Luci and PELP1i knockdown cell lines were maintained as noted above and 
treated with doxycycline (Sigma-Aldrich; 2 µg/mL) to induce the shRNA expression 
for a minimum of 9 days.  For most experiments, only one shRNA for PELP1 was 
used (#2), as it gave a higher degree of PELP1 depletion.  Both shRNAs were tested in 
gene-specific expression studies to determine off-target effects (Figure 4.9).  For 
ChIP-qPCR and RT-qPCR experiments, only the Luci and PELP1i “+ dox” conditions 
were compared due to the apparent leakiness of the system in the “- dox” condition. 
MCF-7 parental, Luc and macroH2A1 knockdown, or Luci and PELP1i 
knockdown cell were serum-starved by washing the cells in PBS and replacing the 
medium with MEM without serum for 24 h or treated with 12-O-
Tetradecanoylphorbol-13-acetate (TPA, Enzo Life Sciences; 100 ng/mL) for 3 h 
(expression) or 1.5 h (ChIP), where indicated. 
 
Chromatin immunoprecipitation assays - ChIP assays were performed essentially as 
described previously (Gamble et al., 2010; Krishnakumar et al., 2008).  The 
immunoprecipitations were performed from crosslinked parental or knockdown MCF-
7 cells with antibodies against macroH2A1, PELP1, or histone H3, using “no 
antibody” as a control.  The resulting input and ChIP DNA material were used for 
ChIP-chip or gene-specific ChIP-qPCR analyses where indicated. 
 
ChIP-chip - The ChIP-chip sample processing and analyses were done essentially as 
described previously (Gamble et al., 2010; Krishnakumar et al., 2008).  Briefly, 
PELP1-specific immunoprecipitated genomic DNA and reference DNA was blunted, 
amplified by ligation-mediated PCR (LM-PCR), labeled with Cy5 and Cy3, 
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respectively, and used to probe a custom human oligonucleotide genomic array 
(Nimblegen) (Gamble et al., 2010; Krishnakumar et al., 2008).  The PELP1 ChIP-chip 
was run in duplicate to ensure reproducibility.  Detailed information about the 
genomic regions included on the custom array and the data from the hybridizations 
described in this study can be accessed from the National Institutes of Health GEO 
Database (http://www.ncbi.nlm.nih.gove/geo) using accession number GSE22254. 
 
Genomic Data Analyses - The Genomic data analyses for the PELP1 ChIP-chip were 
performed as described previously (Gamble et al., 2010), using the statistical 
programming language R (R Development Core Team).  All data processing scripts 
are available on request.  Briefly, PELP1-bound regions were defined as at least three 
consecutive windows with (i) positive means, (ii) at least six probes, and (iii) P-value 
< 0.016.  PELP1-unbound regions were defined as at least three consecutive windows 
with (i) negative means, (ii) at least six probes, and (iii) P-value < 0.016.   
For PELP1-macroH2A1 genomic comparisons, the macroH2A1 data set was 
accessed from the National Institutes of Health GEO Database using accession number 
GSE9607.  For expression-based classification of genes, MCF-7 expression 
microarray data was accessed from the National Institutes of Health GEO Database 
using accession number GSE9253, and expressed genes were divided into pentiles 
based on the degree of expression.  The data were then compared to the genes 
represented on the ChIP-chip array, as described previously (Gamble et al., 2010). 
For gene ontology analyses, specific gene lists were entered into the Generic 
Gene Ontology Term Finder (http://go.princeton.edu/egi-
bin/GOTermFinder/GOTermFinder).  A multiple testing corrected P-value of 0.002 
was used as the cutoff for significant enrichment. Specifically, we considered genes (i) 
bound by PELP1 (independent of macroH2A1 status), (ii) bound by macroH2A1 
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(independent of PELP1 status), (iii) genes bound by both PELP1 and macroH2A1, (iv) 
genes bound by PELP1 and not by macroH2A1, and (v) genes bound by macroH2A1 
and not by PELP1.  The gene lists can be found in Table 4.3. 
For the multiple ChIP-chip correlation analysis, 362 ChIP-chip data sets were 
accessed from the National Institutes of Health Geo Database using criteria described 
previously (Gamble et al., 2010).  The data were processed with 1-kb windows 
identical to that of the macroH2A1 and PELP1 data sets and Spearman correlations 
were determined between PELP1 and each factor.  A correlation coefficient of ±0.20 
and P-value of < 10-100 was used as cutoffs for significant correlation. 
 
mRNA expression analyses by RT-qPCR - For gene-specific mRNA expression 
analyses, total RNA was isolated using Trizol Reagent (Invitrogen), reverse 
transcribed, and subjected to real-time quantitative PCR using a set of gene specific 
primers.  All target gene transcripts were normalized to the β-actin transcript, which 
was unaffected by macroH2A1 or PELP1 knockdown (data not shown).  All 
experiments were conducted a minimum of three times with independent RNA 
isolations to ensure reproducibility. 
 
Quantitative PCR analyses (RT-qPCR and ChIP-qPCR) - Gene-specific mRNA 
expression and ChIP analyses were analyzed by quantitative PCR in a similar manner.  
Briefly, reactions containing DNA from either source, 1x SYBR Green PCR master 
mix, and forward and reverse primers (500 nM) were used in 40-45 cycles of 
amplification (95°C for 15 sec, 60°C for 1 min) using a Roche LightCycler® 480 
System (384-well) following an initial 3 min incubation at 95°C.  Melting curve 
analysis was performed to ensure that only the targeted amplicon was amplified. 
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Statistical analyses - For the ChIP-qPCR and RT-qPCR assays in Figures 4.6-4.13, a 
paired Student’s t-test with a P-value threshold of < 0.05 was used to determine the 
significance of differences between the control and experimental samples.  The 
enrichment test in Figure 4.4 was determined using a Fisher’s exact test. 
 
Primer Sequences – The primer sequences listed below were used for both RT-qPCR 
and ChIP-qPCR amplification reactions. 
 
RT-qPCR - 
Gene Name Primer Sequence  
β-ACTIN forward 5’-AGCTACGAGCTGCCTGAC-3’ 
β-ACTIN reverse 5’-AAGGTAGTTTCGTGGATGC-3’ 
AREG forward 5’-GAGAAGCTGAGGAACGAAAG-3’ 
AREG reverse 5’-GGCTATGACTTGGCAGTGAC-3’ 
ASCL1 forward 5’-ACTGGGACCTGAGTCAATGC-3’ 
ASCL1 reverse 5’-GCTGTGCGTGTTAGAGGTGA-3’ 
CCL2 forward 5’-CCCCAGTCACCTGCTGTTAT-3’ 
CCL2 reverse 5’-GCTTCTTTGGGACACTTGCT-3’ 
H2AFY forward 5’-AAGAAGGGACGGGTCACAC-3’ 
H2AFY reverse 5’-GGGTGGATGTTGGGTAACAC-3’ 
IL24 forward 5’-AGGCGGTTTCTGCTATTC-3’ 
IL24 reverse 5’-CTGCATCCAGGTCAGAAG-3’ 
MAPK12 forward 5’-ACCTGGCTGTGAACGAAG-3’ 
MAPK12 reverse 5’-CACCACGTACCCAGTCATC-3’ 
NELL2 forward 5’-TGAAGGGAACCACCTACC-3’ 
NELL2 reverse 5’-ATTTGCCATCCACATACG-3’ 
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PARP1 forward 5’-GTGTGGGAAGACCAAAGGAA-3’  
PARP1 reverse 5’-TTCAAGAGCTCCCATGTTCA-3’ 
PELP1 forward 5’- CACCAGAGACACCTGCAGAA-3’ 
PELP1 reverse 5’- AGCTGTGTCATCCTGCTCCT-3’ 
SOCS2 forward 5’-ACACGTCAGCACCATCTCTG-3’ 
SOCS2 reverse 5’-TGGCACCGGTACATTTGTTA-3’ 
TFF1 forward 5’-TGCTTCTATCCTAATACCATCG-3’ 
TFF1 reverse 5’-AGATCCCTGCAGAAGTGTC-3’ 
TMOD3 forward 5’-GGAAGTAGTAATGGTGTTGACC-3’ 
TMOD3 reverse 5’-GCTCATCAAATACCGGAAG-3’ 
TNFSF10 forward 5’-TCACATAACTGGGACCAGAG-3’ 
TNFSF10 reverse 5’-AGTTCACCATTCCTCAAGTG-3’ 
TSPAN5 forward 5’-ACACTGGACAGACCCAGCTT-3’ 
TSPAN5 reverse 5’-TGTCAGTGAGCAGCATTTCC-3’ 
 
ChIP-qPCR - 
Gene Name Primer Sequence 
AREG -3.0 kb forward 5’-TTGTTCCCCTTTGTCTCTGC-3’ 
AREG -3.0 kb reverse 5’-GATGTGTCATGGCATTCTGG-3’ 
AREG +1.5 kb forward 5’-TTCCCCTGTGAGTGAAATGC-3’ 
AREG +1.5 kb reverse 5’-AGCCAGGTATTTGTGGTTCG-3’ 
ASCL1 -2.0 kb forward 5’-GACTCTGCTTTTGGGTGCTC-3’ 
ASCL1 -2.0 kb reverse 5’-TTCACACCTCAGGCCTTTCT-3’ 
ASCL1 +2.0 kb forward 5’-GAGCAACTGGGACCTGAGTC-3’ 
ASCL1 +2.0 kb reverse 5’-CTATAACGCGTGTGCTGCTC-3’ 
CCL2 -1.5 kb forward 5’-ACCTAACGAAAGCTGGGTTG-3’ 
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CCL2 -1.5 kb reverse 5’-TTCAGGGAGTCAGGTATGGTG-3’ 
CCL2 +1.0 kb forward 5’-TGGCCTGAAGTTCTTCCTTG-3’ 
CCL2 +1.0 kb reverse 5’-GGGGTTCACTTTTTCCCTTG-3’ 
IL24 +2.0 kb forward 5’-AGGGCCAAGAATTCCACTTT-3’ 
IL24 +2.0 kb reverse 5’-GTCTTTCACAGCCCAGAAGG-3’ 
MAPK12 +3.0 kb forward 5’-TTCACCCCAACCAAACAGA-3’ 
MAPK12 +3.0 kb reverse 5’-CTCTTTCCATAGCGCTGTCC-3’ 
NELL2 -1.5 kb forward 5’-TCAGAATTCGGGAGCTCTTT-3’ 
NELL2 -1.5 kb reverse 5’-TTTCAAATTTGGGAAATTGCAT-3’ 
SOCS2 -2.0 kb forward 5’-AAGTTCTCTGGAAGCCACAGG-3’ 
SOCS2 -2.0 kb reverse 5’-CGGTGAGTTTGGATTTTTCTG-3’ 
SOCS2 +4.0 kb forward 5’-AGTTCTCTCGCTTGCGATTC-3’ 
SOCS2 +4.0 kb reverse 5’-ACCGGGATACTTGCAATCTG-3’ 
TFF1 -3.0 kb forward 5’-TGGGTTCCGCCCACTCT-3’ 
TFF1 -3.0 kb reverse 5’-CTGCCCCCGGGACTCT-3’ 
TMOD3 -2.5 kb forward 5’-TCTGGCCCCATATGTGGTAT-3’ 
TMOD3 -2.5 kb reverse 5’-TGCAGTTTGATGGTGGATTT-3’ 
TNFSF10 -2.0 kb forward 5’-AGGCATGAAACGAAGGAATG-3’ 
TNFSF10 -2.0 kb reverse 5’-CTTGACCTGACCCCGAGATA-3’ 
TSPAN5 -3.0 kb forward 5’-TTGACTCAGCAGTCCCTCTTC-3’ 
TSPAN5 -3.0 kb reverse 5’-TCCATCTGCTGGGGTATTTC-3’
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Systems and Reagents Designed to Aid in the Study of PARP-1, PARG, and 
NAD+-Synthesizing Enzymes* 
 
 
 
 
 
 
 
 
 
* Contributors to the work described herein include:  Esther Chong & Jany Chan 
(Appendix A.2; mutant and construct design); Dr. Mi Young Kim (Appendix A.2 and 
A.4; mutant design and initial construction); Dr. David A. Wacker (Appendix A.4; 
mutant design and initial construction); Dr. Nasun Hah and Trevor Halle (Appendix 
A.5; MCF-7 TetR cell line assembly and initial testing); Paul Tempst and Hediye 
Erdjument-Bromage (Appendix A.6, mass spectrometry analysis); Dr. Tong Zhang 
(Appendix A.6 & A.7; construct design and configuration); and Emily Reasor 
(Appendix A.7; construct development). 
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A.1.  Summary 
 
Poly(ADP-ribosyl)ation (PARylation) is an enzymatic reaction whereby ADP-ribose 
units from donor NAD+ molecules are covalently attached onto target proteins.  The 
regulation of this reaction is overseen by two nuclear enzymes, Poly(ADP-ribose) 
polymerase-1 (PARP-1) and poly(ADP-ribose) glycohydrolase (PARG), that modify 
target proteins in the nucleus by the addition and removal, respectively, of ADP-ribose 
polymers.  Recent studies have revealed a role for PARP-1 in transcriptional 
regulation, while the role of PARG is less characterized.  One of the ways in which 
PARP-1 (and PARG) activities might be controlled is by substrate availability 
(discussed in Chapter 1).  For example, where does PARP-1’s substrate, NAD+, come 
from?  How is it synthesized?  How can this impact the functions of PARP-1 in the 
nucleus?  In this Appendix, I describe systems, reagents, and initial experimental 
results designed to aid in the study of PARP-1, PARG, and NAD+-synthesizing 
enzymes.  Many of the conclusions made are preliminary and require parallel or 
follow-up studies to verify the results.  In addition, the methodologies described can 
also be applied to other proteins of interest that pose similar questions. 
 
A.2.  PARG Protein Purification and Antibody Characterization 
 
 Poly(ADP-ribose) polymerase-1 (PARP-1) and poly(ADP-ribose) 
glycohydrolase (PARG) are enzymes that modify target proteins in the nucleus by the 
addition and removal, respectively, of ADP-ribose polymers (D'Amours et al., 1999; 
Kim et al., 2005).  The molecular actions of PARP-1 are widely studied and a large 
number of commercially available reagents exist to aid in those studies.  However, 
very few reagents are available in order to study the molecular actions of PARG in 
329 
vivo.  I required an antibody that could be used for standard assays such as Western 
blotting, immunofluorescence, and immunoprecipitation.  Since commercially 
available antibodies were not proving to be useful through initial experiments, I set out 
to generate an antiserum for use these types of assays.  Purified, recombinant rPARG 
protein was used as antigen for injection into rabbits and the resulting antiserum was 
then tested for its ability to recognize recombinant, exogenous, and endogenous PARG 
protein forms in various contexts.  Overall, the antiserum generated through this 
method proved useful in multiple assays, including chromatin immunoprecipitation. 
 
A.2.1.  Results and Discussion 
 
Purification and characterization of wild type and catalytically inactive PARG 
protein.  To generate an antiserum against PARG, I expressed and purified rat PARG 
protein from E. coli, which was then used as antigen for injection into rabbits.  
Notably, rPARG, whose domain structure is shown in Figure A.1A, is ~85% 
conserved in both nucleic acid and protein sequence to that of hPARG, including 
nearly 100% identity of the catalytic domain itself.  I constructed three versions of this 
protein (i.e., changing HIS tag location, with or without spacer) and purified them with 
varying success (Table A.1).  Only the original construct (i.e., N-terminal HIS tag with 
a short spacer) yielded the highest quality and quantity of rPARG full-length protein, 
which was subsequently used in my studies. 
In addition to the wild type enzyme (Wt), a catalytically inactive mutant 
(Y788F/Y791A, CatMut; Figure A.1A) was also used for antiserum generation.  The 
purified, recombinant Wt and CatMut antigens (Figure A.1B) were tested for activity 
in an Auto-Poly(ADP-ribosyl)ation assay.  As shown in Figure A.1C, the activator-
dependent auto-PARylation of PARP-1 is dramatically reduced in the presence of Wt 
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Figure A.1.  Purification of wild type and catalytically inactive rPARG and 
characterization of anti-PARG antibody (generated in-house).  A, Schematic 
diagram of the rat PARG structural and functional domains.  The regulatory domain, 
catalytic domain, active site, nuclear localization signal (NLS), and nuclear export 
signal (NES) are shown. The open circles indicate the location of the inactivating 
point mutations (Tyr 788 to Phe and Tyr 791 to Ala) that inhibit PARG enzymatic 
activity in the catalytically inactive mutant (CatMut).  B, Coommassie stained SDS-
PAGE gel of native purified wildtype (Wt) or catalytically inactive (CatMut) rPARG 
from E. coli.  The full-length rPARG protein is ~113 kDa.  C, In vitro PARylation 
assay using radiolabeled 32P-NAD+ as a substrate confirms activator-dependent auto-
modification of PARP-1 is inhibited in the presence of Wt PARG, but not CatMut 
PARG.  D, Primary antibody bleeds were tested for their ability to recognize PARG 
protein by Western blotting.  Recombinant Wt or CatMut rPARG protein (left) or 
293T cell lysates over-expressing rPARG (right) were analyzed.  E, Various 
production bleeds were tested against recombinant protein or over-expression cell 
lysates, as described in panel D.  A decreasing dilution series of each production bleed 
(1:5000, 1:15000, and 1:45000; block arrow) was tested and compared to the pre-
immune sera (e.g., isolated from the rabbit prior to antigen injection; PI) and a 
secondary antibody alone (i.e., no primary antibody, 2°) to assess background signal.  
Assessment of endogenous protein detection is shown in Figure 2.1. 
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Table A.1.  Summary of rPARG Wt & CatMut protein purification using various 
E. coli expression vectors and 6xHIS-tag locations. 
 
Vector 6xHIS Locationa Size (kDa) Notes  
    
pET28a N-term (spacer) 113 Original constructb 
    
pET28a N-term (no spacer) 113 FL/Breakdown ratioc ↓ 
    
pET15b C-term (no spacer) 99 Smaller size; Yield ↑; Wt only  
 
a Location of 6x HIS tag denoted by N- or C-terminal.  Spacer indicates the 6x HIS tag 
is from the vector and a spacer is located between the tag and protein sequence.  
No spacer indicates the 6x HIS tag is placed directly before or after the cDNA by 
PCR. 
b Original construct was ultimately used for purification of PARG Wt and CatMut 
protein for use in antisera production. 
c FL/Breakdown ratio is the approximate ratio of the full length (FL; 113 kDa) protein 
product relative to the largest breakdown product (~66 kDa). 
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PARG, but not in the presence of CatMut PARG.  These Wt and CatMut rPARG 
constructs were also used in gene regulatory studies described in Chapter 2. 
 The Wt and CatMut recombinant proteins were quantified and sent to the 
Pocono Rabbit Farm and Laboratory, Inc. (Canadensis, PA) for injection into a rabbit.  
The resulting antiserum were collected over numerous production bleeds and a final 
exsanguination bleed.  The production bleeds were tested for PARG protein 
recognition against sera from the same rabbit prior to antigen injection (i.e., pre-
immune).  The antiserum successfully detected recombinant Wt and CatMut rPARG 
(the antigen; Figure A.1D and A.1E), exogenously expressed rPARG in cells (Figure 
A.1D and A.1E), and endogenous hPARG in cells (Figure 2.1).  The antiserum proved 
useful for Western blotting, immunoprecipitation (Figure 2.7), and chromatin 
immunoprecipitation (ChIP; Figure 2.7).  Furthermore, the validity of the PARG 
antiserum was demonstrated by a reduction in signal upon expression of a sequence-
specific shRNA against endogenous PARG (Figure 2.1 and 2.7).  Although tested, 
initial immunofluorescence experiments displayed near background signals for 
endogenous PARG protein in cells (data not shown).  This is likely due to the overall 
low level of PARG expressed in cells and the lack of compartmental localization. 
 
A.2.2.  Experimental Procedures 
 
PARG expression constructs - Wild-type (Wt; kindly provided by Mitsuko Masutani) 
and catalytically inactive point mutants (CatMut) of rat PARG were used in the studies 
described herein.  The catalytically inactive rat PARG contained changes at Tyr 788 
and 791 to Phe and Ala, respectively (Y788F/Y791A) (Shimokawa et al., 1999).  Both 
Wt and CatMut cDNAs were cloned into the pET28a bacterial expression vector 
(Novagen) using PCR-based cloning via the BamHI and XhoI restriction sites.  CMV-
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based mammalian expression constructs (with a carboxyl-terminal FLAG tag) were 
generated by PCR-based cloning of the tagged cDNAs into pCMV5. 
 
Protein purification - hPARP-1 and Wt and CatMut rPARG were expressed in E. coli 
and purified by standard nickel-NTA affinity chromatography as described previously 
(Kim et al., 2004).  Notably, induction of PARG proteins were done for 3hrs at 30°C. 
 
Auto-PARylation assay – The activator-dependent auto-PARylation assay was 
performed essentially as described previously (Kim et al., 2004).  Briefly, PARP-1 
was incubated with 32P-NAD+ (substrate) and sssp DNA (activator) in the absence and 
presence of purified Wt or CatMut rPARG proteins for 30 minutes at 27°C.  The 
reactions were analyzed by SDS-PAGE, visualized by autoradiography, and quantified 
using ImageQuant software (Molecular Dynamics). 
 
Exogenous expression of PARG in 293T cells - The pCMV5-PARG constructs (Wt 
and CatMut) were transiently transfected into 293T cells using Fugene 6 Transfection 
Reagent (Roche).  The cells were collected 24 hrs post-transfection and whole cell 
lysates were subject to SDS-PAGE and Western blot analysis using PARG antiserum. 
 
A.3.  Generation and Testing of short hairpin RNAs Targeting PARP-1 and 
PARG in Human Cells 
 
PARP-1 and PARG play important roles in an overlapping set of biological 
processes, including DNA damage detection and repair, cell death pathways, and 
transcriptional regulation (Kim et al., 2005).  However, the mechanistic details of such 
processes are not fully characterized.  One useful approach to further elucidate the 
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mechanism of action of PARP-1 and PARG is depleting the enzymes in vivo and 
determining the functional consequence of the targeted depletion in any of the cellular 
activities noted above.  To this end, I designed various short hairpin (shRNA) 
sequences targeting either PARP-1 or PARG and used these shRNAs to generate 
stable depletions of PARP-1 and PARG in MCF-7 cells.  Herein, I describe the design 
and generation of stable PARP-1 and PARG knockdown MCF-7 cell lines. 
 
A.3.1.  Results and Discussion 
 
To explore the molecular actions of PARP-1 and PARG in vivo, I designed 
shRNA sequences to target the depletion of each enzyme in human cells using a 
retroviral delivery system.  While previous groups have reported RNAi target 
sequences for PARP-1, none existed for PARG.  Therefore, I designed shRNA 
sequences targeting both factors using available resources (i.e., Dharmacon 
siDESIGN® Center software and Invitrogen BLOCK-iT™ RNAi Designer).  Each 
target sequence (Table A.2) targeted a different nucleic acid location along the mRNA 
(Figure A.2A).  The majority of sequences targeted exons, while two targeted 3’ UTR 
regions.  Varying the location of shRNA sequences along the mRNA may lead to 
varying degrees of protein depletion.  Sequence accessibility, mRNA half-life, and 
frequency/rate of transcription and protein turnover are all factors that can alter the 
efficacy of shRNAs to deplete their target protein. 
I cloned shRNA target sequences (six for PARP-1, four for PARG, and one for 
luciferase control) into the pSUPER.retro shRNA expression vectors (see 
Experimental Procedures), generated retrovirus, infected MCF-7 parental cells, and 
selected for stably transduced cells.  Then, I tested the degree of shRNA-mediated 
knockdown of PARP-1 and PARG by Western blot analysis (Figure A.2B) and 
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Table A.2.  Summary of shRNA sequences tested for PARP-1 and PARG stable 
knockdown in human cells. 
 
 Sequencea Siteb % KDc Sourced  
 
hPARP-1 
#1 gggcaagcacagtgtcaaa 2829 95 {Ju, 2004 #68; Shah, 2005 #122} 
#2 aagcctccgctcctgaacaat 2143 70 {Kameoka, 2005 #862} 
#3 aagatagagcgtgaaggcgaa 2512 10 {Kameoka, 2005 #862} 
#4 acacctctctactatataa 2942 80 Dharmacon 
#5 aaaccaaagcttcgttaga 3507e 0 Dharmacon 
#6 ggtggctgtggtatgaattca 3231e 0 Invitrogen 
 
hPARG 
#1 ccagttggatggacactaa 239 10 Dharmacon 
#2 caataccactcctgaaaca 1832 30 Dharmacon 
#3 ttacgaaggtaccatagaa 2163 0 Dharmacon 
#4 agagaccgctgaccattca 2892 50 Dharmacon 
 
a The 19 or 21 bp shRNA sequence is given in the 5’ to 3’ orientation. 
b Site of shRNA binding is denoted within the open reading frame relative to the start. 
c Percent of knockdown of the target factor is relative to the Luc knockdown control 
in MCF-7 human breast cancer cells, as shown in Figure A.2 and Figure 2.6.  
Value is an average over at least two independently generated cell populations, and 
quantified by semi-quantitative Western blot (dilution series). 
d shRNA sequences were based on sequences reported in the literature or designed 
using the Dharmacon siDESIGN® Center software or the Invitrogen BLOCK-iT™ 
RNAi Designer. 
e Sequences #5 and #6 are located outside of the open reading frame, within the 3’ 
untranslated region. 
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Figure A.2.  Comparison of independent shRNA sequences targeting PARP-1 in 
MCF-7 cells.  A, Schematic diagram of hPARP-1 mRNA (top) and hPARG mRNA 
(bottom) is drawn in the 5’ to 3’ orientation.  The exons (blue bars) and 5’ and 3’ 
untranslated regions (red bars) are shown.  The numbered regions represent the 
binding locations of the six shRNAs tested for PARP-1 knockdown and four shRNAs 
tested for PARG knockdown, as described in Table A.2.  The shRNAs tested bind 
sequences within the coding region, as well as within 3’ untranslated region (for 
PARP-1 only).  B, Whole cell lysates were collected from Luc, PARP-1, or PARG 
stable shRNA-mediated knockdown cell lines.  Six independent shRNA sequences 
(#1-6) targeting PARP-1 and four independent shRNA sequences (#1-4) targeting 
PARG were analyzed by Western blotting for their ability to knockdown PARP-1 
relative to the Luc control (L).  C, Stable Luc and PARP-1 knockdown cell lines were 
subjected to immunostaining with a PARP-1 antibody and visualized by confocal 
microscopy.  A dotted circle denotes a single nucleus in each panel.  The reduction in 
PARP-1 signal using a combination of shRNA #1 and #4 is consistent with panel B, 
which shows a high level of PARP-1 knockdown using shRNA #1 or #4, relative to 
the Luc control.  The PARG antibody was not useful for immunostaining purposes. 
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immunofluorescence analysis (Figure A.2C).  For PARP-1, shRNA #1, #2, and #4 
showed a clear reduction of PARP-1 protein, albeit at varying levels, relative to the 
Luc control.  This result was also apparent by immunostaining for endogenous PARP-
1 protein by confocal microscopy in Luc and PARP-1 knockdown cell lines.  To 
achieve the greatest degree of knockdown, PARP-1 shRNA #1 and #4 were combined 
and labeled #1 and #2, respectively, for simplicity (described in Chapter 2).  For 
PARG, only shRNA #2 and #4 seemingly reduced endogenous PARG levels relative 
to the Luc control.  As noted in Appendix A.2, the PARG antiserum was not useful for 
immunofluorescence assay due to the low abundance of PARG in MCF-7 cells.  To 
achieve the greatest degree of knockdown, PARG shRNA #4 and #2 were combined 
and labeled #1 and #2, respectively, for simplicity (described in Chapter 2). 
 
A.3.2.  Experimental Procedures 
 
Antibodies - To test the degree of knockdown by each shRNA sequence, whole cell 
lysates from stable knockdown cell lines were subject to SDS-PAGE and Western blot 
or immunostaining analysis using PARP-1 and PARG antisera.  The custom rabbit 
polyclonal antibodies against PARP-1 and PARG were generated by using a purified 
fragment of human PARP-1 (amino-terminal, PARP-N (Kim et al., 2004)) and full-
length rat PARG as antigens (described in Appendix A.2). 
 
PARP-1 and PARG knockdown constructs - Short hairpin RNA (shRNA) expression 
constructs for retroviral-mediated knockdown of PARP-1 and PARG were made using 
the pSUPER.retro vector (OligoEngine).  Double stranded oligonucleotides containing 
shRNA sequences targeting either luciferase (Luc control), PARP-1, or PARG were 
cloned into the vector using BglII and XhoI restriction sites as described by the 
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manufacturer.  The shRNA sequences, listed in Table A.2, were based on sequences 
reported in the literature (Ju et al., 2004; Shah et al., 2005) or designed using the 
Dharmacon siDESIGN® Center software (www.dharmacon.com).  All shRNA 
sequences were cloned into both pSUPER vectors (distinguished by resistance marker; 
puromycin or neomycin) and were confirmed by sequencing. 
 
Generation and culture of MCF-7-derived cell lines - Parental MCF-7 human breast 
cancer cells, kindly provided by Dr. Benita Katzenellenbogen, were maintained in 
MEM Eagle medium containing Hanks' salts, L-glutamine, and non-essential amino 
acids (Sigma-Aldrich) supplemented with 5% bovine calf serum (CS; Sigma-Aldrich), 
20 mM HEPES (pH 7.6), 100 units/mL penicillin, 100 µg/mL streptomycin, 25 µg/mL 
gentamycin, and 0.22 % sodium bicarbonate.  Knockdown cell lines were generated 
by retroviral infections of parental MCF-7 cells with the shRNA expression vectors. 
Retroviruses were generated by transfection of the pSUPER.retro vector 
described above with an expression vector for the VSV-G envelope protein into 
Phoenix Ampho cells using GeneJuice transfection reagent (Novagen) according to 
the manufacturer’s protocol.  The resulting viruses were collected, filtered through a 
0.45 µm syringe filter to remove any remaining cells, and used to infect the parental 
MCF-7 cells.  Stably transduced cells were isolated under appropriate selection with 
puromycin (Sigma-Aldrich; 0.5 µg/mL) or G418 sulfate (Gibco/BRL; 800 µg/mL) and 
tested for degree of knockdown by Western blotting and immunostaining analyses.   
 
Immunofluorescence - Stable PARP-1 or PARG MCF-7 knockdown cell lines were 
grown on coverslips in 6-well plates for a minimum of 24 hrs. The cells were fixed in 
the dish with 3.7% formaldehyde solution with PBS for 20 minutes at room 
temperature, washed twice with PBS, and permeablized with 0.1% Triton X solution 
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in PBS for 20 minutes at room temperature.  Cells were then washed twice with PBS 
and incubated with PARP-1 or PARG antibody (1:2000 – 1:5000 dilution in PBS) for 
1 hour at room temperature (in the dark).  After two washes with PBS, the cells were 
incubated with goat-α-rabbit rhodamine-conjugated secondary antibody (1:3000 
dilution in PBS; Jackson) and Hoechst DNA stain (1:5000 dilution in PBS; Jackson) 
for 1 hour at room temperature (in the dark).  Finally, the cells were washed three 
times with PBS and coverslips mounted onto microscope slides using Vectashield 
Mounting Media (Vector Laboratories).  Staining was visualized using a Leica 
Confocal Microscope System at Cornell University’s Microscope Imaging Facility. 
 
A.4.  A Complementation System for the Stable Re-expression of PARP-1 Point 
and Deletion Mutants in the Context of a Stable PARP-1 Knockdown 
 
 Previous studies have provided mixed results about the requirement for PARP-
1’s enzymatic and DNA binding activities during gene regulation.  In addition, little is 
known about the requirement for the various functional domains of PARP-1 as it 
pertains to gene regulation.  While the involvement of PARP-1 in transcriptional 
outcomes is being unveiled, the details of how PARP-1 functions at particular genes 
are still unknown.  Questions still remain regarding the many characterized activities 
of PARP-1.  At which genes is the catalytic activity of PARP-1 required?  Does 
PARP-1 interact with the DNA through the DBD or protein-protein interactions 
through another region of the protein at particular promoters?  How do post-
translational modifications of PARP-1 affect its gene regulatory activities?  How does 
the extent of PAR alter the gene expression outcome?  To answer some of these 
questions, I devised a system to stably re-express FLAG-tagged versions of wild-type 
or point/deletion mutants of PARP-1 in the context of a PARP-1 knockdown cell line 
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using retrovirus-mediated gene transfer.  By re-introducing a given PARP-1 mutant, 
we can further understand the mechanism of action of PARP-1 at its target genes. 
 
A.4.1.  Results and Discussion 
 
In order to study the role of each PARP-1 domain in gene regulation, I have 
devised a system that allows for the exogenous expression of various PARP-1 mutants 
in the context of a PARP-1 stable knockdown cell line.  To prevent knockdown of the 
re-expressed proteins in the PARP-1 MCF-7 knockdown cell lines, I generated 
shRNA-resistant versions of the PARP-1 wild-type and mutant cDNAs (Described in 
Chapter 2, Figure A.3A, and Table A.3; see Experimental Procedures).  This strategy 
maintains a low endogenous expression of PARP-1 (shRNA is constitutively 
expressed), while the mutant of interest is expressed (shRNA resistant).  In addition, 
the exogenous proteins are FLAG tagged so that their expression and localization can 
be monitored through the use of both protein- and FLAG-specific antibodies using 
various read-outs (i.e., Western blotting, ChIP assay).   
As shown in Figure A.3A, there are several mutants of interest that have been 
designed for use in this system.  Each mutant obliterates an activity or domain of 
PARP-1, the consequences of which can be examined through various read-outs.  The 
point mutants include: (i) a DNA binding mutant (DBDMut) that cannot bind DNA 
Hassa, 2001 #60; Kim, 2004 #74}; (ii) a catalytically inactive mutant (CatMut) that 
cannot modify target proteins Hassa, 2001 #60; Kim, 2004 #74; Marsischky, 1995 
#93; Rolli, 1997 #118}; (iii) a phosphorylation mutant (PhosMut) that mimics a 
constitutively active PARP-1 (Kauppinen et al., 2006); and (iv) a branching mutant 
(BranchMut) that preferentially modifies target proteins in branched PAR formation, 
rather than linear (Rolli et al., 1997).  All of these point mutants have been created and 
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Table A.3.  Summary of PARP-1 point and deletion mutants designed for re-
expression in PARP-1 KD cells (RNAi-resistant). 
 
 Size   Express  Express 
Mutant (kDa) pET19ba pCMV5b in Cells?c pQCXIHd in Cells?e  
 
Wt 116 Yes Yes Yes Yes Yes 
DBDMut 116 Yes Yes Yes Yes Yes 
CatMut 116 Yes Yes Yes Yes Yes 
PhosMutf 116 Yes (dbl) Yes Yes Yes (sgl) n/tg 
BranchMut 116 Yes (RK) Yes Yes Yes n/t 
ΔDBD 93 Yes Yes Yes Yes Yes 
ΔBRCT 100 Yes Yes Yes Yes Noh 
ΔCAT 72 Yes Yes Yes Yes Yes 
ΔNBD 85 Yes Yes Yes Yes Yesi 
DBD-NBD 69 Yes Yes Yes Yes Noh 
 
a Most pET19b constructs were designed and cloned by D.A.W. and M.Y.K., with the 
exception of PhosMut and ΔDBD (K.M.F.), and BranchMut (R.K.). 
b Mutants were cloned into the pCMV5 mammalian expression vector in both normal 
and RNAi-resistant forms. 
c pCMV5 expression was tested in transient transfection/Western blot experiments 
using PARP-1 and FLAG antibodies in 293T cells, MCF-7 parental, Luc KD, or 
PARP-1 KD cells (in some cases, more than one cell type). 
d Mutants were cloned into the pQCXIH retroviral expression vector in the RNAi-
resistant form only. 
e pQCXIH expression was tested by retroviral infection followed by hygromycin drug 
selection/Western blot experiments using PARP-1 and FLAG antibodies in MCF-7 
Luc KD, PARP-1 cells, or both. 
f PhosMut exists in two forms, a double mutant (dbl) or a single mutant (sgl).  Only 
the double mutant was cloned into pET19b; both were cloned into pCMV5, and 
only the single mutant was cloned into pQCXIH. 
g Mutant not tested (n/t) for expression in any cell line. 
h ΔBRCT and DBD-NBD mutants were generally not detected as stably re-expressed 
in PARP-1 KD cells, although faint signals could be detected at early time points. 
i ΔNBD mutant was detected as stably re-expressed in PARP-1 KD cells (population) 
but was lost over time; while stable re-expression in PARP-1 KD cells (clonal) 
was not detected after drug selection (Figure A.3) 
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Figure A.3.  Stable re-expression of human PARP-1 point and deletion mutants 
in PARP-1 knockdown MCF-7 cells.  A, Schematic diagram of the human PARP-1 
structural and functional domains and various point and deletion mutants.  The DNA 
binding domain (DBD), zinc fingers (Zn Fingers), nuclear localization signal (NLS), 
third zinc binding domain (Zn3), automodification domain (AMD), and PARP 
"signature" motif are also shown.  Open triangles indicate the location of the 21-
nucleotide shRNA recognition sequences used for knockdown.  Filled circles indicate 
the location of the silent point mutations engineered into the cDNAs to make them 
resistant to the shRNAs in order to re-express them in the context of a PARP-1 
knockdown.  The open circle indicates the location of the various point mutations 
indicated.  B, FLAG-tagged RNAi-resistant wild type and mutants described in panel 
A were stably re-expressed in MCF-7 PARP-1 knockdown cell lines.  Re-expression 
was confirmed by Western blotting for PARP-1 and FLAG.  An empty vector was 
used as a control (Empty) in both Luc and PARP-1 knockdown cell lines.  Two 
deletion mutants, ΔBRCT and DBD-NBD, did not express in PARP-1 knockdown 
cells, although they were confirmed for the ability to express in another cell line.  C, 
To combat differential levels of re-expression, deletion mutants were re-expressed in 
clonally selected PARP-1 KD cell lines.  While the levels of re-expression were 
similar among wild type or mutant constructs, not all mutants expressed as they did in 
the population background (i.e., ΔNBD). Wt, wild type; DBDMut, inactive DNA 
binding; CatMut, catalytically inactive; PhosMut, mimics phosphorylated residues, 
increasing activity; BranchMut, increases branching frequency; Luc, luciferase. 
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characterized in some form in previous reports.  In addition to the point mutants, there 
are several deletion mutants, many of which also have been previously created and 
characterized with respect to chromatin compaction (Wacker et al., 2007).  They 
include:  (i) !DBD that is missing the zinc finger DNA binding region; (ii) !BRCT 
that is missing the central BRCT motif; (iii) !CAT that is missing the C-terminal 
catalytic domain; (iv) !NBD that is missing the NAD+-binding region only; and (v) 
DBD-NBD fusion that is missing the central AMD and part of the catalytic domain. 
Upon cloning the wild-type (Wt) and each mutant into the retroviral 
mammalian expression vector, they were introduced into the PARP-1 knockdown cell 
line and compared to the Luc KD control.  An empty vector was used as a control for 
proper drug selection.  Using the Luc and PARP-1 KD cell lines described in Chapter 
2, some of the mutants were successfully expressed at the expected molecular weight 
(Figure A.3B) after retrovirus-mediated gene transfer and drug selection.  However, 
the level of re-expression was vastly different across the panel (i.e., compare Wt and 
DBDMut).  This was likely due to a number of reasons, including differential infection 
rates and level of expression in each cell.  In fact, initial screening of PARP-1 mutant 
expression via immunofluorescence suggested that only a handful of cells were 
expressing the mutants (data not shown).  In addition, this panel of stable cell lines 
seemingly lost exogenous protein expression over time. 
To combat some of these problems, I first clonally selected the Luc and PARP-
1 KD cell lines.  After screening a number of clones, I selected a single clone for each 
Luc and PARP-1 KD that resembled the original population for level of knockdown at 
the mRNA and protein level, as well as a similar profile for PARP-1-regulated genes 
(data not shown).  Subsequently, I re-introduced the panel of mutants by retrovirus-
mediated gene transfer and drug selection.  This approach allowed for the same 
PARP-1 KD “background” for each mutant and significantly helped maintain equal 
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expression levels (Figure A.3C).   The Wt, !DBD, and !CAT expressed well, while 
!BRCT, !NBD, and DBD-NBD did not, even though they were tested for ability to 
express in transient transfection/Western blot assay (data not shown).  This could be 
due to several reasons, including protein mis-folding or poor integration site.  Follow-
up studies are necessary to determine why these particular mutants do not express.  
Notably, other than Wt and CatMut, no other re-expressed mutant cell line was 
analyzed for NAD+ and PAR levels, as described in Chapter 2. 
Initial experiments were conducted to determine the effect of !DBD and 
!CAT on gene expression.  However, for the panel of genes tested, only a few 
restored gene expression levels to that of the Luc control upon Wt re-expression.  In 
addition, there were no visible differences in gene regulatory patterns between the Wt 
and mutants as would be expected, given previous reports (data not shown).  
Furthermore, while Wt and CatMut proteins were detected at target gene promoters by 
ChIP assay (Krishnakumar and Kraus, 2010), these newly developed cell lines did not 
show detectable exogenous PARP-1 proteins (Wt or mutant) at target gene promoters 
(data not shown).  Together, these results indicate in depth technical problems that 
need to be resolved in order to use this complementation system to its full potential. 
 
A.4.2.  Experimental Procedures 
 
Antibodies - The custom rabbit polyclonal antibody against PARP-1 used for Western 
blotting was generated by using a purified fragment of human PARP-1 (amino-
terminal, PARP-N (Kim et al., 2004)) (Pocono Rabbit Farm and Laboratory, Inc.).  
The mouse monoclonal FLAG antibody used for Western blotting was purchased from 
Sigma-Aldrich (F3165). 
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Oligonucleotides - The sequences listed below were used for site-directed 
mutagenesis to generate point mutants and RNAi-resistant hPARP-1 cDNAs: 
 
PhosMut - 
1. Double Mutant (Dbl; S372E, T373E) 
5’ - ccacgcctccgcccgaagaagcctcggctcctgc - 3’ and  
5’ - gcaggagccgaggcttcttcgggcggaggcgtgg - 3’ 
Specific changes relative to the first nucleotide of the first codon: 
t1114g, c1115a, c1116a, a1117g, c1118a 
 
2. Single Mutant (Sgl; T373E) 
5’ - ccacgcctccgcccgaagaagcctcggctcctgc - 3’ and  
5’ - gcaggagccgaggcttcttcgggcggaggcgtgg - 3’ 
Specific changes relative to the first nucleotide of the first codon: 
a1117g, c1118a 
 
BranchMut - 
5’ - gacacgtcgctgctgcataacgagtacattgtc - 3’ and  
5’ - gacaatgtactcgttatgcagcagcgacgtgtc - 3’ 
Specific changes relative to the first nucleotide of the first codon: 
t2956c 
 
RNAi-resistant hPARP-1 cDNAs – 
1. Recognition site #1 (Wt and CatMut) 
5’ - caggttacccaagggcaaacatagcgttaaaggtttgggcaaaac - 3’ and  
5’ - gttttgcccaaacctttaacgctatgtttgcccttgggtaacctg - 3’ 
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Specific changes relative to the first nucleotide of the first codon: 
g2835a, c2838t, t2841c, c2844t 
 
2. Recognition site #2 (Wt) 
5’ - ctggtgtgaatgacacgtcgctgctgtataacgagtacattgtc - 3’ and  
5’ - gacaatgtactcgttatacagcagcgacgtgtcattcacaccag - 3’ 
      Specific changes relative to the first nucleotide of the first codon: 
c2946g, t2949g, a2952g, a2955g 
 
  
3. Recognition site #2 (CatMut) 
5’ - ctggtgtgaatgacacgtcgctgctgtataacaagtacattgtc - 3’ and  
5’ - gacaatgtacttgttatacagcagcgacgtgtcattcacaccag - 3’ 
      Specific changes relative to the first nucleotide of the first codon: 
  c2946g, t2949g, a2952g, a2955g 
 
PARP-1 expression constructs - Wild-type and point/deletion mutants of human 
PARP-1 were used in the studies described herein.  The DNA binding point mutant 
(DBDMut) contained changes at Cys 21 to Gly (C21G), Cys 125 to Gly (C125G), and 
Leu 139 to Pro (L21P) (Hassa et al., 2001; Kim et al., 2004).  The catalytically 
inactive point mutant (CatMut) contained a change at Glu 988 to Lys (E988K) (Hassa 
et al., 2001; Kim et al., 2004; Marsischky et al., 1995; Rolli et al., 1997).  The 
phosphorylation mimic point mutant (PhosMut) contained changes at Ser 372 to Glu 
(S372E) and Thr 373 to Glu (T373E) (Kauppinen et al., 2006).  The branching point 
mutant (BranchMut) contained a change at Tyr 986 to His (Y986H) (Rolli et al., 
1997).  The CMV-based mammalian expression constructs for full length wild-type, 
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!DBD, !BRCT, !CAT, !NBD, and DBD-NBD deletion mutants were generated by 
PCR-based cloning of the tagged cDNAs (a carboxyl-terminal 6xHis/FLAG tag) into 
pCMV5.  The pCMV5-hPARP-1-His/FLAG and pET19b-hPARP-1 wild-type vectors 
were used simultaneously as templates to generate the PhosMut and BranchMut point 
mutants by site-directed mutagenesis (QuikChange® Site-Directed Mutagenesis Kit 
from Stratagene) in both bacterial and mammalian expression vectors. 
The pCMV5-hPARP-1-His/FLAG vectors were then used as templates to 
generate cDNAs resistant to the shRNAs (described in Chapter 2 and Appendix A.3) 
by site-directed mutagenesis (QuikChange® Site-Directed Mutagenesis Kit from 
Stratagene).  The following nucleotides relative to the first nucleotide of the first 
codon were changed in the hPARP-1 cDNA: g2835a, c2838t, t2841c, c2844t (for 
shRNA#1) and c2946g, t2949g, a2952g, a2955g (for shRNA#2).  Positive clones were 
identified by sequencing and then cloned into the pQCXIH retroviral expression 
vector (BD Biosciences; hygromycin resistant) using NotI and BamHI restriction sites.  
 
Generation and culture of MCF-7-derived cell lines - Parental MCF-7 human breast 
cancer cells, kindly provided by Dr. Benita Katzenellenbogen, were maintained in 
MEM Eagle medium containing Hanks' salts, L-glutamine, and non-essential amino 
acids (Sigma-Aldrich) supplemented with 5% bovine calf serum (CS; Sigma-Aldrich), 
20 mM HEPES (pH 7.6), 100 units/mL penicillin, 100 µg/mL streptomycin, 25 µg/mL 
gentamycin, and 0.22 % sodium bicarbonate.  The shRNA knockdown + shRNA-
resistant re-expression ("knockdown/add-back") cell lines used in these studies were 
generated by sequential retroviral infections of parental MCF-7 cells with the 
appropriate shRNA and cDNA expression vectors (see below).  The Luc and PARP-1 
knockdown cells, expressing two distinct shRNA sequences targeting the intended 
factor (described ini Chapter 2), were either used as a population or clonally selected. 
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Retroviruses were generated by transfection of the pSUPER.retro or pQCXIH 
vectors described above with an expression vector for the VSV-G envelope protein 
into Phoenix Ampho cells using GeneJuice transfection reagent (Novagen) according 
to the manufacturer’s protocol.  The resulting viruses were collected, filtered through a 
0.45 µm syringe filter to remove any remaining cells, and used to infect the parental 
MCF-7 cells.  Stably transduced cells were isolated under appropriate selection with 
puromycin (Sigma-Aldrich; 0.5 µg/mL), G418 sulfate (Gibco/BRL; 800 µg/mL), or 
hygromycin (Cellgro; 200 µg/mL), expanded, and frozen in aliquots for future use. 
 
A.5.  Tet-inducible Depletion of PARP-1 (Tet-On) 
 
While a stable shRNA-mediated knockdown of PARP-1 has yielded interesting 
facets regarding the role of PARP-1 in gene regulation, there are certain drawbacks 
that are unavoidable with such a system.  Primarily, constitutive expression of a 
PARP-1 shRNA over time can lead to adjustments within the cell that may not be 
directly attributable to the knockdown of PARP-1.  In other words, there is no way to 
distinguish immediate early effects versus long-term compensatory effects upon 
PARP-1 knockdown.  For this reason, and others, I developed a stable, tet-inducible 
knockdown system for PARP-1.  This system allows for the stable integration of a 
PARP-1 shRNA sequence (much like described in Chapter 2 and Appendix A.2), the 
expression of which is controllable by doxycycline.  Therefore, a time component of 
PARP-1 knockdown can be incorporated, yielded further information about the 
mechanisms of action of PARP-1 in gene regulation.  This system has unveiled unique 
aspects of PARP-1 that were hypothesized from previous reports from our lab and 
others.  That is, (i) chromatin-bound PARP-1 is not rapidly turned over, and (ii) the 
level of PARP-1 depletion at promoters is directly linked to gene regulation. 
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A.5.1.  Results and Discussion 
  
Previous reports from our lab used a stable, retrovirus-mediated shRNA 
expression cell line to deplete PARP-1 and determine the consequences as it pertains 
to gene regulation (Frizzell et al., 2009; Krishnakumar et al., 2008; Krishnakumar and 
Kraus, 2010).  Unlike other knockdown systems (i.e., siRNA transfection), the stable 
knockdown is constitutively expressed and maintained over several passages.  Every 
effort is made to conduct experiments at the earliest time points of shRNA expression 
as possible using this system.  However, upon several passages, the immediate early 
effects of PARP-1 knockdown cannot be distinguished from secondary, tertiary, or 
further downstream effects.  How does the cell compensate for such dramatic 
reductions in PARP-1?  Are the changes in gene regulation attributable to promoter-
bound PARP-1 directly or through downstream mechanisms? 
To combat this issue, I developed a stable, tet-inducible knockdown cell line 
for PARP-1.  To generate this “Tet-on” system, two independent steps were necessary.  
First, parental MCF-7 cells were stably transfected with a cDNA for the Tet repressor 
(TetR) protein and clonally selected (Nasun Hah).  Stable transfectants were expanded 
and tested for TetR expression by Western blotting (Figure A.4A).  The resulting cell 
lines are terms “MCF-7 TetR”.  Importantly, TetR expression does not alter the 
endogenous levels of PARP-1, or the estrogen receptor α (ERα), an important 
transcription factor in the biology of MCF-7 cells.  In fact, TetR expression does not 
alter the ability of MCF-7 TetR cells to respond to a signal, such as estrogen, as shown 
by profiling standard estrogen-responsive genes by RT-qPCR (Figure A.4B). 
The activity of the TetR in the cells was tested by transient transfection and 
luciferase reporter gene assay (Figure A.4C).  Here, a luciferase reporter lies 
downstream of a pCMV promoter harboring two Tet operon (TO) sequences.  In the 
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absence of doxycyline (dox), the TetR would bind the TO sequences and repress the 
expression of the luciferase reporter, while the addition of dox would bind and 
sequester the TetR away from the promoter, allowing for the transcription of the 
luciferase reporter.  Upon transfection of the reporter and subsequent dox treatment 
(see Experimental Procedures), the activity of luciferase was measured in the cell 
extracts of various MCF-7 TetR clones.  Only those clones that expressed the TetR 
protein showed tet-responsive activity, however, to varying degrees.  Therefore, the 
inducible knockdown cell lines were generated using MCF-7 TetR clone #3, which 
displayed the highest TetR expression level and activity.  For the second step, a dox-
responsive Luc or PARP-1 shRNA was introduced into the MCF-7 TetR cell line, 
resulting in inducible knockdown cell lines, Luci and PARP-1i. 
The cells were treated with or without dox and tested for cellular PARP-1 
levels by Western blot analysis (Figure A.4D) and PARP-1 mRNA levels by RT-
qPCR (Figure A.4E).  Total PARP-1 protein and mRNA levels were significantly 
reduced after 4 days of dox treatment, as compared to the Luci control.  Notably, 
PARP-1 mRNA levels are slightly reduced in the absence of dox (i.e., baseline), which 
is likely due to the “leakiness” of the system, however protein levels remain high. 
Given the level of reduction at 4 days of dox treatment, I hypothesized that 
PARP-1-dependent gene regulation would also be evident at that time.  I examined the 
expression levels of previously identified PARP-1 target genes (Frizzell et al., 2009) 
using the Luci and PARP-1i cell lines by RT-qPCR over a time course of dox 
treatment.  My analyses showed that no target genes were regulated at early dox time 
points (i.e., 4 days) when total PARP-1 levels are maximally reduced.  However, as 
dox treatment time was extended out to 12 days, evidence of PARP-1-dependent gene 
regulation was evident (Figure A.5A).  In fact, as time of dox treatment progressed, 
the percentage of regulated genes increased (data not shown).  Concurrent with this, 
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Figure A.4.  Generation of stable MCF-7 inducible PARP-1 knockdown cell line.  
A, and B, The Tet repressor protein (TetR) is stably expressed and active in MCF-7 
cells.  Parental MCF-7 cells were stably transfected with a TetR expression cDNA and 
clonally selected using hygromycin.  Whole cell extracts were isolated from individual 
clones and monitored for TetR protein levels by Western blotting (A) and TetR 
activity using a doxycycline (dox)-inducible luciferase reporter assay (B).  TetR 
expression has no effect on total cellular PARP-1 levels; ERα was also monitored as a 
loading control.  Only the clones showing detectable TetR protein in panel A (i.e., 
clones 1, 3, and 4) showed dox-inducible luciferase expression and activity, indicating 
an active TetR protein.  MCF-7 TetR clones 3 and 4 were used in future experiments, 
as they displayed the highest activity.  C, TetR expression does not disrupt signal-
mediated gene expression patterns.  Total RNA was isolated from vehicle (U) or 
estrogen-treated (E) MCF-7 TetR cells, reverse transcribed, and subjected to qPCR 
using gene-specific primers.  Each bar represents the mean + SEM (error bars) from 
two independent determinations.  D and E, Dox-inducible shRNA-mediated depletion 
of PARP-1 in MCF-7 cells.  Dox-inducible shRNA constructs were stably transduced 
into MCF-7 TetR cells by retroviral infection.  PARP-1 protein (D) and mRNA (E) 
levels were monitored upon treatment with dox up to 15 days, using methods 
previously described.  Both PARP-1 protein and mRNA levels were reduced at least 
90% in as early as 4 days of dox treatment, as compared to an shRNA targeting 
luciferase.  Subsequent experiments used only shRNA #1, as it yielded faster and more 
effective knockdown of PARP-1.  Luc, luciferase; i, inducible; dox, doxycycline; 
TetR, tet repressor; TO, tet operon. 
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Figure A.5.  Levels of chromatin-associated PARP-1 reflect PARP-1-dependent 
changes in gene expression.  A, PARP-1-dependent changes in gene expression are 
evident at a minimum six days shRNA induction by doxycycline (dox).  Total RNA 
was isolated from Luci and PARP-1i knockdown cells at various time point of dox 
treatment.  The RNA was reverse transcribed and subjected to qPCR using gene-
specific primers.  GDF15 and PFDN1 were previously shown to be regulated by 
PARP-1 in MCF-7 cells by constitutive shRNA expression (Figure 2.5).  B, Box plot 
of PARP-1 ChIP signals after shRNA induction by dox.  The promoter occupancy of 
PARP-1 was examined by ChIP analyses.  The box plot represents the collective data 
from 15 PARP-1 target gene promoters.  A reduction of PARP-1 on the chromatin is 
significantly reduced about 50% after 12 days of dox treatment compared to the Luci 
control.  Significance was determined using a Studen’t t-test with a p-value threshold 
of < 0.01 and is denoted by an asterisk (*).  However, some promoters show a slight 
reduction at six days, reflective of gene regulation at the same time point. 
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analysis of PARP-1 levels at target gene promoters by ChIP assay showed little 
change in PARP-1 promoter occupancy at early time points, while later time points 
showed reductions in PARP-1 occupancy, albeit to varying degrees (Figure A.5B).  
Overall, my results suggest that (i) chromatin-bound PARP-1 is not rapidly turned 
over, as is the case for non-chromatin-bound PARP-1, and (ii) the level of PARP-1 
depletion at promoters is likely directly linked to gene regulation.  However, further 
analysis is required to conclusively demonstrate this result in the most stringent way. 
 
A.5.2.  Experimental Procedures 
 
Antibodies - The custom rabbit polyclonal antibody against PARP-1 used for Western 
blotting and ChIP assays was generated by using a purified fragment of human PARP-
1 (amino-terminal, PARP-N (Kim et al., 2004)) (Pocono Rabbit Farm and Laboratory, 
Inc.).   The custom rabbit polyclonal antibody against ERα used for Western blotting 
was generated using a purified fragment of human ERα (Pocono Rabbit Farm and 
Laboratory, Inc.) (Kim et al., 2006).  The rabbit polyclonal antibody against the Tet 
repressor (TetR) was purchased from Abcam (ab14075). 
 
Luciferase reporter assay – MCF-7 TetR clones were seeded at ~1.5 x 105 cells per 
well in 6-well plates and grown for 24 hrs.  The cells were transfected with 800 ng 
pCMV-driven luciferase reporter harboring two Tet operon binding sites 
(pcDNA4/TO; kindly provided by H. Th. Marc Timmers) and 400 ng pCMV-β-
galactosidase expression vector (used for normalization) using GeneJuice transfection 
reagent (Novagen) according to the manufacturer’s protocol.  The following day (24 
hrs), cells were treated with or without doxycycliine (Sigma-Aldrich; 2 µg/mL) for an 
additional 24 hours.  The cells were collected and lysed in ProMega 5X Lysis Buffer, 
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and the supernatant was collected by centrifugation.  Luciferase and β-galactosidase 
assays were performed in parallel essentially as previously described (Kim et al., 
2006).  Luciferase and β-galactosidase activities were measured in extracts using a 96-
well plate luminometer (LD400; Beckman Coulter).  The assays were conducted twice 
with independent transfections to ensure reproducibility. 
 
Oligonucleotides - The oligonucleotide sequences listed below were used for the 
shRNA constructs.  Those sequences denoted with an asterisk (*) were chosen based 
on priority score described at the website. 
 
Target Sequence Source 
Luc 5’ - gatatgggctgaatacaaa - 3’ (Reynolds et al., 2004) 
hPARP-1 #1 5’ - gggcaagcacagtgtcaaa - 3’  (Ju et al., 2004; Shah et al., 2005) 
hPARP-1 #2* 5’ - acacctctctactatataa - 3’ Dharmacon siDESIGN® Center 
 
Luci and PARP-1i inducible knockdown constructs - For the “Tet-on” inducible 
knockdown constructs (Luci and PARP-1i), the pSUPER.retro vector (puromycin 
resistant) was first modified by replacing the H1 promoter with one harboring a Tet 
operator sequence (from the pTER+ modified vector, kindly provided by H. Th. Marc 
Timmers (van de Wetering et al., 2003)) using BglII and EcoRI restriction sites.  The 
resulting vector is termed pSUPER.retro.TO (Tet operon).  Double stranded 
oligonucleotides sequences targeting either luciferase (Luc) or PARP-1 were cloned 
into the pSUPER.retro.TO (puromycin resistant) vector using BglII and XhoI 
restriction sites, as described by the manufacturer and confirmed by sequencing. 
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Generation, culture, and treatments of MCF-7-derived cell lines - Parental MCF-7 
human breast cancer cells, kindly provided by Dr. Benita Katzenellenbogen, were 
maintained in MEM Eagle medium containing Hanks' salts, L-glutamine, and non-
essential amino acids (Sigma-Aldrich) supplemented with 5% bovine calf serum (CS; 
Sigma-Aldrich), 20 mM HEPES (pH 7.6), 100 units/mL penicillin, 100 µg/mL 
streptomycin, 25 µg/mL gentamycin, and 0.22 % sodium bicarbonate. 
 For the “Tet-on” inducible knockdown system, parental MCF-7 cells were 
stably transfected with a Tet Repressor (TetR) cDNA (pcDNA6/TR; kindly provided 
by H. Th. Marc Timmers).  Stable transfectants were clonally selected using 
hygromycin (200 µg/mL), expanded, and tested for TetR expression and activity by 
Western blotting and transient transfection/luciferase reporter gene assay, respectively.  
The resulting cell line, termed MCF-7 TetR, was maintained under similar conditions 
as described above, with the exception of the serum (5% Tet-approved FBS (Tet 
FBS); Clonetech) to reduce background shRNA expression in the absence of 
doxycycline.  MCF-7 TetR cells clone #3 and #4 were used to make the Luci and 
PARP-1i knockdown cell lines by retroviral infection with the appropriate shRNA 
vectors.  However, experiments were only conducted with MCF-7 Clone #3. 
Retroviruses were generated by transfection of the pSUPER.retro.TO vectors 
described above with an expression vector for the VSV-G envelope protein into 
Phoenix Ampho cells using GeneJuice transfection reagent (Novagen) according to 
the manufacturer’s protocol.  The resulting viruses were collected, filtered through a 
0.45 µm syringe filter to remove any remaining cells, and used to infect MCF-7 TetR 
cells.  Stably transduced cells were isolated under appropriate selection with 
puromycin (Sigma-Aldrich; 0.5 µg/mL), expanded, and frozen in aliquots for future 
use.  Luci and PARP-1i knockdown cell lines were maintained as noted above and 
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treated with doxycycline (Sigma-Aldrich; 2 µg/mL) to induce the shRNA expression 
for a minimum of 2 days (expression analyses) and 6 days (ChIP analyses). 
 
mRNA expression analyses by RT-qPCR - For gene-specific mRNA expression 
analyses, cells were treated with or without dox for the time points noted in the figure 
legends, or with vehicle or 17β-estradiol (E2; 100 nM) for 3 hrs.  Total RNA was 
isolated using Trizol Reagent (Invitrogen), reverse transcribed, and subjected to real-
time quantitative PCR using gene specific primers.  All target gene transcripts were 
normalized to the β-actin transcript, which was unaffected by PARP-1 knockdown 
(data not shown).  All experiments were conducted a minimum of two times with 
independent RNA isolations to ensure reproducibility. 
 
Chromatin immunoprecipitation assays - ChIP assays were performed essentially as 
described previously (Krishnakumar et al., 2008).  The immunoprecipitations were 
performed from crosslinked Luci and PARP-1i knockdown MCF-7 cells with 
antibodies against PARP-1, using “no antibody” as a control.  The resulting input and 
ChIP DNA material were used for gene-specific ChIP-qPCR analyses. 
 
Quantitative PCR analyses (RT-qPCR and ChIP-qPCR) - Gene-specific mRNA 
expression and ChIP analyses were analyzed by quantitative PCR in a similar manner.  
Briefly, reactions containing DNA from either source, 1x SYBR Green PCR master 
mix, and forward and reverse primers (500 nM) were used in 40-45 cycles of 
amplification (95°C for 15 sec, 60°C for 1 min) using a Roche LightCycler® 480 
System (384-well) following an initial 3 min incubation at 95°C.  Melting curve 
analysis was performed to ensure that only the targeted amplicon was amplified. 
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Primer Sequences – The primer sequences listed below were used for both RT-qPCR 
and ChIP-qPCR amplification reactions. 
 
RT-qPCR – 
Gene Name Primer Sequence  
β-ACTIN forward 5’-AGCTACGAGCTGCCTGAC-3’ 
β-ACTIN reverse 5’-AAGGTAGTTTCGTGGATGC-3’ 
CA12 forward 5’-CACTGCCAGCAACAAGTC-3’ 
CA12 reverse 5’-ACATGTTGAAGGTGACTGAAG-3’ 
GDF15 forward 5’-CTACAATCCCATGGTGCTCA-3’ 
GDF15 reverse 5’-TATGCAGTGGCAGTCTTTGG-3’ 
GREB1 forward 5’-GCCGTTGACAAGAGGTTC-3’ 
GREB1 reverse 5’-GGGTTGAGTGGTCAGTTTC-3’ 
ID1 forward 5’- CCGTTCGGGCCTCAAT-3’ 
ID1 reverse 5’-TTTTTCCCATATTCACTTTCTCACTTC-3’ 
ID2 forward 5’-TATTGTCAGCCTGCATCACC-3’ 
ID2 reverse 5’-AATTCAGAAGCCTGCAAGGA-3’ 
PFDN1 forward 5’-TGCCTTCTCCCATACATTCC-3’ 
PFDN1 reverse 5’-CAGGATTATGGCGTCCATCT-3’ 
PARP1 forward 5’-GTGTGGGAAGACCAAAGGAA-3’  
PARP1 reverse 5’-TTCAAGAGCTCCCATGTTCA-3’ 
PDZK1 forward 5’-CCTCAGTGATTGAGGATACTCCTGTA-3’ 
PDZK1 reverse 5’-CAACCCCCAATCCTGTTAGGAT-3’ 
TFF1 forward 5’-TGCTTCTATCCTAATACCATCG-3’ 
TFF1 reverse 5’-AGATCCCTGCAGAAGTGTC-3’ 
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ChIP-qPCR – 
Gene Name Primer Sequence 
ABHD2 forward 5’-GCCTCCACTCTGAGGAACAG-3’ 
ABHD2 reverse 5’-TTGTTCATTGGGCAGTTCAG-3’ 
ASCL1 forward 5’-CAAGAGAGCGCAGCCTTAGT-3’ 
ASCL1 reverse 5’-GCAAAAGTCAGTGCTGAACG-3’ 
GDF15 forward 5’-CTCAGATGCTCCTGGTGTTG-3’ 
GDF15 reverse 5’-CTCGGAATCTGGAGTCTTCG-3’ 
GREB1 forward 5’-TGGGATTTTACCTCAAAGTGC-3’ 
GREB1 reverse 5’-AGGTCCTCAAGAGCTGCAAG-3’ 
ID1 forward 5’-TCCGTTCGGGCCTCAAT-3’ 
ID1 reverse 5’-TTTTTCCCATATTCACTTTCTCACTTC-3’ 
ITPR1 forward 5’-ACTGAGGTCGCGGTTTGTAT-3’ 
ITPR1 reverse 5’-AAGGAGCCGTGTTGTGACTT-3’ 
LGALS3BP forward 5’-GGGCACCCCTCTCTCTACAC-3’ 
LGALS3BP reverse 5’-TGATTGTTGCTGGACTCAGG-3’ 
NAT1 forward 5’-CCGGCTGAAATAACCTGGTA-3’ 
NAT1 reverse 5’-TATGTGCCAGCCACACTTTC-3’ 
NELL2 forward 5’-TCCCCGGAGGAGCAGTCT-3’ 
NELL2 reverse 5’-CGCCCGAACCTGTTGTAAAG-3’ 
NVL forward 5’-TGCAACCAAACGGATCAATA-3’ 
NVL reverse 5’-TGAATTAAGTATTAGATTTCCCACTCA-3’ 
PVALB forward 5’-GCTCCCCTATCTGCACACTC-3’ 
PVALB reverse 5’-CAAAGGCTGTTTGGAAGCTC-3’ 
RAPGEF4 forward 5’-GTAACTCCCGACGACAGCTC-3’ 
RAPGEF4 reverse 5’-CTGTCACAGCCTGGAAACAA-3’ 
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SCN1A forward 5’-ACCCTCCTCTCTCTCCTTGC-3’ 
SCN1A reverse 5’-GGGAGGAGGAGAAATTCGTT-3’ 
SOCS2 forward 5’-TTCAAGCTTTCGAGCAGTGA-3’ 
SOCS2 reverse 5’-CCCTTAACAATCACGGGAAA-3’ 
TMOD3 forward 5’-TGCCTCTCTTGGGCTTTAGA-3’ 
TMOD3 reverse 5’-TTGTAAAGAAGCGCACATGG-3’ 
 
A.6.  Tet-inducible Over-expression of PARP-1 (Tet-Off) 
 
PARP-1 binds to a variety of nuclear proteins and is likely a member of 
multiple complexes within cells.  Most of the complexes were discovered under 
various conditions of signal-mediated transcriptional activation (i.e., NF-κB; (Hassa et 
al., 2001; Hassa and Hottiger, 1999; Hassa and Hottiger, 2002; Kameoka et al., 
2000)).  The list of factors with which PARP-1 has been shown to interact includes 
transcription factors (i.e., NF-κB, RAR), transcriptional coregulators (i.e., Mediator, 
histone deacetylases 1,2,3), DNA repair proteins (i.e., DNA Ligase III), and 
centromeric or telomeric proteins (i.e., CENP-A).  However, complexes in which 
PARP-1 has been identified have been isolated based on other factors, not PARP-1.  
To identify the composition of complexes in which PARP-1 is central, I have 
developed an inducible expression system in MCF-7 cells to isolate PARP-1 and 
identify and characterize PARP-1-interacting proteins. 
 
A.6.1.  Results and Discussion 
 
Previous reports have identified numerous PARP-1 binding partners ranging 
from transcription factors to DNA repair proteins.  However, the composition of 
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complexes in which PARP-1 is central has yet to be determined.  To isolate native 
PARP-1 complexes from human cells, initial experiments constitutively expressed 
FLAG-tagged PARP-1.  However, due to the toxic levels of PARP-1, stable 
integration and expression of PARP-1-FLAG proved unsuccessful.  To get beyond this 
technical hurdle, I developed a stable, tet-inducible expression cell line for PARP-1.  
Using MCF-7 Tet-Off cell line constitutively expressing the Tet activator 
(commercially available), I introduced a dox-responsive expression construct for 
FLAG-tagged PARP-1 (Wt and CatMut) and GFP (control) by retrovirus-mediated 
gene transfer.  In this system, the absence of dox represses transcription of the target 
gene, while the addition of dox induces the binding of the Tet activator to the Tet 
operon sequences, leading to active expression of the gene.  FLAG-tagged PARP-1 
was efficiently expressed after 4 days of dox treatment (Figure A.6A). 
PARP-1 was immunoprecipitated from the cells after 4 days of dox treatment 
using FLAG affinity resin.  After a series of washes, the bound proteins were eluted 
from the resin using the FLAG peptide as a competitor.  The resulting fractions from 
each step of the immunoprecipitation were analyzed by Western blot using both 
PARP-1- and FLAG-specific antibodies (Figure A.6B).  PARP-1 was only captured in 
the FLAG-PARP-1 expressing cell line as compared to the GFP control.  In addition, 
endogenous PARP-1 does not bind the resin, as it is only found in the unbound 
fraction.  The eluates were separated by SDS-PAGE and visualized by silver staining 
(Figure A.6C).  PARP-1-specific bands were excised from the gel, trypsinized, and 
protein fragments were identified by mass spectrometry. 
While many of the excised bands were unable to be identified due to low 
quantity, three proteins were successfully identified by mass spectrometry analysis 
(Figure A.6C).  Importantly, the bait protein, PARP-1, was identified.  The other two 
proteins were identified as NCL (nucleolin) and PRTF (polymerase I and transcript 
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Figure A.6.  A Tet-off PARP-1 over-expression cell line reveals PARP-1 
interactors.  A, FLAG-tagged PARP-1 is only expressed in the absence of 
doxycycline (dox).  GFP and PARP-1-FLAG cell lines, wild type (Wt) or catalytically 
inactive mutant (CatMut), were grown in the absence and presence of dox (2 µg/mL) 
for four days.  Whole cell extracts were then subjected to Western blotting analysis for 
FLAG-tagged PARP-1.  B, PARP-1 was immunoprecipitated (IP) from GFP and 
PARP-1-FLAG cell lines treated with dox (as in panel A) using FLAG-conjugated 
resin and eluted using FLAG peptide.  Fractions at each stage of the IP were subjected 
to SDS-PAGE and Western blotting analysis using PARP-1- and FLAG-specific 
antibodies.  Endogenous PARP-1 that is not FLAG-tagged is seen in the unbound (Un) 
fraction, relative to the input (In) or elutions (E), while FLAG-tagged PARP-1 is 
captured.  C, The resulting eluates from (B) were subjected to SDS-PAGE and 
visualized by silver stain.  PARP-1-specific protein bands were excised from the gel, 
trypsinized, and identified by mass spectrometry.  PARP-1 (the bait) and two 
identified interacting proteins are shown (Nucleolin and PTRF).  D, Description of 
PARP-1-interacting proteins identified in (C).  For each identified protein, the gene 
symbol, protein name, and known cellular functions are listed. 
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release factor), both of which are involved in rDNA transcriptional processes (Figure 
A.6D).  Notably, NCL was identified previously as a PARP-1 complex-containing 
protein (Ju et al., 2004).  Together, these results provide a feasible system to isolate 
and identify PARP-1-interacting or complex components.  However, additional 
chromatography steps are likely required in order to fully elucidate PARP-1-
containing complex components.  For example, glycerol gradient fractionation was 
applied to an attempt to separate various complexes.  Although this particular method 
was not successful, other chromatography or gradient techniques can be applied to 
enhance the complex purification.  In addition, verification of all identified proteins is 
also required to draw strong and conclusive results about interacting proteins.  
Furthermore, this system is applicable to all PARP-1 deletion mutants described in 
Appendix A.2, which can provide domain-specific and activity-dependent interactions. 
 
A.6.2.  Experimental Procedures 
 
Antibodies - The custom rabbit polyclonal antibody against PARP-1 used for Western 
blotting was generated by using a purified fragment of human PARP-1 (amino-
terminal, PARP-N (Kim et al., 2004)) (Pocono Rabbit Farm and Laboratory, Inc.).  
The mouse monoclonal antibody against FLAG used for Western blotting was 
purchased from Sigma-Aldrich (F3165).  
 
PARP-1 expression constructs - Wild-type (Wt) and catalytically inactive (E988K; 
CatMut) human PARP-1 were used in the studies described herein.  The Tet-inducible 
retroviral mammalian expression constructs were generated by sub-cloning the tagged 
cDNAs (a carboxyl-terminal 6xHis/FLAG tag) from the pCMV5 vector to the pREV-
TRE vector (Clonetech) using BamHI and XbaI restriction sites.  The control vector 
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expressed GFP (untagged) and was generated in the same way by T.Z.  Although not 
shown, wild-type and catalytically inactive (Y788F/Y791A) rat PARG Tet-inducible 
retroviral mammalian expression constructs were also generated by PCR-based 
cloning of the tagged cDNAs (a carboxyl-terminal FLAG tag) into pREV-TRE.  [In 
addition, both PARP-1 (Wt and CatMut) and PARG (Wt and CatMut) tagged cDNAs 
were inserted into the pTRE-TIGHT (Clonetech) retroviral mammalian expression 
vector for use with the Tet-On MCF-7 cell line in a similar manner.] 
 
Generation, culture, and treatments of MCF-7-derived cell lines - Tet-Off MCF-7 
human breast cancer cells (Clonetech) were maintained in MEM Eagle medium 
containing Hanks' salts, L-glutamine, and non-essential amino acids (Sigma-Aldrich) 
supplemented with 5% Tet-approved FBS (Tet FBS; Clonetech), 20 mM HEPES (pH 
7.6), 100 units/mL penicillin, 100 µg/mL streptomycin, 25 µg/mL gentamycin, and 
0.22 % sodium bicarbonate.  The Tet-inducible exogenous expression cell lines used 
in these studies were generated by retroviral infections of Tet-Off MCF-7 cells with 
the pREV-TRE expression vectors.  [In a similar manner, Tet-On MCF-7 (Clonetech) 
cell lines were generated with the pTRE-TIGHT expression vectors.  However, these 
cell lines not used after initial testing displayed considerable basal expression of the 
tagged protein (i.e., the system was quite leaky).] 
Retroviruses were generated by transfection of the pREV-TRE vectors 
described above with an expression vector for the VSV-G envelope protein into 
Phoenix Ampho cells using GeneJuice transfection reagent (Novagen) according to 
the manuf/acturer’s protocol.  The resulting viruses were collected, filtered through a 
0.45 µm syringe filter to remove any remaining cells, and used to infect the Tet-Off 
MCF-7 cells.  Stably transduced cells were isolated under appropriate selection with 
hygromycin (Cellgro; 200 µg/mL), expanded, and frozen in aliquots for future use. 
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GFP and PARP-1 Wt or CatMut Tet-Off cell lines were maintained as noted 
above in the presence of doxycycline (Sigma-Aldrich; 2 µg/mL) to maintain 
expression of the exogenous protein in the “off” state.  To induce expression, 
doxycycline was removed for a minimum of 4 days. 
 
FLAG immunoprecipitation and protein identification - GFP and PARP-1 Wt Tet-
Off cell lines were seeded in 4 15-cm dishes each and grown in the absence of 
doxycycline for at least 4 days.  Cells were washed with PBS, scraped, and collected 
by centrifugation.  Cells were lysed in 2.5 mL of lysis buffer [20 mM Tris•HCl (pH 
7.5), 420 mM NaCl, 10% glycerol, 0.5 mM EDTA, 0.1% NP-40, 1 mM DTT, 1mM 
PMSF, 40 µg/mL aprotinin, 40 µg/mL leupeptin, and a protease inhibitor cocktail 
(Roche Molecular Biochemicals)], and dounced on ice twice every 10 minutes for a 
period of 30 minutes, following an initial 8-10 dounces.  Lysates were then mixed in a 
1:1 ratio with dilution buffer [20 mM Tris•HCl (pH 7.5), 10% glycerol, 0.5 mM 
EDTA, 0.1% NP-40, 1 mM DTT, 1mM PMSF, 40 µg/mL aprotinin, 40 µg/mL 
leupeptin, and a protease inhibitor cocktail (Roche Molecular Biochemicals)], 
incubated at 4°C for 30 minutes, and centrifuged for 4°C for 20 minutes at a speed of 
17,000 rpm (Sorvall SS-34 rotor).  The supernatent was then transferred to a 15-mL 
conical vial and incubated with 50 µl of FLAG affinity resin (Sigma-Aldrich; A1080) 
at 4°C for 3 hrs, following equilibration of the resin with dilution buffer.  FLAG resin 
was collected using a clinical centrifuge, washed four times with wash buffer [20 mM 
Tris•HCl (pH 7.5), 200 mM NaCl, 0.5 mM EDTA, 0.1% NP-40, 1 mM DTT, 1mM 
PMSF, and a protease inhibitor cocktail (Roche Molecular Biochemicals)], and bound 
proteins were eluted by competition with FLAG peptide (Sigma-Aldrich; F3290) in 
elution buffer [20 mM Tris•HCl (pH 7.5), 200 mM NaCl, 10% glycerol, 0.2 mM 
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EDTA, 0.1% NP-40, 1 mM DTT, 1mM PMSF, 500 µg/mL insulin, 200 µg/mL FLAG 
peptide, and a protease inhibitor cocktail (Roche Molecular Biochemicals)]. 
For mass spectrometric identification, the bound proteins were separated by 
SDS-PAGE and visualized by silver staining.  Proteins excised from the gel were 
digested with trypsin and resulting peptide pools were analyzed by matrix-assisted 
laser-desorption / ionization reflectron time-of-flight (MALDI-reTOF) MS using a 
BRUKER UltraFlex TOF/TOF instrument (Bruker Daltonics; Bremen, Germany) 
(Erdjument-Bromage et al., 1998; Sebastiaan Winkler et al., 2002).  Selected 
experimental masses (m/z) were taken to search the human segment of a non-
redundant protein database (‘NR’ on April 8th 2010; ~233,131 entries; National Center 
for Biotechnology Information; Bethesda, MD), utilizing the Mascot Peptide Mass 
Fingerprint (PMF) program, version 2.3.01 for Windows (www.matrixscience.com), 
with a mass accuracy restriction better than 40 ppm, and maximum one missed 
cleavage site allowed per peptide.  To confirm PMF results with scores <40, mass 
spectrometric sequencing of selected peptides was done by MALDI-TOF/TOF 
(MS/MS) analysis on the same prepared samples, using the UltraFlex instrument in 
‘LIFT’ mode.  Fragment ion spectra were taken to search NR using the Mascot 
MS/MS Ion Search program (Matrix Science, www.matrixscience.com). 
 
A.7.  Reagents to Study NAD+-Synthesizing Enzymes 
 
PARPs and Sirtuins (SIRTs) are two families of enzymes that utilize NAD+ to 
carry out ADP-ribosyalation and deacetylation reactions, respectively, which occur in 
all cellular compartments.  Therefore, it is conceivable that NAD+ is synthesized in the 
nucleus, cytoplasm, and mitochondria to supply these types of enzymes with a 
substrate.  In fact, not only is NAD+ synthesized in these compartments from dietary 
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products (the De Novo Pathway), the product of PARP and SIRT enzymatic reactions, 
nicotinamide (NAm), is also recycled to re-synthesize NAD+ (the Salvage Pathway) 
(Kim et al., 2005).  Within these pathways, there are a series of enzymes that 
participate in the synthesis of intermediate products, all in an effort to generate NAD+ 
(Figure A.7A).  Some are solely active in the De Novo Pathway (i.e., NADS), while 
others are involved solely in the Salvage Pathway (i.e., NRK1).  Still others are active 
in both pathways, such as NMNATs, which are crucial for the final conversion step to 
NAD+.  Part of understanding how PARPs and SIRTs gene regulatory functions in 
vivo is being able to understand how substrate availability can affect their actions.  
Therefore, in an effort to study the NAD+-metabolic pathway enzymes and their 
potential effects on PARP-1’s gene regulatory functions in particular, I obtained all 
cDNAs, expressed them in mammalian cells, and determined their cellular localization 
patterns by immunofluorescence assays.  My results suggest that NMNAT-1 is not the 
only nuclear NAD+-synthesizing enzyme, as previously thought. 
 
A.7.1.  Results and Discussion 
 
Regarding the enzymes involved in the NAD+-synthesis pathway (Figure 
A.7A), there is little information known about their involvement with transcriptional 
regulation.  To determine if there are such potential functions for any of these enzymes 
to affect gene regulation on their own or in combination with NAD+-utilizing enzymes 
(i.e., PARPs, SIRTs), one would expect those enzymes to be localized completely or 
partially in the nucleus.  To answer this question, I obtained cDNAs for the enzymes 
highlighted in Figure A.7A and exogenously expressed FLAG-tagged versions in 
293T cells by transient transfection assay.  They include:  nicotinate phosphoribosyl 
transferase (NPT), NAD+ synthetase (NADS), nicotinamide mononucleotide 
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Figure A.7.  Schematic of the NAD+ synthesis pathway.  A, NAD+ is synthesized 
via the de novo pathway and the salvage pathway.  The enzymes responsible for the 
ultimate synthesis of NAD+ are highlighted in blue (modified from Kim et al., 2005).  
B, cDNAs for the enzymes from panel (A) were FLAG-tagged, cloned into the 
pCMV5 mammalian expression vector, and tested for expression by transient 
transfection in 293T cells.  Whole cell extracts were isolated 24 hrs post transfection 
and subjected to Western blotting using a FLAG-specific antibody.  The enzymes 
within each pathway are indicated.  Three constructs, NPT, NMNAT-3, and NRK1 did 
not display a visible FLAG signal, indicating the exogenous protein did not express, 
the protein is mis-folded and degraded, or the FLAG peptide was cleaved. 
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adenylyltransferase -1, -2, -3 (NMNAT), nicotinamide phosphoribosyltransferase 
(NAMPT), and nicotinamide riboside kinase -1, -2 (NRK). 
Western blot analysis using a FLAG-specific antibody showed that one some 
of the enzymes were expressed (at the correct molecular weight), while others were 
not (Figure A.7B).  For those that did not express (i.e., NPT, NMNAT-3, and NRK1), 
there are several explanations including:  (i) the protein is toxic to the cells and was 
thus degraded; (ii) the protein was expressed, but the FLAG-tag was cleaved from the 
protein; or (iii) the localization of these particular enzymes are within membranous 
organelles that could not be lysed with the protocol used.  Since protein-specific 
antibodies do not exist for nearly all of these proteins, the second explanation could 
not be eliminated.  The third explanation makes sense considering previous reports 
suggesting NMNAT-3 localizes to the mitochondria (Berger et al., 2004).  A cellular 
fractionation of the lysates is required in order to determine if this is true. 
To determine the cellular localization of those enzymes that expressed (i.e., 
NADS, NMNAT-1, NMNAT-2, NAMPT, and NRK2), I performed the same transient 
transfection experiment followed by immunofluorescence analysis.  In this assay, the 
cells were co-stained with an antibody against FLAG (green) to detect the exogenous 
protein and PARP-1 (red) to detect a nuclear protein (Figure A.8A).  NMNAT-1 
clearly localized to the nucleus, overlaying nearly perfectly with PARP-1.  NMNAT-2 
anti-localized with PARP-1, and seemingly concentrated near the nuclear membrane, 
perhaps indicative of localization to the endoplasmic reticulum or golgi apparatus.  
Antibodies against proteins specific to the endoplasmic reticulum and the golgi 
apparatus would be necessary to compare with the localization patterns of NMNAT-2 
to confirm this result.  NADS localized to the entire cytoplasm in a uniform manner.  
Interestingly, NRK2 and NAMPT seemingly localized to the nucleus and cytoplasm, a 
result that was seen throughout cross sections of the entire cell (data not shown).  This 
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Figure A.8.  NAD+-synthesizing enzymes localize to various cellular 
compartments.  A, 293T cells transfected with each enzyme from Figure A.7 were 
subjected to immunostaining with a FLAG-specific antibody (green) and visualized by 
confocal microscopy.  The cells were co-stained with a PARP-1-specific antibody 
(red), as a control for nuclear localization.  B, The same experiment was conducted in 
the presence of leptomycin B (LepB), which blocks nuclear export, to determine if 
NMNAT-1 is the only nuclear NAD+ synthesizing enzyme.  LepB caused NAMPT to 
be sequestered in the nucleus, indicating that NAMPT actively shuttles between the 
cytoplasm and nucleus compartments in vivo. 
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suggests that perhaps these particular enzymes are shuttled between compartments.  
To answer this question, the cells were treated with leptomycin B (LepB), an inhibitor 
of nuclear export.  Treatment with LepB had no effect on NRK2 localization, 
suggesting that NRK2 is ubiquitously expressed throughout the cell.  However, 
treatment with LepB caused a large percentage of NAMPT to be sequestered in the 
nucleus, indicating that NAMPT actively shuttles between the cytoplasm and nucleus. 
Taken together, these results suggest that while it is possible that any of these 
enzymes can affect total cellular NAD+ concentrations, it is likely that NMNAT-1 and 
NAMPT can affect local, nuclear NAD+ concentrations that can ultimately change the 
activities of NAD+-utilizing enzymes, such as PARPs and SIRTs.  In addition, nuclear 
localization of NMNAT-1 and NAMPT also leaves the possibility for gene regulatory 
functions independent of their enzymatic activity.  In fact, a recent report suggests that 
both NMNAT-1 and NAMPT can not only localize to the nucleus, but also can 
localize to chromatin, and can alter the gene regulatory activities of SIRT1 through 
physical interactions (Zhang et al., 2009).  It is highly likely that PARP-1 gene 
regulatory functions are also altered by NMNAT-1 and NAMPT.  While the total 
NAD+ levels created by NMNAT-1 and NAMPT are important, it still remains elusive 
how direct and promoter-localized NAD+ concentrations contribute. 
 
A.7.2.  Experimental Procedures 
 
Antibodies - The mouse monoclonal antibody against FLAG used for Western blotting 
and immunostaining was purchased from Sigma-Aldrich (F3165).  The custom rabbit 
polyclonal antibody against PARP-1 used for immunostaining was generated by using 
a purified fragment of human PARP-1 (amino-terminal, PARP-N (Kim et al., 2004)) 
(Pocono Rabbit Farm and Laboratory, Inc.). 
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NAD+-synthesizing enzymes expression constructs - The cDNAs for NPT and 
NAMPT were purchased from ATCC.  The cDNAs for NADS, NMNAT-1, NMNAT-
2, NMNAT-3, NRK1, and NRK2 were kindly provided by Dr. Nobumasa Hara, Dr. 
Mathias Ziegler, Dr. Hiremagalur Jayaram, Dr. Hong Zhang, Dr. Charles Brenner 
(both NRK1 and 2), respectively.  The pCMV mammalian expression constructs were 
generated by PCR-based cloning of the tagged cDNAs (an amino- or carboxy-terminal 
FLAG/6xHis tag) into pCMV5.  All constructs were confirmed by sequencing.  The 
ability to express was tested by transient transfection in 293T cells followed by 
Western blotting with a FLAG-specific antibody. 
  
Immunofluorescence – 293T cells transiently transfected with FLAG-tagged cDNAs 
were grown on coverslips in 6-well plates for a minimum of 24 hrs.  The cells were 
treated with or without 10 ng/mL leptomycin B (LepB, LC Laboratories) for 2 hrs 
prior to fixation.  The cells were fixed in the dish with 3.7% formaldehyde solution 
with PBS for 20 minutes at room temperature, washed twice with PBS and 
subsequently permeablized with 0.1% Triton X solution in PBS for 20 minutes at 
room temperature.  Cells were then washed twice with PBS and incubated with FLAG 
or PARP-1 antibody (1:2000 – 1:5000 dilution in PBS) for 1 hour at room temperature 
(in the dark).  After two washes with PBS, the cells were incubated with goat-α-rabbit 
rhodamine-conjugated or goat-α-mouse FITC-conjugated secondary antibody (1:3000 
dilution in PBS; Jackson) and Hoechst DNA stain (1:5000 dilution in PBS; Jackson) 
for 1 hour at room temperature (in the dark).  Finally, the cells were washed three 
times with PBS and coverslips mounted onto microscope slides using Vectashield 
Mounting Media (Vector Laboratories).  Staining was visualized using a Leica 
Confocal Microscope System at Cornell University’s Microscope Imaging Facility. 
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